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THESIS ABSTRACT 
Campath-IH is a humanised antibody which has entered clinical trials for both 
Rheumatoid arthritis and lymphoma. The clinical trial material was expressed in and 
isolated from Chinese Hamster Ovary (CHO) cells. It is proposed that variations observed 
in preliminary antibody-dependent cellular-cytotoxicity (ADCC) assays, in which 
human 
mononuclear cells were used as effectors and CHO Campath-1H was compared with 
Campath-IH prepared from rat YO cells, are correlated to host and/or culture condition 
related changes in antibody N-linked glycosylation. 
To investigate the hypothesis, CHO Campath-1H mediated assays including ADCC, 
monocyte mediated cytostasis, antigen engagement and subsequent crosslinking were 
analysed as was the antibody N-linked carbohydrate composition. The total removal of 
the carbohydrate ablated ADCC activity, decreased the cytostatic effect seen with intact 
antibody but did not alter antigen binding. Campath-IH cDNA was recloned into Celltech 
Glutamine Synthetase expression vectors and transfected into mouse NSO cells for 
antibody isolation. Comparisons of antibody made during NSO Campath-1H 
development from clone to fermentor and between CHO and YO Campath-1H with the 
various stages of NSO antibody revealed variations in both assay response and N-linked 
carbohydrate structure. The glycosylphophatidylinositol (GPI)-anchored antigen CDw52 
recognised by Campath-1H was isolated from Wien 133 B cell cDNA by polymerase 
chain reaction and sequenced in preparation for expression cloning. Two sequence 
variants of the antigen were present in the cDNA, differing by two amino acids outside of 
the antigen coding region but, at a site controlling GPI-anchor attachment. Both cDNAs 
were expressed in CHO cell lines for comparison but only one could be detected by 
Campath-IH. In vivo and in vitro studies on the two forms are described. Chimeric forms 
of the T cell antigen CD4, linked to either of the CDw52 antigen GPI attachment 
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CHAPTER ONE: INTRODUCTION 
1.1 Aims 
The work described in this thesis was designed to investigate the influence of N-linked 
glycosylation on Campath-1H antibody in defined assays (resulting from antibody 
expression in different cellular hosts) and antibody/antigen interactions. This introduction 
reviews topics which may be of importance in the understanding of the data presented. 
1.2 Introduction 
The human immune system can, theoretically, be divided into two highly interactive arms 
(Roitt 1991). One arm is concerned with adaptive responses to antigen, whilst the other is 
responsible for non-specific innate immunity, with antigen being defined as molecules 
which can be classified as either 'self or 'non-self. The responses classed as adaptive 
encompass those in which either T cells (cellular immunity) or B cells (humoral 
immunity) develop antigen specificity which can increase with time after the initial 
exposure to antigen. Subsequent lack of exposure to antigen usually leads to a decline in 
both B and T cell responses unless re-exposure occurs, in which case mechanisms of 
memory can be evoked. Recognition of non-self is mediated through the major 
histocompatibility complex genes or MHC. Innate responses, are non-specific but usually 
have a rapid onset. The initial display of innate immunity often occurs as an antigen 
penetrates the physical barriers of the body. If foreign material passes beyond the initial 
barriers or persists at mucosal surfaces, a repertoire of non-specific cells and 
macromolecules are released to defend the body. Cells such as macrophages, monocytes, 
neutrophils, killer and natural killer cells recognise general determinants, such as 
carbohydrate on the invading molecules. The subsequent attachment of the immune cells 
to the foreign entity via these determinants can lead to its clearance by phagocytosis or 
lysis. Phagocytosis is enhanced by the deposition of opsonins such as complement 
components on the surface of the invading organism. IFNs act by mediating the inhibition 
of growth and replication. 
The two different arms of the immune system can interact together to confer specificity to 
the non-specific mechanisms (Medzhitov et al 1997). The use of antibody is a very good 
method for achieving this interaction. The presence of a specific antigen on the foreign 
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cell or organism's surface can lead to antibody attachment via the antigenic recognition 
or Fab domain. Phagocytic cells such as macrophages and monocytes, as well as 
cytotoxic cells including natural killer cells, express some or all of the members of the 
IgG Fc receptor (Fc R) family on their surface (Hogg 1988, Metzger 1991, van de Winkel 
et al 1993). The non-specific protective cells react with the exposed Fc portion of the 
antibody, via Fc receptors, and become activated. The result is the removal of the antigen 
bearing organism though phagocytosis or lysis. 
Although the therapeutic use of antibody has been pursued for many years the approach 
was hampered either by the lack of sufficient antibody or the inability to prevent an anti- 
globulin response by the recipient against a foreign protein. The use of recombinant non- 
human monoclonal antibodies can overcome the problem of supply, but the complication 
of immune cross-reactivity persists. In an attempt to reduce the inherent immunogenicity 
of non-human antibodies, the cDNA of antibodies such as Campath have been engineered 
to substitute all possible animal sequences with human equivalents. The resulting 
humanised cDNA has been used in heterologous expression systems for large scale 
manufacture. Antibodies produced in this way were initially hoped to pave the way for 
startling new therapies but unexpected consequences of manufacture soon became 
apparent. 
The first antibody to be humanised and manufactured for clinical trial was Campath-1H. 
Results from several clinical trials in which the efficacy of Campath-1 H was assessed 
have now been published (Brett et al 1996a and b, Isaacs et al 1996a and b, Dyer et al 
1997, Osterborg et al 1996 and 1997, Pawson et al 1997, Bowen et al 1997, Moreau et al 
1996). The early clinical trial data reveal that Campath is very efficient at depleting 
lymphocytes which are CDw52 positive and in the majority of patients the depleted cells 
return to their original levels within several months of treatment. However, in a few 
cases, as the lymphocytes are replenished with time, CDw52 negative cells are detected 
(Brett et al 1996a, Hertenstein et al 1995). On further analysis, the expression defect was 
shown to involve the mechanism by which the GPI-anchor is attached to CDw52 antigen 
(Hertenstein et al 1995, Taylor et al '1997) and in these patients all lymphocyte GPI- 
anchored molecules were affected. A naturally occurring defect of GPI-anchors, 
paroxysmal nocturnal haemoglobinuria (PNH) is already known and arises as a mutation 
in an X-linked autosomal gene (Bessler et al 1994), symptoms exhibited include anaemia 
caused by nocturnal lysis of red cells. 
This thesis attempts to address the problems associated with the expression of Campath 
antibody for therapeutic purposes. It is now acknowledged that engineered antibodies are 
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influenced by the expression system from which they are derived (Patel et al 1992). Both 
the host cell line and the method of culture have the ability to create minor changes in 
post-translational modifications added to the protein backbone. The host cell line in 
which Campath-1H was expressed at Wellcome Research Laboratories is the Chinese 
Hamster Ovary (CHO) cell line and for production purposes the cells are cultured in eight 
thousand litre fermentor vessels in protein-free medium. In Chapter three, I define the 
mechanisms of action of selected in vitro assays which may constitute the mechanisms by 
which CHO Campath-1H acts in vivo. Preliminary experimentation with Campath-1H in 
one of the selected assays, the antibody-dependent cellular cytotoxicity assay or ADCC, 
had indicated that antibodies with identical antigen specificity exhibited assay variation 
when expressed and isolated from different animal cells. To explore this further, the 
humanised cDNA for Campath-1H antibody heavy and light chains were re-isolated and 
cloned into the alternative Glutamine Synthetase expression system (Bebbington et al 
1992). The first part of Chapter four outlines the cloning and expression of Campath-1H 
in this alternative system and includes both the outline of media development and the 
comparisons of antibody isolated at various stages in that development. The latter part of 
Chapter four describes the comparisons of three Campath-1H antibodies derived from 
different mammalian host cells. In Chapter five, I describe experiments defining CDw52. 
The mature antigen CDw52 is composed of twelve amino acids which are attached to the 
cell membrane via a glycosyl-phosphatidyliniositol (GPI)-anchor. The sequence of 
CDw52 had been published prior to the start of the thesis and subsequent isolation of the 
antigen cDNA revealed two versions of the sequence (Xia et al 1991, Hale et al 1996). 
Both isolates contained identical CDw52 sequences in the mature protein, but differences 
were apparent in the region which controlled the site of GPI-anchor attachment. The 
differences were limited, at the genetic level, to two base pairs but the positioning of 
these mutations led to changes in two adjacent amino acids. Both the authentic and 
alternative isolates of antigen were cloned and expressed in cells in order to have a 
readily available stock of positive cells for comparison of properties as well as assay 
development. The expression of the two forms and their comparisons are discussed. 
1.3 Antibodies 
1.3.1 General antibody structure 
A single antibody molecule is composed of four polypeptides, two short light (L) chains 
and two longer heavy (H) chains (Roitt 1991). The four chains are held together by a 
series of di-sulphide bridges to form aY shaped molecule. Within the antibody molecule 
are two distinct functional areas influencing both specificity and effector functions. The 
specificity determining area or Fab region contains the amino (NH2)-termini of one heavy 
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and one light chain that fold together to form one of two antigen binding sites. Within the 
Fab portions, the two H and two L chains are both composed of outer variable (V and 
therefore, VHI and VLl) and inner constant (C and therefore CH1 and CL1) sequence 
domains. It is the amino acid sequence within the VH1 and VL1 variable domains which 
determines the precise antigen specificity. Each variable domain is composed of three 
short regions of hypervariable sequence called the complementarity determining regions 
(CDR), interspersed between the more conserved sequences of the variable region. The 
conserved sequences in both the variable and constant domains contribute to the 
backbone or framework of the Fab which provides the conformational structure of the 
antigen binding site. 
The portion of the antibody governing the effector function is the Fe region and this is 
composed of the carboxy (COOH)-termini of both H chains, which are of matched a, 7, 
S, e or .t isotype. Each heavy chain consists of two or three constant domains (CH2, CH3 
and CH4), depending on the isotype. IgG is composed of the two y heavy chains and has 
two constant domains, CH2 and CH3 (Deisenhofer 1981). The two heavy chains are held 
together by one or more di-sulphide bridges near to the join or hinge with the Fab region. 
The length of the hinge determines the flexibility of the two Fab arms and the Fc region 
in relation to each other and varies with isotype and subclass. 
On protein analysis, all normal mature IgG antibody molecules have been demonstrated 
to contain a carbohydrate component, which is attached to the asparagine residue at 
position 297 in the CH2 domains of the Fc fragment (Kabat et al 1987). The carbohydrate 
is added as a whole moiety during a co-translational event (see later text). It is the 
carbohydrate which provides the antibody molecule with its ultimate conformation and 
which influences the regions of the hinge and constant region domains that are exposed 
for interactions with effector cells and macromolecules. Loss or structural change of the 
attached carbohydrate can alter the function and stability of an antibody molecule and 
such alterations are observed in diseases such as rheumatoid arthritis (RA) (Parekh et al 
1988b). 
Structural analysis of IgG antibody molecules by proteolytic digestion with papain 
releases two Fab fragments and one Fc fragment per molecule. This is a consequence of 
the cleavage of the antibody, by papain, at a position above the di-sulphide bridges in the 
hinge region. In contrast pepsin cleavage of IgG antibody gives rise to one F(ab')2, that is 
two Fab units joined by a disulphide bridge, plus a shorter Fc, or pFc', region. The 
nomenclature mentioned here will be referred to in the later text when describing 
genetically modified antibody fragments. 
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1.3.2 The structural differences between human antibody isotypes 
Although the sequence variation between various isotypes of human antibody can be 
small, the differences seen both between and within isotypes can lead to considerable 
functional variations (Wawrzynczak 1995). The antibody isotypes IgM and IgE, although 
not containing a hinge region, do possess an additional CH4 domain (Roitt 1991). Also, 
several antibody isotypes are capable of forming polymeric structures via the use of an 
additional tail region at the COOH-terminal of the Fc portion. Isotypes which have this 
property are IgM, IgA and IgD (Roitt 1991). Polymeric antibodies tend to have high 
avidity for their epitopes, even when the affinity is low, as a consequence of the increased 
number of antigen binding sites. 
1.3.3 The relationship between human antibody isotype, subclass and complement 
fixation 
Each antibody isotype has distinct functional properties. Some isotypes react with certain 
cell types through Fc R on the cell surface whilst, once the antibody has bound antigen, 
others interact with serum components such as complement. IgA and IgM have the ability 
to activate complement as do some subclasses of IgG. Within normal human serum, the 
ratios of the various subclasses are 70% IgGI, 20% IgG2,6% IgG3 and 4% IgG4 
(Furakawa and Kobata 1991). IgG myelomas encompass the subclasses IgGI, IgG2, 
IgG3 and IgG4 which all exhibit large regions of structural homology and so maintain 
reactivity with anti-IgG antibodies. Minor differences between the subclasses reside 
within the heavy chains y 1,2,3 and 4 and influence their ability to activate complement. 
The IgG subclasses IgGI and IgG3 are the most effective at activation, IgG2 of 
intermediate activity and IgG4 ineffective (Roitt 1991). The activation of the first 
complement component, Clq by IgG, occurs by the interaction of the C1q with a 
characteristic amino acid motif within the CH2 domain of the antibody (Greenwood et al 
1993, Brekke et al 1995). The binding and activation of C1q are dependant on the 
presence of carbohydrate on the asparagine residue in this domain (Leatherbarrow et al 
1985, Zhang et al 1994, Wright and Morrison 1994). Also, antibody complexed with 
antigen has an influence over the C1q binding ability of that antibody in that 
conformational restraints are imposed on the antibody by the bound antigen. An 
additional effect of antigen density and distribution is also imposed on the antibodies 
ability to activate complement due to the likelihood of the complement binding multiple 
sites of adjacent Fc regions. 
1.3.4 Rat/Mouse antibody subclasses in relation to human subclasses 
Mouse IgG subclasses IgGI, IgG2a, IgG2b and IgG3 are classified in a similar way to the 
human IgG subclasses IgGI, IgG2, IgG3 and IgG4. The rat subclasses are IgGI, IgG2a, 
30 
IgG2b and IgG2c. All antibody subclasses have different inter- and intra-species amino 
acid sequences, distribution of di-sulphide bonds and physiological properties, but 
comparisons can be made on a functional basis (Wawrzynczak 1995). Mouse IgG2a, 2b 
and IgG3 and rat IgGI, IgG2a and 2b can be equated with human IgGI, 2 and 3 in that 
they activate complement. Also both mouse IgG2a and rat IgG2b antibodies are able to 
interact with human IgG Fc R and thus can trigger mechanisms such as phagocytosis via 
human effector cells (Hale et al 1985). 
1.3.5 Human IgG subclass structure and Fc receptor binding 
The structural differences between IgG subclasses include both different amino acids and 
interchain disulphide bridging which contribute to alterations in biological activity (Roitt 
1991, Brekke et al 1995). IgGi is able to bind Fc R adequately and is distinct in its form 
of di-sulphide bridging between the H and L chain. Most subclasses exhibit linkage 
between a cysteine residue in the COOH-terminus of the L chain with a cysteine residue 
sited between the VH and CH1 domain. The site of linkage in IgGI is via a cysteine in 
the hinge region located between the CH 1 and CH2 domains. IgG3 contains an extended 
hinge region which seems to be a quadruplication of the IgG1 hinge and, whilst it binds 
Fc R as well as IgGl, it is the only subclass to demonstrate self aggregation. The 
extended hinge is not required for Fc R mediated activity but the di-sulphide bridging is 
essential (Aase et al 1993). IgG4, like IgGi, contains two inter-chain di-sulphide bridges 
in the hinge region and is not thought to bind to Fc R on monocytes in vitro. However, 
this is disputed for in vivo use (Isaacs et al 1996c). IgG2, contains four disulphide bridges 
in the hinge region and binds to Fc R but not with high affinity. 
1.3.6 IgG antibody glycosylation 
Mutational analysis of the protein backbone of IgG antibody indicates that the residue for 
carbohydrate attachment in the Fc region is the asparagine residue at position 297 (Kabat 
et al 1987). This residue is within CH2, which is limited conformationally by the hinge 
di-sulphide bonds at the NH2-terminus and by the form of linkage to the CH3 domain at 
the COOH-terminus (Rudd et al 1991). The carbohydrate moiety attached to the 
asparagine residue can be composed of a variety of structures or isoforms, which may 
vary according to the species from which the antibody is derived (Parekh et al 1989, 
Rademacher et al 1988), the disease state of the host species (Parekh et al 1988b) and, if 
the antibody is recombinant, the source and culture conditions of the host cell line in 
which it is expressed (Paulson 1989, Patel et at 1992, Goochee et al 1990). The CH2 
domains are unlike the other domains in that they lack extensive protein-protein 
interactions and rely on the carbohydrate residues on each heavy chain to maintain 
conformation. Loss of the carbohydrate also influences biological activity (Nose and 
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Wigzell 1983, Leatherbarrow and Dwek 1983, Leatherbarrow et al 1985, Elbien 1991, 
Furukawa and Kobata 1991, Boyd et al 1995, Lifely et al 1995). Glycosylation sites can 
also be present in the variable regions of antibodies if in the correct context of 
asparagine-X-serine/threonine. 
1.3.6.1 Carbohydrate structure 
The carbohydrate isolated from IgG Fc has been demonstrated to be of bi-antennary 
complex-type structure (Parekh et al 1989, Rademacher et al 1983), which is one of three 
possible classes of N-linked oligosaccharide. The oligosaccharides, when isolated, are 
rarely the same on both heavy chains and the monosaccharide combinations feasible 
within the oligosaccharides are numerous. At least thirty different oligosaccharide 
structures are possible on each site (Parekh et al 1985, Rudd et al 1991). Each 
oligosaccharide is manufactured prior to addition and is transferred, co-translationally, to 
the site of attachment onto the nascent polypeptide (Parekh et al 1989, Goochee et al 
1990). Oligosaccharide moieties are composed of a core structure of two N-acetyl 
glucosamine (G1cNAc) residues often with one fucose residue on the inner G1cNAc (86% 
of normal serum) and three mannose residues (Rademacher et al 1983, Rudd et al 1991). 
Additional outer arm residues of either none, one or two G1cNAc, none, one or two 
galactose residues, and possibly none, one or two sialic acid residues can also be present. 
Within normal human serum the ratios of none, one and two sialylated oligosaccharides 
tends to remain constant at 76: 18: 6 (Furakawa and Kobata 1991). Extra G1cNAc residues 
can also bisect the two armed core and lead to further complexity of the structure (see 
Fig.!.! ). These are seen in 18% of normal human serum but not in mouse sera (Furakawa 
and Kobata 1991). 
Figure 1.1 A diagrammatic representation of the possible carbohydrate structure associated with IgG Fc. 
NeuAc represents sialic acid, Gal represents galactose, G1cNAc represents N-acetyl glucosamine, Man 
represents mannose and Fuc represents fucose. oc and (3 refer to the linkage types. 
i 
NeuAc a2 -6 Gal ß 1- 4 G1cNAc ß 1- ", 2 Man a1 Fuc a1 ti 
66 
G1cNAc ß1; 4 Man ß 1- 4 G1cNAc ß 1- 4 G1cNAc 
3 
NeuAc a2 -6 Gal ß 1- 4 GIcNAc ß 1- 
12 Man a1 
variable core 
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Within each oligosaccharide entity it is possible to identify defined secondary structures 
and the bi-antennary conformation arises from the two glycosidic linkages between the 
three mannose residues (Rudd et al 1991). The a(1-6) linkage, which forms one arm of 
the bi-antennary structure, can assume one of two conformations which allows a certain 
flexibility. It is this arm, on each of the two oligosaccharides, which interacts with the 
antibody backbone on the opposite heavy chain. Once the interaction has occurred the 
flexibility of the sugars is then constrained. The a(1-3) linkage is more rigid and it is this 
arm, on one of the sugars, that interacts with the core of the opposing oligosaccharide. To 
enable this to occur, the terminal sialic acid and galactose residues of this arm are absent, 
exposing the GlcNAc for interactions. The remaining free a(1-3) arm of the second 
oligosaccharide extends outwards between the antibody domains with no apparent steric 
restraints on its length. To enable comparisons between oligosaccharide structures to be 
made, a universal numbering system for the residues has been devised (described in 
Lifely et al 1995). Each residue, from the outermost inwards, has a number referring to 
the number of those residues, such that 004301 represents no terminal sialic residues, no 
galactose residues, four G1cNAc, three mannose, no bisecting G1cNAc and one core 
fucose. The example in figure 1.1 would be represented by 224311. 
1.3.6.2 The biosynthesis and addition of N-linked carbohydrate 
A precursor oligosaccharide is synthesised by the sequential addition of the sugars 
GIcNAc, mannose and glucose, from their activated glycosyl donors, to the lipid carrier 
dolichol-P that results in a G1c3Man9GlcNAc2-pyrophosphoryl-dolichol lipid-linked 
oligosaccharide moiety (Elbein 1991). The reactions are all catalysed by membrane- 
bound glycosyl-transferases and occur in the endoplasmic reticulum (ER) prior to 
processing (Goochee et al 1990). The antibiotic tunicamycin blocks the action of G1cNAc 
transferase, the enzyme responsible for the transfer of G1cNAc-l-phosphate (P) from 
uridine di-phosphate (UDP)-G1cNAc to dolichol-P and thus prevents the formation of the 
precursor (Goochee et al 1990). The precursor structure is a common intermediate of all 
three classes of N-linked oligosaccharides and the final oligosaccharides are synthesised 
from the intermediate by exoglycosidase trimming of the oligosaccharides whilst still in 
the ER. The immature N-linked oligosaccharides are attached covalently, via a N- 
glycosidic bond, to the NH2 group of asparagine when displayed in the context of 
asparagine-X-serine/threonine. Not all asparagine residues found in the correct context 
are glycosylated and it would seem necessary for the residue to be in an exposed region 
such as a ß-turn (Elbein 1991). Once attached and whilst the polypeptide continues to be 
synthesised, the oligosaccharide is processed further by glucosidases 1 and 2 to remove 
the three glucose residues. Mannosidases (alpha- and endo-) further delete either one or 
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two of the mannose residues before the protein is transferred to the Golgi apparatus. 
On 
transfer, the enzyme mannosidase 1 removes between one and four mannose residues to 
give Man5GlcNAc2-protein prior to the addition of a G1cNAc residue from its UDP- 
G1cNAc donor. The excess mannose residues are now removed by the action of 
mannosidase 2 and the oligosaccharide elongated to its final form. This is achieved by the 
addition of various sugars utilising specific glycosyl transferases located in the trans- 
Golgi. 
1.3.6.3 Effects of glycosylation on polypeptides 
Oligosaccharide additions to polypeptides such as antibodies are acknowledged to have 
profound effects in that they can alter their biological properties (Leatherbarrow et al 
1985, Nose and Wigzell 1983) such as Fc binding (Jefferis et al 1995) and complement 
activation (Zhang and Lachmann 1994). Evidence (Elbein 1991) from the use of either 
site directed mutagenesis, enzymatic removal or glycosidase inhibitors, has also shown 
that the presence or absence of carbohydrate can alter protein conformation, thermal 
stability, charge and solubility as well as location and distribution. In vivo studies on the 
immunogenicity of glycoproteins (Schauer 1988) have demonstrated that terminal 
sialylation of proteins reduces their immunogenicity and it is interesting to note that 
during pregnancy, the amount of sialic acid and galactose residues found on antibody 
increases (Rook et al 1991). In the absence of terminal sialic acid, proteins are rapidly 
cleared from circulation by hepatocytes and macrophages via carbohydrate specific 
receptors (Ashwell and Harford 1982). In rheumatoid arthritis (RA) (Parekh et al 1985), 
the degree of terminal sialylation and galactosylation of synovial fluid IgG decreases and 
the extent of reduction can be shown to correlate with severity of disease. Pregnancy can 
reverse the outcome of this reduction and give temporary relief from symptoms (Rudd et 
al 1991). When referring specifically to the administration of antibodies for therapy, the 
types of oligosaccharide present are also critical. Within human serum there is 
approximately 1% of an antibody which is specific to Gala l -3)Gal residues, outer arm 
oligosaccharides found on antibodies from New World monkeys and non-primate 
mammals such as mice (Galili et al 1988, Thall and Galili 1990, Galili 1993). The 
presence of this antibody enhances the clearance of mouse antibodies administered 
systemically and drastically limits their use (Borrebaeck et al 1993). Glycoproteins 
expressed in yeast or insect cells may also be rapidly cleared because both of these 
systems produce carbohydrates with terminal mannose residues (Paulson 1989). When 
placed into either complement lysis or ADCC assays, antibodies expressed in yeast do 
not activate complement but still exhibit ADCC activity (Horwitz et al 1988). 
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The cells in which polypeptides are expressed can also influence the glycosylation and 
this has been demonstrated for many proteins. A well documented example is the Thy-1 
molecule in the rat which, whilst maintaining its protein backbone, is found to display 
very different glycosylation patterns in the forms isolated from either the brain or thymus 
(Parekh et al 1987). 
1.3.6.4 In vitro factors affecting carbohydrate composition 
Pregnancy, RA and other physical conditions are well documented in terms of their 
association with changes in the glycosylation of cellular proteins (Muramatsu 1993) and 
antibody Fc domains (Rudd et al 1991, Parekh et al 1985, Knight 1989, Rook et al 1994). 
In vitro conditions are also able to influence carbohydrate addition. Lund and colleagues 
(1993) provided evidence that the protein backbone of antibody produced in vitro 
imposed some restraint on the oligosaccharide content in that, under controlled 
conditions, the preference for sites of galactosylation correlated with isotype. Glucose 
starvation during the culture of cells such as CHO or mouse 3T3 cells can lead to either 
aberrant glycosylation (Gershman and Robbins 1981) or more dramatically, total lack of 
glycosylation i. e. in monoclonal antibody light chain synthesis from MOPC-46 cells 
(Stark and Heath 1979). Hormones such as retinoic acid have been demonstrated to play 
an important role on the differentiation state of epithelial cells in vivo (Wolf 1984), 
whilst the hormone can exhibit an influence on glycoprotein oligosaccharide processing 
in vitro (Chan and Wolf 1987). Another known cause of altered antibody glycosylation is 
the method of protein production (Anderson et al 1985) and it was noted that IgM 
produced from different harvests of mouse ascites fluid differed in sialic acid content 
whilst antibody produced in cell culture exhibited incomplete oligosaccharide processing. 
This observation has been confirmed by Lund et al (1993) who clearly demonstrated that 
culture conditions influenced the extent of galactosylation, with the highest levels 
monitored in cells cultured as monolayers. They also showed that the cell type in which 
the antibody was produced was critical. In these experiments the carbohydrate profiles of 
human/mouse and mouse immunoglobulins expressed in mouse J558L cells were 
compared with similar immunoglobulins from CHO cells. Only the antibody from the 
mouse J558L cells was found to contain Gal(a l-3)Gal linkages. Host cell lines 
themselves possess different arrays of glycosyl-transferases as found in CHO (Hokke et 
al 1990) and HeLa cells (Nilsson et al 1993). Evidence for the influence of tissue culture 
method was supplied by Patel (et al 1992), whose data inferred that not only culture 
method but also media could alter the oligosaccharide profile of a protein. They 
compared IgG1 monoclonal antibody produced from cells grown in serum-free or serum 
containing medium with those isolated from ascites. The differences were that terminal 
sialylation and galactosylation varied. The antibody from ascites contained 98% 
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asialylated oligosaccharides whilst cells cultured in medium produced antibody with 
81% 
asialo, 15% mono- and 4% di-sialylated molecules in the presence of serum and 
71% 
asialo, 18% mono- and 11% di-sialylated oligosaccharides when cultured 
in serum-free 
medium. Both of the cell culture methods produce antibody with similar ratios to 
human 
IgG sialylation (76: 18: 6, Furakawa and Kobata 1991). When the galactose content was 
compared, antibody from cells cultured in serum was found to be below that of the other 
two forms of antibody. These findings correlate with the data produced by Lifely (Lifely 
et al 1995) and those described in Chapter five, which indicate that the method of culture, 
species of cell line and composition of medium does indeed influence antibody 
glycosylation patterns. 
1.3.6.5 The consequences of the removal of carbohydrate from IgG 
Rademacher (et al 1988) observed that when placed into in vitro assays in comparison 
with intact antibodies, a- or de-glycosylated antibodies demonstrated a divergence in 
efficiency. In the ADCC experiments, deglycosylated antibodies failed to activate 
effector mechanisms whilst complement activation and C1q, protein A and antigen 
binding were not altered. As Rademacher pointed out, this reflected an effect on "all 
interactions with cellular bound receptors, whereas fluid-phase reactions are unaffected". 
Deglycosylation of mouse monoclonal antibodies by tunicamycin treatment of hybridoma 
producing cell lines, revealed no loss of staphylcoccal protein A binding (Leatherbarrow 
and Dwek 1983) whilst a reduction in their specific activity in terms of Fc R recognition 
and complement activation was observed (Leatherbarrow et al 1985). The latter were 
found to activate ADCC less efficiently. These results are entirely in line with more 
recent data (Boyd et al 1995) that showed that deglycosylation of Campath-1H led to a 
loss of both ADCC and complement lysis whilst the antibody retained antigen and 
protein A binding activity. The same group illustrated that the removal of the terminal 
sialic acids was ineffectual, whilst the subsequent removal of the Campath galactose 
residues reduced activity in complement lysis assays but not ADCC. Pound and his 
colleagues (1993a) have demonstrated the ability of aglycosylated IgG3 to trigger the 
human phagocyte respiratory burst. 
The removal of carbohydrate is also thought to affect the catabolism of the protein and 
thus clearance rate (Wawrzynczak et al 1992). When intact or aglycosylated IgG2b 
mouse antibody was administered to rats, and measured by both enzyme-linked 
immunosorbent assay (ELISA) and radiolabel tagging, the antibody half-life of the latter 
antibody was reduced from 7.4 days to 4.8 days. 
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1.4 The use of antibodies in therapy 
1.4.1 The early history 
The idea of antibodies being used therapeutically (review by Riethmuller et al 1992) was 
first postulated in the late 1800s by Metchnikoff (Metchnikoff 1899) who described the 
possible use of antibodies in vivo. This concept was fostered by Paul Ehrlich who 
envisaged the antibody molecules as `magic bullets or immunobodies'. He recognised 
that they were capable of both antigen recognition and complement activation and thus of 
potential use as targeting and blocking agents. In suggesting this approach, Ehrlich also 
anticipated the anti-idiotype network. Perlmann in 1959 (Perlmann 1959), took antibody 
therapy one step further by demonstrating that not only could antibodies block, but they 
could also activate as indicated by their ability to stimulate sea urchin eggs to divide. His 
data led to the early use of antibodies as stimulants of lymphocytes by the application of 
anti-lymphocyte globulin (ALG). A major step forward in the development of antibody 
technology was taken by Waksman and colleagues in the 1960s (Waksman et al 1961), 
who utilised the property of antibody binding to specific determinants on cells to block 
immune reactions in vivo and soon manufacturers were producing ALG to be used as an 
immunosuppressive reagent for organ transplantation. In terms of mechanism of action it 
was not clear at that time whether it was necessary to remove lymphocytes or merely 
suppress their action. It was difficult to prove that depletion through complement- 
mediated or Fc-mediated lysis could be separated from suppression. Riethmuller 
(Riethmuller et al 1968) clarified the issue by demonstrating that both F(ab') and F(ab')2 
fragments of antibody failed to induce immunosuppression but the requirement for lysis 
remained not proven. It was only when in vivo tests on monkeys became routine, that the 
involvement of the Fc portion in effector activation was clarified. 
1.4.2 Monoclonal antibody technology 
It was not until the novel hybridoma technology of Kohler and Milstein (Kohler and 
Milstein 1975) was established in 1975, that the large scale manufacture of antibodies for 
clinical use became possible. Up until this major leap forward in methodology the use of 
antibodies in therapy had been severely limited to treatment of patients with polyclonal 
serums raised in animals as demonstrated by the early work of von Behring and Kitasato 
(1890). By the use of hybridoma techniques, it was possible to consider the generation of 
specific monoclonal antibodies of rat, mouse and even human origin. Some of the first 
antibodies generated by the new technique were anti-lymphocytic, i. e. OKT 3, which is a 
mouse anti-human CD3 monoclonal antibody (Ortho 1985). Campath-1M (Hale et al 
1983) was another monoclonal antibody, derived from rats immunised with human T 
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cells, which was utilised for the in vitro depletion of 
lymphocytes from graft bone 
marrow. 
The mouse monoclonal OKT3 was first placed into trial and reported 
in 1985 by the 
Ortho multicentre study group (Ortho 1985) whilst Campath-1M was 
initially utilised in 
vitro and reported in 1983 (Hale et al 1983) and subsequently administered 
in vivo in 
1989 (Dyer et al 1989). Since that time however, several problems associated with the 
utilisation of animal cell derived antibodies have been encountered. 
1.4.3 The problems encountered with the use of animal cell derived antibodies 
1.4.3.1 Monoclonal isotypes 
The process of derivation of a monoclonal antibody usually involves the fusion of an 
immunised rat or mouse spleen cell with cells from a rodent B cell tumour line (Kohler 
and Milstein 1975). The resulting hybridomas are able to secrete antibody in high 
quantities and by selection in defined media, unfused tumour cells are killed and 
unconjugated spleen cells die. On dilution cloning and characterisation, antibody 
producing clones of distinct specificity can be obtained. The initial immunisation 
schedule of the animals governs the final isotype and specificity of the antibody. In the 
early stages, the majority of monoclonal clones were of the IgM isotype. This outcome 
was due to the lack of T cell recognition sites on many of the immunogens utilised i. e. 
peptides and resulted in the lack of co-operation between T and B cells when 
immunisation occurred. Unfortunately, only the mouse IgG2a and the rat IgG2b isotypes 
(Hale et al 1985) are able to engage human effector cell mechanisms, whilst both IgM 
and IgGs activate complement. This problem has now been overcome by the selective 
and rational choice of immunogen. 
1.4.3.2 Human monoclonal production 
Attempts to produce human monoclonals have been fraught with difficulties. The only 
reliable source of immunised cells are those from the peripheral blood and the route of 
immunisation is generally through natural infection, cancer or autoimmunity. In vivo 
immunisation specifically for the purpose of raising monoclonals is thought of as 
unethical whilst in vitro immunisation of human cells (Borrebaeck 1989) is possible but it 
generally produces antibody of the IgM isotype which is of low affinity and diversity. To 
immortalise the immune cells, it has proved difficult to find human tumour cell lines with 
similar properties to those of the rodent lines. Alternative strategies have involved fusion 
to either mouse cell myelomas or to human/mouse heteromyelomas (Hancock et at 1988). 
Transformation of the immune cells with Epstein-Barr virus (EBV) as a means of 
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immortalisation has also been attempted (Thompson et al 1986, Borrebaeck 1989) but the 
levels of antibody produced are low and the resulting cell lines unstable. 
1.4.3.3 Human Fc receptor polymorphisms 
In vitro and in vivo studies utilising mouse and rat derived antibodies to mediate human 
effector functions indicate that not all rodent isotypes are able to elicit identical immune 
responses (Hale et al 1987, Dyer et al 1989). This is also true for interaction of human Fc 
receptors with human antibody. The reason for the variation is IgG Fc R polymorphism. 
It is known that both human Fc Rll and Rill exhibit polymorphic forms which interact 
with human IgG in different ways. Fc Rlla is found on phagocytes such as monocytes and 
neutrophils and is the only receptor which can interact with human IgG2 raised in 
response to bacterial capsular polysaccharides and therefore influences bacterial 
susceptibility. There are two Fc Rlla alleles, R131 and H131, with the former interacting 
poorly with complexed human IgG2 whilst the latter H131 binds well (Sanders et al 
1995). These qualities are reflected in the ability of cells bearing the receptors to 
phagocytose human IgG2 opsonised bacteria. In reverse, Fc RI I a-H 131 donors poorly 
phagocytose bacteria opsonised with mouse IgGi whilst the opposite is true for the - 
R131 form. Mouse IgG2b antibody was found to interact only with Fc Rlla-H131 
(Haagen et al, 1995). There are similar polymorphisms for IgG binding found with Fc 
Rilla, -158V or F, on NK cells (Koene et al 1997) and Fc Rlllb, a GPI-anchored receptor 
also on neutrophils, with the alleles termed Fc Rlllb-NA1 and NA2 (Salmon et al 1992) 
These receptor polymorphisms all strongly influence individuals responses to bacterial 
infection as well as to immunotherapy. 
1.4.3.4 The half-life of animal derived antibodies 
Studies on the therapeutic use of antibodies derived from sources other than man have 
demonstrated that clearance rate from the circulation is faster than that of normal human 
immunoglobulin. Mouse IgG administered to humans exhibits a half-life of 7-8 days 
(Wawrzynczak et al 1992) whilst human IgG subclasses 1,2 and 4 have a half-life of 
approximately three weeks. Human IgG3 has a shorter half-life of one week as a 
consequence of its extended hinge region which leaves it prone to proteolytic 
degradation. The half-life of human IgM is also less than the majority of IgG subclasses 
because its large size limits its ability to cross out of the vascular system. Attempts to 
define the catabolic site on IgG have identified residues within the CH2-CH3 junction 
(Kim et al 1994). The carbohydrate additions on the human IgG CH2 domain protect the 
antibody from catabolism and the loss of these enhance its degradation leading to a 
reduction in half-life to 4.8 days (Wawrzynczak et al 1992). Antibodies derived from 
animals, when injected into humans, can induce immune recognition which leads to the 
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formation of antibody/antigen complexes. As stated previously, 1% of human IgG is 
directed against the Gal((xl-3)Gal linkage present in mouse derived antibodies (Galili et 
al 1988, Thall and Galili 1990, Galili 1993). If not cleared by the reticulo-endothelial 
system (RES) quickly, the complexes can become deposited on basement membranes and 
elicit inflammation via the activation of complement. 
1.4.3.5 Human anti-species response 
When monoclonal antibodies were originally considered as therapeutic agents the 
potential problems of repeated use in vivo were foreseen from experience with polyclonal 
antibodies. The first experiments documented with monoclonals such as Campath-1M 
were constrained to in vitro studies in which the antibody was utilised in conjunction with 
complement to deplete cell populations of specific antigen bearing subsets (Hale et al 
1983). A year later in 1984, Cobbold administered the monoclonal anti-mouse equivalent 
of the human Leu3/T4 marker in vivo and achieved good depletion (Cobbold et al 1984). 
However after several trial situations in which the earlier in vitro experiments were 
followed by multiple in vivo treatments, it became evident that patients developed 
immune responses to the foreign material. In clinical cases where monoclonal antibody 
was only administered once, this was not considered to be a problem. But, when the 
possibility of multiple treatments became a reality, this was a potential hazard. 
Experimentally, mice were found to respond to multiple administration of antibody by 
producing either anti-allotypic or anti-idiotypic antibodies of their own (Benjamin et al 
1986a and b, with anti-Leu3/T4 antibody) which eventually lead to inactivation of the 
administered antibody. Examples of these responses in the early Campath-1G trials were 
found in two of the twenty-nine patients (Dyer et al 1990b). Methods to overcome the 
problem were actively sought and several techniques evolved (Mountain and Adair 
1992). Probably the most significant solution arose from the studies of Winter (1989) 
who devised the strategy of `Humanisation. ' 
1.4.3.6 Bio-availability of target 
When investigating the utilisation of antibody immunotherapy several factors should be 
considered prior to treatment (Chester and Hawkins 1995). For the majority of cases, it is 
essential that the antibody to be utilised must demonstrate non-cross reactivity with 
normal tissue, whilst the antigen or epitope to which it is raised must be expressed to a 
sufficiently high level on the abnormal cell to provide a good target. The choice of 
antibody isotype must also reflect the ultimate use of the reagent, in that if activation of 
effector cells is required the IgGI or IgG3 isotypes are more suitable than IgG4 which 
does not bind Fc receptors. However, if the therapy involves the blocking of antigens or 
capture of cytokines, Fab fragments, IgG4 (Hutchins et al 1995) or Fc-mutated antibodies 
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would be more advantageous. When treating solid tumours, rather than blood borne 
disease, penetration of the tissue must be optimised and is best achieved by the use of 
small fragments of antibody. These, in addition, can be coupled to toxic (Mansfield et al 
1997a and b) or radioactive compounds to ensure maximum by-stander killing. 
1.5 Mechanisms utilised to alleviate responses to animal derived antibody products. 
1.5.1 Chimeric antibodies 
Using molecular biological techniques, the rodent antibody variable heavy and light chain 
domains are isolated and recloned into vectors containing the coding sequences for the 
constant domains of the human Ig of the isotype required. This process retains the antigen 
specificity characteristics of the mouse antibody whilst incorporating the human effector 
functions. Horwitz and colleagues (1988) utilised yeast cells to express products of this 
type and were able to demonstrate target cancer cell binding and ADCC activity. 
Sometimes however, the human Fc sequences can decrease the affinity of the Fab region 
for the antigen, because of structural restraints. If non-human primate antibodies are 
chimerised in this manner the term used to describe the product is primatised (Newman et 
al 1992). For both techniques, the foreign amino acid sequences can still give rise to both 
anti-idiotypic and anti-allotypic responses as they constitute about 30% of the total Ig 
structure. 
1.5.2 Humanised antibodies 
The CDR regions of the rodent antibody variable domains are rescued by polymerase 
chain reaction (PCR) and replaced into the nearest match of human framework possible 
(Winter and Milstein 1991, Winter and Harris 1993). Extensive remodelling of the 
variable regions may be required, to ensure the correct conformation of the CDR, as the 
removal of mouse framework sequences can alter antigen binding properties. The 
substitution of framework sequences with mouse sequence to reshape the Fab region may 
be required to retain or improve the original binding pattern. If human sequences are 
utilised to reshape the structure it is called resurfacing (Roguska et al 1994). 
Concurrently, the constant domains of the rodent antibody are also replaced with those of 
a desired human isotype and subclass to ensure correct effector functions. The technique 
of humanising antibodies was originally established as a means of bypassing the patient 
anti-species reaction but anti-idiotypic reactions can still occur as the foreign sequence 
still constitutes 3% of the Ig structure. 
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1.5.3 Recombinant antibody fragments 
Two of the many problems associated with the engineering of whole rodent antibodies is 
the limitation imposed by the need to utilise existing antibodies as template and the 
inability of prokaryotic expression systems to process the antibodies correctly in terms of 
glycosylation. For antibody fragments composed of Fab or F(ab') components only, the 
expression host is not so important because generally these regions are not glycosylated. 
1.5.3.1 Fab and F(ab') fragments 
The expression of the light chain in combination with the VH and CH1 domains is 
achieved by cloning the rodent antibody sequences into vectors containing either 
bacterial sequences which target the product to the periplasm of the host Escherichia coli 
or yeast sequences which allow secretion (Horwitz et al 1988). The signal sequences are 
cleaved naturally and the two chains associate and form both inter- and intra- di-sulphide 
bonds in the periplasm. F(ab')2 fragments can also be generated in this way if the cloned 
VH and CH1 region include extra COON-terminal sequences corresponding to either the 
hinge region or a sequence which includes one or more cysteine residues. When 
expressed, the two chains re-associate to form the F(ab')2 structure. 
1.5.3.2 Fv fragments 
Fragments of antibody smaller than the Fab and Fab' portions still retain antigen 
specificity and the isolated VH and VL domains can be cloned into bacterial vectors for 
expression (Glockschuber et al 1990b). It is usual to link the two in some way because 
they lack the natural sites for di-sulphide bridging and therefore form only weak non- 
covalent bonds between themselves. The type of links formed can be simple amino acid 
changes within the actual fragments to create di-sulphide bond sites, or involve the 
introduction of spacers between the heavy and light chain sequences which allow the two 
fragments to fold back onto themselves once expressed. The latter results in a structure 
referred to as a single-chain Fv or scFv (Rumbley et al 1993). The scFv fragments have 
been demonstrated to be at least ten times more stable than the isolated domains 
(Glockschuber et al 1990a and 1992). 
1.5.3.3 Single domain antibodies 
Individual domains of the heavy and light chains can recognise and bind antigen (Davies 
and Reichmann 1995). It is possible to express either VH or VL domains in bacteria 
although VH tend to demonstrate higher diversity due to earlier recombination events. As 
the domains are not protected by the interaction with the corresponding partner . 
domain 
they demonstrate greater susceptibility to degradation but camelization can improve the 
stability (Davies and Reichmann 1996). 
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1.5.3.4 Multiple specificity antibodies 
Antigen specificity of an antibody can be diversified by the artificial linking of two or 
more F(ab') fragments from different antibodies (Holliger et al 1993 and 1996, Malygin 
et al 1994, van de Winkel et al 1997). The isolated F(ab') fragments are treated 
chemically in such a way as to form either di-sulphide or thio-ester bonds which link 
them together. More complex interactions involving more than two fragments are 
possible but require the use of polyfunctional crosslinkers to allow conjugation. The 
therapeutic use of these complexes can be extended by the addition of one or more 
human Fc regions to stimulate effector functions in vivo (Ellis et al 1995) or by genetic 
modification of Fc terminal structures to enable multiple-domain antibodies to be 
constructed (Greenwood et al 1994). 
By the utilisation of bacterial expression systems it is possible to create recombinant bi- 
specific Fab fragments. As for the single Fab, the VH and VL and CHI sequences are 
cloned but at the COOH-terminus the sequence for one half of a leucine zipper, such as 
fos or jun, is added (Roitt 1991). When two Fab regions are co-expressed in bacteria the 
two halves of the leucine zipper associate and create the Fab dimer. Similar methodology 
which introduces inherent links between two different scFv allows dimeric scFv to be 
formed on co-expression in the host. The leucine zipper technique can be applied to scFV 
but the most common forms of linkage are of the physical type in which long polypeptide 
linkers join the COOH-terminal of one scFv construct with the NH2-terminal of the 
second. An alternative approach is to express all four regions together with peptide links 
between the VH of one antibody with the VL of the other. When produced, the VH and 
VL of the authentic scFV re-associate but as a dimer in conjunction with the second scFv. 
The latter are termed diabodies (Holliger et al 1993 and 1996). 
1.5.3.5 Phage display libraries 
Experimentation in the 1990s (Hoogenboom et al 1991, Clackson et al 1991, Williams et 
al 1993, Winter and Winter 1994, Kettleborough et al 1994, Nissim et al 1994) explored 
the possibility of expressing various antibody domains in bacterial filamentous phage 
whose products were not only formed but displayed on the phage surface. The technique 
has the advantage that it anchors the antibody fragments for further screening and 
amplification procedures. The technique requires the antibody fragments to be cloned as 
fusions to a phage coat protein, either pVIII or pIII. The former protein is present in the 
phage in 2000-3000 copies and constitutes the majority of the phage coat, whereas pill is 
only present in 3-5 copies and is expressed only on the tip of the phage particles. The 
process of joining the antibody fragment to the carboxy-terminus of either pVIII or pill 
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ablates their infectivity, but this can be overcome by utilising a phagemid partner, which 
expresses wild type pVIII or pIII, to infect bacteria. The diversity of natural V domains 
for possible use in this system can be enhanced artificially by the use of not only domains 
from immunised donors but also those from naive individuals or even synthetic 
randomised gene sequences (Davies and Reichmann 1995 and 1996). 
1.5.3.6 Intracellular antibodies 
The recent application of expressing antibody within transfected cells has opened the 
possibility of direct treatment of patients without incurring the injection of antibody 
(Richardson and Marasco 1995, Biocca and Cattaneo 1995). The natural NH2-terminal 
signal sequence of an antibody directs its transport to the plasma membrane. If this is 
removed or replaced with a hydrophilic signal sequence, the resulting antibody can be re- 
directed to the cell cytosol. The addition of alternative signal sequences can further re- 
direct the antibody to the nucleus or other cellular organelles. The technique at present 
has only been utilised to express antibody or fragments of antibody within laboratory 
transfected cells and so the problem of targeting in patients has not been fully explored. 
1.6 Derivation of the Campath series of antibodies 
1.6.1 The monoclonal antibodies 
Campath is the trade name of the Glaxo-Wellcome monoclonal antibody product which 
recognises the antigen CDw52. When first isolated as monoclonal hydridoma fusions in 
the early 1980s, the antibodies produced were of either IgM (Campath-1), IgG2a 
(YTH34.5) or IgG2c (YTH86.1) isotype. As therapeutic agents they were useful in vitro 
but of limited potential for in vivo utilisation because of their isotypes (Hale et al 1985). 
The IgM antibody was utilised in several trials in which human bone marrow was 
depleted of lymphocytes prior to transplantation into immunosuppressed patients (Hale et 
al 1983, Morgan et al 1986). However, in the former trial the depletion was only transient 
and some of the patients developed graft versus host disease (GVHD). 
1.6.2 The class switch of IgG2a to IgG2b 
To develop a rat antibody of different isotype which could be utilised in vivo i. e. IgG2b, 
the IgG2a producing hydridoma line YTH34.5HL-G2a was subjected to long-term 
culture which favoured class switching (Hale et al 1987). The resultant hydridoma lines 
raised from the process produced either IgGI (YTH34.5HL-G1) or IgG2b (YTH34.5HL- 
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2b) antibody after 8-9 months in culture, but at a very low frequency of 0.8-0.9x10 
8/cell/generation. When the resulting antibodies were compared in biological assays, both 
IgG2a and IgG2b as well as IgGI were able to lyse radiolabelled human mononuclear 
cells in the presence of complement (Hale et al 1987). However IgG2a and 2b were of 
equivalent activity whilst IgGI was less efficient. Assays demonstrating the binding of 
Clq by the antibodies indicated that IgG2b was three times more efficient than IgG2a 
whilst in ADCC assays, IgG2b was the most active. Consequently the IgG2b isotype was 
selected for continued development as a therapeutic reagent and in an exploratory trial 
IgM (Campath-1), IgG2a (YTH34.5) and the IgG2b antibody referred to as Campath-1G, 
was administered therapeutically in vivo (Dyer et al 1989). 
1.6.3 Humanisation strategy for Campath-1G 
The use of Campath-1G in vivo raised the possibility of anti-rodent responses occurring 
in patients during repeated infusions of rodent monoclonal antibodies. To avoid these 
consequences, a strategy of molecular alterations was devised and performed for the rat 
antibody in three -stages (Reichmann et al 1988). The monoclonal hydridoma expressing 
Campath IgG2a, or YTH 34.5, was utilised as the donor of the variable region CDRs for 
restructuring of the antibody. The heavy chain CDRs were isolated and placed, as stage 
one, into the NEW human heavy chain framework after noting the alteration of residues 
41 and 45. In most heavy chains these are represented by proline and leucine 
respectively, but YTH 34.5 contained alanine and proline. On checking the antigen 
binding of an intermediate form of the antibody it was found that binding was poor in 
comparison to the original monoclonal. By introducing mutations into two residues 
within the NEW first hypervariable loop, binding was restored. The second stage of 
humanisation involved attachment of the rat heavy chain variable domain from step one 
onto each of the constant domains of human IgG subclasses 1,2,3 and 4. Subsequent 
comparison of the different subclasses in complement lysis and ADCC assays indicated 
that the IgGI form was the most effective at lysing target cells. The final stage was that 
of reassembling the IgGi plasmid with the rat light chain CDRs cloned into the REI 
human light chain framework. For antibody expression in rat YO myeloma cells the 
engineered antibody chains were placed, in genomic context, under control of the 
immunoglobulin promotor/enhancer. The resulting antibody is known as Campath-1H 
and two patients with non-Hodgkins lymphoma (Hale et al 1988, YO source). and eight 
with RA (Isaacs et al 1992, CHO source) were treated in vivo. The flow diagram overleaf 
(Fig. 1.2) represents the development strategy of the antibody from monoclonal to 
humanised recombinant antibody. 
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Figure 1.2 Development of Campath from Campath-IM monoclonal to humanised 
Campath-1H antibody. 
Campath-1(IgM) Campath IgG2a and IgG2c 
(YTH34.5HL-G2a) (YTH86.1) 
ZN 
class switched humanised 
IgG 1 and IgG2b Campath-1 H 
(YTH34.5HL-G1) (YTH34.5HL-2b) 
Campath-1 G 
1.6.4 YO Campath 1H expression system 
Campath-1H expressed from YO cells was found to be of low yield (10-20 gg/ml). This 
was unexpected as both lymphocytes and hybridoma cells are capable of producing 200 
pg/ml antibody using the immunoglobulin promotor/enhancer system (Cleveland et at 
1983). The integration of DNA into the cellular genome of cells is a random event 
therefore, the low expression might have been a consequence of integration at a sub- 
optimal location. The re-cloning of the antibody genes into expression vectors bearing 
selectable drug resistance genes and the screening of large numbers of YO transfectants 
for those with high antibody expression was undertaken (Crowe et at 1992). The heavy 
and light chain variable regions were isolated from YO cells and placed, in genomic 
context with their immunoglobulin promotors, into pSV2gpt or pSV2neo plasmids, 
respectively. Both the immunoglobulin intron/enhancer and the human IgGI heavy chain 
or kappa light chain constant domains were introduced into those plasmids as Bam HI 
DNA fragments. The resulting plasmids were designated pSVgptHuVHCAMP-HuIgGl 
(heavy chain) and pSVneoHuVLCAMP-HuIgK (light chain). Electroporation of the 
linearised plasmids, as co-transfections, into YO myeloma cells, followed by culture in 
medium containing xanthine, hypoxanthine and mycophenolic acid led to the 
development of colonies after ten days. Selection of transfectants was performed utilising 
medium containing either mycophenolic acid in combination with both xanthine and 
hypoxanthine or, aminopterin in the presence of hypoxanthine and thymidine. Two 
colonies, out of 700 screened, were found to produce 40 µg/ml antibody over a 10 day 
period. However this was of insufficient amount to permit the treatment of large numbers 
of patients in clinical trials. 
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1.6.5 CHO Campath-1H expression system 
The Campath-1H antibody used in current clinical trials is expressed in the CHO cell 
system using heterologous control sequences (Page and Sydenham 1991). Due to limited 
levels of expression in YO rat cells, the cDNA of the antibody heavy and light chains 
were reisolated from the YO myeloma cells and cloned into separate mammalian 
expression vectors under ß-actin promoter/polyadenylation signals with either Simian 
virus (SV)-40 or metallothionein control elements directing the expression of the relevant 
drug selection. For the light chain cDNA the drug selection was designed around the 
amplifiable dihydrofolate reductase system (Simonsen and Levinson 1983) whilst the 
heavy chain cDNA was placed under neomycin selection (Southern and Berg 1982). Both 
plasmids were co-transfected into CHO cells for expression of the antibody. The resulting 
transfected cells were cultured in selection medium and subsequently exposed, initially to 
Geneticin G418 at 500 gg/ml to stabilise expression and later to varying concentrations 
of methotrexate (MX), an inhibitor of dihydrofolate reductase, to select for amplification 
of the exogenous gene copy number. When the transfectant expression levels stabilised, 
the cells were cloned and individual clones were found to be able to produce antibody 
with concentrations in the range of 200 jg/ml, a great improvement on the YO level. 
Initially eight patients with RA were treated with CHO Campath-1H (Isaacs et at 1992). 
Throughout the lifespan of each batch of antibody producing cells, the cellular DNA is 
monitored for Campath-IH heavy and light chain gene copy number and the DNA 
cleaved with restriction enzymes to detect cellular re-arrangements. Yields are assayed 
from each production batch and specific activity levels are assessed in standardised 
ADCC assays so as to be able to correct the activity of each batch for use in clinical 
trials. It was noted (Michelle Scott, personal communication) that yields tend to fall with 
continued culture and that heavy and light chain copy number fluctuated slightly. When 
yields become too low a fresh batch of cells are initiated. 
Despite high levels of expression, CHO cells are not ideal for large scale fermentor 
culture. The parental cell line is an adherent cell line, whereas fermentor culture is suited 
to suspension cell lines. This leads to problems of clumping and settling of the cells 
whilst high stirring speeds in the fermentors leads to shearing of the cells. The parental 
CHO cells are also routinely cultured, for small scale use, in medium containing 10% 
(v/v) FCS. This makes the isolation of antibody expressed from large scale culture 
potentially difficult. The latter problem has been overcome by the development of a 
custom made serum-free medium (Keen 1995a), which is now used routinely for CHO 
clinical trial antibody production. The lack of suitable suspension host cell line has also 
been addressed by the use of NSO cells transfected with expression vectors bearing the 
Glutamine Synthetase genes (Bebbington et al 1992). 
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1.6.6 Recent clinical trials utilising Campath antibody 
Published data recording the results from recent in vivo Campath-111, -1G and -IM trials 
has been encouraging. Other than the initial affects of administration such as 
fevers, 
nausea, headaches, flu-like symptoms and rashes, the antibody has 
been tolerated well by 
the majority of patients. Trials are under way in the Royal Marsden NHS 
Trust in London 
for chronic lymphocytic and B-prolymphocytic leukaemia (Bowen et al 1997, Dyer et al 
1997, Ginaldi et al 1998) plus T-cell prolymphocytic leukaemia (Pawson et al 1997); at 
Addenbrookes Hospital in Cambridge for multiple sclerosis (Moreau et al 1996), RA 
(Isaacs et al 1996a) and diffuse cutaneous scleroderma (Isaacs et al 1996b); at the 
Hadassah University Hospital in Jerusalem for hepatitis-associated severe aplastic 
anaemia (Nagler et al 1996) and for pre-transplant immunosuppression, although possible 
side-effects of severe migratory polyarthritis have been noted (Varadi et al 1995); at 
Brigham Women's Hospital in the USA for refractory RA (Weinblatt et al 1995); at the 
Karolinska Hospital in Stockholm for chronic lymphocytic leukaemia (Osterborg et al 
1996 and 1997) and B cell lymphoma (Osterborg et al 1997). In vitro usage (Heit et al 
1986, Hale and Waldmann 1994, Naparstek et al 1995) is also continuing for the T cell 
depletion of bone marrow samples prior to transplantation and in vivo for suppression of 
GVHD (Hale and Waldmann 1994). 
1.7 Modifications applied to antibodies for cancer therapy 
1.7.1 Radiolabelling 
When utilising antibody therapy for the treatment of solid tumours, the problem of 
antibody penetration must be addressed. Large fragments of antibody are the least able to 
enter solid tissue even if the majority of the tumour has been removed by surgery. 
Conversely, smaller fragments, which are able to penetrate, do not initiate cytolytic 
effector mechanisms. Conventional radio-therapy involves either localised irradiation or 
whole body irradiation of the patient. The former technique may not effect outlying 
tumours whilst the second does not distinguish normal from diseased tissue. To enhance 
the action of antibody on the inner regions of tumours, anti-tumour antibodies have been 
coupled to radionuclides such as the ß-emitter 
90Yttrium (90Y) or they-emitters 125Iodine 
(1251) and13'Iodine (131I)(Steplewski 1993). The method of coupling is critical in that the 
antibody should not be inactivated by the process (Awwad et al 1994). The coupling 
procedure may also alter the physical parameters of the antibody such as rates of decay 
and clearance as well as metabolism in vivo. Radiolabelled antibodies act as targeting 
agents which transport radionuclides specifically to the tumour site (Grossbard and 
Nadler 1993). The radiation emitted is of restricted pathlength and consequently limited 
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to localised action but, can prove toxic over several cell depths distant from the original 
antibody/antigen binding site. Attempts to reduce the damage caused by circulating 
conjugate has involved the utilisation of two step procedures in which an antibody-biotin 
or -streptavidin combination is given and allowed to localise to the tumour. This 
is 
followed by the administration of a radionuclide-avidin or -biotin conjugate which is 
captured at the site. The small size and thus better tumour penetration of biotin makes it a 
more suitable partner for the localisation of radionuclide to the bound antibody conjugate. 
1.7.2 Linkage to chemicals 
As with radiation therapy, the use of un-conjugated chemicals to treat tumours is not 
specific. Current chemotherapy involves the systemic application of toxic compounds 
which affect both normal and diseased tissue throughout the patients body. The drug is 
selected to be toxic only when internalised into cells. The conjugation of toxic 
compounds to antibody molecules, allows the directed targeting of the drug to sites of 
specific tumour antigen expression for internalisation of the conjugate into only tumour 
cells. When inside the cells, the drug is released from the antibody by proteolytic 
cleavage. Therefore, the choice of coupling linkage is again important (Awwad et al 
1994). There must be the maximum concentration of drug molecule bound to the 
antibody without affecting the physical properties and yet the linkage should be readily 
cleaved only when inside the cell. The utilisation of naturally occurring bacterial and 
plant toxins, such as ricin, for this mode of therapy has also proved very efficient 
(Colnaghi et al 1993, Grossbard and Nadler 1993, Wallace 1994). To overcome the 
inherent cell binding properties of the complete toxin, the active A chain has been 
separated from the cell binding B chain. Subsequent conjugation of the A chain to 
antibody results in a very potent toxin whose action is specific on the target cell 
(Mansfield et al 1997a and b). 
1.7.3 Pro-drug usage 
The efficacy of antibody-chemical conjugates can be enhanced by the use of inert pro- 
drug chemical compounds. Enzyme-antibody conjugates which can activate the drug are 
initially targeted to the tumour by the antibody. Subsequent administration of the pro- 
drug leads to activation in situ and results in the localised release of comparatively large 
amounts of the toxic compound. This antibody-directed enzyme pro-drug therapy or 
ADEPT approach (Chester and Hawkins 1995) has been applied to the use of pro-drugs 
such as 5-fluorocytosine which is converted to the active compound 5-fluorocil by the 
enzyme cytosine deaminase. The major problem associated with ADEPT is that enzymes 
specific for the cleavage of the pro-drugs are usually not human and therefore 
49 
immunogenic (Wentworth et al 1996). To overcome this, human enzymes have been 
modified to be specific for the substrate (Smith et al 1997) or the antibody utilised can be 
generated against transition-state analogues so as to act directly on the prodrug as an 
abzyme and therefore replace the enzyme (Wentworth et al 1996). The latter mechanism 
is referred to as antibody-directed abzyme prodrug therapy or ADAPT. 
1.8 Possible mechanisms of action of antibody both in vitro and in vivo 
1.8.1 Antibody-dependent cellular cytotoxicity (ADCC) 
ADCC is the mechanism whereby effector cells are directed to antigen expressing target 
cells by antigen specific IgG antibody (Fanger et at 1989). Effector cells, of both 
phagocytic and non-phagocytic myeloid origin as well as large granular lymphocytes 
(Ortaldo et at 1987), which bear FcR utilise this mechanism to bind to the complexed 
antibody via Fc CH2 and CH3 domains. A requirement of the mechanism is that close 
contact between the target and effector cells is achieved, the involvement of adhesion 
molecules ensures this (Robertson et at 1990, Werfel et at 1991, Jonjic et at 1992, 
Kushner and Cheung 1992, Voltarelli et at 1993, Majima et al 1993) and in in vitro 
assays there is a requirement for divalent cations (Graziano et at 1989). The process of 
binding activates the effector cell to release granules of perforin (Lu et at 1992, Doherty 
1993, Salcedo et at 1993), granzymes (Talento et at 1992), cytotoxins and proteases 
(Sayers et at 1992, Doherty 1993) which puncture the cell wall and influence DNA 
degradation of the target cell. The receptor which is the key mediator of this event on 
CD56 positive NK cells is Fc RIII or CD 16 (Ritz et at 1988, Fanger et at 1989). 
Monocytes or CD14 positive cells, are also able to mediate ADCC activity but utilise Fe 
RI and Fc RII or CD 64 and CD32 respectively (Fanger et at 1989). The effector cells are 
defined as non-specific in that they do not rely on MHC recognition events, however for 
NK cells, a theory of 'missing self has been proposed as a method of identification of the 
target cell (Raulet 1992). In general terms, a lack of or masked or aberrant MHC class 1 
expression, is sufficient to label a cell as not-self and therefore undesirable. Cells with 
defects in MHC class 1 antigen processing can have sensitivity to NK lysis reversed by 
the transfection of TAP 1/2 genes (Salcedo et at 1994). Not all MHC class 1 molecules 
can confer protection against NK-mediated lysis (Christiansen et at 1993, Kaufman et at 
1993, Lin et at 1993, Correa et at 1994, Ciccone et at 1994). The receptor for the MHC 
HLA-C molecules on the NK cells has been postulated to be p58 (Moretta et at 1993). 
The induction of ADCC is dependent on the type and state of activity of the effector cell 
(Cifone et at 1993), the density of the antigen on the target and the isotype of the 
targeting antibody (Hale et at 1985, Ortaldo et at 1987, Miklos et at 1992, Michaelsen et 
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at 1993). Activity of the effector cells can be modulated by chemical mediators such as 7- 
interferon (IFN) (van Schie et at 1992, Martin and Edwards 1994)), a-IFN (Vuist et at 
1993), granulocyte and macrophage colony stimulating factor (GM-CSF) (Bianchi et at 
1989) and cytokines including interleukin (IL) 2 (Bianchi et at 1989, Naume and Espevik 
1991, Chan et at 1992), IL 4 (Ting and Hargrove 1992b, Snoeck et at 1993), IL 10 (te 
Velde et at 1992, Gazzinelli et at 1992, D'Andrea et at 1993), natural killer cell 
stimulatory factor (NKSF) or IL 12 (Chehimi et at 1992, Robertson et at 1992). Inhibitors 
of protein synthesis have been demonstrated to augment activity (Tripathi et at 1991) as 
do inhibitors of protein tyrosine kinase signalling (Ting et at 1992a, O'Shea et at 1992, 
Borrego et at 1993, Whalen et at 1993) but not inhibitors of G binding proteins (Whalen 
et at 1992). 
1.8.2 Complement lysis 
Irrespective of effector cell activation, antibody complexed with antigen can lead to the 
deposition of complement component Clq on antigen bearing target cell or organism. 
The site for Cl q binding is in the antibody CH2 domain close to residues glutamine 318, 
lysine 320 and lysine 322 (Duncan and Winter 1988). The levels of binding can however, 
be influenced by the presence or absence of the CH1 domain (Mizutani et al 1993). 
Antigen density is an important feature in the initiation of this mechanism as several C1q 
sites need to be engaged for the process to occur. Once Cl q is bound, C3 convertase 
promotes the complement cascade by the conversion of C3 to components C3b and C3a 
leading ultimately to the formation of the membrane attack complex (MAC). Studies by 
Anton and his colleagues (Anton et al 1994) demonstrated that C3b binds directly to 
IgGI at several sites in both the Fab (40% of the total) and Fc (30% of the total) regions. 
He suggests that this process, by the generation of conformational changes in the 
antibody, is one that aids the solubilisation of complexes and inhibits their precipitation. 
In support of these findings, antibodies engineered to reduce their Fab flexibility (Shopes 
1993), continued to induce the lysis of antibody coated targets. However and in contrast, 
antibody isotypes which have a short or non-existent hinge region and are thus less 
flexible i. e. human IgG4 or mouse IgGI were shown by Ole Brekke to be unable to fix 
complement (Brekke et al 1995). 
1.8.3 Target cell cytostasis 
Monocytes which have been activated by mechanisms such as the detection of non-self 
components on cells (antibody-independent) or Fc R mediated interactions with antibody 
complexed with antigen on cells (antibody-dependent), have the ability to influence the 
growth kinetics of those cells (Kobayashi et at 1992). The mediators of the cytostasis are 
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postulated to be soluble factors which include tumour necrosis factor (TNF)-a, 
transforming growth factor (TGF)-ß, IL 1, oxygen radicals and nitric oxide in addition to 
arginine metabolism via the enzymes arginase to ornithine/urea (Mills et al 1992) or 
nitric oxide synthase to citrulline/NO. It was demonstrated that contact was not required 
for cytostasis to occur (Kobayashi et al 1992). When considering antibody mediated 
cytostasis, the IgG Fc RI, RII and RIII receptors are all thought to be involved. 
Experimentally, Levy Polat, demonstrated that by crosslinking the IgG Fc receptors on 
cells with goat anti-Ig F(ab')2 fragments, increased TNF production was induced (Levy 
Polat et al 1993). Activation of monocytes can be modulated by y-IFN (Martin et al 1994) 
and lipopolysaccharide (LPS)(Kobayashi et al 1992). 
1.8.4 Apoptosis 
Apoptosis or programmed cell death occurs as a terminal cellular response to events such 
as those involved with T cell clonal selection during thymic development. The 
mechanism is characterised by membrane blebbing of target cells, condensation of the 
cytoplasm of those cells, fragmentation of the cellular DNA and is very different from the 
appearance of necrosis. Ligands and genes, such as Fas (previously known as APO-1, 
Dhein et al 1992, Schulze-Osthoff et al 1994) and Bc1 respectively, regulate the incidence 
of apoptosis and, as such, have become indicators of the mechanism. Recent evidence 
from Knight (Knight et al 1996) and Eischen (Eischen et al 1996) suggests that activated 
NK cells not only kill targets via the release of pore-forming granules but also by 
granule-independent mechanisms. According to Eischen's data, FcR crosslinked 
stimulation of NK cells induces the transcriptional up-regulation of the Fas ligand on the 
surface and they then interact with targets bearing Fas receptor. Antibodies which 
crosslink Fas (Dhein et al 1992) can induce cells to undergo apoptotic death, whilst 
antibodies which block the receptor inhibit the response. It has also been suggested that 
some anti-CD4 antibodies (Choy et al 1993) mediate monocyte induced apoptosis of CD4 
cells rather than deplete by direct lysis. 
1.8.5 Blockade of receptor/ligand interaction 
Not all antibodies utilised for in vivo therapy are required to initiate the depletion of 
specific populations of cells. Prior to therapy, clinicians must define their specific 
antigenic target and design suitable antibody-based treatment (Chester and Hawkins 
1995). For therapy with antibodies such as anti-CD4 or anti-TCR, the desired outcome 
might be to induce target blockade in such a way that the T cell survives but is restricted 
in its action and a state of anergy is induced (Steinman 1990, Kupiec-Weglinski et al 
1993, Eto et al 1994, Isaacs and Waldmann 1994). This approach would be required for 
diseases thought to be autoimmune-related such as multiple sclerosis (Ebers 1994, 
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ffrench-Constant 1994, Moreau et al 1996). To achieve this action the choice of antibody 
isotype is critical. Antibodies which activate ADCC mechanisms via Fc R are not 
suitable, whereas isotypes such as IgG4 or Fc-mutated IgGI can be utilised. Intact IgGI 
antibodies can be candidates if Fab or F(ab')2 fragments are constructed or as in the case 
of the mouse IgG2a anti-colon tumour antibody, 17-1A (Khazaeli et al 1988, Riethmuller 
et al 1993 and 1994), low affinity antibodies (10_7 ) are selected. Anti-cytokine/cytokine 
receptor antibodies i. e. anti-TNF, anti-IL 2R (Tanaka et al 1993) and anti-IFN are 
administered with the objective of either engaging soluble cytokine or blocking the 
receptor in the body and thus reduce their ability to activate cells. Anti-adhesion molecule 
(ICAM-1 and LFA-1) antibodies are surmised to work by interfering with cellular 
interactions (Metcalfe et al 1993). 
1.8.6 Opsonisation and phagocytosis 
Macrophages and neutrophils are known to express complement receptors which bind to 
complement components deposited on target cells. Activation of the effector cells by the 
presence of complement induces the opsonisation and frequently phagocytosis of the 
target cells and their eventual destruction. Phagocytosis can be either opsonin- 
independent or opsonin-dependent (Krauss et al 1994) and the latter mechanism was 
demonstrated when both complement receptor (CR) 3 and Fc-y RIIIB were co-expressed 
in usually non-phagocytic fibroblasts. The presence of both adenosine Al (Salmon et al 
1993) and histidine-rich glycoprotein in plasma (Chang et al 1992 and 1994) has been 
shown to enhance Fc R expression and Ig-mediated phagocytosis. 
1.9 IgG Fc receptors, distribution, structure and recognition sequence 
Circulatory antibodies, such as IgGI, are recognised via cell surface expressed receptors 
on effector cells. The receptors become activated through the action of binding antibody 
which initiates signalling cascades (Liebson et al 1990, Azzoni et al 1992, Wirthmueller 
et al 1992, Greenberg et at 1993, Agarwal et al 1993, Cone et al 1993, Stahls et at 1994) 
within the cell and induce typical effector cell properties. If the antibodies are themselves 
linked, through their Fab regions, to cell surface expressed antigen, those antigen bearing 
cells become the target for the effector cell action. For IgGI there are three distinct 
classes of receptor, Fc RI, II and III, with all displaying polymorphism in structure and 
showing diversity in cell type expression. 
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1.9.1 Fc RI (CD 64) 
This receptor is found predominantly on monocytes with lower numbers present on 
unstimulated macrophages. It is also displayed on activated neutrophils and eosinophils. 
The receptor is a member of the Ig super-family and is a 72kD glycoprotein displayed in 
four isoforms, two of which are soluble. The receptor possesses an extracellular region of 
a maximum 292 amino acids formed into two or three Ig-like domains, a 21 amino acid 
transmembrane region and when present, a 61 amino acid cytoplasmic region (van de 
Winkel and Capel 1993). It has a high affinity for monomeric IgG demonstrating a 
preference for subclasses IgGI and IgG3, whilst binding IgG4 with a ten-fold lower 
affinity. It does not bind IgG2 at all (Woof et al 1986). The receptor synthesis is 
stimulated by the presence of antibody and when the receptor on monocytes is engaged 
by antibody complexed with cell surface antigen, it can induce the cells to exhibit ADCC 
activity. There has been demonstrated a requirement for the co-expression of the TCR- 
CD3 y chain component for efficient signal transduction (Takai et al 1994). 
The recognition sequence for Fc RI binding is located in the lower hinge region of IgG 
between the di-sulphide bridge and the amino-terminus of the CH2 domain in the region 
of amino acid residues 234-239 (Lund et al 1990, Pound et al 1993b). There is an 
absolute requirement for the presence of the N-linked carbohydrate on residue 297 for Fc 
RI binding and residue glutamine 235 appears to be critical for recognition (Woof et al 
1986, Duncan et al 1988). 
1.9.2 Fc RII (CD32) 
Fc RII is displayed on subsets of lymphocytes (Hadley et al 1992, Mantzioris et al 1993), 
monocytes and macrophages, as well as cells from the polymorphonuclear lineage such 
as neutrophils, eosinophils and platelets (Slupsky et al 1992). It is further reported to be 
expressed and secreted from epidermal Langerhans cells (Astier et al 1994). The receptor 
is displayed as several isoforms, at least five membrane bound and one soluble. The 
membrane bound receptor is of 40kD and is usually composed of a 180 amino acid 
extracellular region formed of two Ig-like domains, a 27-29 amino acid transmembrane 
region and a cytoplasmic domain of variable length of between 44 and 76 amino acids 
(van de Winkel and Capel 1993). Complexed antibodies of subclasses IgG1 and IgG3 
bind to the receptor with low affinity and in the case of platelets, activation leads to the 
induction of thrombosis. IgG4 binding has not been demonstrated. The site of recognition 
of Fc RII lies within the same region for that of Fc RI and the two possibly overlap. 
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1.9.3 Fc RIII (CD16) 
Lymphocytes (Hadley et al 1992), macrophages, activated monocytes, neutrophils and 
NK cells (Ritz et al 1988) express Fc RIII with the receptor on neutrophils being linked 
to the cell surface via a glycosylphosphatidylinositol (GPI)-anchor. Due to extensive 
glycosylation the apparent molecular weight varies between 50 and 80kD. The receptor 
contains two Ig-like extracellular domains of 190 amino acids and, if present, a 
transmembrane region of 39 amino acids and a 25 amino acid cytoplasmic tail (van de 
Winkel and Capel 1993, Stahls et al 1994). There are two soluble, as well as membrane 
and GPI-anchored, isoforms. Complexes of the membrane bound receptor and a variety 
of di-sulphide linked dimeric subunits i. e. the y and ý chains of the T cell receptor (TCR)- 
CD3 complex (Anderson et al 1989, Jensen et al 1992, Romeo et al 1992, Moingeon et al 
1992, Wirthmueller et al 1992, Biassoni et al 1993, Alevy et al 1993, Takai et al 1994), 
have been demonstrated to be essential for expression of the receptor and subsequent 
signalling events. The receptor binds complexed IgG1 and IgG3 preferentially, but also 
monomeric IgG with low affinity. The interaction of this receptor on NK cells with 
antibody complexed with cell surface bound antigen is the prime mediator of ADCC 
activity. 
As with Fc RI and II, the recognition sequence for Fc RIII lies within the CH2 domain of 
the antibody. Removal of carbohydrate from the antibody leads to a subsequent loss of 
binding to the receptor on target cells and is suggested to be due to minor structural 
changes. Experiments have located the important residues close to histidine 268 (Lund et 
al 1990). 
1.10 Glycosylphosphatidylinositol-anchored molecules 
1.10.1 Types of protein anchoring 
Surface associated molecules can be attached to the cell via several mechanisms the most 
common of which is by a transmembrane region spanning the lipid bilayer. In this 
arrangement there is usually an internal cytoplasmic tail of variable length through which 
the external molecule links to the cell signalling mechanisms and this is seen in both type 
one (the NH2-terminal is extracellular) and two (the COOH-terminal is extracellular) 
proteins. Soluble proteins can be generated from transmembrane linked molecules by 
either differential splicing, early stop codons or proteolytic cleavage. Glycosyl 
phosphatidylinositol (GPI) attachment is an alternative form of anchoring seen in 
mammalian species. They were discovered in protozoan parasites in the 1980s (review 
Cross 1990), and involve the retention of the protein in the bilayer by the use of a lipid 
entity which does not span the outer cell membrane but merely sits within it. The anchor 
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has no internal cytoplasmic portion and therefore has high lateral mobility (Zhang et al 
1991) but can signal via associated molecules (Robinson 1991, Stefanova and Horejsi 
1991, Garnett et al 1993, Shenoy-Scaria et al 1993). Soluble GPI-anchored molecules can 
be released by cleavage with phophatidylinositol specific phospholipase C or PIPLC. 
1.10.2 Amino acid sequence requirements for GPI-anchoring 
Most of the evidence for consensus amino acid sequence requirements for GPI-anchors 
has come from work on either the decay accelerating factor (DAF) or CD55 which is 
associated with the prevention of damage to mammalian cells by complement (Cervoni et 
al 1993, Simpson and Holmes 1994), or from studies on the mouse surface thymocyte 
marker Thy-1 (Fasel et at 1989). DAF is a GPI-anchored molecule found on both red 
cells and nucleated cells and its mechanism of action is that of blocking the assembly of 
complement C3 convertase (Funabashi et al 1994) which eventually would lead to the 
damage of the cell membrane. Thy-1 is also a GPI-anchored molecule which is found on 
rat and mouse thymocytes and has been indicated in cell activation by crosslinking 
experiments (Robinson 1991). Data generated from studies on DAF indicates that there 
are strict amino acid sequence requirements to direct GPI-anchorage (Moran and Caras 
1991a and b, Coyne et at 1993). The first necessity is that there must be a suitable small 
acceptor amino acid at the site of anchorage. By deletion and replacement experiments 
the number of suitable amino acids has been demonstrated to be limited to six, with a 
hierarchy within these. The most preferred amino acid is serine followed by alanine, 
glycine, asparagine, aspartic acid and finally cysteine in decreasing order. The second 
requirement is the presence of two small amino acids in positions two and three 
immediately downstream of the anchorage site, possibly to limit steric hindrance. Once 
again there are preferred amino acids in these positions with these being serine, glycine, 
alanine, asparagine, aspartic acid or arginine. The next requirement is that there is a 
spacer region of between 12-20 hydrophilic amino acids between the anchorage site and 
the sequences which direct the anchoring. This final region should be a stretch of at least 
15-20 amino acids which are hydrophobic. In the case of DAF the GPI-anchorage 
information is within the last 37 COOH-residues of the coding sequence with the site of 
anchorage being serine 319 followed by glycine at residue 320. The spacer which is 
found in DAF is a 12 amino acid span rich in serine and threonines followed by a 17 
amino acid hydrophobic domain which directs the anchoring. In some cases (Coyne et at 
1993) it is possible to replace the natural signal region with a synthetic signal composed 
of three serines followed by 8-12 threonines and then 11-14 leucines and achieve GPI 
attachment to the first serine. 
56 
1.10.3 The structure of GPI-anchors 
GPI-anchors were first described in the literature by Slein and Logan 
in 1963, when a 
bacterial enzyme, phospholipase C, was shown to be able to remove alkaline phosphatase 
from the surface of mammalian cells. The results were confirmed in the 1970s when 
purified phosphatidylinositol specific phospholipase C (PIPLC) was 
demonstrated to be 
the enzyme involved in this cleavage. However, a lack of the substrate in 
large quantities 
limited the advances in studying the anchor structure. In the 1980s it was shown by 
Ferguson (Ferguson et al 1995) that the variant surface glycoprotein (VSG) of the 
protozoan parasite Trypanosoma (T) brucei was also GPI-anchored. The fact that the 
parasites could be cultured to high density led to much of the present understanding of 
the basic structure. GPI anchors are added as post translational modifications to 
transcribed and translated nascent polypeptides which have been directed to the ER by 
their 5' signal sequence. The anchors are preformed in the lumen of the ER (Cross 1990, 
Englund 1993, Yeh et al 1994). They are added to the polypeptide by an transamidation 
reaction which occurs at the same time as cleavage of the polypeptide one amino acid 
downstream of the anchor attachment site, the process having been previously directed by 
the downstream cleaved sequences (Englund 1993). All anchors are composed of a basic 
structure to which minor modifications are added. The basic GPI core is composed of a 
fatty acid tail, which is the point of attachment to the cell membrane, phosphate linked to 
an inositol ring (Cross 1990). In turn this is linked to a glucosamine ring to which are 
attached three mannose residues in series. The last mannose ring is linked via another 
phosphate linkage to an ethanolamine residue. It is the ethanolamine residue which 
becomes joined to the GPI-anchoring amino acid by the transamidation reaction. 
Variations to the general core structure mainly fall into three categories, these being extra 
palmitylation of the inositol ring (Treumann et al 1995), variable glycosylation of the 
mannose rings including the addition of extra ethanolamine residues and the remodelling 
of the fatty acid tail components (Cross 1990). 
1.10.4 The synthesis of GPI-anchors 
Evidence for the process of GPI-anchor synthesis has been collected from various 
sources. Firstly, the study of a range of murine and human T cell hybridoma mutant cell 
lines which form a series of complementation classes (Table 1.1, copied from Yeh et at 
1994). These cells have defects, in either the different steps involved in GPI synthesis 
pathways or lack glyco-transferases, which add GPI components to Thy-1 (Englund 
1993). Secondly, from patients who suffer from an acquired X-linked defect, of varying 
degrees of severity, called Paroxysmal Nocturnal Haemoglobinuria or PNH (Ueda et al 
1992, Takeda et al 1993, Schubert et al 1994, Bessler et al 1994). The defect results in the 
symptom of nocturnal lysis of red blood cells as a consequence of the reduced or absent 
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production of GPI-anchored molecules. GPI-anchored molecules such as DAF would 
normally protect the red cells from lysis (Simpson and Holmes 1994). Additionally 
information has been obtained from the long term study of the protozoan parasite T. 
brucei (Cross 1990). 
Table 1.1 GPI synthesis mutant murine T cell lines and their molecular defects. Class refers to the Thy-1 
complementation status of the cells. ETN represents ethanolamine, M mannose, G1cNAc N-acetyl 
glucosamine and PI phosphatidylinositol. 
Mutant cell line Class Molecular defect 
BW/A, TIMI/A, S49/A A Transfer of G1cNAc to PI 
PNH blood cells A Transfer of G1cNAc to PI 
Sl A/B B Addition of M3 to M2 
TIMI/C C Transfer of G1cNAc to PI 
BW/E E Synthesis of mannosylated GPIs 
EL4/F F Addition of ETN to M3 
S49/H H Transfer of GIcNAc to PI 
Ltk- H Transfer of GIcNAc to PI 
In the early 1980s T. brucei parasites were shown to use GPI-anchored molecules as a 
host survival mechanism in which homogeneous arrays of GPI-anchored molecules were 
displayed sequentially on the outer parasite coat. When a host immune response to the 
highly immunogenic GPI molecules was raised, parasites which had developed the next 
phase of GPI molecules survived. The host was left with both a redundant repertoire of 
antibodies to the first antigen and the next generation of parasites. The pathway of GPI 
manufacture was determined by incorporating radiolabelled precursors into, or 
chemically inhibiting the synthesis of, the parasite anchors (Field and Menon 1992). 
The synthesis of the GPI-anchors begins in the cytoplasmic leaflet of the ER where a 
UDP-glucosamine donor molecule donates a GlcNAc molecule to a PI-lipid acceptor 
molecule to form a GlcNAc-PI residue (Cross 1990, Englund 1993, Yeh et al 1994). 
From experiments using the Thy-1 T cell mutant hydridomas it has been shown that at 
least three enzymes are involved in this reaction and these fall into the complementation 
classes A, C and H (patients with the disease PNH also have a deficiency in the 
manufacture of GPI-anchors at this point). The complex is then de-acetylated to give 
G1cN-PI and both of these two intermediates are PIPLC sensitive (Yeh et al 1994). Fatty 
acids, usually alkylacylglycerols, are then added to the lengthening structure of GIcN-PI 
to generate G1cN-acyl PI which, due to its hydrophobic nature, now translocates to the 
luminal surface of the ER. The GPI-anchor becomes resistant to PIPLC treatment at this 
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point in its biosynthesis. Within the ER lumen there is another 
donor molecule, dolichol- 
P-mannose (Cross 1990, Englund 1993, Yeh et al 1994), which is common to this 
pathway and that of carbohydrate addition to molecules such as antibodies and 
it is by 
using this donor that the three mannose rings are sequentially added to the G1cN-acyl-PI 
structure. Cells that contain a defect at the complemention group B locus cannot add the 
third and final mannose ring and therefore have defective anchors. When all of the 
mannose rings have been assembled onto the precursor anchor, the addition of 
ethanolamine to those rings occurs (Englund 1993). Parasitic GPI-anchors, unlike 
mammalian anchors, do not have ethanolamine additions to all of the mannose rings 
(Englund 1993, Yeh et al 1994) but they do have extra glycosylation in the form of 
galactose and N-acetyl glucosamine residues. Cells with the complementation group F 
defect are deficient in the enzymes required at this step in the synthesis of GPI-anchors. 
The GPI-anchors, once synthesised to this stage, are ready to be transferred to the protein. 
This is achieved by the simultaneous transamidation of the amino group of the 
ethanolamine to form an amide bond with the activated carboxyl group of the protein 
acceptor residue (Cross 1990, Englund 1993, Yeh et al 1994). The carboxyl-terminus of 
the protein, which corresponds to the residue one amino acid downstream of the anchor 
site, is cleaved off at the same time. At some point within the manufacture process close 
to this reaction the GPI-anchors are de-acylated, transferred to the cell surface and regain 
PIPLC sensitivity. Proteins which bear an uncleaved signal remain in the ER (Moran and 
Caras 1992). A final modification that can take place after the addition of the GPI anchor 
is that the fatty acids of the anchor can be substituted for others such that, in 
trypanosomes, the main component is myristic acid (Englund 1993) whilst in the 
mammalian placental alkaline phosphatase both steric and palmitic acids are found in 
equal amounts (Cross 1990). 
1.10.5 Cellular distribution and potential signalling mechanism of GPI-anchored 
molecules 
The purification of mature GPI-anchored molecules from cell membranes in Triton x-100 
containing buffers results in the molecules partitioning into detergent insoluble fractions 
(Brown and Rose 1992, Zurzolo et al 1994, Ferguson 1994). The insolubility is seen to be 
acquired after the precursor molecules leave the endoplasmic reticulum and is thought to 
be a consequence of involvement with apical sorting mechanisms within the cell. Other 
molecules endowed with this property are cholesterols and glycosphingolipids (Lisanti et 
al 1994). Data such as this, in combination with the identification of Calveolae (Anderson 
1993a and b), has led to the belief that GPI-anchored and high glycolipid content 
molecules cluster into distinct regions of the cell membrane (Lisanti et al 1993). 
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Calveolae were first described as invaginations on epithelial and endothelial cells seen on 
transmission electron micrographs and a key component is the 22kD protein caveolin. 
Caveolae were demonstrated to be distinct from clathrin coated pits, which associate with 
the cytoplasmic surface of the plasma membrane, when the analysis of sequenced 
calveolin cDNA identified putative membrane spanning domains. The internalisation of 
GPI-anchored molecules through mechanisms separate from clathrin coated pits was also 
proved (Bamezai et at 1992, Keller et at 1992) whilst protein kinase C inhibitors have 
been demonstrated to prevent potocytosis via internalisation of calveolae (Smart et at 
1994). It has recently been proposed that GPI-anchored molecules interact with caveolin, 
on epithelial cells, for signalling purposes (Sargiacomo et at 1993). 
In support of this, data has located calcium pumps within caveolae (Fujimoto 1993), 
whilst experiments (Shenoy-Scaria et al 1993 and 1994) have further demonstrated that 
palmitylation of the amino-terminal cysteine motif of the protein tyrosine kinases p55fgr, 
p56hck, p561ck and p59lyn is critical for their partition into caveolae for subsequent 
interaction with GPI-anchored proteins. Similar interactions are found on neutrophils 
(Morgan et al 1993). The cross-linking of GPI-anchored molecules on monocytes induces 
calcium fluxes and activation of the oxidative burst (Lund-Johansen et al 1993) whilst 
GPI-anchored molecules, on T cells, are regarded as accessory molecules for activation 
(Robinson 1991, Stefanova and Horejsi 1991, Malek et al 1994, Rowan et al 1994) 
although there is no evidence for a physiological role. In the absence of the T cell 
receptor (TCR) i. e. in TCR negative cell lines, activation fails to occur, but can be 
restored on transfection of the TCR gene. The loss of GPI-anchored molecules severely 
diminishes the cells ability to be activated by either phytohaemaglutinin (PHA) or 
concanavalin (Con) A (Schubert et al 1992). 
1.1 0.6 PNH 
PNH is an acquired clonal blood disorder manifested following a mutation in the 
phosphatidylinositol glyco-transferase (PIG) A gene (Ueda et al 1992, Takeda et al 1993, 
Bessler et al 1994, Schubert et al 1994). The product of the normal gene is a transferase 
involved in the biosynthesis of GPI-anchored molecules. The mutation commonly leads 
to either a frame shift in the PIG A gene or the formation of stop codons. Both scenarios 
culminate in a partial or total loss of GPI-anchors on short-lived stem cells of 
haemopoetic lineage and rarely in long-lived lymphoid lineages. Red blood cells and 
neutrophils isolated from PNH patients can be either normal, totally or partially deficient 
in GPI-anchored molecules whilst lymphocyes are not often effected. Treatment with 
Campath antibodies in vivo has recently been observed to occasionally induce defects 
referred to as PNH-like conditions within patients suffering from B cell non-Hodgkin 
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lymphoma (Hertenstein et al 1995) or RA (Brett et al 1996a) predominantly in 
lymphocytes. Three (out of twenty five) RA patients receiving Campath-1H were noted 
to have CDw52 negative lymphocytes. Of the lymphocytes, nearly all of the CD4 and 
CD8 T cells were deficient whilst 40-80% B cells were affected. The T cell defect 
persisted for over 20 months whilst the B cells regained expression within three months 
of treatment. Unlike PNH, detailed analysis of PIG A PCR products of CDw52 negative, 
RNA from Campath-IH treated patients performed in Glaxo-Wellcome revealed that 
there was no defect in the PIG A gene (Taylor et al 1997). This would suggest that the 
defect arose by mechanisms different from those which cause PNH. Controversially, 
others (Hertenstein et al 1995) have shown deletions within the PIG-A gene. 
1.11 The Campath antigen (CDw52) 
1.11.1 Sequence data 
The Campath antigen (CDw52) is a cell surface molecule found on most mature 
lymphocytes, monocytes and sperm and is composed of a 12 amino acid mature peptide 
which is linked, via a GPI-anchor, to the outer membrane of the cell (Xia et al 1991 and 
1993b, Hale et al 1990). The antigen is one of the smallest cell surface antigens identified 
up to the present time and its function is still not known. Campath antigen is however, an 
exceedingly good lymphocyte target for both complement (Hale et al 1983, Xia et al 
1993a) and ADCC (Hale et al 1985) assays whilst Fabian (Fabian et al, 1993) 
demonstrated that whilst having little effect on neutrophils, both Campath-1M and -1G 
are also able to depress the functional activity of monocytes. The complete cDNA 
sequence of CDw52 was determined by the sequencing of a cDNA library (Xia et al 
1991) and revealed that the 61 amino acid structure is composed of a 24 amino acid 
leader sequence and a 37 amino acid region consisting of the 12 amino acid mature 
peptide sequence and a proceeding 25 amino acid region which regulates the site of GPI- 
anchorage and subsequent cleavage (Fig. 1.3). 
The mature peptide has one N-linked glycosylation site at position three and several 
potential serine/threonine 0-linked glycosylation sites, although there is no evidence for 
this type of carbohydrate being present (Xia et al 1991). The epitope for recognition, by 
the antibody Campath 1H, is documented to reside in the COOH-terminal portion of the 
antigen and has been shown to correspond to the GPI-anchor plus the last three amino 
acids (Xia et al 1993b) of the mature peptide. The majority of antigen moieties are, as a 
consequence of their GPI-anchors, sensitive to enzymatic cleavage with the enzyme 
PIPLC and this results in the release of the antigen from the cells and loss of reactivity to 
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the antibody. However, not all of the antigen is PIPLC sensitive (Treumann et al 1995) 
and this was shown to be primarily due to the presence of extra palmitic acid having been 
incorporated onto the myo-inositol ring in approximately 20% of the GPI-anchors. 
Therefore, PIPLC treatment of the cells only leads to a partial loss of antigen from the 
surface. 
Figure 1.3 The published CDw52 sequence. A figure showing the position and composition of the 5' and 3' 
PCR primers, the amino acids in bold type, the translated products in three letter code (Maniatis et al 1982) 
and the major codon numbering 
5' PCR PRIMER 
-24 
CCT ACC AAA ATG AAG CGC TTC CTC TTC CTC CTA 
MET LYS ARG PHE LEU PHE LEU LEU 
-9 
CTC ACC ATC AGC CTC CTG GTT ATG GTA CAG ATA 
LEU THR ILE SER LEU LEU MET VAL GLN ILE 
123456 
CAA ACT GGA CTC TCA GGA CAA AAC GAC ACC AGC 
GLN THR GLY LEU SER GLY GLN ASN ASP THR SER 
7 8 9 10 11 12 16 17 
CAA ACC AGC AGC CCC TCA GCA TCC AGC AAC ATA 
GLN TNR SER SER PRO SER ALA SER SER ASN ILE 
AGC GGA GGC ATT TTC CTT TTC TTC GTG GCC AAT 
SER GLY GLY ILE PHE LEU PHE PHE VAL ALA ASN 
GCA ATA ATC CAC CTC TTC TGC TTC AGT TGA GAA 
ALA ILE ILE HIS LEU PHE CYS PHE SER STOP 
TCA CTG GCC WC GGT TTA CAC GTC GTC ACT GGA 
Z7 T r'r 11r T1 
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Two sets of sequence for CDw52 were identified in the early experiments but one 
sequence was thought to have been an artefact (Xia et al 1991). The two sequences, when 
compared, differed at two amino acid positions in the region downstream from the mature 
peptide in the sequences that regulates the GPI-anchorage site. Evidence presented in this 
thesis implies that both sequences represent forms of Campath recognised by Campath- 
1H antibody. The accepted cDNA sequence for Campath antigen is outlined in figure 1.3. 
The alternative sequence, seen in both this and the original work (Hale et al 1996, Xia et 
al 1991), varies at positions 16 and 17 and results in the change of these amino acids from 
asparagine/isoleucine to serine/methionine, a change that could generate an alternative 
GPI-anchoring position. Interestingly, gene products including HE5, isolated from human 
epidiymal tissue (Kirchhoff et al 1993), have been show to possess the same eDNA 
sequence as CDw52 and thus an identical protein backbone suggesting that these gene 
products may represent allelles. Perry (et al 1992) has also documented an similar 
sequence in monkey epidiymal tissue. 
1.11.2 What is the evidence for the CDw52 antigenic epitope ? 
Experimental evidence for the Campath antigen epitope has been derived from enzymatic 
cleavage of the mature protein to remove either the N-linked sugars, the O-linked sugars 
or the GPI-anchor (Xia et al 1991). N-glycanase treatment reduced the apparent 
molecular weight from 20-28kD to approximately 6kD, whilst broad specificity proteases 
such as pronase reduced it substantially. Neither of these treatments altered antigenicity. 
Alkali treatment of the antigen resulted in loss of detection by ELISA and western blot. 
This latter evidence was postulated to indicate that O-linked sugars were potentially 
involved in reactivity and other experimenters supported this theory (Valentin et at 1992). 
The use of the enzyme PIPLC to cleave the GPI-anchor component from CDw52 positive 
cells led to a reduction but not total loss in the immunofluorescent detection of those 
cells. Later experimentation (Xia et al 1993b) demonstrated that the isolated antigen 
could be separated into two fractions differing in PIPLC sensitivity. One fraction was 
PIPLC sensitive and the other resistant. The resistant fraction was found to bear an 
additional fatty acid residue on the inositol ring of the anchor which interfered with the 
action of the enzyme. Proteolytic digestion of the antigen showed that Campath antibody 
bound to a C-terminal tripeptide plus associated GPI-anchor. This was confirmed by the 
use of both a tri- and a twelve residue peptide corresponding to the antigen. Neither 
demonstrated significant binding with Campath antibody when bound directly to ELISA 
plates nor inhibited the binding of antibody to the native antigen, similarly bound. N- 
linked sugars were shown to be associated with asparagine at position three in the native 
antigen whilst no O-linked glycosylation was demonstrated. In 1995, the definitive 
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oligosaccharide structure of CDw52s N-linked sugar and GPI-anchor was published 
(Treumann et al 1995). 
1.11.3 Distribution and biological function of CDw52 
When visualised by Campath antibodies, the antigen (CDw52) is expressed on the 
majority of lymphocytes as well as on neutrophils, macrophages and monocytes (Hale et 
al 1990, Xia et al 1991 and 1993) with a density of approximately 5x105 molecules per 
cell. Additional although refuted evidence, suggested that a similar antibody, 097, 
detects the antigen on erythrocytes (Valentin et al 1992). An identical cDNA transcript 
can be isolated from human epididymal tissue (Kirchhoff et al 1993) and a eDNA 
transcript similar to the CDw52 precursor has been isolated from monkey epididymal 
cDNA libraries (Perry et al 1992) and is demonstrated to share 85% homology with it. 
The potential role of CDw52 is unknown but, from its GPI-anchor, it appears similar to 
other GPI-anchored molecules belonging to the complement regulatory membrane 
protein family. This family includes membrane cofactor protein (MCP) or CD46, decay- 
accelerating factor (DAF) or CD55 and membrane attack complex inhibitory factor 
(MACIF) or CD59 and these are all GPI-anchored. These proteins are found on 
erythrocytes, sperm and in epididymal fluid (Simpson and Holmes 1994) and if lost from 
cells, as in acquired disease states such as PNH, an increased incidence of cell lysis is 
seen (Takeda et al 1993, Ueda et al 1992). Results presented in this thesis, in which mice 
intra-dermally inoculated with cells transfected with CDw52 cDNA expression plasmids 
developed tumours, whilst untransfected cells did not (Hale et al 1996), provides 
evidence that those CDw52 expressing cells may have been protected from 
immunological intervention in some way. 
Campath antigen has been demonstrated to be an exceptionally good target for 
complement-mediated lysis (Hale et al 1983, Xia et al 1993a, Gilleece and Dexter 1993) 
and ADCC (Hale et al 1985), as well as a co-stimulatory molecule on lymphocytes 
(Rowan et al 1994). Perhaps it becomes a good target because the inactivation of the 
antigen by crosslinking enables lytic events to occur. 
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 CELLS AND MEDIUM 
2.1.1 Wien 133 cells 
Wien 133 cells (Nacheva et al 1987, Dyer et al 1990a), were cultured in filter sterilised 
Iscoves modified Dulbeccos medium (IMDM) supplemented with 10% (v/v) heat- 
inactivated foetal calf serum (FCS), 2 mM L-glutamine and 500 international units 
(IU)/ml penicillin / 500 µg/ml streptomycin. The cells were subcultured once a week by 
transferring 2.5 ml of the existing stock into 22.5 ml fresh medium and returning the new 
flask to a humid CO2 incubator at 37°C. 
2.1.2 Jurkat J6 cells 
Jurkat J6 cells were cultured in filter sterilised RPMI 1640 medium supplemented with 
10% (v/v) heat-inactivated FCS, 2 mM L-glutamine and 500 IU/ml penicillin / 500 pg/ml 
streptomycin. The cells were subcultured once a week by transferring 2.5 ml of the 
existing stock into 22.5 ml of fresh medium. The new flask was maintained at 37°C in a 
humid C02 incubator. 
2.1.3 Chinese Hamster Ovary (CHO) dihydrofolate reductase negative (dhfr') cells 
CHO (dhfr-) cells were cultured in filter sterilised Dulbeccos modified Eagles medium 
(DMEM) supplemented with 10% (v/v) heat-inactivated FCS, 2 mM L-glutamine, non- 
essential amino acids, hypoxanthine, thymidine and 500 IU/ml penicillin / 500 µg/ml 
streptomycin. When subculturing this cell type it was necessary to loosen the adherent 
cell monolayer by pre-treatment with 0.02% (w/v) EDTA containing 1.25% (w/v) trypsin. 
The cell suspension was then diluted with an equal volume of complete medium before 
being centrifuged at 1500 rpm in a Sorvall RT6000B bench centrifuge to harvest the cells. 
Finally the cell pellet was resuspended in 10.0 ml of fresh medium to remove all residual 
trypsin/EDTA before taking 1.0 ml to another flask containing 24.0 ml medium. The cells 
were maintained at 37°C in a humid CO2 incubator. 
2.1.4 NSO myeloma cells 
NSO cells were cultured in DMEM, commercially prepared to contain sodium pyruvate at 
110 µg/ml but without glutamine or ferric nitrate. The medium was supplemented with 
5% (v/v) heat-inactivated FCS, lx non-essential amino acids, lx ribonucleosides (50x 
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composed of 35 mg each of adenosine, guanosine, cytidine and uridine in addition to 12 
mg thymidine per 100 ml), lx glutamate and asparagine (100x composed of 600 mg of 
glutamic acid and 600 mg asparagine per 100 ml) plus 500 IU/ml penicillin / 500 pg/ml 
streptomycin. As the cells were mildly adherent, the cell monolayers were pre-treated 
with 0.02% (w/v) EDTA to loosen the cells prior to being washed in medium, 
resuspended in 10.0 ml fresh medium and then an aliquot of 1.0 ml being transferred to a 
fresh flask containing 24.0 ml of the same medium. 
2.1.5 Transfected Jurkat cells 
Jurkat cells were cultured as for the parental cell line but in addition the medium was 
supplemented, depending on the resident plasmid, with the selection drug of choice. In 
most cases the plasmid used was p321neo (Southern and Berg 1982) which confers G418 
resistance and therefore the drug G418 Geneticin (Gibco) was incorporated into the 
medium at 500 µg/ml. 
2.1.6 Transfected CHO dhfr- cells 
If dhfr based plasmids were employed (Simonsen and Levinson 1983), the cells were 
cultured in medium which slightly differed from that used for the parental cell line and 
which selected for maintenance of the resident plasmid. The medium was composed of 
DMEM supplemented with 10% (v/v) heat-inactivated dialysed FCS, 2 mM L-glutamine, 
non-essential amino acids and 500 IU/ml penicillin / 500 p g/ml streptomycin. To select 
for increased expression of the gene of interest, methotrexate (MX) an inhibitor of dhfr, 
was added to the medium at an initial level of 3x10-8 M. This procedure selected for 
random amplification of the resident plasmid DNA associated with higher level 
heterologous gene expression. Once growth of the transfectants was stable at 3x10-8 M 
the methotrexate concentration was increased to 1x10-7 M. A repeat of several rounds of 
amplification led to maximal expression levels for the selected gene. The highest 
concentration of methotrexate employed was in the order of lx10-6 M. If drug resistant 
plasmids other than dhfr based, were utilised in CHO dhfr- cells, the drug of choice was 
added directly to the same medium that was in use for the growth of the parental line. 
2.1.7 Transfected NSO cells 
For antibody production, the parental NSO cells had been electroporated in the presence 
of DNA encoding the heavy and light chains of the antibody of choice in plasmids 
containing an amplifiable glutamine synthetase cDNA (Bebbington et al 1992). This 
conferred resistance on the resulting cell line to the drug L-methionine sulphoximine 
(MSX) which is an inhibitor of glutamine synthetase. Transfected NSO cells containing 
these plasmids were cultured in Select medium which differed from the medium used to 
66 
culture parental cells in that it contained dialysed serum instead of normal serum and it 
was supplemented with various levels of MSX to select for random amplification of the 
foreign genes. 
2.1.8 Freezing and thawing cells 
Adherent and suspension cells to be frozen were taken while in a healthy state i. e. at least 
95% viable. Adherent cells, were removed from the flasks by treatment with 0.02% (w/v) 
EDTA containing 1.25% (w/v) trypsin. The suspensions were centrifuged at 1500 rpm in 
a Sorvall RT6000B bench centrifuge to harvest the cells which were then resuspended at 
1x106/ml in their original medium containing 10% (v/v) dimethylsulphoxide (DMSO). 
The cells were aliquoted in 1.0 ml volumes into sterile cryotubes (Corning) and kept 
overnight at -700C. The following day the frozen cells were transferred to liquid nitrogen 
dewars for long term storage. To recover frozen cells from liquid nitrogen, the vials of 
cells were taken from the dewar and, after checking that they were tightly sealed, the vial 
was dropped into a plastic beaker containing 370C water. As soon as the cells had thawed 
the liquid was transferred to a 15.0 ml polypropylene tube containing 9.0 ml medium and 
the cells were washed, by centrifugation, at 1500 rpm for 5 minutes in a Sorvall RT6000B 
bench centrifuge. The cells were resuspended in 25.0 ml fresh medium and transferred 
into flasks that were placed into a CO2 incubator at 370C to recover. 
2.1.9 Dilution cloning of transfected CHO cells 
To select for highly expressing clones from pools of transfected cell lines or laboratory 
strains, the cells were serially diluted to 10,3,1 or 0.3 cells/100 µl in the relevant medium 
and aliquoted at 100 µl/well into 96 well flat bottomed plates, using one plate per dilution. 
The cells were maintained at 370C in a CO2 incubator for approximately two weeks and 
were monitored for the appearance of single colonies over that time. As colonies 
developed, the contents of wells containing single colonies were expanded slowly and 
sequentially into 48,24, then 6 well plates and eventually up into flasks. At the 6 well 
stage the cells were checked for expression and a sample was frozen down in liquid 
nitrogen. Selected clones were maintained in 75 cm2 flasks (Costar) during the course of 
the experiments and backup stocks of these clones were kept in liquid nitrogen in case of 
contamination. 
2.1.10 Dilution cloning of NSO cells after electroporation 
NSO cells (1x107 cells/ml) which had been electroporated and resuspended in 30.0 ml of 
myeloma culture medium were taken and 20.0 ml dispensed into the wells of 2x 96 well 
microtitre plates wells as 50 µl aliquots. This approximated to 1.67x104 cells/well. A 10.0 
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ml volume of the residual cells was diluted further to give the equivalent of 4.2x103 
cells/50 µl and this was also dispensed into 5x 96 well microtitre plates. A 10.0 ml 
volume of the remaining diluted cells was diluted further to give the equivalent of 
8.3x102 cells/50 µl and was also dispensed into 5x 96 well plates. The cells were 
transferred to a 37°C CO2 incubator for growth to occur overnight. The next day, each 
well was supplemented with 100 µl of the medium utilised for transfected cells and the 
plates replaced into the incubator to await colony development. If the plates were 
screened at an early stage i. e. before one month and before the medium changed colour, 
the numbers of single colonies per well could be assessed more accurately. Clones which 
produced human antibody were taken, referenced by plate, row and well (i. e. plate C7 row 
F well 10), and progressively expanded through 24 and 6 well plates in Celltech select 
medium. They were eventually expanded into 25 and 75 cm2 flasks at which point excess 
cells were frozen in ampoules of 1.0 ml aliquots in liquid nitrogen. On reaching this step 
in the process of antibody production the selected cell lines were screened for the level of 
antibody production over time. 
2.1.11 Calculation of specific production rates (SPR) for antibody expressed by 
transfected NSO cells 
Following the Celltech guidelines, 75 cm2 flasks of antibody producing cells were taken 
and the cells harvested by treatment with trypsin diluted in EDTA, prior to centrifugation. 
The cells were counted and resuspended in fresh select medium at 2.5x105 viable 
cells/ml. Several 5.0 ml volumes of diluted cells were dispensed into 25 em2 flasks for 
overnight culture to allow the cells to adhere. The following day the medium was 
removed from each flask and replaced with 5.0 ml fresh, pre-warmed select medium and 
the flasks replaced into culture. Exactly twenty four hours later, 0.5 ml of supernatant was 
removed from each flask for human immunoglobulin (Ig) analysis by enzyme-linked 
immunosorbent assay (ELISA), whilst the remaining adherent and non-adherent cells 
were collected and counted. The specific production rates (SPR) were calculated as total 
yield of antibody in µg/24 hours/106 viable cells. 
2.1.12 Procedure to select for the random amplification of transfected gene product 
When antibody producing first round cell lines (such as the clone C7F 10) had been 
identified and several SPR assays performed reproducibly, a strategy of selecting for 
random gene amplification was designed. Flasks of the cells to be screened for 
amplification were taken, the cells harvested and resuspended at 1x105/ml in select 
medium. The cells were aliquoted into multiple 96 well flat bottomed plates, 100 µl/well. 
Twenty-four hours later, an additional 100 µl of select medium containing L-methionine- 
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sulphoximine (MSX) diluted to generate final concentrations of 5,10,15,20 or 25 µM, 
was added, one concentration per one or two plates. The cells were incubated at 370C, fed 
with extra relevant medium if required, until colonies reappeared (usually a period of one 
month). Positive colonies were designated a second series of plate, row and well numbers 
such as the 5 µM MSX amplification clones of C7F 10, -9D4 and -10G9 (plates 9 and 10, 
rows D and G, wells 4 and 9). 
2.1.13 Dilution cloning of amplified NSO cell lines 
To guarantee clonality of the selected colonies, cultures of the clones were grown in 
medium containing their relevant MSX concentration and were expanded from the 96 
well plates into 48,24 and 6 well plates and on into 25 and 75 cm2 flasks. From cultures 
in 75 cm2 flasks the cells were diluted to 50,25 and 5 cells per ml and 200 µl aliquots 
dispensed into 96 well flat bottomed plates and left to grow at 37°C. Colonies which 
appeared were given a third series title relating to plate, row and well and were gradually 
subcultured into increasing amounts of medium until each cell line was in a volume of 1.0 
ml in a single well of 6 well plates. Aliquots of 50 µl cell supernatant were analysed for 
antibody content and high producing clones selected. Samples of all clones were stored 
frozen at -70°C. 
2.1.14 Preparation of peripheral blood mononuclear cells (PBMC) 
Fresh human blood (50.0 ml) from healthy randomised patients was collected from the 
Occupational Health Centre at Wellcome Research Laboratories, Beckenham, and 
defibrinated by rapid stirring with a sterile glass rod. The blood was centrifuged at 1500 
rpm in a Sorvall RT6000B bench centrifuge for 5 minutes and the patients serum removed 
for heat inactivation (56°C for 30 minutes). The remaining cells were diluted to 80.0 ml 
using phosphate buffered saline (PBS) pH 7.2, and 20.0 ml aliquots were layered onto 
four 10.0 ml lymphoprep (Nycomed) gradients. The gradients were centrifuged at 1500 
rpm for 30 minutes in a Sorvall RT6000B bench centrifuge after which the PBMC were 
removed from the interface above the blood cell pellets. The PBMC were resuspended in 
50.0 ml PBS and kept on ice ready for further treatment. 
2.1.15 Preparation of peripheral blood polymorphonuclear cells (PPMN) 
Having prepared and removed the PBMC, the residual blood pellets were resuspended in 
40.0 ml PBS and re-layered as 10.0 ml aliquots onto four 10.0 ml Polymorph prep 
(Nycomed) gradients. The gradients were spun at 1500 rpm in a Sorvall RT6000B bench 
centrifuge for 30 minutes and then the PPMN were harvested from the interface. The cells 
were washed and resuspended in RPMI 1640 medium containing 10% (v/v) FCS, 2 mM 
L-glutamine and 500 IU/ml penicillin / 500 p g/ml streptomycin for use in assays. 
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2.1.16 Preparation of peripheral blood monocytes (PBM) 
PBMC prepared previously were taken and resuspended in 50.0 ml RPMI 1640 medium 
containing 2 mM L-glutamine, 10% (v/v) heat-inactivated autologous serum plus 500 
IU/ml penicillin / 500 gg/ml streptomycin. The cells were dispensed equally into two 75 
cm2 flasks and these were placed into a humid CO2 incubator at 370C for three hours to 
allow the monocytes to adhere to the plastic. The flasks were swirled gently before the 
supernatants were removed to be either discarded or used to prepare other lymphocyte 
populations, the remaining adherent cells were rinsed several times in the same medium 
and then left, bathed in medium, at 370C until required. 
2.1.17 Preparation of peripheral blood lymphocytes (PBL) 
Flasks in which PBM had been allowed to adhere for three hours were taken and the non- 
adherent cells were removed to sterile tubes. The adherent cells were washed several 
times with 5.0 ml aliquots of RPMI medium containing 10% (v/v) heat-inactivated FCS, 2 
mM L-glutamine and 500 IU/ml penicillin / 500 µg/ml streptomycin and the washes 
pooled with the non-adherent cells. If the monocytes were required they were returned to 
the incubator bathed in medium. The non-adherent cells were pelleted and resuspended in 
medium to be used in further assays. 
2.1.18 Preparation of peripheral blood T lymphocytes (T PBL) 
PBMC prepared previously were resuspended in 50.0 ml RPMI 1640 medium containing 
10% (v/v) heat-inactivated autologous serum, 2 mM L-glutamine and 500 IU/ml 
penicillin / 500 µg/ml streptomycin. The cells were dispensed equally into two 75 cm2 
flasks which were incubated at 37°C for three hours for the monocytes to adhere to the 
plastic. The non-adherent cells were subsequently removed to tubes, washed once in PBS, 
and then resuspended in 2.0 ml PBS to which was added a combination of 100 tl of 
mouse anti-human CD8 or CD4, CD16 and CD19 antibodies (Becton Dickinson), these 
being antisera to surface markers found on cytotoxic or helper T cells, NK cells or B cells 
respectively. The monocyte depleted PBMC were incubated with the antibodies at room 
temperature (RT) for 2 hours before being washed once in PBS and then passed slowly 
through a small column of fine glass beads which had previously been coated initially 
with myeloma protein and subsequently with rabbit anti-mouse antibody. All mouse 
antibody coated cells bound to the beads of the column and specific cell types could be 
eluted and used in further assays. 
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2.1.19 Preparation of mononuclear cells depleted of specific cell types 
PBMC were prepared as outlined previously and were counted and diluted to 1x107/ml in 
PBS and aliquoted into five equal samples. To each sample 100 Rl of mouse antibody to a 
specific human cell surface marker i. e. CD3 (T cells), CD19 (B cells), CD14 (monocytes), 
CD56 (NK cells) or PBS was added. The cell fractions were incubated at room 
temperature for 1 hour and were then pipetted into sterile Petri dishes which had 
previously been coated with rabbit anti-mouse serum at 1 µg/ml and then washed and 
blocked with 1% (w/v) bovine serum albumin (BSA) in PBS. The cells were left in the 
Petri dishes for 1 hour at 40C before the non-adherent cells were removed by gentle 
washing. The resulting cell fractions were resuspended to a concentration of 2.5x106/ml 
based on their original cell count and used in ADCC assays. Samples of all of the aliquots 
were checked for their specificity by the addition of fluoroscein isothiocyanate (FITC)- 
labelled anti-CD3, CD14, CD19 and CD56 antibodies and by subsequent fluorescence 
activated cell scan (FACS) analysis. 
2.2 IMMUNOASSAYS 
2.2.1 FACScan (FACS) analysis and flow cytometry 
2.2.1.1 Surface antigen detection 
Cell lines or freshly isolated human cells were washed and resuspended in FACS buffer 
(5% (v/v) FCS, 0.1% sodium azide (NaN3) in PBS) at lx105cells/ml. The cells were 
dispensed into 96 well U-bottomed micro-titre plates at 100 µl per well and either 10 gl 
FITC- or phycoerythrin (PE)- labelled antibody or 10 µl unlabelled antibody was added. 
The cells were incubated at 40C for 30 minutes, to stain, before the plate was centrifuged 
at 1500 rpm in a Sorvall RT6000B bench centrifuge for 5 minutes. The excess liquid was 
removed by flicking and the cell pellets were resuspended in 100 µl wash buffer (0.1% 
NaN3 in PBS) and the process repeated twice more. If the first antibody used was 
unlabelled, the cells were resuspended in a further 100 µl FACS buffer to which was 
added 10 µl FITC- or PE- labelled relevant anti-species antibody. The cells were once 
again incubated at 40C for 20 minutes before being washed in wash buffer. Once the cells 
had been fluorescently labelled they were finally resuspended in 100 µl FACS fix buffer 
(1% paraformaldehyde in PBS) and either analysed on a FACScan (Becton Dickinson) 
immediately or left in the dark at 40C until they could be analysed, this being no longer 
than three days later. 
2.2.1.2 Titration of antibody/antigen binding 
To compare antigen binding, samples of either concentration corrected or occasionally 
uncorrected test antibodies were serially diluted ten fold in FACS buffer (5% (v/v) FCS, 
0.1% sodium azide (NaN3) in PBS) and 50 t1 of each dilution was placed into a well of a 
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U-bottomed 96 well micro-titre plate. Wien 133 cells (50 µ1) diluted to lx106cells/ml in 
FACS buffer were dispensed into the wells and the plate incubated at 40C for 30 minutes. 
The cells were washed twice in FACS buffer, utilising centrifugation at 1500 rpm in a 
Sorvall RT6000B bench centrifuge for 5 minutes to pellet the cells. The cells were 
resuspended by tapping the plate and 100 µl goat anti-human IgG-FITC labelled 
secondary antibody (Sigma), diluted one in 100 in FACS buffer, was added. After a 
further 25 minute incubation at 40C, the cells were washed three times in FACS buffer 
prior to resuspension in 100 µl FACS fix buffer (1% paraformaldehyde in PBS). The 
results from analysis on the Becton Dickinson flow cytometer enabled the construction of 
binding curves utilising antibody concentration (X axis) and mean fluorescence intensity 
(MFI, Y axis). 
2.2.2 Human IgG ELISA 
To assay for antibody production from a transfected cell line, a range of dilutions of the 
cell supernatant was checked by ELISA for human Ig content. The assay was set up in 96 
well flat bottomed plates which had been coated overnight, at 4°C, with 100 RI/well 
sheep anti-human IgG at a final concentration of 2 . tg/ml in PBS. The coated wells were 
washed five times with a wash buffer (PBS containing 0.1% (v/v) Tween 20) and were 
then blocked overnight with 100 µl/well PBS plus 2% (w/v) BSA, again at 40C (the assay 
plates could be stored at 40C at this stage). Before the supernatant dilution's were tested, 
the wells were again washed three times with 100 µl/well wash buffer. A reference curve 
of a known antibody standard was prepared over the range 250 ng/ml to 3.9 ng/ml, using 
doubling dilution's in PBS containing 0.2% (w/v) BSA, 0.05% (v/v) Tween 20 (PBT), 
and either 100 µl volumes of the standard dilution's or the test sample dilution's were 
added to the assay plate in duplicate or triplicate. After 60 minutes at room temperature 
the plate was washed five times with the wash buffer and the wells replenished with 100 
Ri horseradish peroxidase (HRP) conjugated anti-human IgG antibody (Sigma) diluted 
one in 2000 with PBT and left at RT for a further 30 minutes. The plates were washed 
five times in wash buffer and the reaction developed by the addition of diluted TMB 
substrate (Sigma, I tablet dissolved in 5.0 ml water, 5.0 ml TMB buffer) 100 Rl/well. The 
colour development was allowed to proceed until a discernible blue colour was visible 
and then 100 µl of 2M H2SO4 was added to each well. The plate was placed in a 
scanning spectrophotometer (Anthos) and the results monitored at 450 nm. The test 
sample result values were calculated from the standard curve. Those obtained from 
diluted samples were considered to be more accurate as they were derived from the linear 
region of the standard curve. 
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2.2.3 ADCC assay 
Utilising a variation of the method devised by Ortaldo and colleagues (1987), freshly 
subcultured Wien 133 cells (Nacheva et al 1987) were taken and centrifuged at 1500 rpm 
in a Sorvall RT6000B bench centrifuge for five minutes. The cell pellet was resuspended 
in 200 µl sodium chromate (51 Cr) at 5 mCi/ml and the cells left, within lead shielding, to 
label at 37°C for 1 hour in a humid CO2 incubator. The suspension was agitated gently 
every 20 minutes to enhance the efficiency of the reaction. Finally, the cells were washed 
extensively in medium and resuspended at 2x105/ml, before they were aliquoted into 96 
well 'U' bottomed microtitre plates at 50 µl/well. 
Triplicate antibody dilutions were prepared in 200 µl medium, in fresh 96 well plates 
starting at the selected concentration and titering out at one in ten dilutions. A volume of 
50 µl of each of the resulting dilution was transferred, in triplicate, into the plates already 
containing 50 µl labelled target cells. Assay controls were set up such that nine wells 
containing target cells were filled with 50 µl medium only. The plates were left at 37°C 
for 1.5 hours in a humid CO2 incubator. 
Effector (usually PBMC) cells were prepared as described elsewhere and were diluted, in 
medium, to a final concentration of 2.5x106/ml. The effector cells were dispensed onto 
the antibody pre-coated labelled cells, 100 tl/well, resulting in a ratio of 25 effector cells 
per target cell. The effector cells were also added to one triplicate set of control wells (to 
monitor non-antibody mediated lysis) whilst medium alone was added to yet another set 
of control triplicates (to monitor spontaneous lysis). The plates were centrifuged for 5 
minutes at 1500 rpm in a Sorvall RT6000B bench centrifuge and prior to being replaced 
at 37°C for 5 hours, 100 µl of water containing 1% (v/v) Triton x100 was added to the 
final set of control triplicate wells (to monitor total release). At the end of the incubation 
period 100 µl of medium was removed from each well and counted in a 'y counter 
(Wallac, Wizard). The level of specific release was calculated as follows: 
% specific release = (mean cnm of antibody mediated release)-(mean cpm of-spontaneous-release) x 100 
(mean cpm of total release) - (mean cpm of spontaneous release) 
2.2.4 Monocyte-mediated, target cell growth inhibition assay 
A method derived from that of Kobayashi et al (1992) was employed. Monocytes were 
harvested from cultures that were at least one week old by removing the RPMI 1640 
medium overlay, adding 5.0 ml 0.02% (w/v) EDTA containing 10% (v/v) heat-inactivated 
FCS and replacing the flask into the 370C incubator for 15 minutes. The cells were then 
released from the plastic by the addition of 5.0 ml Iscoves complete medium followed by 
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gentle loosening with sterile cell scrapers. The monocytes were washed twice in Iscoves 
complete medium, resuspended at 1x105 cells/ml and dispensed into 96 well flat 
bottomed microtitre plates at 100 µl/well. Control plates containing 100 µl medium/well 
were set up at the same time. Excess monocytes were employed to check the cell 
phenotype by staining a small sample of each for the cell markers CD3 (T cells), CD 19 (B 
cells), CD14 (monocytes), CD16 (Fc IgG RIII) and CD56 (NK cells) as well as a PBS 
control. The following day, triplicate 200 µ1 antibody dilutions, starting at 40 µg/ml, were 
prepared in Iscoves complete medium, in fresh 96 well plates. The antibodies were 
diluted in one in ten steps and included medium, lacking antibody, as controls. Triplicate 
aliquots of 50 tl of each antibody dilution were transferred into either the monocyte or 
control wells followed by the addition of 50 tl freshly subcultured and washed Wien 133 
cells at 8x104 cells/ml. The plates were returned to the 370C humid CO2 incubator for 
five days before all wells were pulsed overnight with 20 µl of low activity 3H thymidine 
diluted to 0.05 µCi/ml with medium. The next day the cellular DNAs were harvested onto 
multiwell filter mats using a cell harvester (Skatron), the filters were dried and then 
counted on a Beta plate counter (Wallac) in sealed bags in the presence of 10.0 ml of 
scintillant. The inhibition of cell growth results were expressed as percentage of the 
control values and were calculated as follows. 
% control = (mean cpm of antibody dilution value) x 100 
(mean cpm of control value) 
2.2.5 Crosslinking assay (in the absence of effector cells) 
Antibodies under investigation were initially diluted (in triplicate), to a concentration of 
90 µg/ml, in 200 µl of RPMI 1640 complete medium. These were then further diluted in 
96 well plates, using one in three steps, to give a range of concentrations which were then 
further dispensed into fresh 96 welled 'U' bottomed plates at either 50 or 100 µl/well. A 
second, crosslinking anti-human IgG was diluted in RPMI 1640 complete medium to a 
concentration of 20 gg/ml and 50 µl was aliquoted into the wells containing 50 µl of the 
test antibodies. Target cells, which were either Jurkat cells transfected with the gene for 
CDw52 or control untransfected cells, were washed twice in RPMI 1640 complete 
medium before they were resuspended to 1x105/ml and dispensed at 100 p1/well into 
either the antibody alone or the crosslinked antibody samples. The plates were replaced 
into a 370C humid incubator for five days before the cells were labelled overnight with 20 
µl/well of filter sterilised low activity 3H thymidine diluted to 0.05 µCi/ml with medium. 
The cells were harvested onto filter mats the following day using a cell harvester 
(Skatron) and the dried mats counted in the presence of 10.0 ml scintillant on a Beta plate 
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counter (Wallac). The results for both test and control target cells were calculated as 
follows: 
% of control = (mean cpm of antibody dilution value) x 100 
(mean cpm of control value) 
2.3 MOLECULAR TECHNIQUES 
The majority of these techniques were derived from those described in Maniatis (et al 
1982) or from kit instructions. 
2.3.1 Restriction endonuclease cleavage of plasmid DNA 
Plasmid DNA concentrations were routinely estimated by measuring the absorbance at 
the optical density (OD) of 260 nm. DNA corresponding to the required amount was 
dissolved in a total volume of 20-50 µl single strength digestion buffer (supplied as lOx 
stock for each enzyme by Boehringer Mannheim) containing the restriction enzyme or 
enzymes required, and incubated at 370C for several hours. The resulting cleaved DNA 
was mixed with 5 tl five times concentration loading dye per 20 µl, and electrophoresed 
on 1% (w/v) agarose gels in single strength TBE buffer (10.5 g Tris base, 5.5 g Boric 
acid, 4 ml 0.5M EDTA/litre) at between 75-150 volts in a Pharmacia electrophoresis tank 
model G100. 
2.3.2 Agarose gel loading buffer for DNA 
A five times concentrated stock solution of 40% (w/v) sucrose containing 0.25% (w/v) 
bromophenol blue was used as a method of visualising the buffer front in all DNA 
agarose gels. An aliquot of 5 tl was added to each 20 µl digest at the end of the 
incubation time and before loading the sample onto the agarose gel. 
2.3.3 Purifying cleaved DNA fragments from agarose gels 
Fragments of DNA which were to be purified for further manipulations were excised, 
under UV light, from agarose gels with a sharp blade and the slice of gel containing the 
DNA was put into a small length of sterile dialysis sacking. One end of the sacking was 
sealed with a clip and the enclosed gel slice was immersed in 1.0 ml of single strength 
TBE buffer before sealing the other end. The complete bag, with gel slice, was placed into 
an electrophoresis tank (Pharmacia model G100) filled with single strength TBE and the 
current applied at 150 volts. The DNA was electroeluted from the gel into the buffer, 
within the sack, from where it was purified as follows. The buffer containing DNA within 
the dialysis sacking was applied, after mixing with 1.0 ml of sterile water, to an Elutip 
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column (Schlieker and Schuell) which had been previously equilibrated with a series of 
salt buffers (one wash with 1.0 ml of a high salt, 1.02 M NaCl, solution followed with one 
wash of a low salt 0.2 M NaCl, 0.02 M Tris pH 7.4,1 mM EDTA solution). Once bound 
to the column the DNA was washed with 1.0 ml low salt buffer and was finally eluted 
with 300 µl high salt buffer. The DNA was precipitated, with 750 µl ethanol in the 
presence of 1 µl 10 mg/ml dextran 500 as a carrier, on dry ice for 15 minutes. After 
centrifugation at 14000 rpm for 10 minutes in an Eppendorf microfuge, the DNA pellet 
was washed in 70% ethanol and air dried. The resulting DNA was resuspended in 20 µl 
sterile distilled water for use. 
2.3.4 Ligation of DNA fragments into molecular vectors 
Purified, enzyme cleaved, DNA fragments were ligated into plasmid vectors with 
corresponding restriction enzyme overhangs by resuspending both together in a total 
volume of 16 gl sterile H2O in 1.5 ml polypropylene Eppendorf tubes. Control reactions 
in which the vector or insert alone were resuspended in 16 µl of H2O were also set up. A 
2 µl aliquot of IOx T4 DNA ligase buffer (New England Biolabs) containing 1 µl 20 mM 
ATP was added to each reaction followed by I t1 T4 DNA ligase (New England Biolabs). 
The reagents were gently mixed and quickly sedimented in an Eppendorf microfuge and 
were then placed in a 150C waterbath overnight. The ligations were then either stored at - 
200C or a transformation was performed. 
2.3.5 Preparing competent cells 
The bacterial strain DH5a is a recombinant-deficient suppressing strain of E. co1i used for 
plating and growth of plasmids and cosmids and is defined in Maniatis (et al 1982) as 
being supE4401acU169(ý801acZDM15)hsdRl7recA1endA1gyrA96thi-1relA1. The data 
in brackets refers to an insert which permits a-complementation with the amino terminus 
of ß-galactosidase encoded in pUC vectors (Hanahan 1983). DH5a bacterial cells were 
spread onto L-agar plates and cultured overnight at 37°C. A single colony was picked 
into 50.0 ml L-broth and cultured overnight in a shaking incubator at 370C. A volume of 
25.0 ml of the overnight culture was transferred to each of two 500.0 ml aliquots of pre- 
warmed sterile L-broth and cultured at 37°C until the 550 nm absorbance value reached 
0.48 OD units. The bacterial cells were centrifuged at 5000 rpm in a Sorvall RC5B 
Superspeed centrifuge, rotor GSA, for ten minutes at 4°C and the pellets were 
resuspended in 400.0 ml ice-cold TFB I buffer (100 mM rubidium chloride, 50 mM 
manganese chloride, 30 mM potassium acetate, 10 mM calcium chloride, 15% (v/v) 
glycerol) pH 5.8. After cooling the cells to 4°C for 5 minutes they were recentrifuged at 
5000 rpm for 5 minutes. The cells were resuspended in 40.0 ml TFB II buffer (10 mM 
MOPS, 10 mM rubidium chloride, 75 mM calcium chloride, 15% (v/v) glycerol) pH 6.5, 
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and were maintained on ice for a further 15 minutes before they were dispensed into 500 
µl aliquots and snap frozen on dry ice. Competent cells made in this way were stored at - 
700C until required. 
2.3.6 Transformations 
A 10 µl aliquot of each ligation sample was taken and mixed with 100 t1 freshly thawed, 
ice-cold, competent DH5 a cells in sterile Eppendorf tubes and the tubes were maintained 
on ice for a further 30 minutes. After a 1.5 minutes heat shock at 420C, the tubes were 
replaced onto ice for 2 minutes and then 250 µl L-broth was added to each sample. The 
tubes were placed into a 370C shaking incubator for 1 hour and the reaction mixes were 
then spread onto pre-warmed L-agar plates into which was incorporated 100 µg/ml 
ampicillin. The plates were placed, inverted, in a 370C incubator overnight to allow 
bacterial growth to occur. 
2.3.7 Mini-scale plasmid DNA preparations 
Single colonies were picked from overnight plate cultures into 5.0 ml volumes of L-broth 
containing 100 µg/ml ampicillin. The cultures were grown overnight at 37°C in a shaking 
incubator. A volume of 3.0 ml of each culture was transferred to fresh tubes for isolation 
of the DNA utilising the reagents from a Wizard kit (Promega) and the remaining 2.0 ml 
stored at 4°C. The 3.0 ml aliquots were centrifuged at 1500 rpm in a Sorvall RT6000B 
bench centrifuge and the pellets resuspended in 200 tl resuspension buffer before they 
were transferred to 1.5 ml Eppendorf tubes. A volume of 200 t1 cell lysis buffer was 
added to each sample and the tubes inverted several times. The reactions were stopped 
after 5 minutes by the addition of a further 200 µl of neutralisation buffer. The tube 
contents were centrifuged at 14000 rpm for 5 minutes in an Eppendorf microfuge and the 
supernatants transferred to fresh 1.5 ml Eppendorf tubes. The addition of 1.0 ml DNA 
binding resin to each sample and the application of the resin/DNA mix onto individual 
mini columns via a suction device led to the DNA being rescued. The column and 
contents were washed with 2.0 ml of the kit wash buffer and the columns centrifuged, 
inset into Eppendorf tubes, to remove excess buffer. The DNA was retrieved by the 
addition of 50 µl H2O to each column and the eluates retrieved into fresh Eppendorf tubes 
by centrifugation. The DNA was either stored at -20°C until required or analysed by 
either restriction enzyme analysis or sequencing. 
2.3.8 Maxi-scale plasmid DNA preparations 
A small 100 µl sample (either a residual mini-scale bacterial culture or a glycerol stock of 
a culture) was used as a seed for a large scale plasmid DNA preparation. The plasmid 
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harbouring bacterial culture was grown overnight, shaking at 37°C, in 500.0 ml L-broth 
into which was incorporated 100 p g/ml ampicillin. The following day each culture was 
centrifuged in sterile centrifuge pots at 5000 rpm and at 4°C in a Sorvall RC5B 
Superspeed centrifuge, rotor GSA, having previously removed a 2.5 ml aliquot as a stock 
sample. The 2.5 ml sample was mixed with 2.5 ml glycerol and stored frozen at -20°C as 
a future starter culture. The remaining bacterial pellet was resuspended, in the centrifuge 
pot, using a total of 20.0 ml of a lysozyme mix (0.25 g lysozyme, 0.45 g D-glucose, 1.5 
ml Tris-HC1 pH 8.0 and 1.0 ml 0.5M EDTA per 50.0 ml water) and left at RT for five 
minutes. At the end of the incubation period 40.0 ml of a SDS/NaOH buffer was added 
(4.0 ml 5M NaOH, 10.0 ml 10% (w/v) SDS per 100.0 ml water) and the mix was shaken 
gently and maintained on ice for fifteen minutes. Finally, 20.0 ml of a lysis buffer (3M 
potassium acetate which was 5M with respect to acetic acid) was added and the mix 
shaken and returned to ice for a further five minutes. The resulting plasmid lysate was 
centrifuged at 8000 rpm in a Sorvall RC5B Superspeed centrifuge, rotor GSA, to remove 
the debris. The supernatant was filtered through gauze into a fresh centrifuge pot and the 
DNA precipitated with 48.0 ml iso-propanol, followed by centrifugation, in a Sorvall 
RC5B Superspeed centrifuge, at 5000 rpm. The DNA pellet was air-dried before 
preparing a Caesium chloride (CsC12) gradient. For the gradient, the DNA was 
resuspended in 9.5 ml TE pH 8.0 (10 mM Tris-HCL pH 8.0,1 mM EDTA) to which was 
added 10.5 g CsC12. The CsC12 was agitated until dissolved and then 660 µ1 1M Tris- 
HCL pH 8.0,120 µl 0.5M EDTA and 660 µl ethidium bromide 10 mg/ml was added. The 
sample was loaded, using a syringe with an attached 19G needle, into a 10.0 ml heat- 
sealable tube which was sealed and centrifuged at 45000 rpm for two days using a 70.1 Ti 
rotor in a L8-55 ultra-centrifuge (Beckman). 
2.3.9 Recovering plasmid DNA from Caesium chloride gradients 
The heat-sealable tube containing the plasmid DNA was recovered from the ultra- 
centrifuge. The tube was clamped upright over a UV light source and above a beaker, and 
the top of the tube was pierced with a sterile needle. The UV light source was illuminated 
and the DNA band visualised via the incorporated ethidium bromide. A wide bore (19G) 
needle attached to a 2.0 ml syringe was used to puncture the tube at a point adjacent to 
the plasmid DNA layer and the DNA removed by suction into the syringe. The DNA was 
expelled into a sterile polypropylene tube and the waste gradient materials were allowed 
to drain into the beaker for disposal. The ethidium bromide was dissociated from the 
DNA by vortexing the sample with an equal volume of N-butanol and removing the upper 
colourless layer to a sterile Corex tube. The DNA was diluted with an equal volume of 
sterile distilled water and precipitated with 2.5 volumes of ethanol on dry ice for 15 
minutes. After centrifugation at 8000 rpm at 40C in a Sorvall RC5B Superspeed 
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centrifuge, rotor SS-34, the pellet was resuspended in 70% ethanol and re-centrifuged to 
precipitate the DNA. Finally the DNA was dissolved in 400 µl sterile distilled water and 
the OD value was recorded at 260 nm. The DNA sample was then stored at -200C until 
required. 
2.3.10 Transfection of DNA into mammalian cells other than NSO 
Adherent cells to be transfected were aliquoted (10.0 ml) into 10 cm tissue culture grade 
Petri dishes at 1-5x105 cells/ml medium and incubated overnight at 370C in a C02 
incubator. Before transfection the cells were washed several times with serum-free 
medium and were maintained in 5.0 ml serum-free medium in the 37°C CO2 incubator 
until required. Suspension cultures, prior to transfection were taken from their stock flask 
and centrifuged in a Sorvall RT6000B bench centrifuge at 1500 rpm to pellet the cells. 
The cells were washed several times in serum-free medium before they were counted, 
adjusted to 0.4-2x106/ml and 5.0 ml aliquoted into tissue culture plates. The DNA to be 
transfected was diluted with 0.3 M NaCl to a concentration of between 1-10 tg in a final 
volume of 250 tl and mixed with an equal quantity of Transfectam (Promega) solution at 
a concentration of 40 µg/ml. The resulting 500 pl DNA/Transfectam mix was dripped 
evenly onto the plate of cells to be transfected, the plate was gently swirled to mix and 
placed at 37°C for five hours. At the end of the incubation period, 5.0 ml of medium 
containing 10% (v/v) FCS was added to each plate and the cells were then incubated at 
37°C for 2 days. After this period the cells were sub-divided, at a range of dilutions, into 
medium containing the selection drug of choice depending on the original plasmid vector 
used. Over the following two weeks the cells were monitored for the outgrowth of 
transfected cell colonies which were then checked for expression by various methods. 
2.3.11 Electroporation of the final Campath-1H plasmid into NSO cells 
Following Celltech guidelines, 40 µg of the plasmid pEE6H12L#4 was taken and 
linearised overnight at 37°C with the restriction enzyme Sal I. The cleaved DNA was 
vortexed with an equal volume of phenol/chloroform mixed 1: 1, centrifuged in an 
Eppendorf microfuge at 14000 rpm and the resulting aqueous layer treated with one 
volume of chloroform and recentrifuged. The upper aqueous layer was precipitated with 
2.5 volumes ethanol in the presence of 150 mM NaCl. Post precipitation at -800C for 30 
minutes, the DNA was washed in 70% (v/v) ethanol using an Eppendorf microfuge at 
14000 rpm and the pellet air-dried before resuspension in 50 tl sterile distilled water. 
NSO cells which were to be electroporated and had been subcultured the previous day, 
were treated with 0.02% (w/v) EDTA to release all adherent plus non-adherent cells and 
the cell suspensions were pooled and pelleted by centrifugation at 1500 rpm in a Sorvall 
RT6000B. After washing and resuspension in ice-cold PBS, the cells were counted and 
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adjusted to 1x107/ml before 1.0 ml aliquots were incubated in cuvettes on ice with either 
50 tl experimental DNA (equivalent to 40 µg), 50 µl control vector DNA or 50 µl PBS 
for five minutes followed by electroporation with a capacitance of 2 pulses of 3 µF, using 
a Biorad Gene pulser. The cuvettes were replaced on ice for two minutes prior to the cells 
being rinsed out into 30.0 ml of pre-warmed medium. 
2.3.12 Recovery of cellular DNA from cell cultures 
DNA transfected or untransfected parental cells were harvested from tissue culture, 
utilising EDTA and trypsin if necessary, and the cell pellets were washed extensively in 
PBS by centrifugation in a Sorvall RT6000B bench centrifuge at 1500 rpm. Prior to the 
final spin, the cells were counted using trypan blue exclusion and after centrifugation 
were resuspended in TE (Tris 10 mM, EDTA 1 mM) pH 8.0, containing 100 µg/ml 
proteinase K (BDH), at 108 cells/ml. Once the cells had dissolved, a small volume of 10% 
(w/v) SDS was added to a final concentration of 0.5% SDS and the tube gently inverted to 
mix the contents. The cell mix was incubated in a 370C waterbath for three hours before 
sodium chloride was added to a final concentration of 150 mM. The DNA was isolated by 
two treatments with an equal volume of Tris buffered phenol pH 7.0-8.0 in which the 
upper aqueous phase was retained after each centrifugation. This step was followed by a 
subsequent treatment of the aqueous layer with an equal volume of phenol/chloroform 
mixed in the ratio of 1: 1. The resulting aqueous layer was precipitated overnight at -200C 
in the presence of 2.5 volumes ice-cold 100% (v/v) ethanol. The following day the DNA 
pellet was washed once with 70% (v/v) ethanol and the pellet air-dried. After 
resuspension of 108 cells in 0.5 ml TE pH 8.0, RNAase A was added to a final 
concentration of 20 µg/ml and the mix placed at 37°C, in a waterbath, for two hours. The 
RNA-free DNA was adjusted to 0.2 M sodium chloride/0.1% (w/v) SDS, and an aliquot 
of proteinase K was added to give a concentration of 100 tg/ml and the mixture placed at 
370C for a further two hours. The DNA was isolated utilising one phenol treatment 
followed by one phenol/chloroform treatment as previously described. The aqueous layer 
was mixed with 2.5 volumes of 100% (v/v) ethanol and placed at -200C overnight to 
precipitate the DNA. To perform assays with the DNA, the DNA pellet was washed once 
in 70% (v/v) ethanol, air-dried and subsequently redissolved in a small volume of sterile 
distilled water. An OD reading at 260 nm was used to assess the amount of DNA present. 
2.3.13 Southern blotting of cellular DNA 
2.3.13.1 Preparation of samples for electrophoresis 
To assess gene copy number and the presence of desired DNA gene fragments, purified 
DNA was cleaved utilising restriction enzymes which were known to cleave at certain 
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DNA sequences and yield restriction fragments of predicted sizes. The DNA to be 
cleaved was prediluted with a single strength buffer, which was supplied commercially as 
a lOx stock (Gibco or Boehringer Mannheim), several hours prior to the addition of the 
required enzyme or enzymes, to aid dissolution of the high molecular weight DNA. The 
enzyme/enzymes, of choice, was incorporated into the DNA/buffer mix such that it 
constituted no more than 10% (v/v) of the total volume and the solution placed at 370C 
overnight. The following day, the cleaved DNA was precipitated with 100% (v/v) ethanol 
in the presence of 150 mM sodium chloride, at -800C on solid CO2, for 30 minutes, 
washed once in 70% (v/v) ethanol and air-dried. The final cleaved DNA was resuspended 
in a small volume of sterile distilled water and the DNA content assessed by OD. A small 
amount, 0.5-1.0 . tg, of the cleaved DNA was checked for complete digestion by 
electrophoresis on a 1% (w/v) agarose gel. For the actual experimental gel, 1.0-10.0 µg of 
cleaved DNA was loaded into the wells of a 250.0 ml 1% (w/v) agarose gel alongside 
molecular weight markers and control samples which were either parental cellular DNA 
as negative control or parental DNA spiked with known amounts of the expected DNA 
fragments to act as gene copy number positive controls. The gel was electrophoresed at 
30 volts overnight and photographed before transfer onto either nitro-cellulose or nylon 
sheets. 
2.3.13.2 Blotting of the electrophoresis products from gel to paper 
To blot onto paper, the gel was first soaked in 250.0 ml 0.25 M HCl for fifteen minutes to 
depurinate the DNA and ensure even transfer of all sizes of fragments. After rinsing in 
distilled water, the gel was further treated with two, thirty minute washes in 250.0 ml 500 
mM NaOH, 1M NaCl to denature the DNA and finally the gel was neutralised with two, 
thirty minute washes in 250.0 ml 500 mM Tris pH 7.4,2.5 M NaCl. Preferentially the gel 
was blotted onto nylon Hybond-N sheets (Amersham) utilising the method outlined by 
Southern (1975). This process involved transfer of the DNA, by capillary action via lOx 
SSC buffer (0.15 M Na citrate, 1.5 M NaCI), from the gel onto the paper of choice by the 
use of a thick filter paper wick. The nylon paper retaining the transferred DNA was air- 
dried, wrapped in Saran wrap and briefly exposed to ultra-violet light, in a Stratagene 
cross-linker, to adhere the DNA to the paper. 
2.3.13.3 Probing Southern blots 
Nitro-cellulose filters containing UV cross-linked DNA were placed into Techne glass 
hybridisation tubes with 50.0 ml, 650C pre-heated pre-hydridisation solution (6x SSC, 5x 
Denhardts solution, 0.5% (w/v) SDS and 100. tg/ml single stranded calf intestinal DNA) 
and were rotated at 650C for at least one hour. The pre-hybridisation solution was then 
removed and replaced with a fresh volume of 25.0 ml pre-heated solution containing an 
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aliquot, equivalent to 5x106 counts per minute (cpm), of labelled probe which had been 
freshly heated to 95°C for 5 minutes. The filters were rotated in the hybridisation solution 
at 65°C overnight. The filters were washed using two 15 minute rinses in 2x SSC at 
65°C, followed by two thirty minute washes in 2x SSC containing 0.1% (w/v) SDS at 
65°C and finally two 10 minute rinses in 0. lx SSC at 65°C. The filters were then air- 
dried and placed into a photographic cassette overlaid with photographic film. After an 
overnight exposure at -80°C the film was developed and, if necessary, a longer exposure 
was set up. 
2.3.14 Labelling of DNA fragments for use as probes and markers 
2.3.14.1 Nick translation of DNA probes 
DNA fragments, between 250 and 1500 bp long, were isolated as mentioned previously in 
section 2.3.3 and the DNA resuspended in a small volume of distilled water. The DNA 
concentration was calculated spectrophotometrically and a volume equivalent to 1 µg was 
placed in a sterile Eppendorf tube and the volume made up to 9 p1 with water. To label, a 
4gl volume of dNTP mix (minus dATP), followed by 5 µl oc32P dATP and 2 µl DNA 
polymerase 1 (all from an Amersham Nick translation kit) was added to the DNA, mixed 
and the tube placed in a 150C waterbath for 2 hours. To stop the reaction, 30 tl of water 
and 3.3 µl 5M NaOH were added and the reaction placed at room temperature for 10 
minutes. On the addition of a further 46.7 µl distilled water the probe was purified on a 
small column of G. 50 Sepharose. The labelled DNA was eluted and 5 µl counted in a 
Beta counter (Wallac). A volume equivalent to 5x106 cpm was used to probe Southern 
blots. 
2.3.14.2 Random priming of DNA probes 
To achieve labelling of higher specific activity than that possible with the nick translation 
method, a random priming kit (Prime-it) from Stratagene was employed. A volume of 
purified DNA solution, equivalent to 1 µg, was adjusted to 24 µl, with water, and 10 µl of 
random nonanucleotide primers (27 OD units/ml) was added. After heating to 95°C for 5 
minutes and cooling to room temperature, 10 µl 5x buffer (0.1 M dNTPs minus dATP), 5 
µl a32P dATP and 1 µl T7 DNA polymerase (2 U/µl) was added and the reaction allowed 
to continue at 37°C for 10 minutes before the addition of 2 µl stop mix (100 µl 0.5 M 
EDTA pH 8.0). The probes were purified by passage through G. 50 columns and a5 µl 
sample of the eluted product counted on a Beta counter (Wallac). A volume equivalent to 
5x106 cpm was used to probe blots. 
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2.3.14.3 End labelling of markers for Southern blots 
To assist the size determination of labelled fragments on Southern blots, it was 
advantageous to include radio-labelled markers on each gel. To achieve labelling of 
markers which were of varying fragment length, the method of end labelling was 
employed. A 15 µl volume of commercially made Lambda DNA (Boehringer 
Mannheim), enzymatically digested with both Eco RI and Hind III (Boehringer 
Mannheim), was mixed with 3 µl distilled water, 3 µ110x Klenow buffer (0.5 M Tris-HCI 
pH 7.6,0.1 M MgC12), 3 µl dNTP mix minus dATP (20 mM each), 5 µl a32P dATP and 
I µl Klenow polymerase I. The reaction was allowed to proceed at room temperature for 
20 minutes followed by 20 minutes at 370C and finally, 10 minutes at 65°C. The probe 
volume was adjusted to 100 µl with distilled water and the labelled DNA purified on a 
column of G. 50 Sepharose. After counting a5 µl sample in a Wallac Beta counter, a 
volume equivalent to 5x106 cpm was incorporated into each experimental gel run in 
addition to unlabelled markers. 
2.3.14.4 Campath antigen RNA nuclear run-on probes 
To probe cellular RNA extracts for Campath antigen RNA levels, it was necessary to 
radioactively label the RNA transcripts from a Bluescript KS+ vector based plasmid 
(Stratagene), in which the gene encoding the antigen CDw52 was cloned as an Hind III/ 
Eco RI insert. The vector incorporates the T3 and T7 promotors either side of the 
multiple cloning site to aid in vitro transcription in either orientation. The plasmid was 
linearised with either of the restriction enzymes Xba I (forward probe) or Asp 718 (reverse 
probe) to ensure transcripts of known length. The probes were transcribed, employing 
reagents from a Promega RNA protection kit in either forward (T3 promotor) or reverse 
(T7 promotor) orientation, by mixing 0.1 . tg of linearised plasmid with 3.5 Ri distilled 
water, 4 µl 5x buffer, 2 µl 100 mM dithiothreitol (DTT), 1 Ri RNAase-inhibitor, 4 µl 
dNTP mix minus dCTP, I µl dCTP, 2.5 µl a32P dCTP and I µl of the relevant promotor 
polymerase. After gentle mixing and centrifugation, the reaction was incubated at 370C 
for 1 hour proceeded by the addition of 1 µl RNAase and 1 µl RQ DNAase and further 
incubation at 370C for 15 minutes. The reaction was terminated by adding 25 Ri TE (10 
mM Tris-HCI, 1 mM EDTA pH 8.0) followed by purification of the probes via 
centrifugation through pre-equilibrated microspin columns (Pharmacia). A1 Ri sample 
was counted in a Beta counter (Wallac) and a volume equivalent to 105 cpm used in each 
assay. 
2.3.15 Nuclear run-on assays for the detection of Campath antigen (CDw52) 
To assay for Campath RNA transcripts, cells were harvested by centrifugation at 1500 
rpm in a Sorvall RT6000B bench centrifuge, washed in PBS three times and resuspended 
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at 107/ml in the lysis buffer supplied in a kit from the company Upstate Biotechnology 
(USB). The cell pellets and buffer were mixed by vortexing, left on ice for 10 minutes to 
allow lysis to proceed and the lysates frozen at -80°C until required. On thawing, 50 µl 
aliquots of each lysate were mixed with 105 cpm of either forward (control) or reverse 
(test) orientation nuclear run-on labelled probe and the reaction tubes placed at 37°C 
overnight to allow annealing. Once the annealing reaction had occurred, 500 µl of an 
RNAase mix (450 tl water, 50 µl lOx buffer plus 2 µl RNAase) was added to each tube 
and the tubes were gently inverted and placed at 37°C for 30 minutes to digest any 
remaining free probe. This was followed by the addition of 20 µl 10% (w/v) SDS and 20 
µl protease also from a Promega RNA protection kit. The tubes were vortexed, quickly 
centrifuged and returned to 37°C for 30 minutes prior to the addition of 500 µl iso- 
propanol. The precipitated labelled fragments were pelletted by centrifugation in an 
Eppendorf microfuge at 14000 rpm, washed in 180 µl 70% (v/v) ethanol and the pellets 
air-dried. Each pellet was resuspended in 10 µl sequencing dye from a Sequenase 2 kit 
(USB), heated to 95°C for 5 minutes and 5 µl loaded onto a 75.0 ml prewarmed 6% 
sequencing gel alongside 5 µl labelled p b174 / Hinf size markers and 1-5 µl undigested 
probe. After a2 hour electrophoresis run at 40 mA the gel was transferred to Whatman 
3MM paper, dried at 70°C and placed into an autoradiograph cassette with Kodak film. 
The film was developed the next day. 
2.3.16 Purification and isolation of cellular RNA 
Cells were harvested from flasks, pelletted by centrifugation in a Sorvall RT6000B bench 
centrifuge, washed in PBS three times and counted. The cells were resuspended to 107/ml 
in an aliquot of stock solution (250 g guanidinium iso-thiocyanate, (Fluka/Sigma) 
dissolved, at 65°C, in 293.0 ml water; 17.6 ml 0.75M sodium citrate pH 7.0; 26.4 ml 10% 
(v/v) sarcosyl), 36 pl of ß-mercaptoethanol was added to each 5.0 ml aliquot immediately 
prior to addition to the cell pellet (Chomczynski and Sacchi 1987). A 1/10th volume of 
2M sodium acetate, an equal volume of phenol: water (1: 1) and 1/5th volume chloroform: 
isoamyl alcohol (24: 1) was added sequentially and the reaction tubes were shaken 
vigorously for 10 seconds and placed on ice for 15 minutes. Following centrifugation at 
14000 rpm, in an Eppendorf microfuge at 40C, each upper aqueous layer was removed to 
a fresh tube, an equal volume of iso-propanol was added and the tube was placed at -200C 
for 1 hour. A further centrifugation at 14000 rpm, at 40C for 20 minutes was followed by 
the resuspension of the resulting pellet in the guanidinium iso-thiocyanate plus ß- 
mercaptoethanol solution (300 µl/ml) and an equal volume of isopropanol was added. 
After at least 1 hour at -200C the solution was centrifuged for 10 minutes, 14000 rpm at 
4°C, washed in 75% (v/v) ethanol, recentrifuged and the pellet air-dried. When required, 
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the RNA pellet was redissolved in 50 t1 sterile distilled water which had previously been 
treated with di-ethyl pyrocarbonate (DEPC). 
2.3.17 The preparation of messenger RNA (m-RNA) 
Total RNA was assessed for RNA content spectrophotometrically at 260 Mn and a 
volume equivalent to 75 µg was adjusted to 100 µl with DEPC treated distilled water. The 
RNA solution was heated to 65°C for 2 minutes and added to 1 mg of pre-washed 
magnetic Dynabeads from a m-RNA purification kit (Dynal). Following gentle mixing 
and hydridisation of the RNA to the beads for 3-5 minutes, the reaction tube was placed 
within the Dynal MPC-E-1 magnet for 30 seconds and whilst in situ, the excess 
supernatant removed. The beads, plus bound m-RNA, were washed twice with 200 µl of 
washing buffer as per kit instructions. The application of a small volume of elution buffer 
(5 µl) followed by heating the reaction mix to 65°C for 2 minutes and subsequent use of 
the magnet, enabled the eluted m-RNA to be removed in solution. The m-RNA was stored 
frozen at -700C until required. 
2.3.18 The preparation of cDNA from m-RNA 
2.3.18.1 1st strand synthesis of cDNA 
Reagents from a Superscript kit (Gibco/Life Technologies) were employed to convert m- 
RNA to first strand cDNA. A volume of m-RNA equivalent to 5µg, plus 2 tl of 5 µg/µ1 
Not 1 primer-adaptors, was diluted to 10 µl with DEPC treated water. The mixture was 
heated to 70°C for 10 minutes and quickly cooled on ice. The tube contents were briefly 
centrifuged in a microfuge prior to the addition of 4 tl 5x first strand buffer, 2 µl 0.1M 
DTT, 1 µl 10 mM dNTP mix and 1 µl a-32P dCTP (Amersham 1 tCi/µl). Once mixed, 
the reaction was allowed to equilibrate at 37°C for 2 minutes prior to the addition of 2 tl 
(400 units or U) Superscript Reverse Transcriptase. A further incubation at 37°C for one 
hour followed. The reaction was terminated by placing the tube on ice and to calculate 
first strand dCTP specific activity and eDNA yield, a2 µl sample was removed, mixed 
with 43 t1 20 mM EDTA plus 5 tl yeast t-RNA for subsequent dotting onto duplicate 
glass fibre filters. The remaining 18 tI was taken directly onto second strand synthesis. 
2.3.18.2 2nd strand synthesis of cDNA 
On ice, 18 µl first strand cDNA was mixed with 93 µl DEPC treated water, 30 . tl 5x 
second strand buffer, 3 µl 10 mM dNTP mix (a, 32P dCTP is optional for this step), 1 tI 
10 unit/µl E. coli DNA ligase, 4 p1 10 unit/µl E. coli DNA polymerase and 1 p12 unit/µl 
E. coli RNAase H. The tube contents were mixed and incubated at 160C for 2 hours prior 
to the addition of 2 µl (10 U) T4 DNA ligase. The reaction was incubated for a further 5 
minutes at 160C before termination with 10 µl 0.5M EDTA. If radioactive dCTP had 
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been incorporated in the assay, a 10 gl sample was removed and mixed with 35 µl 20 mM 
EDTA plus 5 µl yeast t-RNA for second strand yield calculations. The remaining reaction 
mix was vortexed thoroughly with 150 µl phenol: chloroform: isoamyl alcohol (25: 24: 1) 
and centrifuged in an Eppendorf microfuge for 5 minutes at 14000 rpm. The upper 
aqueous phase was removed to a fresh tube containing 70 µ17.5M ammonium acetate and 
500 µl -200C absolute ethanol was added and the tube immediately centrifuged for 20 
minutes at 14000 rpm. The supernatant was carefully discarded and the pellet washed 
with 180 µl 70% (v/v) ethanol prior to drying at 370C for 10 minutes. The cDNA was 
resuspended in sterile distilled water and stored at -70°C. 
2.3.19 Polymerase chain reaction (PCR) 
Reagents from a Perkin Elmer GeneAmp PCR kit were employed for routine 
amplification assays (Saiki et al 1988). Initially an overlay of 100 tl of light mineral oil 
(Sigma) was added to each 0.5 ml sterile Eppendorf tube followed by the individual 
reagents in the following order, 61.5 µl sterile water, 10 µl IOx amplification buffer (100 
mM Tris-HC1 pH 8.3,500 mM KCI, 15 mM MgC12 and 0.01% (w/v) gelatine), 8 µl of a 
blend of dNTP's (mixed 1: 1: 1: 1,200 pM each final concentration), 0.5 t1 Taq polymerase 
(500 units/100 µl, Perkin Elmer Cetus), 5 p1 each of 0.2 µg/µl forward and reverse 20-30 
mer oligonucleotide primers and finally either 100 ng of plasmid DNA, cellular DNA or 
cDNA in a 10 p1 volume. The specific primers for each target were custom made by Hugh 
Spence in the Department of Molecular Biology, Wellcome Research Laboratories, 
Beckenham. Controls for each assay routinely included known positive controls (if 
available), plus sample tubes containing mixes minus either target DNA or primers. In the 
situation in which several samples shared common components, these were made up as a 
premix from which aliquots were removed into separate sample tubes prior to the addition 
of DNA. The components were vortexed and gently sedimented by centrifugation, the 
tubes placed into a Hybaid intelligent thermocycler block and a pre-programmed series of 
one 1.5 minute 94°C strand separation step followed by thirty cycles of 37°C for two 
minutes, 72°C for three minutes, 94°C for one minute, executed. A final cycle of 37°C 
for two minutes, 72°C for ten minutes prior to cooling, completed each amplification 
experiment. PCR products were isolated from the overlay of oil by the addition of 100 Al 
of chloroform to, and the vortexing and centrifugation of, each tube and the removal of 
the upper aqueous layer to a fresh tube for storage at -200C. Confirmation of PCR product 
was shown by the electrophoresis of a 10 µl aliquot of the aqueous layer (mixed with 5 µl 
DNA loading dye) on a 50.0 ml 3% (w/v) GTG agarose (FMC): 1% (w/v) agarose gel. 
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2.3.20 Sequencing of cloned DNA inserts 
Aliquots of 1-5 µg plasmid preparation were placed into a sterile 0.5 ml tube and the 
volume adjusted to 18 µl with distilled water. A2 tl amount of fresh 2M NaOH/2 mM 
EDTA was added and the tube contents mixed and placed at 65°C for 15 minutes prior to 
the addition of 2 µl 3M NaOAc and 50 µl 100% ethanol. The tube was placed on dry ice 
for 30 minutes to allow precipitation of the denatured DNA. The resulting pellet was 
washed in 180 µl 70% ethanol by centrifugation in an Eppendorf microfuge, 14000 rpm 
for 5 minutes and air-dried. The pellet was resuspended in 6 µl of distilled water and 
utilising reagents from a USB Sequenase 2 kit (Tabor and Richardson 1987 and 1989), 
mixed with 4 µl annealing mix (1 µl relevant sequencing primer, 2 µl 5x buffer, 1 gi 
water). The tube contents were sedimented by quick centrifugation, heated to 65°C for 10 
minutes and annealed by slow cooling to room temperature. After cooling, a 5.5 gi 
volume of labelling mix (2 µl of 1 in 5 diluted dNTP's, 2 µl 1 in 8 diluted Sequenase T7 
DNA polymerase, 1 µl 0.1 M DTT and 0.5 µl 
35S dATP) was added to the sample on ice 
and the tube transferred to 37°C for 15 minutes. To permit strand extension and 
termination, 3.5 µl aliquots of the mix were transferred into four fresh tubes, each of 
which contained 2.5 gl of either pre-heated ddATP, ddCTP, ddGTP or ddTTP 
respectively and the tubes replaced at 37°C for 10 minutes. The reactions were stopped 
by the addition of 4 µl dye mix and were often stored frozen, at this stage, until required. 
After heating to 95°C for 2 minutes, 4 µl samples of the sequencing reactions were 
electrophoresed on a prewarmed 8% sequencing gel which had been assembled the 
previous day. The electrophoresis conditions were 40 mAmp (mA) for 1.5 hours. The 
reloading and further electrophoresis of additional 4 µl aliquots of the same samples was 
used if longer stretches of sequence were required. Transfer of the gel onto 3MM paper 
(Whatman), which was subsequently dried and exposed to Kodak autoradiographic film, 
led to the visualisation of the sequence patterns. 
2.3.21 The preparation of sequencing gels 
A volume of 75.0 ml urea/SDS gel mix 8 from Gibco/Life Technologies was mixed with 
450 µl 1% (w/v) ammonium persulphate. This was then gradually pipetted into a pre- 
assembled sequencing mould composed of two large glass plates, separated by two 0.4 
mm spacers, sandwiched together and taped on both sides and the bottom with waterproof 
sequencing tape (Gibco). Whilst still liquid, a 0.4 mm 48-toothed sharkstooth comb was 
inserted into the top of the gel and the whole assembly rested almost horizontal to 
solidify. When set, the top of the gel assembly was wrapped in Saran cling wrap and the 
gel stored overnight at 4°C. To prewarm, the gel was electrophoresed at 40 mA in lx 
TBE buffer (lOx stock solution 108g Trizma base, 55g Boric acid, 40.0 ml EDTA per 
litre) for 1.5 hours prior to the loading of sequencing reactions. 
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2.4 BIOCHEMICAL TECHNIQUES 
2.4.1 Tunicamycin treatment of engineered NSO cells to remove N-linked 
carbohydrate 
Prior to full tunicamycin treatment, cells in tissue culture were pre-treated for 6 hours by 
the addition of 1.0 ml of 1000x stock tunicamycin solution (Boehringer Mannheim 1 
mg/ml in 0.1M NaOH) to each litre of cells in culture. For full treatment, the cells were 
harvested with trypsin and EDTA, centrifuged in 250.0 ml sterile centrifuge pots for 10 
minutes at 1500 rpm in a Sorvall RC5B and then resuspended in the same volume of fresh 
medium containing 1 mg/ml tunicamycin. The cells were replaced into a humid CO2 
incubator at 370C for 3 days. The resulting aglycosylated antibody was isolated by fast 
protein liquid chromatography (FPLC, Pharmacia) and the level of aglycosylation 
assessed by reduced sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) analysis. 
2.4.2 3H ethanolamine labelling of cells 
Transfected or parental CHO cells were harvested from tissue culture utilising trypsin and 
EDTA, washed in the relevant medium and adjusted to 5x104 cells/ml. Aliquots of 2.0 ml 
were pipetted into duplicate wells of 6 well tissue culture plates and the plates incubated 
at 37°C until the cells became 80% confluent. A volume of 3H ethanolamine (1 mCi/ml 
Amersham) was diluted 1 in 10 in the relevant medium and 0.2 ml was added to each 
tissue culture well. After an 18 hour incubation period, the cells were harvested, washed 
twice in PBS and resuspended, in PBS, to a concentration of 106 cells/ml. To assess 
incorporation of 3H ethanolamine into GPI-anchors, the cells were further diluted either I 
in 10 or 1 in 100 with reducing sample buffer for analysis on SDS-polyacrylamide gels 
alongside unlabelled and 14C labelled rainbow markers (14300-200000 molecular weight, 
Amersham). 
2.4.3 35S methionine labelling of cells 
Cells to be radioactively labelled were harvested from tissue culture flasks with trypsin 
and EDTA and washed, in methionine-free medium (Gibco/Life Technologies), by 
centrifugation in a Sorvall RT6000B centrifuge at 1500 rpm for 5 minutes at room 
temperature. The cells were counted by trypan blue exclusion and corrected to 2x105 
cells/ml in methionine-free medium prior to aliquoting a volume of 10.0 ml into a 25 cm2 
tissue culture flask which was laid horizontal to permit adherence. Once the cells had 
adhered, the medium was removed and 10.0 ml fresh methionine-free medium added and 
the flask replaced at 370C in a humid CO2 incubator for several hours. A 14 tl aliquot of 
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35S methionine 70% / cysteine 30% (Amersham, 
35S methionine 5 mCi per 500 t1 / 
cysteine 2.5 mCi per 500 µl ) was added and the 
incubation continued overnight. After 
harvesting with trypsin and EDTA and washing the cells in three washes of 
PBS, the 
pellets were analysed for 
35S incorporation on SDS-polyacrylamide gels alongside 
unlabelled and 14C labelled rainbow markers. 
2.4.4 Phosphatidylinositol specific Phospholipase C (PIPLC) treatment of cells to 
remove GPI-anchored antigen 
Cells to be treated were harvested with trypsin and EDTA prior to three washes in 
medium containing 1% (v/v) FCS. The cells were resuspended to 
2x106 cells/ml in the 
same medium and for each antigen to be assayed, three aliquots of 150 µl dispensed 
into 
sequential wells of a round bottomed 96 well microtitre plate. To one of the wells, 7 µl of 
PIPLC (Boehringer Mannheim, 308 U/200 µl) was added whilst the remaining two wells 
were left as controls. The plate was placed at 370C for 90 minutes and then the cells 
washed, in situ, with three washes of PBS. To visualise each antigen, all cells were 
resuspended in 100 µl FACS staining buffer and two wells (one of which was PIPLC 
treated) were stained with specific FITC-labelled antibodies as described in 2.2.1, whilst 
the third well was stained with a non-specific antibody or left in PBS. All samples were 
analysed on a Becton Dickinson FACScan analyser. 
2.4.5 Removal of oligosaccharides from antibody by Hydranzinolysis 
Utilising a technique derived from an Oxford Glycosystems N-glycan Recovery kit and 
based on hydrazine cleavage (Patel et at 1993), a volume of antibody equivalent to 5 mg 
was dialysed twice against one litre changes of water overnight prior to freeze drying in 
an acid-washed glass ampoule. Hydrazine (0.1 ml) was added and the ampoule heated, in 
a thermostatically controlled block, to 950C for 5 hours. The released oligosaccharides 
were isolated by resuspending the sample in 1.5 ml butanol: ethanol: acetic acid solution 
(4: 1: 0.5) and passing the mixture through a 1.0 ml Whatman CF-11 cellulose column, 
previously equilibrated with 4.0 ml of the same solution. After three 1.0 ml washes with 
butanol: ethanol: acetic acid (4: 1: 0.5), followed by three 1.0 ml washes with butanol: 
ethanol: water (4: 1: 1) the bound oligosaccharides were finally washed with 1.0 ml of 
methanol and the column flow stopped. N-reacetylation of the samples occurred by the 
sequential addition of 1.0 ml methanol and 0.4 ml acetic anhydride, the majority of which 
was allowed to pass through the column prior to stopping the column flow for 30 minutes. 
The bound oligosaccharides were again washed four times in 1.0 ml aliquots of butanol: 
ethanol: water (4: 1: 1) proceeded by a 1.0 ml methanol wash. To elute the free 
oligosaccharides, the column was washed with two 1.0 ml volumes of 0.2M sodium 
acetate and the eluate collected. Final treatment of the sample involved the addition of 0.1 
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ml acetic anhydride and after 30 minutes at room temperature, the addition of 0.1 ml of 
0.1M copper acetate in 0.1M acetic acid and a further 30 minute incubation. Passage of 
the isolated oligosaccharides through a 1.0 ml column of mixed bed ion exchange resins 
Chelex 100 and AG-50 (pre-washed with water), led to the recovery of water eluted 
oligosaccharides ready for freeze drying. The oligosaccharides were later analysed by 
either high-performance anion exchange chromatography (HPAEC, Dionex) or by laser 
desorption-mass spectrophotometry (LDMS, Finnigan). 
2.4.6 Analysis of oligosaccharides by Dionex HPAEC 
Separation of oligosaccharides was by Dionex HPAEC using a Carbopak PA-1 column, 
elution buffer with a linear gradient of 24-36 mM sodium acetate in 125 mM NaOH over 
20 minutes and a flow rate of 1.0 ml/minute. Detection of the samples was by pulsed 
amperometry using a gold electrode. An internal standard of sialyic acid (neuraminic 
acid) was included to determine relative retention times of the isolated oligosaccharide 
peaks. 
2.4.7 Analysis of oligosaccharides by LDMS 
Samples of desialylated oligosaccharides (1-20 pmol) in 1 µl of water were mixed with I 
µl 2,3-dihydroxy benzoic acid (DHB, 10 mg/ml in 50% (w/v) ethanol) as the matrix 
component and aI tl aliquot allowed to dry onto a sample slide. Ionisation by irradiation 
with a pulse of laser light was followed by analysis with a Lasermat time-of-flight mass 
spectrophotometer (Finnigan MAT). 
2.4.8 Enzymatic removal of carbohydrate from oligosaccharides 
These techniques were performed by Robert Lifely and Susan Boyce of the department of 
Molecular Immunology, Wellcome Research Laboratories, Beckenham and the methods 
are briefly outlined below. Analysis of oligosaccharides was by Dionex HPAEC and 
LMDS (Finnigan). 
2.4.8.1 Desialylation of oligosaccharides 
Oligosaccharides were treated with 40 mM trifluoracetic acid at 800C for 1 hour under 
helium. The trifluoracetic acid was removed under a stream of air at 400C and the sialic 
acid content measured by Dionex HPAEC. 
2.4.8.2 Exoglycosidase treatments of oligosaccharides 
Exoglycosidases including bovine testes galactosidases, bovine epididymis fucosidase 
and jack bean meal N-acetylhexosaminidase were obtained from Oxford Glycosystems. 
Oligosaccharides (5-10 g) were incubated with enzyme, following the manufacturers 
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instructions, at 370C for 48 hours. Samples were purified by passage through a column of 
mixed bed ion exchange resins, 0.3 ml Dowex AG-50 layered upon 0.3 ml 
Dowex AG-3 
and were eluted with water. The samples were lyophilised prior to analysis on a 
Dionex 
HPAEC. 
2.4.9 Isolation of NSO-F and CHO-Campath-111 antibody from culture supernatants 
Transfected NSO. F and CHO cell culture supernatants were harvested from 8000 litre 
bioreactors, clarified by centrifugation and passed through 0.2µm filters. The antibodies 
were captured on protein A-Sepharose columns and eluted with 0.1M citrate 
buffer (pH 
3.0), then bound to S-Sepharose ion-exchange columns and eluted with 20mM citrate- 
phosphate buffer containing 200mM NaCL. The eluates were concentrated, 
desalted and 
monomeric antibody separated from dimeric and polymeric antibody utilising a Superdex 
200 size-exclusion column. (Lifely et al 1995). The CHO Campath-1H utilised in assays 
was of a single clinical trial batch made and lyophilised prior to the start of this project. A 
single batch of NSO. F Campath-1H was produced from the clone C7F10 9D4-5A11 in 
October 1993. 
2.4.10 Isolation of NSO. S, PF and CF antibody from culture supernatant utilising 
fast protein liquid chromatography (FPLC) 
Transfected NSO cell culture supernatants were collected and pooled after each 
subculture. The antibody containing fluid was centrifuged in a Sorvall RT6000B 
centrifuge at 1500 rpm for 5 minutes to remove cell debris and filter sterilised through a 
0.2 micron filter prior to storage at 40C. When 100.0 ml volumes were available, the 
amount of antibody in the supernatant was assessed by an anti-human Ig ELISA and the 
antibody purified. A Pharmacia FPLC system was programmed to siphon the supernatant 
through a 1.0 ml Hi-Trap protein G column at 2.0 ml/minute, wash the column with 
excess PBS and elute the antibody in 0.1M glycine pH 2.0. Protein G usage minimised 
bovine Ig contamination from FCS containing supernatants. The resulting eluate was 
neutralised with 1M Tris-HC1 pH 8.8 prior to extensive dialysis against PBS over a 48 
hour period. The antibodies were re-sterilised by filtration and stored at 40C until 
required. Two batches of NSO. S (#s 1 and 2) were produced in August 1992, two batches 
of NSO. PF (# 1) in October 1992 and (#2) in February 1993 and one batch of NSO. CF in 
May (1993). Unless stated, all antibodies utilised in the assays were from the clone OF 10 
9D4-5A11. 
2.4.11 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Utilising a variation of the method of Laemmli (1970) and a stock solution of pre-mixed 
30% (w/v) acrylamide/0.8% (w/v) bis acrylamide, variable percentage acrylamide gels 
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were prepared for SDS-PAGE analysis. The gel mix was diluted to the desired 
concentration (usually 10%, therefore 10.0 ml) by the addition of water up to 18.7 ml and 
the sequential addition of 11.2 ml of 1M Tris-HC1 pH 8.8, followed by 0.3 ml 10% (w/v) 
SDS, 0.1 ml 10% (w/v) ammonium persulphate and 20 gi tetramethylethylenediamine 
(TEMED, Sigma). After gentle mixing by inversion, the liquid gel was pipetted into a 
mould of two glass plates, separated by 0.75 mm spacers, sandwiched together in a 
Hoeffer mini gel apparatus. An overlay of 2.0 ml N-butanol was pipetted onto the gel and 
the whole left to polymerise. Once solid, the gel surface was rinsed with several washes 
of water, drained well and a 5% stack gel containing 1.67 ml 30% gel mix, 1.25 ml 1M 
Tris-HC1 pH 6.8,0.1 ml 10% (w/v) SDS, 50 gl 10% (w/v) ammonium persulphate and 
10 µl TEMED in a final volume of 10.0 ml was poured around a 10 slot 0.75 mm toothed 
comb. To electrophorese samples in a reduced form, 0.65 ml sample buffer (1.88 ml 1M 
Tris-HC1 pH 6.8,6.0 ml 10% (w/v) SDS, 3.0 ml glycerol and 2.12 ml water) was pre- 
mixed with 0.1 ml 1.5M dithiothreitol/0.1% (w/v) bromophenol blue and an equal volume 
added to the test sample (if the samples were to be electrophoresed in a non-reduced form 
the dithiothreitol was omitted). The sample was heated to 100°C for 5 minutes and cooled 
on ice prior to electrophoresis at 40 mA in a single strength run buffer of 3.03g Trizma 
base, 14.42g glycine and 1. Og SDS per litre of water. 
2.4.12 Immunoprecipitation of antigens 
Pellets of between 5x106 and 107 cells were resuspended in 500 µ1 lysis buffer (0.5g 
octylglucoside, 2.8 ml 2.5M NaCl, 500 µl 1M Tris-HCl pH 8.0,200 µ10.5M EDTA, 250 
µ10.2M phenylmethylsulphonyl fluoride (PMSF), 500 tl aprotinin 2 mg/ml and a small 
amount of iodoacetamide per 50.0 ml water), mixed well and placed on ice for 30 
minutes. Cell debris was removed by centrifugation at 14000 rpm, 40C for 30 minutes in 
an Eppendorf refrigerated 5402 centrifuge. Pre-clearing of the lysate was accomplished 
by a 20 minute end-over-end rotation with 100 t1 of 50% (v/v) Sepharose 4B beads which 
had been previously washed in three changes of 100 gl lysis buffer. Immunoprecipitation 
of the desired antigen was achieved by exposing the pre-cleared lysate to 20 µ1 washed 
50% (v/v) Sepharose 4B beads which had been pre-coated with a relevant antibody such 
as Campath 1H F(ab')2,4 mg/ml. A 30 minute end-over-end rotation at RT was followed 
by five washes of the Sepharose beads with 5x 1.0 ml aliquots of lysis buffer. To separate 
precipitated antigens, the antigen linked Sepharose beads were mixed with 20 R1 reducing 
sample buffer and electrophoresed on SDS-polyacrylamide gels alongside either 14C 
labelled or unlabelled rainbow markers (Amersham). To visualise the antigens, the gel 
was stained with 1% (w/v) Coomassie blue in 10% (v/v) acetic acid, 45% (v/v) methanol 
prior to destaining in 7% (v/v) acetic acid, 20% (v/v) methanol. If the cells had been 
radioactively labelled prior to the immunoprecipitation, the resulting gel was not stained 
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but soaked in destain solution for 20 minutes, agitated in Amplify solution (Amersham) 
for 20 minutes, dried onto 3MM filter paper and exposed to photographic film overnight 
at -70°C. 
2.4.13 Western blotting and detection of immunoprecipitated proteins 
For antibody detection of specific proteins, SDS-polyacrylamide gels were not stained but 
the proteins were transferred to nitro-cellulose via the method of western blotting 
(Towbin et al 1979). The transfer of proteins was accomplished by the use of an Anthos 
semi-dry blotting apparatus and a blotting buffer composed of 2.9 g glycine, 5.8 g Trizma 
base, 3.7 ml 10% (w/v) SDS and 20% (v/v) methanol per litre. Prior to the gel being 
placed in the apparatus, a sandwich of three squares of 3 MM filter paper and one piece of 
nitro-cellulose paper were cut to the correct size for the gel, soaked in blotting buffer and 
laid, nitro-cellulose uppermost, onto the cathode face of the apparatus. The gel was 
removed from the gel template and placed onto the nitro-cellulose paper. A further three 
pieces of buffered soaked filter paper were overlaid onto the gel and by the use of rolling 
a glass rod over the stack, air bubbles were carefully removed. The anode face of the 
blotting apparatus was lowered onto the gel stack and a current of 200 mA applied for 15 
minutes. The nitro-cellulose paper bearing the proteins was removed from the apparatus 
and soaked in 10.0 ml PBS containing 3% (w/v) milk powder (Marvel) overnight at 4°C. 
The following day, the PBS/milk reagent was replaced with a fresh 10.0 ml aliquot to 
which was added 30 µl biotinylated antibody of choice, i. e. biotinylated anti-CD4 
antibody Q4120 (Sigma). If biotinylated antibody was not available, unlabelled antibody 
was used at the same dilution. After 1.5 hours of gentle agitation at room temperature, the 
filter was washed six times in PBS containing 0.1% (v/v) Tween 20 prior to the addition 
of a1 in 1000 dilution of the detecting reagent, streptavidin bound horse radish 
peroxidase (Strep-HRP Sigma). If an unlabelled antibody had been applied previously, 
the same dilution of an anti-species antibody coupled to HRP was substituted. The 
visualisation of the specific protein was achieved by utilising an enhanced 
chemiluminescence, ECL, detection kit (Amersham) as per the manufacturers 
instructions. 
2.5 GRAPHICS 
The graphics were devised utilising the Origin (version 3.5) software package. The 
concentration of antibody giving either 50% of the maximum value specific lysis or 50% 
inhibition in each experiment is presented at the bottom of each graph or in the associated 
text. 
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CHAPTER THREE: RESULTS - MECHANISM OF ACTION OF THE CHO 
ANTIBODY 
3.1 Introduction: 
Campath-1H was the trade name of a Glaxo-Wellcome IgGI 'humanised' antibody which 
recognises the CDw52 antigen on mature lymphocytes, monocytes and macrophages. It is 
derived from a rat IgG2a, class-switched to IgG2b, monoclonal antibody isolated 
following the immunisation of rats with human T cells (Introduction, section 1.6). The rat 
monoclonal antibody, Campath-1G, was found to be particularly effective in vitro at 
depleting human cells of CDw52 bearing cells prior to transplantation (Hale et al 1987). 
To overcome the problem of human anti-rat antibody (HARA) responses to Campath-1 G 
in vivo (Dyer et al 1990b), the antibody producing rat B cells were used as the source 
from which the heavy and light chain genomic DNA sequences, complete with the CDRs 
of the variable portions, were isolated for 'humanisation' (Reichmann et al 1988). The 
'humanised' heavy and light chain DNA's were re-cloned into expression vectors and 
transfected into rat YO myeloma cells for expression but yields were low. To achieve 
high expression levels, the cDNA of the heavy and light chains were re-isolated from the 
myeloma cells and re-cloned into two mammalian expression vectors (Page and 
Sydenham 1991) and both plasmids were co-transfected into CHO cells for expression. 
Preliminary ADCC data comparing YO and CHO-derived Campath-1H suggested that 
the antibodies differed in efficacy in in vitro assays (Crowe et al 1992). A hypothesis was 
established predicting that the variation might be due to differences in N-linked 
glycosylation of the Fc portion of the antibody induced by the expressing cell line. To 
investigate this theory it was thought necessary to define the mode of action of CHO 
Campath-1H in a limited range of assays. 
3.2 Results discussed within this chapter 
This chapter describes the characterisation of Campath-IH antibody derived from CHO 
host cells in order to establish certain criteria on which to compare antibody prepared 
from different recombinant cell lines (Chapter four). The characterisation has been 
limited to assays which were considered to be important in the biological function of 
Campath-1H administration to patients and encompasses ADCC, monocyte mediated 
inhibition of target cell growth, the engagement of cell surface antigen and carbohydrate 
analysis. A detailed investigation of each assay attempts to define the cell types involved, 
the individual IgG FcR used plus concentration and time responses. By the use of CDw52 
negative cells, the antigen specificity of these responses was investigated. 
94 
Results 
3.3 The carbohydrate composition of Campath-IH antibody expressed in CHO cells 
3.3.1 Campath-1H aggregate levels 
Samples of Campath-1H clinical trial material which were to be used routinely in the 
following experiments were sent, for size exclusion HPLC aggregate analysis to 
determine contaminating levels of polymeric antibody, to Dr. Mark Easton in the 
Department of Biological Development, Wellcome Research Laboratories, Beckenham, 
Kent. All samples were found to contain 1.1 % polymeric aggregate. 
3.3.2 Carbohydrate profile of Campath-1H 
Dr. Robert Lifely of the Wellcome Research Laboratories, Beckenham, Kent, determined 
that within CHO Campath-1H Fc there was a major family of fucosylated N-linked 
oligosaccharides whose members differed only in terminal galactosylation (Lifely et al 
1995). He also isolated a minor non-fucosylated component. The three major peaks 
obtained from the fucosylated series represented either none, one or two terminal 
galactose residues. By releasing the monosaccharides from the oligosaccharide 
complexes, it was shown that Campath-IH contained mannose, galactose, N- 
acetylglucosamine and fucose in addition to less than 5% N-acetylneuraminic acid. No 
bisecting G1cNAc residues were identified. The structure determined to be associated 
with Campath-1H derived from CHO cells is shown in Fig. 3.1 and the carbohydrate 
profile is described in more detail in Chapter four. 
Figure. 3.1 A schematic representation of the major carbohydrate structure associated with Campath-1H. 
The dotted vertical line defines the boundary between variable and core residues. 
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3.4 The Antibody -Dependent Cell-mediated Cytotoxicity (ADCC) assay 
3.4.1 Campath-1H ADCC dose response using Wien 133 cells as targets 
ADCC assays in which Campath-1H was diluted over a range of concentrations show 
that the antibody can direct optimal cell-mediated cytotoxicity of Wien 133 target cells 
down to a concentration of 0.03 µg/ml (Fig. 3.2). The lytic effect decreased as the 
concentration was reduced below this. Multiple assays indicated that different isolates of 
effector cells varied in the level of lytic response mediated by Campath-IH and therefore 
assays were repeated several times with a selection of donor sources. Donors were found 
to vary in the concentration of Campath-1H required to achieve 50% of maximum 
specific release with the concentrations ranging between 0.0 13 and 0.0017 µg/ml. 
Figure 3.2 A Campath-1H dose response ADCC assay demonstrating donor variation. Wien 133 cells at 
2xlO5cells/ml were pre-treated with Campath-1H antibody at the amount shown prior to incubation with 
effector PBMC from three different donors. R represents donor J, " represents donor S and A represents 
donor I. The data plotted are mean % specific release ± standard errors for each concentration. The solid 
horizontal lines are maximum specific lysis (75% donor I, 65% donor S and 57% donor J) and the dotted 









Antibody concentrations leading to 50% of maximum specific lysis are; 0.0028 µg/m1 donor I, 0.0017 
µg/ml donor S and 0.0 13 µg/ml donor J. 
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3.4.2 The importance of effector cell to target cell ratio 
Effector to target cell ratios of between 100: 1 and 0.5: 1 were used to define the 
appropriate conditions over which to monitor antibody function. The antibody was used 
at a concentration of 1 . tg/ml, a level previously shown to mediate killing of target cells 
by all donor effector cells. The results (not shown) implied that adequate lysis occurred at 
effector to target cell ratios of greater than 10: 1. Subsequent assays were designed to 
incorporate a minimum ratio of 25: 1, with the targets at 104/well and the effectors at 
2.5x 105/well. 
3.4.3 Cell types involved in ADCC 
ADCC assays were performed in which cell types within PBMC effector populations 
were removed and their role in cell-mediated killing investigated. Different ratios of the 
resulting effector cell populations were used with Campath-1H at 10 4g/ml (Fig. 3.3). 
When CD3 (T) (69.13% of PBLs by FACS) or CD20 (B) (13.94%) positive cells were 
reduced to 29.27% and 0.87% respectively there was no affect. However, when CD 14 
positive monocytes were selectively reduced from 17.13% to 3.48% the ADCC response 
was also reduced. The reduction of CD56 positive cells (from 25.23% to 7.24%) totally 
ablated the ADCC response suggesting that natural killer (NK) cells are the major cell 
type involved. 
To confirm that the cell type which was critical for the ADCC response resided within 
the mononuclear cell fraction, further separations of whole blood were performed in 
which both the mononuclear and polymorphonuclear cell populations were isolated by 
differential separation on lymphoprep gradients. The two cell populations were utilised as 
effector cells over a range of effector cell to target cell ratios (Fig. 3.4) and the cell 
morphology was confirmed by Giemsa staining of cytocentrifuge samples (not shown). 
Within the polymorphonuclear effector population there was an increasing incidence of 
mononuclear cells at ratios higher than 10: 1, and thus any increase in specific lysis could 
be accounted for by the few mononuclear cells. The most active cell population for 
killing was confirmed as the mononuclear cell fraction. 
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Figure 3.3 A Campath-1H ADCC assay demonstrating the effects of PBMC effector cells depleted of 
various cell types. Wien 133 cells at 2x I O`cells/ml were treated with 10 µg/ml Campath- IH prior to 
incubation with various ratios of effector cells depleted with antibody.   represents total PBMC, " 
represents PBMC minus CD56 positive cells, A represents PBMC minus CD 14 positive cells, V represents 
PBMC minus CD20 positive cells and f represents PBMC minus CD3 positive cells. The data plotted are 
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Figure 3.4 A Campath- IH ADCC assay demonstrating the differences between mononuclear and 
polyrnorphonuclear cells as cilector populations. Wien 133 cells at 2xI05cells/ntl were treated with 
Campath-IH or medium prior to incubation with various ratios of either mononuclear or 
polymorphonuclear effector cells.   represents mononuclear cells in the presence of' Campath- I H_ " 
represents polymorphonuclear cells in the presence of Campath- I H, A and V represent mononuclcar and 
polymorphonuclear cells, respectively, in the absence of' Campath- IH antibody. The data plotted are mean 
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3.4.4 Fc R usage by peripheral blood effector cells 
'Co determine which IgG Fc receptors wcrc most prominently utilised by the IIBM(' 
effectors, antibodies (Medarex) specific for IgG Fc receptors were incorporated, (due to 
cost considerations) at a single dose of 0.5 µg in 10 µl, with effector cells prior to their 
addition to the ADCC assay. Unfortunately, the anti-Fe reagents were not tested 
independently prior to the experiments and thus were not demonstrated to influence 
receptor function. The preliminary data in Fib!. 3.5 suggests that IgG Fc Rill is the key 
receptor required for the antibody-mediated killing. Treatment with anti-Fe Rlll antibody 
increased the concentration of Campath-11-1 required to achieve 50% of maximum 
specific release from 0.00018 pg/nil to 0.06 pg/ml. Antibodies which specifically 
interfered with the Fc RI receptor also indicated a minor effect (0.0006 µg/ml required). 
At levels ofCampath-I II antibody above 0.2 µg/ml there was indiscernible inhibition. 
Figure 3.5 Fc RIII is used preferentially in Campath- I H-mediated ADCC. Wien 133 cells at 2x IO5cells/ml 
were treated with Campath- IH prior to incubation with CIlectt, r cells previously treated with anti-I ý 
receptor antibodies.   represents untreated mononuclear cells. A represents cells treated with anti-Fe RIII 
antibody. " represents cells treated with anti-Fe It11 antibody and V represents cells treated with anti-Fe RI 
antibody. The data plotted are mean (% spcrihc release ± standard errors for each concentration. Maximum 
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Antibody concentrations required for 50% of maximum specific release were, 0.00019 µg/mI untreated or 






3.4.5 Carbohydrate involvement in the ADCC mode of action - Effects of removal 
3.4.5.1 Tunicamycin treatment of antibody producing cells 
To investigate whether the carbohydrate of Campath-1H Fc CH2 antibody domain was 
involved in the interaction with the Fc receptor on the ADCC effector cell, batches of 
CHO cells producing Campath antibody were pre-treated with tunicamycin prior to the 
antibody being harvested and purified. The resulting purified aglycosylated antibody was 
compared with the standard Campath-1H, initially by SDS-PAGE to confirm the 
molecular weight change (data not included) and then in an ADCC assay to determine 
any loss of activity. Although the actual results are not shown they were similar to those 
in Fig. 3.6, in which purified antibody which had been deglycosylated with N-glycanase 
was demonstrated to be inactive in ADCC assays when used at 0.1 µg/ml and below. 
Lysis at higher concentrations of deglycosylated Campath-1H might be due either to 
carbohydrate remaining after N-glycanase treatment which was of insufficient level to be 
detected by SDS-PAGE or toxic formulation. 
3.4.5.2 Enzymatic treatment of the purified antibody 
Further studies investigating the involvement of carbohydrate structures in ADCC were 
undertaken. The various carbohydrate moieties known to be associated with Campath-1H 
(Fig. 3.1) were sequentially removed, enzymatically, from the whole purified antibody 
and the resulting antibodies were adjusted to the same protein concentration (280nm 
absorbance values) prior to utilisation in ADCC assays (Fig. 3.6). The data shows that 
pre-treatment of antibody with hexosaminidase to remove the glucosamine moiety does 
not greatly alter activity whilst the removal of all of the carbohydrate with N-glycanase 
ablates the response. In these experiments the control Campath-1H was mock treated at 
the same time as the experimental groups and all antibodies were checked by Dionex 
HPAEC prior to use in assays (performed by R. Lifely and S. Boyce). To confirm that the 
loss of activity was not due to denaturing of the antibodies during enzyme treatment, all 
samples employed in the ADCC were further checked for antigen binding using ELISA 
(data not shown) and FACS antigen binding tests (Fig. 3.7). Binding to antigen was not 
altered in either case following treatment. In future investigations it would be desirable to 
treat the antibody with enzymes to remove mannose and fucose sequentially to determine 
in more detail which core carbohydrate components are essential for IgG Fc receptor 
recognition. 
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3.6 A Campath-1 H ADCC dose response assay demonstrating the effects of various carbohydrate 
modifications. Wien 133 cells at 2xlO cells/ml vvcrc brr-treated with dilutions of enzymatically modified 
Campath- IH prior to mixing with effector cells.   represents un-modi tied Campath- I H, " represents 
Campath- IH treated with hexosaminidase to remove N-ac etylglucosamine and A represents Campath- IH 
deglycosylated with N-glycanase. The data plotted are mean 17 specific release ± standard errors for each 









Antibody concentrations required to achieve 50% of maximun, specitic lysis were; 0.0009. tg/mI for C III, 
0.003 µg/ml for hexosaminidase treated C III and 0.09 pg/ml for deglycosylated C 111. 
For FACS analysis, aliquots of antibody were taken and diluted in a series of ten fold 
dilutions (From their original concentration). The dilutions were mixed with antigen 
expressing cells and binding detected as described in the Materials and Methods section. 
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When mean fluorescence intensity values were plotted against antibody concentration the 
binding curves obtained (Fig. 3.7) were very similar. 
Figure 3.7 The mean fluorescence intensitv (MFI) of Campath- IH dilutions after enzymatic treatment of 
the antibody. Dilutions (50µI) of control  . mock hexosaminidase treated ". hexosaminidase treated A or 
deglycosylated CHO Campath-IH antihodý V were mixed with 5x10' Wien 133 cells prior to detection 
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3.5 Cytostatic effects following the engagement ot'targct cell associated ('0w52 with 
Campath-111 alone or crosslinked with anti-human Ig(; 
3.5.1 Optimisation of target cell numbers in the assay 
Four concentrations 01 Wien 133 cells were exposed to Campath-III antibody dilutions 
för five days, prior to monitoring thymidine incorporation (Fi 
. 
3.8). At the cell densities 
of 1.6,0.8 and 0.4x 104 cells/ml, thymidine incorporation reduced as the cell number 
decreased. This was independent of the presence or absence of' Campath- III antibody. As 
expected, the highest density cells incorporated thymidine at the highest level. Cells at 
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the lowest density (0.2x 104/ml) grew erratically and labelled poorly even in the absence 
of antibody. Similar assays in which CDw52 transfected Jurkat cells (see Chapter five for 
details of the clone 313/11 ) were utilised as targets gave similar results (data not shown). 
Subsequent experiments utilising either target cell line were performed with the cells at 
densities of either 4x 103 cells/well in 50 µl (Wien 133 cells) or 1x104 cells/well in 50 µl 
(transfected and parental Jurkat cells) with Campath dilutions at 50 pi well. 
Figure 3.8 The effects of the engagement of Camhath antigen (CI)w52) on Wien 133 target cells by 
Campath- I H. Wien 133 cells at I. 6(0). O. 4(A) and 0.2) V )x 10' cells/well were incubated with 
Campath- IH dilutions over a five day period prior to thymidine incorporation. The data are platted as mean 
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3.5.2 Effects of Campath-1H concentration in the assay 
Wendy Rowan (Department of Cell Biology) had shown that over a five day period, 
utilising Wien 133 cells as targets and Campath-1H at a concentration of 20 µg/ml in the 
presence of anti-human IgG (20 gg/ml), the cells stopped growing and apoptosed (Rowan 
et al 1998). Unfortunately, Wien 133 CDw52 negative variants were not available as 
controls at this time, so utilising her results as a basis, experiments were devised to 
examine the effect of Campath-1H concentration on transfected cells. Jurkat J6 cells, 
which had been transfected with the cloned cDNA for CDw52 and had been shown by 
FACS to have high Campath antigen expression (Chapter five), were used as positive 
controls in experiments which determined the effects of engaging and crosslinking the 
cell surface antigen. The parental untransfected cell line served as the negative control. 
The plates were incubated at 37°C for five days before thymidine incorporation was 
measured and the results were calculated as a percentage of the control value to aid 
comparisons between the two cell lines. When Campath antigen was expressed at high 
levels on the cell surface, as in the case of Jurkat cells expressing CDw52 (3B/11), 
Campath-11-1 antibody had a concentration dependent inhibitory effect on the final 
thymidine incorporation of those cells (Fig. 3.9). This effect was amplified by the 
introduction of the anti-human IgG antibody. In subsequent assays it was found that the 
anti-human IgG antibody was as effective at 20 gg/ml as at 40 µg/ml (data not shown). 
The thymidine incorporation of the control cells did not alter in the presence of either 
concentration. In further assays in which antibodies were compared at single doses, both 
the targeting antibody and crosslinking antibody, if present, were utilised at 50 µl/well of 
40 or 20 µg/ml. When both antigen positive and negative cells were included, the data 
was expressed as percentage control values to standardise the comparisons between the 
two cell lines. There are no standard errors with this form of data. 
3.5.3 Influence of aggregated antibody 
Campath-IH clinical trial antibody had previously been demonstrated to contain 1.1% 
polymeric aggregate by HPLC. However, if the antibody in the above assays was 
substituted with a less pure Campath antibody containing 80% aggregate i. e. di- and 
polymeric antibody, the effect of engagement with the antibody alone was more 
exaggerated (Fig. 3.9). This suggests that the mode of action was dependent upon 
crosslinking the antigen as no effector cells were involved. 
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Figure 3.9 The effects of engagement of' the Cumpath antigen (CDw52). on parental or transfected Jurkat 
cells, with Campath-1H in the absence or presence of anti-human IgG. Parental Jurkat cells or Jurkat cells 
transtected with CDw52 cDNA (10' cells/well) were incubated with 50 µl Camhath- IH dilutions, as %v ell 
with or without anti-human IgG at 40 pg/mI. 50 µl, f'o+r I'ke days Friur tu, thvmidine incorporation.   
represents parental Jurkat cells in the presence of Campath- IH dilution ." represents transfected 
Jurkat 
3/13 11 cells with Campath- IH dilution's, A represents parental Jurkat cells in the presence of both 
Campath- IH and anti-human IgG, V represents transfected Jurkut 3/131 I cells in the presence of both 
Campath- IH and anti-human ILG and " represents transiected Jurkat cells in the presence of' aggregated 
Campath- IH only. The data are plotted as mean °k of' the control value and are typical of several assays. 













Antibody concentrations giving 5(Y inhihitiom were; 0.32 µg/ml for aggregated CIH alone with 313I 
cells, 5.2 µg/ml for CIH plus anti-Hulg with 3/1111 cells and 19 tg/ml for CIH alone with 3/13 II cells. 
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3.6 Campath-I H monocyte-inediated growth inhibition of target cells assay 
3.6.1 Campath-1 H concentration response 
To establish a concentration of Campath-1 II at which monocytes reproducibly blocked 
the growth of a Campath antigen expressing target cell line, a range of antibody dilutions 
were investigated (Fig. 3.10). Inhibition of target cell thymidine uptake was optimal at 
Campath-1H concentrations greater than 0.4 tg/ml (50% inhibition at 0.1 µg/ml) and 
negligible in the absence of monocytes. At antibody concentrations less than 0.04 pg/ml 
the target cell thymidine incorporation was enhanced by the presence of monocytes. 't'his 
effect may be a consequence of monocyte cytokine production and is masked when 
results are calculated as percentage of control value. A more critical factor in the assay 
proved to be the ratio of target cell to monocyte numbers and the length of time that the 
monocytes had been in culture prior to the beginning of the experiment. 
Figure 3.10 The thymidine uptake tat Wien 133 cells over it range ul' Campath- IH concentrations in the 
presence or absence of monocvtes. Moýnocytcs (2xI0'/well in IOt) µl) or medium were precultured 
overnight prior to the addition of Camhath- IH and 4x11)' Wien 133 cells/well. Thymidine incorporation 
was monitored after five dav 5. " represents Wien 133 cells in the presence of Campath- IH whilst   
represents Wien 133 cells in the presence of both Cumpath- IH and inonocytcs. The data are plotted :n 
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3.6.2 Optimisation of monocyte to target cell ratio 
Assays were designed to aid the determination of the optimal monocyte to target cell ratio 
to use routinely in the assays. As monocyte cell numbers were limited (due to the lack of 
donors prepared to give large amounts of blood) the criteria were established by the 
collation of several assays (data not shown). It was found that a ratio of at least 2.5 
monocytes to each target cell was required, with higher ratios giving more consistent 
results. Thus, for all subsequent assays, the monocytes were utilised at a minimum of 
1.0x104/well and the targets at 4.0x103 cells/well. 
3.6.3 Monocyte Fc receptor usage 
Monocytes display an array of IgG Fc receptors on their surface (van de Winkel and 
Capel 1993) all, or some, of which could be involved in the growth inhibition effect of 
monocytes on the antibody coated target cells. To investigate individual receptor 
involvement, anti-Fc R antibodies obtained from Medarex were incorporated as blocking 
reagents within the assay, as in the ADCC experiments. The influence of single, 
combinations or no blocking antibody were explored. The preliminary results are 
displayed as counts per minute of 3H thymidine incorporation and are representative of 
several assays with low standard errors. In some future assays results will be displayed as 
percentage control value. 
In these experiments all three Fc R were indicated to be involved in the inhibition of the 
target cell growth (Fig-3.11a and b). Campath-1 H alone at 0.07 µg/ml induced 50% 
inhibition of thymidine incorporation whilst in the presence of either anti-Fc RI, anti-Fc 
Rll or anti-Fc Rill antisera respectively, 0.2 µg/ml, 0.11 µg/ml and 1.5 µg/ml Campath- 
1H was necessary (Fig 3. lla). Combined treatment with any two blocking antibodies 
(Fig 3.11 b) further reduced the inhibitive effect such that 0.4 µg/ml (anti-Fc RI plus anti- 
Fc Ril), 0.9 µg/ml (anti-Fc Rll plus anti-Fc Rlll) and 3 gg/ml (anti-Fc RI plus anti-Fc Rlll) 
Campath-1H was required to induce 50% inhibition of target cell growth. A combination 
of all three was no more effective than anti-Fc RI plus anti-Fc Rlll. In the absence of 
monocytes, i. e. the control plate, there was no visible inhibition at any Campath-11-1 
concentration (not shown). Unfortunately, the anti-Fc R antibodies were not 
independently assessed prior to the experiments and thus their influence on receptor 
function is not known. 
One feature which became evident during this series of experiments was that the time of 
harvesting of the monocytes was important, possibly because the display of receptors 
varied with time in culture. 
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Figure 3.1 1A monocytc mediated Wien 133 cell inhibition assay over a range of Campath- IH dilutions, in 
which anti-IgG Fc receptor antibodies are used to block the ntonocyte Fe receptors. Monocytes 
(1.5x I04/well) were preincuhated overnight prior to the addition of 4x I O' Wien 133 cells and 50 µ 
Campath- I H. Various anti-Fe antibodies (10 Fl, 50 µg/ml) were included during the h \c (lays prior to 
measuring thymidine incorporation. The following symbols represent; a)   untreated control. " anti-I c RI, 
A anti-Fe Rif, V anti-Fe RILL h)  untreated control, " anti-Fe RI and Rif, A anti-Fe RI and Rill, V anti- 
Fc Rif and Rill .f anti-Fe 
RI, RII and Rill. The data are plotted as mean cpm ± standard errors for each 
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3.6.4 The display of monocyte receptors with time in culture 
To investigate the range of IgG Fc receptors displayed on the cell surface at any one time, 
large amounts of human blood were collected from donors and monocytes set up in 
culture for various time periods. On days 0,7 and 14 of culture the monocytes were 
harvested, counted and aliquoted into 96 well flat bottomed plates for monocyte 
inhibition assays (as described in Materials and Methods). At each time point the 
monocytes IgG Fc R expression was determined by FACS staining using the relevant 
mouse anti-IgG Fc receptor antibody and anti-species FITC-antibody. The results 
indicated that immediately after isolation from blood the cells had a high relative level of 
IgG Fc RII, intermediate levels of IgG Fc RI but little IgG Fc RIII (Table 3.1). After one 
week in culture, the amount of staining by anti-IgG Fc RIII had increased to almost that 
of IgG Fc RI and also, RII levels had at least trebled. By week two the levels of receptor 
types RII and RIII had increased almost tenfold, whilst that of RI had decreased. 
Table 3.1. Summary of the mean fluorescence intensities (MFI) of each IgG receptor with time 
Date of harvest MFI (test minus control) 
of monocvtes PBS Fe RI Fc RII Fe RI!! 
0 0 65.3 143.77 18.1 
7 0 71.01 494.0 58.31 
14 0 38.83 1339.15 125.8 
3.6.5 The biological role of different IgG Fc receptors with time 
Although the data presented in 3.6.4 is useful it gives no indication of the potential 
biological activity of each receptor type. Experiments were performed to investigate the 
biological activity of monocyte receptors in relation to time in culture. They utilised the 
technique of blocking each type of receptor, either singly or in combinations, in assays 
using the same monocytes monitored in section 3.6.4. Campath-1H antibody was used at 
a single dose of 0.1 . tg/ml with 10 Itl of the blocking antibodies (50 µg/ml). Controls, 
minus monocytes, were included. The results are expressed as percentage inhibition of 
the control value i. e. thymidine incorporation into the target cells in the absence of 
blocking antibodies and Campath-1H. From the data in Fig. 3.12, it can be seen that over 
fourteen days, as the expression of IgG Fc receptor RIII increased, any blocking antibody 
treatment that included anti-Fc RIII decreased the level of inhibition. This became more 
pronounced with the length of monocyte culture time. The day 0 plot (Fig. 3.12a) implies 
that the inhibition effect seen in the medium control sample may be largely due to 
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mechanisms independent of IgG Fc receptors, but is still dependent on the presence of 
antibody and monocytes. Fc RIII may only be playing a minor role on fresh monocytes, 
since anti-Fc RIII antibody alone has the same effect as combinations with either anti-Fc 
RI, anti-Fc RII or in combinations of all three. By day 7 (Fig. 3.12b) the IgG receptor RIII 
alone had increased in influence on the inhibition of the target cells. The combination 
treatments of anti-Fc RI or RII antibodies, with anti-Fc RIII, were more than additive at 
this point especially in the case of Fc RI. At the day 14 time point (Fig. 3.12c) the 
influence of RIII was even greater, but RI and RII were also contributing in that the 
control inhibition effect was totally ablated by a combination of anti-Fc RI, RII and RIII 
or partially ablated by a combination of anti-Fc RI and RIII. As a consequence of this 
data, routine assays utilised monocytes which had been in culture for between one to two 
weeks prior to the experiment and the phenotypes of the receptors present were 
monitored by FACS analysis on the day of monocyte harvest. 
3.6.6 Effects of y IFN on the monocyte assay 
The above data suggests that IgG Fc RI has an increasingly synergistic effect with RIII 
when the monocytes have been cultured for longer than one week. Since it has been 
postulated that 'y-IFN increases the activity of IgG Fc RI (van Schie et al 1992), yy-IFN 
treatment of the older monocytes may enhance this effect. To test the hypothesis, 10 Rl of 
either medium or y-IFN at 3x105-0.05x105 units/ml was included throughout the assay 
period (Fig. 3.13). A single sub-optimal dose of 0.1 µg/ml Campath-1H was utilised (0.07 
gg/m1 gave 50% inhibition in Fig 3.11). The results show that, in the presence of 
monocytes, the level of Campath-1H employed in the assay did not result in inhibition of 
target cell thymidine uptake as expected (see Fig 3.11) however, there was a dramatic 
increase in inhibition on the addition of y-IFN to Campath-1H. In the absence of 
monocytes, y-IFN alone or in combination with Campath-1H both enhanced the target 
cell thymidine uptake over the majority of concentrations tested. Unfortunately, the 
monocytes were not assessed for Fc RI levels immediately before and after treatment and 
therefore it has not been confirmed that the receptor expression was altered in any way or 
indeed shown that Fc RI was the causative agent. 
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Figure 3.12 The effects of monocytes which had been in culture fin various lengths Of time on standard 
Campath-I H induced, monocyte mediated growth inhibition of' Wien 133 cells assays. Medium or 
monocytes (I. 5x 104/well fresh, one week or two weeks in culture) were preincuhated overnight prior to the 
addition of 4x103 Wien 133 cell,. 5(1 µl Campath-IH (0.01 µg/ml) and if' present, 10 µl anti-Fe antibody 
(50 µg/ml). The symbols represent " monocytes plus Wien 133 cells and Campath- I H, ý) monocytes plus 
Wien 133 cells only, e medium plus Wien 133 cells and ) medium plus Wien 133 cells and Campath- 
I H,. The data are plotted as mean </ of' the control value and are typical of several assays. The receptors 
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Figure 3.13 The effects of dilutions of y-IFN on a cytostasis assay. Monocytes (1.5x 104/well) were 
preincuhated overnight prior to the addition of 4x 1( )3 133 cells, 50 pl Campath- IH at 0. I pg/ml and 
dilution's of y-IFN (10 µl). Thymidine incorporation was monitored at day 11% c.   represents monocytc 
plus Wien 133 cells and IFN, " represents monocytcs Flus Wien 133 cells. C'umpath- IH and IFN, A 
represents medium plus Wien 133 cells and IFN whilst V represents medium plus Wien 133 cells. 
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3.6.7 Effects of GM-CSF on the monocyte assay 
GM-CSF is documented to increase the activity of Fc RII receptors on neutrophils and 
eosinophils (Bianchi et al 1989, Fanger et al 1989) and it was postulated that it may have 
a similar affect on monocytes. However, when GM-CSF (10 µl of 2x103-0.31x103 
units/ml) was incorporated into monocyte assays no change in efficiency of target cell 
inhibition was detected (data not shown). The experiments were repeated several times 
but changes in the rate or level of inhibition were never detected and therefore the 
experiments were discontinued. 
3.7 The generation of CDw52 negative cells 
3.7.1 The consequences associated with the loss of surface antigen expression 
During the course of these experiments, two CDw52 negative variants of Wien 133 cells 
became available. The first negative cell line, designated MR4, was obtained by Dr. John 
Tite. He exposed Wien 133 cells to Campath-IH in the presence of mononuclear cells as 
in an ADCC assay. After several hours exposure, the Wien 133 cells were retrieved and 
returned to tissue culture flasks for routine subculturing and those that survived were 
subsequently found to be negative for CDw52 expression by FACS analysis. The second 
line designated CV4, was raised by Wendy Rowan (Rowan et al 1998). She exposed 
Wien 133 cells to Campath-1H crosslinked with anti-human IgG and subcultured the 
surviving cells. Both lines had no detectable surface expression of CDw52 when checked 
by FACS analysis. The cell lines are discussed in more detail in Chapter five. However, 
the MR4 line was used in standard ADCC assays to determine the effects of reduced 
CDw52 levels. As seen in Fig. 3.14 the negative cells were totally resistant to directed 
killing by Campath-1H but were still able to respond to lysis by anti-CD38. The antigen 
CD38 (Funaro et al 1993) is abundant on the surface of Wien 133 cells (Ellis et al 1995). 
These data taken together with other information would indicate that for future 
therapeutic use it may be necessary to utilise combined administration of antibodies to 
overcome the problem of possible antigen negative variants arising. 
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Figure 3.14. The affect of antigen expression on a Canipath- IH mediated ADCC assay. CDw52 positive 
and negative (MR4) cells were mixed with either Camputh- IH or anti-CD39 antibody dilutions for I hour 
prior to the addition of PBMC effector cells at a 25: I ratio. `'Cr was measured in the supernatants five 
hours later.   Wien 133 cells plus Canipath- I H, " Wien 133 cells plus anti-CD38 antibody, A MR4 cell, 
plus Campath- IH and V MR4 cells plus anti-CD? h antibody. The results are expressed is percentage 
specific release values ± standard errors. Maximum release values (solid horizontal lines) are taken as 6017( 
for MR4 cells plus anti-CD3K, 57c/ for Wien 133 cells plus anti-CD39 and 531/, for Wien 133 cells plus 










antibody conc. (µb/nmI) 
Concentrations of antibody required to generate 50% of maximum release were 0.0075 pg/ml fier Wien 
cells plus Campath-I H, 0.028 pg/mI for MR4 cells plus anti-Cl)3 
plus anti-CD38.8 
and 0.075 P9,1111 for Wien 133 cells 
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3.8 Discussion 
The aim of the work described in this chapter was to investigate and establish criteria for 
future analysis comparing the Glaxo-Wellcome product Campath-1H expressed in and 
purified from CHO cells with ensuing forms of Campath-1H antibodies produced in 
alternative expression systems. Experiments, performed by Dr. Robert Lifely, clarified 
the carbohydrate composition of the CHO Campath-1H Fc fragment and revealed that the 
majority of isolated oligosaccharide structures were members of a single fucosylated 
family which varied only in terminal galactosylation, a minor family of non-fucosylated 
oligosaccharides was also present (Lifely et al 1995). The removal of the carbohydrate by 
either tunicamycin treatment of the expressing cells in culture or the enzymatic removal 
by N-glycanase treatment of the purified antibody led to the loss of activity in several, but 
not all, of the designated assays and confirmed the previous data of Leatherbarrow et al 
(1985) and Rademacher et al (1988). Partial and sequential removal of selected 
monosaccharides i. e. glucosamine, was demonstrated to have an minor effect on ADCC 
activity but this aspect of the project was not pursued and should be returned to if 
possible. The data obtained from the hexosaminidase treatment is however 
complementary to that of Boyd (et al 1995) who showed that removal of Campath-IH 
galactose residues did not alter ADCC activity. 
The first assay to be fully investigated using CHO Campath-1H was the ADCC assay in 
which the cell type primarily responsible for the lysis of antigen bearing cells was found 
to be the CD56 positive NK cell residing within the mononuclear cell fraction. As the 
target cells were labelled prior to their addition to the assay, lysis was interpreted as 
specific and so care was needed with choice of control. All assays incorporated controls 
for non-specific lysis (no antibody), total lysis (detergent) and medium controls (no 
effectors). The mechanism of resulting target cell lysis was not defined but was thought 
to be by the route of perform-mediated damage to the target cell membrane (Salcedo et al 
1993). For efficient lysis to occur, the ratio of effector to target cell was demonstrated to 
be optimal at at least 10: 1 and the antibody was required to have the majority of the 
carbohydrate moiety intact. To be competent to induce target cell lysis, single doses of 
the antibody were used within the range 10-0.1 p. g/ml depending on the type of response 
required. The use of anti-Fc R antibodies suggested that the effector cell utilised Fc RIII 
to couple itself, via the antibody, to the target cell displaying the Campath antigen on its 
surface. The Fc RI receptor was utilised to a minor level possibly through monocyte 
interactions. This specific data however, must be taken with caution as the blocking 
antibodies were not shown, independently, to influence receptor function. Mononuclear 
effector cells isolated from different donors displayed a range of responses to the single 
antibody and consequently it was necessary to repeat each assay with a range of donors. 
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The reason for the differences between donors was not determined but may be due to 
receptor polymorphism (van de Winkel and Capel 1993, Sanders et al 1995, Koene et at 
1997). However, all donors did give ADCC responses over the same Campath-1H 
concentration range. For ease of comparison, results were found to be optimally 
expressed in terms of percentage specific release. This enabled data to be compared as 
dose of Campath required to achieve 50% of maximum target cell lysis. 
In control experiments, minus effector cells, it became clear that at low cell densities it 
was possible to observe cytostasis of the target cells in the presence of Campath-1H 
antibody. Such effects could be monitored by tritiated thymidine incorporation in a5 day 
assay. Once again care was required with choice of control as in this assay cells surviving 
at day five were radiolabelled and reduced counts were interpreted as cytostasis. It was 
necessary to incorporate controls with either no targeting or crosslinking antibody as well 
as cells with no antigen. Cytostasis was enhanced by deliberate cross-linking of the 
humanised antibody with anti-human IgG. Furthermore, highly aggregated samples of 
Campath-1H were particularly effective at mediating this effect. Experiments outlined in 
both Chapter three and four suggest that these effects are independent of glycosylation as 
deglycosylated Campath was demonstrated to be as active in these assays as the intact 
antibody and may represent the effects of merely cross-linking the CDw52 antigen on the 
surface of the target cell. It has been shown that cross-linking CDw52 in other systems 
leads to the generation of intra-cellular signals (Rowan et al 1995), a feature in common 
with several GPI-anchored cell surface molecules. Studies have show that GPI-anchored 
membrane molecules are enriched in glycolipid enriched membrane domains with 
members of the Src-Kinase family (Shenoy-Scaria et al 1993 and 1994), potentially 
explaining the ability of a GPI-anchored protein to mediate signalling events. 
Monocytes reside within the mononuclear cell population and they were demonstrated, 
by depletion, to have minor effects in the short five hour ADCC assays. However, as a 
cell type, they were demonstrated to be more important in longer assays in which target 
cell thymidine incorporation was monitored after a fixed time. As with previous assays 
controls had to be carefully selected. In response to treatment of CDw52 bearing target 
Wien 133 cells with Campath-1H at doses greater than 0.4 tg/m1, monocytes were able 
to inhibit the thymidine incorporation of those cells over a five day period. A lower dose 
of 0.1 pg/ml was found to be more suitable for sub-optimal responses in situations where 
increases of activity were sought. Such a situation was in the use of y-IFN (van Schie et 
al 1992) to augment the contribution of Fc RI to the inhibitory effects of a sub-optimal 
level of Campath-1H. Attempts to demonstrate similar effects on Fc RII with GM-CSF 
(Fanger et al 1989, Bianci et al 1989) were not successful. To obtain consistently 
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reproducible results it was necessary to utilise the monocytes and target cells at a ratio of 
2.5: 1, with the monocytes having been in culture for no more than two to three weeks. 
It 
was indicated in preliminary experiments, using the same anti-Fc R antibodies as those 
in 
the ADCC experiments, that the individual IgG receptors present on the monocytes 
changed during time in culture and for this reason monocytes were strictly monitored, 
by 
FACS analysis for receptor type, prior to each assay. Freshly isolated monocytes were 
indicated to utilise mainly Fc RI and RIII receptors to mediate antibody redirected 
cytostasis with minor use of Fe Rll. After one or two weeks in culture, monocyte Fc RI 
and RII contributed synergistically with Fc RIII to produce the inhibition effect 
demonstrated. As with the ADCC data these results should be accepted with caution. 
Finally, the antigen specificity of these effects was investigated by utilising antigen 
negative variants of the Wien 133 cell line derived by experimental conditions selecting 
for the loss of expression of the CDw52 antigen on their surface (Rowan et at 1998). 
Clones of the negative variant MR4 were placed into ADCC assays alongside their 
positive parental line to monitor differences entirely due to level of antigen expression. 
The negative MR4 cells were found to be resistant to killing by CHO Campath-1H over 
the range 20-0.002 pg/ml but still susceptible to killing by anti-CD38. The derivation of 
antigen negative variants was an unexpected consequence of Campath-1H treatment and 
highlighted the possibility of this occurring within patient groups. Some data from 
ongoing clinical trials (Brett et at 1996a, Hertenstein et at 1995) does indicate that this 
does occur in a small percentage of people. Perhaps for therapeutic use, antibodies should 
be utilised as cocktails to avoid this event arising. Recent data (Rawstron et at 1999) also 
indicates that some patients may possess low numbers of antigen negative cells prior to 
treatment with Campath which are selected for during therapy. 
Utilising the data from these experiments, in vitro assays were fine tuned for the future 
comparison of Campath-1H antibodies isolated from various expression systems. The 
assays studied were those involving mechanisms deemed to be important in the in vivo 
therapeutic use of Campath-1H in which antibody was required to purge the patient, 
selectively, of CDw52 bearing cells. Therefore, assays in which cell death or growth 
inhibition of CDw52 bearing cells occurred via the engagement of human effector 
mechanisms or by antibody recognition of the antigen, were chosen for investigation. It 
may be that not all of these mechanisms are harnessed in in vivo therapy with Campath- 
1H but they do provide a variety of assays over which to compare the efficacy of the 
individual antibodies in in vitro models. 
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CHAPTER FOUR: RESULTS - CLONING AND EXPRESSION OF CAMPATH- 
1H ANTIBODY IN NSO CELLS: COMPARISON WITH CHO-DERIVED 
ANTIBODY 
4.1 Introduction 
Studies using different Campath-1H antibody preparations had revealed a reproducible 
difference in the level of lytic response in ADCC assays between antibody sourced from 
CHO and YO host cell lines (Crowe et al 1992). Additional experiments demonstrated 
that the enzymatic or tunicamycin-induced removal of N-linked carbohydrate from CHO- 
derived Campath-1H antibody was sufficient to substantially reduce, or totally ablate, 
functional activity in several biological assays (Chapter three). Thus it was hypothesised 
that different host cell lines were capable of adding different post-translational 
modifications, such as alternative oligosaccharide moieties, to the antibody. The changes 
in glycosylation were postulated to affect antibody interaction with receptors on effector 
cells and thus explain the variation in donor lytic response. 
A series of experiments were designed to investigate this theory. To accomplish a full 
comparison of Campath-1H antibody expressed in various cellular hosts, in addition to 
hamster CHO and rat YO antibodies, a third expression system was utilised. The Celltech 
GS vector system was considered a suitable route to generate antibody levels superior to 
that of the CHO dhfr- system and it could also be applied to a wider range of cellular 
hosts (Bebbington et al 1992). The Celltech literature recommended the mouse NSO 
myeloma cell line, with no endogenous GS, as a suitable expression host. The expression 
system involves an amplification of gene copy number similar to that achieved in the 
CHO system. Activity of the GS gene encoded on the Celltech plasmid vectors is 
inhibited by the drug MSX. Low levels of MSX, in the culture medium of cells bearing 
the plasmid, select for cells harbouring an amplification of the GS gene plus flanking 
sequences and consequently an increased expression of product. To express the Campath- 
1H antibody in NSO myeloma cells, it was necessary to re-clone the humanised heavy 
and light chain cDNAs from their pAT 153-based replicons into the GS selection based 
vectors (Fig. 4.1). 
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Figure 4.1 A diagrammatic representation of the Celltech Glutamine synthetase vectors a)pEE6hmcv-Bgl II 
and b)pEE12. Relevant restriction sites are shown. huCMV represents human cytomegalovirus major 
immediate early promotor, poly A represents SV40 early polyadenylation signal, SV40e represents SV40 
early promotor, intron + polyA represents the small t-intron and early polyadenylation signal from SV40, 
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4.2 Aims of this chapter 
This chapter reports on the cloning and transfection of the Campath-1H plasmids into 
NSO cells, and the derivation and selection of the transfected cell lines. The transfected 
cells were adapted from serum-containing (S) medium through protein-free (PF) and 
cholesterol-free (CF) medium to aid antibody isolation. To mimic production methods a 
large-scale fermentor (F) batch of antibody was also produced. Utilising the assays 
defined in Chapter three, the in vitro analysis and comparison of Campath-IH antibodies 
from different stages of medium development were recorded and changes in activity 
identified. N-linked glycosylation profiles for each antibody were derived and 
comparisons with changes in activity made. 
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4.3 Cloning and expression of the Campath-1H cDNA in NSO myeloma cells 
Several steps were involved in constructing and identifying NSO cells that stably directed 
the expression of Campath-IH antibodies under different growth conditions. The 
experimental results for each of these steps are outlined below . 
4.3.1 The construction of GS expression plasmids encoding the heavy and light 
chains of Campath-1H 
Two approaches were used to generate NSO cells expressing Campath-1H. In the first 
approach plasmids were constructed that independently encoded and directed the 
expression of the heavy or light chains of Campath-1H. In the second approach, the 
heavy and light chains were encoded on the same plasmid. For the first method, DNA 
encoding the Campath-1H light chain open reading frame was cloned from pL428 into 
the Celltech vector pEE 12 by transferring a 740 bp Hind III DNA fragment from pL428 
into Hind III cleaved pEE 12. The orientation of the insert was confirmed by cleaving 
with Bam HI, Nco I and Hind III. One plasmid with the expected structure was identified 
and named pEE12+L#20. DNA encoding the Campath-1H heavy chain open reading 
frame was excised from pCAMPH, as a 1500 bp Hind III DNA fragment and ligated into 
the Celltech vector pEE6hcmv-Bgl II which had been previously cleaved with the same 
enzyme. A plasmid of the expected structure was identified by cleavage with Sma I and 
Hind III and named pEE6+H# 11. 
To construct a plasmid harbouring both heavy and light chains of Campath-1H along 
with appropriate expression sequences, pEE6+H# 11 was cleaved with 13g1 I and Sal I to 
release a 4300 bp DNA fragment which was recloned into Bam HI and Sal I cleaved 
pEE12+L#20. A plasmid of the correct structure was identified using Eco RI, Nco I and 
Hind III and subsequently named pEE6H 12L#4 (Fig. 4.2). 
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Figure 4.2 A <g el depicting the restriction mapping of plasmid pFF6H 121. #4. Lanes 1-7 are as 
follows; 
Hind IH / Eco R/ digested lambda DNA markers, in duplicates 2 and 5 Hind Hl digest showing 
fragments 
at 7.4,2.7,1.47 and 0.7 Kb, 3 and 6 EcoRl digest showing bands at 7.9 and 
4.2 Kb, 4 and 7 Neu I digest 











4.3.2. Expression of Campath-Ili antibody in ('OS and NSU cells 
To confirm that the (iS plasmids \\crc capable of' directing the production of active 
antibody. DNA preparations were transfected into COS cells. Co-transfections of' 5 pg 
each of pEl: 6+H#1 I and pI. 1; 12+L#20, or single transfections of 10 . tg of pE, F. 61112L#4 
were utilised for transient expression. The resulting culture supernatants were analysed 
by FACS staining of Wien 133 cells and the antibody produced over three-five days was 
found to compare favourably with ('110 antibody for staining (results not shown). The 
expression of antibody from pEE611121. #4 was consistently more reproducible than that 
of the co-transfectants. 
As a consequence. p! 1.6111 21. #4 was used to construct it stable NSO cell line expressing 
Campath-ill. l. lectroporated NSO cells were dilution cloned into 96 well microtiure 
plates. The average number of colonies obtained at the different dilutions were 44 at 
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1.67x 104 cells/well, 24 at 4.1 x10 3 cells/well and 7 at 8.2x102 cells/well. On testing by 
ELISA, not all colonies were found to produce human antibody. Clones such as C7F10 
which did, were progressively expanded. Specific production rate (SPR) values for first 
round NSO Campath-1H clones were all within the range of 1.35-1.68 µg/106 cells/24 
hours. 
To obtain higher yields of antibody, clones were exposed to medium containing a range 
of MSX concentrations (5-25 µM) to identify cells within the clonal populations which 
may have undergone spontaneous gene amplification. The cell line, C7F10 developed 6 
colonies in 5 gM MSX only and none in higher concentrations. ELISA results for the 
colonies indicated that yields in the range of 2.5-13 µg accumulated antibody had been 
achieved. The Celltech guidelines estimated that a 2-10 fold increase in yield could be 
obtained by the use of this procedure and this appeared to be confirmed. Positive colonies 
such as the 5 µM MSX amplification clones of C7F10, -9D4 and -10G9 were expanded 
through 24 and 6 well plates before transfer to flasks. SPR values increased initially and 
then stabilised until assays on the cell lines gave antibody levels of 4-9 µg/106 cells/24 
hours for -9D4 and 7-9 µg/106 cells/24 hours for -10G9. The amplified cells were 
dilution cloned and single colonies were apparent at 8 days. However, it was not until 26 
days onwards that most of the colonies were sufficiently large enough to expand into 48 
well plates. 
The 35 colonies which appeared in this screening round were given a third series title 
relating to plate, row and well and supernatants were analysed for antibody content. The 
results were utilised to select twelve high producing clones for production purposes. Of 
the twelve lines selected, there was a range of accumulated antibody content between 15 
and 30 µg/ml but, due to the small numbers of cells in each well, SPR values could not be 
estimated. 
4.3.3 Calculation of SPR values for the twelve selected Campath"1H expressing 
clones 
The twelve selected clones were expanded into 25 and 75 cm2 flasks and multiple SPR 
assays performed. Initial results gave SPR values of 5.05-13 µg/106 cells/24 hours. This 
did not take into consideration the long-term growth rates of each clone and it was 
possible that over time the slowest growing clones could produce the highest levels of 
antibody. To investigate this issue further, four OF 10 clones, 9D4-4H3,9D4-4F8,9D4- 
5A11 and 10G9-8C3, were monitored for both cell number and yield changes with time. 
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Fresh ampoules of C717 10 10G9-8C3,9D4-4F8,9D4-5A11 and 9D4-4H3 were thawed 
from liquid nitrogen and cultured in select medium containing 5 mM MSX for 7-14 days 
prior to each experiment. One 25 cm2 flask of each clone was analysed for both human 
antibody content and viable cell count, 24 hours post medium change and SPR values 
calculated. Replicate flasks were analysed 3-4 days post medium change and at other 
later time points (up to 28 days) and the accumulated antibody yield calculated (Table 
4.1).. The resulting antibodies were not tested for biological activity in this series of 
experiments and so levels of degradation were not ascertained 
Table 4.1 The results of monitoring specific OF 10 clones for antibody production with time. The numbers 
in faint type represent total yield, in µg, of the cultures. The results of three to four separate experiments are 
presented with the exact date of sample harvest given in parentheses. The clone 9D4-4H3 proved difficult 
to assay because of persistent low level bacterial contamination. 
Total antibody content (µg) at different harvest dates 
C7F10 Exp. D. 1 D. 3/4 D. 6/7/8 D. 10/11 D. 13/14/15 D. 18 D. 21 D. 25 D. 28 
CLONE No 
10G9-8C3 1 25.9 65.8(4) 146(7) 210(10) 392(13) 553 - 462 - 
2 11.9 39.9(3) 161(6) 273(11) 350(14) 539 504 630 812 
3 5.92 65.1(4) 182(8) 35001) 434(15) 
9D4-4F8 1 30.8 86.8(4) 158(7) 287(10) 462(13) 581 - 532 
2 11.9 36.4(3) 133(6) 371(11) 462(14) 511 644 392 399 
3 5.92 57.4(4) 175(8) 32901) 56705) 
9D4-5A11 1 
2 16.1 53.2(3) 84(6) 392(11) 469(14) 581 413 721 721 
3 4.59 77(4) 315(8) 413(11) 728(15) 
9D4-4H3 1 21.0 - - 
2 - - 
3a 14 32.2(4) 
3b 3.82 
The results in Table 4.1 demonstrate variability in the individual assays when comparing 
antibody accumulation alone. The data is artificial in many ways in that the antibody was 
allowed to accumulate in "rot conditions" such that the cells were not re-fed or sub- 
cultured during the experiment. These are conditions not usually tolerated in production 
techniques, as both the cell number and degradation of antibody is uncontrolled. For 
comparison, the cell counts and calculated SPR values of the day one and four harvests of 
the same experiment are shown in Table 4.2. The results still demonstrate inconsistency 
for the day one samples. 
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Table 4.2 The SPR values of the day one and four supernatant samples from the experiment in Table 4.1. In 
faint type the accumulated antibody yield for each sample has been corrected for total cell count to give gg 
antibody /106 cells/time in culture. The exact date of harvest is shown in parentheses. 
C7FIO Exp. Day 1 Cell Day 1 Day 3/4 Cell Day 3/4 
Clone no. Count x106) SPR values Count x106) SPR values 
10G9-8C3 1 1.4 18.5 1.74 37.82(4) 
2 1.56 7.63 1.38 28.9(3) 
3 0.48 12.3 1.38 47.17(4) 
9D4-4F8 1 0.98 31.43 1.96 44.29(4) 
2 1.44 8.27 0.92 39.6(3) 
3 0.46 12.86 1.42 40.42(4) 
9D4-5A11 1 - - - - 
2 1.88 8.56 1.86 28.6(3) 
3 0.34 13.47 2.2 35.0(4) 
9D4-4H3 1 0.8 26.25 - - 
2 
3a 0.84 16.67 1.28 25.16(4) 
3b 0.32 11.92 - 
To fulfil production requirements, ampoules of the twelve cell lines were transferred to 
Dr. Michelle Scott, of the Biological Development Laboratories, Beckenham for further 
characterisation and for use as production line stocks and also to Mike Keen for the 
development of a custom made protein-free medium for NSO cells (Keen and Steward 
1995b, Keen and Hale 1996). I continued to work with the C7F10 clones 10G9-8C3, 
9D4-4F8 and 9D4-5A11. 
4.3.4 Comparison of NSO clones for growth and yield in serum (S) containing or 
protein-free (PF) medium 
The C7F10 NSO clones 10G9-8C3 and 9D4-4F8 were compared for growth and yield 
with time in culture in different media, (a) Celltech select medium containing serum plus 
5 µM MSX; (b) a protein-free medium, WNS-B, manufactured by the Department of 
Media Production to Mike Keens formulation or (c) a protein-free medium, WNS-C, 
developed from WNS-B by Mike Keen. On days 1,2,3,4 and 6, all adherent and non- 
adherent cells were harvested and counted and the supernatants were analysed for human 
antibody content by ELISA. The results are shown in Table 4.3. 
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antibody 
Table 4.3 The growth and yield, with time, of NSO C7F10 clones 10G9-8C3 and 9D4-4F8 in various 
media. A total number of 1.5x106 cells in 6 ml of mediums Celltech select, WNS-B or WNS-C were 
dispensed into flasks and their growth and antibody production were analysed on days 1,2,3,4 and 6. The 
numbers in faint type represent either total viable cell count for each flask as multiples of 106 cells or total 
human Ig antibody yield in nanogram (ng) per flask. 
C7F1010G9-8C3 C7F10 9D4-4F8 
Select WNS-B WNS-C Select WNS-B WNS-C 
D. 1 count (106) 0.32 0.3 0.22 0.34 0.24 0.22 
yield (ng) 12.6 12.6 9.6 15 7.8 6 
D. 2 count (106) 0.5 0.42 0.32 0.4 0.34 0.2 
yield n 32.4 30.6 22.2 36 19.2 15.6 
D. 3 count (106) 0.86 0.5 0.4 0.56 0.5 0.6 
field n 58.8 56.4 37.2 60 35.4 29.4 
D. 4 count (106) 1.08 1.06 0.7 1.52 1.12 0.96 
yield (ng) 97.8 95.4 69 108.6 63 55.2 
D. 6 count 106 0.52 0.28 0.7 1.10 0.78 1.0 
yield n 146.4 122.4 114 171 112.8 118.8 
Although both clones grew faster and made more antibody in the Celltech media, they 
grew and produced antibody in WNS-B and -C. The cells in WNS-B initially grew more 
rapidly but began to expire by day 6. In WNS-C the initial rate of growth was slower but 
cell numbers did not decline. The latter would enable cells to continue producing 
antibody over a longer period. 
At this stage in the process of selecting NSO clones for antibody production there were 
sufficient amounts of antibody being generated to allow functional comparisons to be 
made. 
4.4 Comparison of NSO and CHO-derived Campath-1H antibodies 
The first batch of NSO-derived Campath-1H to be purified was that from NSO 9D4- 
5A11 cells cultured, under laboratory conditions, in Celltech select medium containing 
5% foetal calf serum (NSO. S#1). The Campath-1H isolated and purified from CHO cells 
for use in clinical trials is produced under serum-free conditions in fermentors. 
Comparisons were made between the two to confirm mode of action. In several assays 
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antibody 
the original YO Campath antibody (donated by Dr. Geoff Hale) was also included for 
comparison. 
4.4.1 ADCC assays 
4.4.1.1 NSO-derived antibody (NSO. S) compared with clinical trial CHO 
Campath-IH for effector cell usage 
NSO. S#1 and CH() Campath-1}l antibodies were incorporated into ADCC assays in 
which either mononuclear or poly morphonuclear cells were used as effector cells 
(Fig. 4.3). As with the earlier CHIO experiments (Chapter three, 3.4.3) both antibodies 
utilised mononuclear cells preferentially and generated identical 50% of maximum lysis 
values. 
Figure 4.3 The comparison of NSO. S and CHO Campath- Ili cell type usage. CHO and NSO. S Canlpath- 
I was compared in an ADCC in which either mononuclear or polymorphonuclear cells were utilised as 
effector cells at a ratio of 25: 1. IQ' Wien 133 cells were mixed with 50 µI CHO Campath plus 2.5x 105 
polymorphonuclear effector cells ( ) or CHO plus mononuclear effector cells (0), NSO Campath plus 
poly morphonuctear effector cells (A) or NSO Campath with mononuclear effector cells (V). The results 
are presented as percentage specific release ± standard errors. Maximum specific release values (solid 
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Antibody concentrations giving 50% of maximum specific release were; 0.015 µg/ml for both CHO and 
NSO. S CIH with mononuclear cells whilst with polymorphonuclear cells 5 µg/ml for NSO CIII and 
greater than 10 pg/mI CHO CIH 
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When a protein-free (PF) medium had been developed for NSO cells, the Campath-1 H 
C7F10 clones 1069-8C 3,9D4-4F8 and 9D4-5A11 were adapted to the new medium. The 
supernatant from the NSO clone C7F10 9D4-5A1 I was purified and is referred to as 
NSO. PF#I. Further development of this clone involved the culture of cells in an 
intermediate cholesterol-free (CF) medium and finally fermentor culture (F) in protein- 
free media. These led to the purification of single batches of the antibodies designated 
NSO-CF and NSO. F respectively. 
4.4.1.2 Comparison of NSO. PF, YO and CHO-derived Campath-1 H. 
NSO. PF#l was incorporated into a standard ADCC assay. The assay used isolated 
mononuclear cells as effector cells, but had both CI-1O and YO antibodies as controls 
(Fig. 4.4). To achieve 50% of maximum specific release it was necessary to utilise 0.0003 
µg/ml YO antibody, 0.0004 tg/ml C'HO antibody and 0.0009 pg/ml NSO. PF antibody. 
Figure 4.4 The comparison of Campath- IH isolated from different cellular sources in an ADCC. C110 (M), 
YO (") and NSO. 1 F (A) Campath-IH was utilised in an ADCC assay in which 10' Wien 133 target cells 
were coated with Campath- III dilutions (50 µl) prior to exposure to mononuclear etTector cells at a ratio of 25: 1. The results are presented as percentage release ± standard errors. Maximum specific release for Cl lo 










Antibody concentrations giving 50% of maximum specific release were; 0.0003 and 0.0004 µg/ml for YO 
and CHO CIH respectively and 0.0009 µg/ml for NSO. PF C H. 
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4.4.1.3 The Ig Fe receptor usage of NSO. S and NSO. PF Campath-I H antibody 
in the ADCC assay. 
NSO. S#1 and NSO. PF#1 Campath-IH antibodies were assessed in an ADCC assay 
(Fig. 4.5) in which anti-Fc RIII antibody was incorporated (at a final concentration of 20 
tg/ml), to block the receptor on the mononuclear effector cells. Clinical trial CHO 
Campath-1 H was utilised as a standard and the blocking antibody was added to half of 
the effector cells one hour prior to their addition to the assay. 
Figure 4.5 The IgG Fc receptor usage of NSO. S and NSO. PF Campath- IH antibodies in an Al)CC. Wien 
133 target cells (104), coated with 50 l' dilutions of CHO, NSO. S or NSO. PF Carnpath-I H, were exposed 
to 2.5x 105 mononuclear effector cells which had been pre-treated or not with anti-Fc Rill antibody. CHO 
antibody with untreated (0) or treated (Y) et1fector cells, NSO. PF with untreated (0) or treated (") effector 
cells or NSO. S with untreated (A) or treated (+) effector cells. The results are expressed as percentage 
specific release ± standard error. Maximum release values (solid horizontal lines) were calculated as 49% 
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Concentrations of antibody generating 50°iä of' maximum release in the presence of-effector cells without 
and with anti-FcRlll treatment were; 0.00025 and 0.08 pg/ml for NSO. S respectively, 0.00025 and 0.025 
µg/ml for CI-1O respectively and 0.00035 and 0.08 µg/ml for NSO. PF respectively. 
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All antibodies in the control experiment were demonstrated to engage mononuclear cells 
to facilitate cell lysis with little difference in efficiency over the majority of doses tested 
for this donor. With untreated effector cells the concentration required to give 50% of 
maximum specific release values for all antibodies was 0.0002-0.00035 µg/ml. The 
addition of anti-Fc Rill antibody to the assay influenced both NSO antibodies to the same 
degree at all concentrations, but CHO Campath-11-1 was less affected within the 0.2-0.002 
range. At 2-20 pg/ml, inhibition of all antibodies was reduced. A similar result was seen 
in earlier CHIO antibody ADCC experiments (Chapter three, section 3.4.4) and was 
thought to be a result of insufficient blocking of the Fc Rill receptor at high doses of 
Campath-I H antibody. As with the CH O experiments, the anti-Fe R antibodies were 
never tested independently and thus not shown to influence receptor function. 
4.4.1.4 Effect of NSO. PF antibody deglycosylation 
NSO. PF#I antibody was deglycosylated enzymatically with N-glycanase by Anne Lines 
of the Department of Biological Development, Wellcome Research Laboratories. Both 
the intact and deglycosylated NSO antibodies were utilised in a standard ADCC: assay, in 
comparison with intact Cl 10 Campath. Deglycosylation ofthe CI 10 antibody had been 
shown previously to ablate activity (Chapter three, section 3.4.5). 
Figure 4.6 The effects of removing the NSO. PF antiboJIy citrhuhydrate. "Cr-Labelled Wien 113 cells (I O) 
were mixed with 50 µI dilutions of CI IO ( ), NSO. I'I (") or deglycosylated NSO. PF( A) ('ampath-III 
prior to the addition of 2xIO mononucIcar effector cells. Results are expressed as mean specific release 
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Antibody concentration generating 50% of maximtnn release was calculated as 0.0021 µg/ml for CI lO and 0.009 tg/ml for NSO. PF. Deglycosylation of NSO. PF ablated activity as seen for CHO-C Ill. 
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Fig. 4.6 demonstrates that, with this donor, the intact NSO. PF#1 antibody mediated 
ADCC less efficiently than CHO antibody at all dilutions under investigation. The 
concentration required to give 50% of maximum specific release was 0.0017 tg/ml for 
the CHO antibody whilst it increased to 0.009 µg/ml for the NSO. PF antibody. 
Deglycosylation of the NSO. PF antibody totally ablated ADCC activity at all doses. 
After trial in an experimental cholesterol-free medium, C7F10 9D4-5A11 was the clone 
chosen for development in a small 2 litre fermentor. It was placed into production, in 
protein-free medium, by Dr. Michelle Scott of the Department of Biological 
Development, Wellcome Research Laboratories, Beckenham, Kent. The antibody was 
produced over a limited period in the absence of feeding and the cells were regularly 
monitored for viability. Yields from day 4 and day 6 culture supernatants were analysed 
and found to contain 11 µg/ml and 44 . tg/ml human antibody respectively (Michelle 
Scott, personal communication). This was not unexpected in that prior analysis had 
shown that antibody was maximally produced when the cells were not dividing rapidly. 
The antibody (NSO. F) was purified in a manner similar to the CHO clinical trial antibody 
and was compared in assays with CHO Campath-1H, previous forms of NSO antibodies 
and YO Campath-IH produced in Cambridge. 
The chronological analysis (see 2.4.9 and 2.4.10 for dates of production) of NSO 
antibody produced from different stages of media development suggested that NSO. S, 
NSO. PF, NSO. CF and NSO. F were not identical when compared with CHO or YO 
antibody in ADCC assays. To investigate the phenomenon fully, antibody samples from 
the different stages were compared simultaneously with CHO and YO Campath in 
antigen binding (Figs 4.8 and 4.10), ADCC (Figs. 4.7 and 4.9), crosslinking (Fig 4.13 and 
Table 4.5) and monocyte assays (Figs 4.15 and 4.16). The observations are displayed and 
discussed. 
4.4.1.5 The NSO. F Campath-1H antibody 
CHO, YO and NSO. F Campath-1H were compared in a standard ADCC assay utilising 
mononuclear effector cells. As can be observed in Fig. 4.7, all antibodies induced 
responses of a similar nature. Maximum release values were 56% for both CHO and YO 
and 52% for NSO. F. The antibody concentrations required to induce 50% of maximum 
release were 0.001 µg/ml for the CHO antibody, 0.00035 µg/ml for the YO antibody and 
0.0015 µg/ml for NSO. F. 
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Figure 4.7 A comparative Campath-I H ADCC. Campath antibody dilutions (50 µl) were mixed with 104 
"Cr labelled Wien 133 cells prior to the addition of 2x 10` mononuclear effector cells. The centrifuged 
supernatants were assessed for Chromium release five hours later. CHO (M), YO (40) and NSO. F (A) 
Campath-1 H. The results are displayed as mean % specific release ± standard error,. Maximum release was 
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Antibody concentrations of 0.00035,0.001 and 0.0015 µg/ml (YO, CHO and NSO. F respectively) were 
required to induce 50% of maximum release. 
The corresponding antibody/antigen binding data for these antibodies is shown in Figure 
4.8. The antibodies were serially diluted from 20 tg/ml and mixed with antigen 
expressing cells as described in Materials and Methods. They demonstrated similar 
antigen binding at concentrations able to mediate AI)CC. 
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Figure 4.8 The mean fluorescence intensity of dilutions of Campath antibodies from different sources. 
Aliquots of antibody (50µI) " YO, A NSO. F and   CHO were mixed with Wien 133 cells (5x104) 
for 30 
minutes prior to detection with anti-human IgG-FI"I'C. Samples were 
fixed and analysed on a Becton 
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4.4.1.6 Comparison of NS() antibodies produced from cells grown under 
different conditions 
Fig-4.9 demonstrates the results of comparing NSO. S#I, NSO. PF#2, NSO. Cl-' arid 
NSO. F, for clarity the data for CHO and YO antibody are not included (see Fig. 4.7 for 
the same experiment). The antibodies generated similar profiles except for NSO. S which 
required 0.006 µg/ml to achieve 50% of nlaxlnlum lysis compared to 0.0015 µg, /ml for 
the others. Prior to the assay, antibody concentration and binding efficiency were 
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determined by anti-human Ig ELISA (data not shown) and FACS analysis (Fig 4.10), 
respectively. 
Figure 4.9 A Campath ADCC comparing different NSO antibodies. Dilutions of NSO antibodies (50 pl) 
were incubated with 10' labelled Wien 133 target cells prior to the addition of 2x10' mononuclear langet 
cells. Chromium release was measured after five hours. Campath- IH antibodies NSO. S ("), NSO. PF (A), 
NSO. CF (Y) and NSO. F (I) are compared. The results are given as mean percentage specific release ± 
standard errors. Maximum release values (solid horizontal lines) were 58% for NSO. PF and NSO. CF, 549 
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Antibody concentration required to generate 50% of maximum release was 0.0015 µg/ml for NSO. PF, CF 
and F. NSO. S required 0.006 pg/ml. 
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Figure 4.10. The mean fluorescence intensity of dilutions of NSO. S, CF, . 
PF and NSO. F Caºnpath 
antibodies. Aliquots of antibody (50µI)   for NSO. S, " NSO. PF, A for NSO. CF and 
V for NSO. F were 
mixed with Wien 133 cells (5x10') for 30 minutes prior to detection with anti-human IgG-FITC. Samples 
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The NSO antibodies were demonstrated to be similar in their antigen binding profiles but 
different with regard to ADCC. NSO. S was least active and generated a 50% of 
maximum specific release value of 0.006 µg/ ml compared with 0.0015 µg, /ml for the 
NSO. PF, CF and F isolates. 
4.4.1.7 IgG4 compared with intact and degly-cosylated Ig(; I 
NSO Campath-1 H of the IgG4 isotype was produced at I3urruu h's Wellcome 
Laboratories, Research Triangle Park, North Carolina, USA. The cell line was sent to 
England for adaptation to protein-free medium and comparison with the NSO. PF Ig(i I 
antibody. The isotype IgG4 was not thought to bind IgG Fc RIII in vitro and as Such 
should not activate ADCC. 
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On incorporation into ADCC assays the intact NSO IgG4 subclass was found to be less 
able than NSO. PF# 1 IgGI to mediate specific lysis of coated targets (Fig. 4.1 1). 50% of 
maximum specific release was achieved with 0.18 µg/ml (IgG4) compared to 0.012 
µg/ml (IgG I ). Deglycosylation of the antibodies ablated both IgGI and IgG4 specific 
lysis at most concentrations. 
Figure 4.1 1A comparison of IgG I and IgG4 isotypes in a Campath-1 II ADCC. Dilutions (50 µl) of intact 
or deglycosylated NSO IgG I and IgG4 antibodies were mixed with 104 "Cr labelled target cells I hour 
prior to the addition of2xl0` mononuclear effector cells. Chromium release was monitored five hours later. 
The data are expressed as % specific release ± standard errors. NSO I-G I intact ( ), IgG I deglycosylated 
("), NSO IgG4 intact (A), IgG4 deglycosylated (V). Maximum release values wwere taken as 81% for 







Antibody concentrations inducing 50% of maximum release were 0.012 µg/ml for NSO. IgG I and 0.1 R 
tg/ml for NSO. IgG4. Deglycosylation of both antibodies led to a requirement of greater than 3 µg/mI. 
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The NSO antibodies used in the ADCC assay (lgG 1 1.26, IgG4 4.0 and deglycosylated 
IgG4 0.14 mg/nil, respectively) were diluted I in 10 from neat and then serially diluted 
stepwise ten fold. The dilutions were checked for antigen binding as in the Material and 
Methods section. The data is shown (in Fig 4.12) and indicates that, irrespective of 
differing starting concentration, the binding slopes were similar except for deglycosylated 
NSO. PF IgGI which, after preparation, was very dilute (0.084 mg/nil). 
Figure 4.12. The Mean fluorescence intensity values of intact or deýglycosylated NSO. PF IgG I and 
NSO. IgG4. Aliquots of antibody (50µI)   NSO. PF IgGI, " NSO. IgG4, A deglycosylated NSO. PF IgG 1 
and V deglycosylated NSO. IgG4 were mixed with Wien 133 cells (5x10) for 30 minutes prior to detection 
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4.4.2 Aggregate content of the NSO. PF and YO antibodies 
Both the NSO. PF#1 and YO antibodies utilised in the previous experiments had been 
produced on relatively small scales. NSO. F and CHO Campath-1H had been 
manufactured by a large scale production method which involved purification of the 
monomeric form only. On testing, the CHO material had been demonstrated to contain 
1.1% aggregate by HPLC (Chapter three, section 3.3.1). 
To determine the levels of aggregate present in the YO, NSO. PF and NSO. F samples, 
aliquots of the antibodies were sent for size exclusion HPLC aggregate analysis, to Dr. 
Mark Easton of the Department of Biological Development. The C7F10 9D4-5A11 
NSO. PF#1 material was found to contain 1.75% aggregate, whilst the NSO. F contained 
1.2% and the YO material had a surprising 22.93%. It was postulated that this large 
amount may have formed due to storage at -200C and was perhaps the reason for the 
antibodies superior performance in ADCC assays. To verify the result, Dr. Geoff Hale 
provided a freshly prepared sample of the YO antibody which was found to contain less 
than 1% aggregate. This was compared with the original YO Campath-1H and was still 
found to be superior to CHO antibody in ADCC assays (data not shown) therefore 
disproving this postulate. NSO. IgG4 was also tested and found to contain 10.4% 
aggregated antibody. 
4.4.3 Antibody effects on the engagement and crosslinking of CDw52 
As with the ADCC assays the different antibodies were analysed chronologically as they 
were produced and then compared simultaneously. 
4.4.3.1 Effects of the engagement of CDw52 antigen on target cells by NSO. PF 
and YO antibodies in comparison with CHO Cam path-ill 
Experiments were designed in which the CHO, YO and NSO. PF#2 Campath-1H 
antibodies were assessed in antigen crosslinking assays to determine whether levels of 
aggregation altered biological efficacy. The antibodies were tested at two concentrations 
selected from the CHO data in Chapter three (section 3.5.2) and the 20 p g/ml results are 
illustrated in Table 4.4 overleaf (data for 40 µg/ml are similar). The target cells utilised 
for these assays were the parental Jurkat line and the cloned CDw52 transfected Jurkat 
line, 3B 11. 
The table shows that Campath antibodies added to the parental Jurkat cell line had little 
effect on their thymidine uptake (control 801,873 cpm reduced by between 56,500 to 
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37,200 cpm) whilst anti-human IgG and anti-HLA reduced the thymidine incorporation 
of parental cells by approximately 30,000 cpm. Crosslinking of any of the 
Campath 
antibodies with anti-human IgG gave incorporation values similar to anti-human 
IgG 
alone. When CHO and YO antibodies were added to CDw52 transfected Jurkat 3B/11 
cells (control 763,662 cpm), they reduced thymidine incorporation by approximately 
80,000 cpm and 17,000 cpm, respectively. The NSO. PF#2 antibody reduced the uptake 
by almost 160,000 cpm. In combination with anti-human IgG, YO, CHO and NSO. PF 
Campath-1H all gave similar results (40,000 cpm). From the data it can be deduced that 
NSO. PF (minus anti-human IgG) is not toxic to Jurkat cells as only the transfected 
3B 11 cells are affected, but suggests that NSO. PF is capable of inhibiting the growth of 
3B 11 cells as a result of binding the antigen in the absence of crosslinking. The effect is 
not a consequence of aggregate content because the YO material (22.3% aggregate) 
demonstrates less inhibition than both NSO. PF (1.75% aggregate) and CHO (less than 
2%) antibodies. However, by substituting CHO monomeric Campath-1H with antibody 
containing 80% aggregate it is possible to achieve identical results to that of NSO. PF in 
the absence of crosslinking (see Chapter three section 3.5.3). 
Table 4.4. The effects of crosslinking CDw52 with intact and deglycosylated (deglyco) Campath-1H 
antibody from different cellular sources. Parental or transfected Jurkat cells were mixed with either 100 µl 
20 gg/ml Campath-IH antibody or 50. tl 20 µg/ml Campath-1H antibody plus 50 µl anti-human IgG (Hulg) 
at the same concentration. Thymidine incorporation was measured at day five. The results are expressed as 
both mean cpm and % control value and are typical of several assays. 
Thymidine i ncorporation 
Antibody used Jurkat cells Jurkat + CDw52,3/B11 
cells 
e pm %control c pm %control 
control 801873.3 100% 763662.9 100% 
CHO 745331.8 92.9% 685252.3 89.7% 
YO 764655.8 95.4% 746310.4 97.7% 
NSO. PF 756188.0 94.3% 604817.5 79.2% 
De 1 co. NSO. PF 728229.7 90.8% 673888.9 88.2% 
a-HLA 774615.1 96.6% 722426.5 94.6% 
HuIg 777165.3 96.9% 737207.5 96.5% 
CHO+HuIg 768236.2 95.8% 404831.9 53.0% 
YO+HuIg 779220.1 97.2% 394105.7 51.6% 
NSO. PF+HuI 792815.8 98.9% 383879.4 50.3% 
Deglyco. NSO+HuIg 793179.5 98.9% 395276.9 51.8% 
a-HLA+HuIg 798878.8 99.6% 756034.2 99.0% 
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Dilution of the same antibodies in dose response curves over the range 90-0.1 µg/ml (data 
not presented) demonstrated that crosslinked YO antibody, became less efficient at 
inhibiting thymidine incorporation once diluted below 10 µg/ml whilst NSO. PF was 
effective even at 1 µg/m1. 
4.4.3.2 Does deglycosylated NSO. PF antibody induce cytostasis? 
Deglycosylated NSO. PF was used in assays in comparison with intact NSO. PF#2 plus 
CHO, YO and anti-HLA controls. The inclusion of the latter antibody was to demonstrate 
antigen specificity. When the antibodies were incorporated into the assay at 20 µg/ml, the 
results tabulated in Table 4.4 were obtained. 
The data indicate that carbohydrate is not essential to inhibit thymidine incorporation. All 
of the antibodies in this assay are demonstrated to be of comparable activity and the 
inclusion of the anti-HLA antibody confirms that the reaction is CDw52 antigen specific. 
4.4.3.3 NSO. F and CHO Campath crosslinking abilities are compared 
Jurkat and transfected Jurkat 3/B 11 cells were utilised as target cells in assays in which 
NSO. F and CHO antibodies (270-0.37 µg/ml, in the presence or absence of anti-human 
IgG), were compared for their ability to inhibit thymidine incorporation (Fig. 4.13). 
If crosslinked with anti-IgG, both NSO. F and CHO Campath-1H were able to inhibit the 
thymidine incorporation of CDw52 transfected Jurkat cells over the range 270-3 µg/ml, 
with maximum inhibition at 3p g/ml. The graduated loss of inhibition observed at 
concentrations greater than 3 µg/ml may indicate that insufficient cross-linking antibody 
was present. CHO antibody was still able to exert a 20% inhibition on the transfected 
cells at 1 µg/ml, whilst NSO. F Campath was not. Values for the concentration of 
antibody required to achieve 50% inhibition are 2 and 2.5 µg/ml for the CHO and NSO. F 
antibodies respectively. In the absence of crosslinking, both antibodies reduced the 
thymidine incorporation of the transfected cells at doses greater than 30 µg/ml. 
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Figure 4.13 The comparison of NSO. F Campath-IH with CHO antibody for engagement and crosslinking 
abilities. CHO or NSO. F Campath-I H was added to either Jurkat or CDw52 transfected Jurkat cells in the 
presence or absence of 50 tl anti-human IgG at 20 µg/ml. Thymidine incorporation was monitored after 
five days in culture. CHO antibody with Jurkat cells, plus (A) or minus ( ) anti-human IgG, CHO 
antibody with transfected Jurkat cells plus (Y) or minus (") anti-human Ig(i. NSO antibody with Jurkat 
cells plus (X ) or minus (") anti-human IgG, NSO antibody with transfected Jurkat cells plus (ý) or minus 
(+) anti-human IgG. The results are presented as % control value with no standard errors and are 








CHO and NSO antibody concentrations required tu aChicve 50"o inhibition were 2 and 2.5 pgh»I 
respectively. 
4.4.3.4 Comparison of NSO isolates ability to engage and crosslink antigen 
NSO. S#1, NSO. PF#2 and NSO. CF were compared with Cl10 and YO Camp. ºth to 
establish whether culture conditions and/or medium could alter their ability to hind to 
antigen. The antibodies were added to parental or transfected 313/11 cells in the presence 
or absence of anti-human IgG antibody and the data is presented overleaf in Table 4.5. 
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Table 4.5 Comparing the ability of NSO antibody isolates to engage and crosslink antigen. Aliquots of 100 
pl or 50 t1 20 gg/ml NSO antibody were incubated with 100 µl parental or CDw52 transfected 3B/11 cells 
(105/ml) in the presence or absence of 50 gI 20 gg/ml anti-human IgG (Hulg). The data is presented as 
percentage control value for each antibody and cell type. 
% Thymidine incorporation 
Antibody used Jurkat Jurkat+ CDw52 
control 100% 100% 
CHO 100.5% 100.6% 
YO 99.8% 83.6% 
NSO. S 98.9% 90.1% 
NSO. PF 101.2% 82.7% 
NSO. CF 95.5% 65.3% 
Hulg 99.5% 99.2% 
CHO + HuI 100.3% 55.7% 
YO + Hulg 97.2% 52.5% 
NSO. S + Hulg 100% 38.8% 
NSO. PF + HuI 102.4% 42.9% 
NSO. CF + Hulg 93.8% 37.3% 
The table illustrates that the CHO, YO and NSO antibodies do not induce cytostasis when 
added to parental Jurkat cells either in the presence or absence of a crosslinking reagent. 
However, on addition to CDw52 transfected 313/11 cells, and as seen previously, the YO 
and NSO Campath isolates have a deleterious effect on their own which is enhanced by 
the introduction of anti-human IgG. The ability of the crosslinked CHO and YO 
antibodies to induce cytostasis is less than that of the various NSO antibodies. The NSO 
antibodies were not demonstrated to bind antigen to different extents by FACS analysis 
(see Fig. 4.8) and thus the observed differences may be entirely due to levels of specific 
toxicity for the transfected cells. 
4.4.3.5 Engagement and crosslinking abilities of IgG4 Campath compared with 
IgGI 
NSO. PF#1 IgGI and IgG4 antibodies were placed into assays in which parental or 
transfected 3B/11 target cells were present and anti-human IgG was utilised as a 
crosslinking agent. The results are tabulated in Table 4.6 overleaf. 
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Table 4.6 A comparison of the engagement and crosslinking abilities of NSO IgG 1 and IgG4 isotypes. A 
summary of the % control values obtained from the mixing of 100 tl 105celis/ml (positive or negative 
for 
CDw52) with either 100 . tl or 50 µl 20 pg/ml intact or deglycosylated (degly) NSO IgGI and IgG4 in the 
presence or absence of anti-human IgG (aHulg) 20 . g/ml. 
Th midine incor oration (% control) 
Antibody used Jurkat cells Jurkat + CDw52 cells 
NSO. I G1 94.3% 79.2% 
NSO. IgG4 93.5% 79.6% 
De 1 co NSO. I G1 90.8% 88.2% 
Deglyco NSO. IgG4 95.9% 90.2% 
anti-HuIg 96.9% 96.5% 
NSO. I Gl+a-HuI 98.9% 50.3% 
NSO. IgG4+a-Hulg 97.9% 55.1% 
De 1 NSO. IgG1+aHuI 98.9% 51.8% 
De 1 NSO. IgG4+aHulg 100.4% 64.4% 
control 100% 100% 
From Table 4.6, it can be seen that intact NSO. IgGI and IgG4 exhibited 79% control 
value incorporation (21% inhibition) when administered un-crosslinked to transfected 
cells. The incorporation of the transfected cells decreased to 50% and 55% of control 
value (50 and 45% inhibition) respectively, in the presence of anti-human IgG. The 
deglycosylation of IgGI antibody did not substantially change the response whereas the 
deglycosylation of IgG4 reduced the inhibition seen with intact crosslinked antibody. 
4.4.4 Monocyte cytostasis assays 
As before the antibodies were placed into assays in comparison with CHO Campath as 
and when produced and then later into single comparative assays. 
4.4.4.1 Comparison of intact and deglycosylated NSO. PF Campath-1H with 
CHO-derived antibody 
Assays, utilising monocytes isolated 3 weeks previously, compared intact and 
deglycosylated NSO. PF#2 Campath-1H with CHO-derived antibody. YO antibody was 
included within the experiment as was anti-HLA antibody. The results of a typical assay 
are displayed in Fig. 4.14. 
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Figure 4.14 A comparison of NSO. PF with YO and CHO Campath-IH for induction of monocvte 
cytostasis. Monocytes cultures or medium were incubated with 50 pl 8x10' Wien 133 cells/ml in the 
presence of either 50 tl dilutions of intact CHO (I), YO (") NSO. PF (A) Campath or a-HLA (") 
antibody or deglycosylated NSO. PF (V). Thymidine incorporation was monitored after five days. The 
results illustrated are in the form of mean epm ± standard errors. Maximum thymidine incorporation (solid 







50% inhibition was generated at concentrations of 0.006 µg/mI for ('110,0.015 pg/mI for YO and NSo). 1'I: 
whilst 0.08 µg/ml of deglvcosylated NSO. PF was required. 
Comparing the results with those described for CHO Campath- IH in Chapter three 
(section 3.6.1 ), all of the intact antibodies perform as expected in the assay. Monocytes 
inhibited the target cell thymidine uptake to varying degrees depending on Campath 
concentration. CHO, YO and NSO. PF antibodies mediated maximum inhibition at 
greater than 0.04 tg/ml. The concentrations of intact antibody required to achieve 50% 
inhibition were as follows; CHO 0.006 pg/ml, YO and NSO. PF 0.015 pg/mI. The 
deglycosylation of NSO. PF reduced but did not ablate its ability to induce cytostasis as 
demonstrated by a shift in the concentration response curve. In terms of antibody required 
to achieve 50% inhibition the amount increased from 0.015 mg/nil (intact) to 0.0 pg/nil 
for deglycosylated. The fact that the antibody was able to induce inhibition is in sharp 
contrast with the failure of deglycosylated antibody to induce ADCC responses. 
145 
antibody cOnc. (µg/ml ) 
Chapter Four: Results - Cloning and expression of Campath-III antibody 
in NSO cells. Comparison with ('110-derived 
antibody 
4.4.4.2 Comparisons of CHO, YO and NSO. F Campath in monocyte cytostasis 
assays 
In experiments similar to those in 4.4.4.1, CHO and YO Campath-1 H was compared with 
NSO. F in assays utilising monocytes which had been in culture for two weeks. The 
results displayed in Fig. 4.15 are the mean of triplicates (cpm) plus or minus standard 
errors. 
Figure 4.15 A comparative Campath monocyte inhibition assay. Dilutions (50 µl) of CHO (s), YO (") and 
NSO. F (A) antibodies were incubated with 4x IO3 target cells (50 µl) in the presence or ahsencc of 
monocytes for five days prior to monitoring thymidine incorporation. The results arc displayed as mean 
cpm ± standard errors. Maximum control cpm (solid horizontal lines) were 380,000 cpm for CHO and YO, 
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50% inhibition was generated with 0.07. tg/ml CHO or YO Campath and 0.04 µg/ml NSO. F. 
In Fig. 4.15, all of the antibodies tested induced maximum monocyte inhibition of Wien 
133 thyrnidine incorporation at greater than 0.3 mg/ml. A value of 50"/c inhibition 
(175000 cpm) was achieved with 0.07 mg/ml CHO or YO antibody. The NSO. F Campath 
only required 0.04 mg/ml to generate the same 50% value. In the absence of monocytes 
(data not shown), concentrations of CHO, YO and NSO. F antibody did not depress the 
thyrnidine incorporation of the target cells. 
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4.4.4.3 NSO Campath isolates compared in monocyte cytostasis assays 
NSO. S#1, NSO. PF#2, NSO. CF and NSO. F Campath-Ill were compared to detect 
changes in antibody action when isolated from cells cultured under different conditions 
and in different media. The results are illustrated in Fig. 4.16 and were derived from the 
same experiment as Fig. 4.15. 
Figure 4.16 A monocyte cytostasis assay comparing Campath NSO. S (! ), NSO. PI (0), NSO. CF (A) and 
NSO. F (V). Dilutions (50 µI) of the antibodies were mixed with 4x 10' Wien 133 cells in the presence or 
absence of monocytes and incubated for five days prior to monitoring thymidine incorporation. The results 
are illustrated as mean cpm ± standard errors. Maximum control values (solid horizontal lines) were 
420,000 cpm for NSO. S and 360,000 cpm for NSO. PF, CF and F. 
cl 
50% inhibition was achieved with 0.035 µg/ml NSO. F whilst 0.1 µg/ml of the remaining antibodies was 
required. 
Comparisons of the different NSO antibodies in the same monocyte cytostasis 
experiment indicates that there are minor differences in their ability to induce cytostasis 
which may be a consequence of their modes of culture. NSO. PF, CF and S are the least 
effective antibodies in this assay, requiring 0.1 µg/ml to achieve 50% inhibition. The 
most active isolate is the antibody isolated from cells cultured under fermentor conditions 
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i. e. NSO. F Campath, which induces 50% inhibition at 0.035 tg/m1. In the absence of 
monocytes, none of the antibodies exhibit toxicity at high concentrations (data not 
shown). 
4.4.4.4 Intact NSO Campath IgGI compared with intact or deglycosylated IgG4 
Intact NSO. PF#1 IgGI, NSO. IgG4, plus de , 
lycosylated IgG4 antibodies were compared 
in monocyte assays. IgG4 was low'id to be active in inducing cytostasis in the presence of 
monocytes (Fig. 4.17). 
Figure 4.17 Ig(] I and IgG4 compared in a monocyte cytostasis experiment. Dilutions (50 µl) of either 
intact IgG I (0), lgG4 (41) or deglyeosylated IgG4 (A) were incubated with 4x10' Wien 133 cells in the 
presence or absence of monocytes for five days prior to monitoring thymidine incorporation. The results 
are with monocytes and expressed as mean cpni ± standard errors. Maximum control values (solid 





Concentrations of antibody generating 50% inhibition were 0.85 µg/ml deglycosylated IgG4,0.015 µg/ml 
IgG I and 0.025 µg/ml IgG4. 
The concentrations of antibody necessary for 50% inhibition of the target cell 
incorporation were 0.015 tg/ml for IgGI and 0.025 µg/ml for IgG4. Deglycosylation of 
the lgG4 Campath-1H depressed, but did not completely ablate, the response as was also 
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found for NSO. PF IgGI antibody. To achieve 50% inhibition, 0.85 µg/ml of 
deglycosylated IgG4 antibody was required, representing nearly a ten fold increase over 
the 0.08 µg/ml of deglycosylated NSO. PF IgGi required (see section 4.4.4.1). 
4.4.5 Carbohydrate comparisons 
During the media development for NSO Campath-1H, the majority of each antibody 
sample was compared, with both YO and CHO Campath-1H, for biological function in a 
series of experimental assays. In parallel to these assays, small amounts of each antibody 
were also prepared for carbohydrate analysis. The antibodies were freeze-dried and the 
N-linked CH2 domain carbohydrate molecules cleaved from the peptide by the method of 
hydranzinolysis. The resulting oligosaccharides were isolated from the peptide and to 
reduce the complexity of interpretation, treated with trifluoracetic acid to remove 
terminal sialic acid residues. The oligosaccharides were then tested for carbohydrate 
composition by both LDMS, to determine molecular weight, and Dionex HPAEC. 
4.4.5.1 The CHO Campath-IH carbohydrate profile 
Dr. Robert Lifely, of the Wellcome Research Laboratories, Beckenham, Kent, had 
previously demonstrated that CHO Campath-1H contained a major family of fucosylated 
oligosaccharides differing only in their terminal galactosylation (Chapter three, Lifely et 
al 1995). The three peaks that he had observed to be associated with the peptide 
represented the oligosaccharide structures either 004301 with no terminal galactose 
residues (peak I, 21.39%, relative retention time 0.59) and of molecular weight 1486.6, 
structure 014301 with one terminal galactose residue and of molecular weight 1648.8 
(peak II, 40.29%, relative retention time 0.67) and structure 024301 of molecular weight 
1811 with two terminal galactose residues (peak III, 15.42%, relative retention time 
0.78). A minor monogalactosylated non-fucosylated component, 014300 of molecular 
weight 1502.6, was also seen in the CHO oligosaccharide sample. 
4.4.5.2 The carbohydrate composition of NSO antibodies isolated from cells 
cultured in different media 
When investigating the carbohydrate associated with the antibody isolated from the 
antibody transfected NSO cells, it was observed that as the cells were adapted to different 
culture mediums, the N-linked carbohydrate moieties altered (HPAEC, Fig. 4.18 and 
LDMS, Fig. 4.19). The samples tested were NSO. S#l, NSO. PF#2 and NSO. CF. 
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Figure 4.18 The HPAEC profiles of carbohydrate isolated from different NSO antibodies. The N-linked 
oligosaccharides of a)NSO. S, b) NSO. PF or c) NSO. CF were analysed by HPAEC in relation to a known 
standard i. e. neuraminic acid (NeuNAc). The standard is indicated by the peak at either 13.283 (S), 13.408 
(PF) or 13.35 (CF) minutes on each profile. The highlighted peaks I, II and III, refer to the three forms of 
oligosaccharide found on IgG. 
NEUNAC 
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Figure 4.19 The LDMS profiles of the carbohydrate from different isolates of NSO antibodies. The N- 
linked oligosaccharidcs of a) NSO. S, b) NSO. PF ) or c) NSO. CF were analysed by LDMS. The highlighted 
peaks I, II and III, refer to the three forms of oligosaccharide found on IgG. 
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By HPAEC analysis (Fig-4.18), the three oligosaccharide peaks observed in all NSO 
antibodies were at the time points 7.417 (S), 7.483 (PF) and 7.438 (CF) minutes for peak 
1,8.383 (S), 8.417 (PF) and 8.373 (CF ) minutes for peak II or 9.65 (S), 9.712 (PF) and 
9.692 (CF) minutes for peak III. By division of the experimental sample retention time 
with that of the reference it was possible to devise a relative retention time value for each 
profile and thus extrapolate the structure/molecular weight by comparison to defined 
oligosaccharide standards. When these were calculated, the relative retention times for 
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the three peaks were 0.56 for peak I, 0.63 for peak II and 0.73 for peak III. These were all 
within the same range as the peaks seen for CHO Campath-1H and suggested that the 
same oligosaccharides are present. When aliquots of the same samples were analysed 
by 
LDMS (Fig. 4.19), peaks at the molecular weights of 1490.5 (S), 1493 (PF) and 1491.1 
(C) for peak I, 1652.6 (S), 1655.8 (PF) and 1653.7 (CF) for peak II and finally 1814.1 
(S), 1819.3 (PF) and 1816.6 (CF) for peak III were identified which were also close to the 
molecular weights of the peaks observed within the CHO material (1486,1649 and 
1811). 
When the overall HPAEC and LDMS profiles for each sample were compared it was 
observed that the height and width of the individual peaks varied in relation to each other, 
reflecting changed composition ratios. In NSO. S (from cells cultured in serum), the most 
prominent peak was peak II (the mono-galactose), whilst peaks I (agalactosyl) was 
minimal and peak III (di-galactose) intermediate. This profile altered for NSO. PF (cells 
cultured in protein-free medium) in that peak II remained the most prominent but, peak I 
became more abundant than III. Further changes occurred when the cells were transferred 
to cholesterol-free medium, such that for NSO. CF a minor level of peak III was observed 
with prominence of both peaks I and II, with peak II slightly more abundant. Thus, as the 
content of peak I increased and peak 111 decreased, the antibodies appeared to become 
more active in ADCC. The observed percentages of the different peaks are summarised in 
Table 4.7. 
4.4.5.3 The carbohydrate content of the fermentor batch of NSO IgG1 
Analysis of NSO. F revealed that the peaks identified by LDMS in the earlier NSO 
antibodies were shadowed by intermediate peaks of 1548.3,1711.2 and 1872.7 
(Fig. 4.20). These represent structures within the possible range for the oligosaccharide 
structures 004310,014310 and 024310 i. e. non-fucosylated bisecting oligosaccharides 
with no, one or two galactose residues. The ratios of the major fucosylated peaks were 
observed to be: peak II (mono-galactose) the most abundant at 28.45%, peak I 
(agalactosyl) of intermediate amount 16.69% and peak III (di-galactose) the minor 
component 10.56% and these are summarised in Table 4.7. 
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Figure 4.20 The LDMS profile of the carbohydrate isolated from NSO. F. The N-linked oligosaccharide 
isolated from antibody prepared from fermentor grown cells was analysed by LDMS. The highlighted 
peaks I, II and III refer to oligosaccharides found on IgG. 
Dr. Lifely later re-analysed the NSO. F material Wifely et at 1995) by Dionex IIPAIl' 
and also found the sane families of oligosaccharides to that seen in the ('I {O antibody 
and confirmed that they differed in ratio. The ratios observed were similar to those seen 
for NSO. PF and further analysis of the intermediate peaks, after single or combination 
exoglycosidase treatments to reduce the oligosaccharides to more simple structures (data 
not shown) demonstrated them to be products of insufficient cleavage during 
hydranzinolysis and not bisecting oligosaccharides. However, a minor fraction of under 
glycosylated oligosaccharides which migrated with shorter retention times was detected. 
4.4.5.4 YO Campath-1 11 
In identical experiments to those mention previously, lyr. Lifely investigated the structure 
of Campath-I H isolated from YO cells. The YO antibody had a more complex prolile 
than either the ('llO or NSO material (data not shown. I, ifely et al 1995). The peaks 
isolated from the YO antibody represented not only the major fucosylated peaks seen in 
both the Cl 10 and NSO samples in the ratio 6.4% agalactosyl, 16.54% monogalactosyl 
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and 7.56% digalactosyl oligosaccharides but also additional non-fucosylated and 
fucosylated bisecting glucosamine (G1cNAc) series (004310,004311,014310,014311, 
024310 and 024311) as determined by exoglycosidase treatments.. Human IgGI is 
known to contain approximately 18% bisecting glucosamine residues (Furakawa et al 
1991). The percentages of the three major YO peaks are tabulated in Table 4.7. 
Table 4.7 A summary of the relative percentages of isolated oligosaccharide peaks present in carbohydrates 
released from different Campath-1H antibodies. Each peak is presented as percentage (%) of total 
oligosaccharide plus as a% of the three peaks 
peak I 
a alactos l 
peak II 
mono alactos l 
peak III 
di alactos l 
Antibody 
used 
% as % of 
(1+11+111) 
% as % of 
(1+11+111) 
% as % of 
1+11+111 
CHO 21.39% 28 40.29% 52.3 15.42% 20 
YO 6.4% 21 16.54% 54 7.56% 24 
NSO. S < 1% 9.8 6.38% 62 2.87% 28 
NSO. PF 8.38% 22 22.64% 60 6.59% 17.5 
NSO. CF 8.17% 34 12.21% 50.8 3.64% 15.2 
NSO. F 16.69% 29 28.45% 51 10.56% 18.9 
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4.5 Discussion 
The cloning of the humanised Campath heavy and 
light antibody fragments into the 
Celltech vectors was not straight forward. The initial phase of transferring the antibody 
inserts from their pUC based holding vectors was problem free, but later manipulations 
were more difficult. The guidelines supplied with the vectors suggested that, when the 
vector pEE6hcmv-Bgl II containing the correct orientation of heavy chain was obtained, 
it should be cleaved with the enzymes Bam HI and Bgl II and the released fragment re- 
inserted into the Bam HI digested vector pEE12 containing the correctly orientated light 
chain. This would result in a plasmid in which both heavy and light chain sequences were 
expressed by their own control elements, in the same direction, with no intervening 
sequences. However, the recommended step of cloning the Bam HII Bgl II digested 
fragment from pEE6 into Bam HI digested pEE12 plus light chain proved impossible to 
achieve. After numerous attempts, an alternative solution was devised in which the vector 
containing the heavy chain was digested with the enzymes Bg1 II plus Sal I and the 
released fragment ligated into the light chain bearing pEE 12 digested with Bam HI and 
Sall I. This resulted in a similar plasmid, pEE6H12L, in which both antibody fragments 
were expressed by their own control sequences in the same direction but with two 
hundred base pairs of intervening sequence between them. 
The expression of pEE6H12L was also not without problems. It was unexpected that so 
many of the colonies resulting from the electroporation of the plasmid into NSO cells 
would result in non producing lines, even under selection. Unfortunately it took several 
weeks to discover this in each case. An additional problem associated with the expression 
and purification of the resulting antibodies was the culture medium. When purifying the 
antibody from serum containing medium, on a laboratory scale utilising FPLC with either 
protein A or G columns, contaminating bovine IgG became a problem for both the 
isolation and the spectrophotometric quantitation. The latter situation was overcome by 
the derivation of the anti-human IgG ELISA for quantitation but the former problem was 
more complex and required the development and manufacture of a specific protein-free 
medium (Keen and Hale 1996). The development of the medium did however provide the 
ideal conditions for the close study of the evolution of the antibody properties in terms of 
both carbohydrate composition and associated biological activity. 
From the initial studies on CHO antibody it had become obvious that it would be difficult 
to define the activity of an antibody in reliable terms in a single assay. Each aliquot of 
effector cells appeared to have an inherent variability when those cells were placed in 
standard assays. However when compared with both CHO and YO isolates of Campath- 
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1H, the NSO antibodies were also found to vary within assays depending on the method 
of their culture. As each step of the media development progressed, it was therefore 
essential to adapt the antibody producing NSO clones to that medium, grow the cells in a 
large batch and isolate that stage of antibody for analysis in several assays, in comparison 
with either or both CHO and YO Campath-1H. To compare the results it was also found 
advantageous to express the data in terms of 50% of maximum specific release values for 
the ADCC assays, where possible, or 50% inhibition for the engagement and crosslinking 
of antigen or monocyte cytostasis experiments. 
In comparative ADCC assays (Figs. 4.7. and 4.9), the earliest NSO antibody purified from 
cells cultured in serum containing medium was less efficient than CHO antibody. The 
amounts of antibody required to establish 50% of maximum specific lysis of target cells 
was 0.006 tg/ml. When NSO. PF antibody was isolated and compared with the standards, 
it was inferior at the 50% of maximum specific release level in that 0.015 tg/ml was 
required instead of the 0.001 and 0.00035 µg/ml for the CHO and YO antibodies 
respectively. Even when cultured under controlled conditions in a fermentor, the NSO. F 
antibody failed to equal either of the two standard Campath-1H antibodies and required 
0.0015 tg/ml to achieve 50% of maximum lysis in comparison with 0.001 tg/ml for the 
CHO antibody and 0.00035 µg/ml for the YO material. The underlying mechanism of 
action of the NSO antibodies, in ADCC assays, was found to be the same as that for the 
CHO antibody in that blockade of the IgG Fc RIII on the mononuclear effector cells 
decreased the activity of the NSO. S and PF antibodies to a similar level as that of the 
CHO antibody in the concentration range 0.0002 to 0.2 µg/ml. As with the CHO 
antibody, the anti-Fe R antibodies used for blocking were not tested prior to the 
experiments and were therefore not shown to influence receptor function. Removal of the 
carbohydrate from the NSO antibody by N-glycanase treatment, totally ablated the 
ADCC response. As the IgG Fc RIII on the effector cell has been suggested to be the 
major receptor involved in ADCC action, it is possible that the antibody recognition or 
binding efficiency of that receptor is altered by glycosylation changes induced by culture 
conditions. 
When comparing the ability of the different NSO isolates to induce effector cell- 
independent cytostasis of transfected Jurkat cells, there appears to be little difference 
when compared to either CHO or YO Campath-IH. The carbohydrate moieties on the Fc 
portion of the antibody were shown to not be necessary for antigen recognition as 
demonstrated by the substitution of the intact NSO. PF antibody with deglycosylated 
material. In the presence of the anti-human IgG crosslinking reagent, deglycosylated 
antibodies generated identical responses to those of the untreated antibody. Equivalent 
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antigen binding was confirmed by the application of dilutions of the different antibodies 
to CDw52 positive Wien 133 cells and detection with FITC-labelled mouse anti-human 
antibody. 
Surprisingly, comparisons of the NSO isolates with CHO and YO Campath antibodies in 
monocyte cytostasis experiments demonstrated that the later stage NSO antibodies were 
sometimes more effective at inducing cytostasis than either of the CHO or YO material 
(Figs 4.15 and 4.16). This is different from the ADCC results. In these experiments 
NSO. F required 0.04 p g/ml, to achieve 50% inhibition of thymidine uptake, compared to 
0.07 . tg/ml for the CHO and YO antibodies. In the same assay, but different graph, the 
various NSO forms were checked against each other. NSO. F antibody (0.035 gg/ml) was 
necessary to achieve 50% inhibition whilst NSO. PF, CF and NSO. S antibodies needed 
0.1 µg/ml. As seen with the ADCC results, the underlying mechanism of action remained 
the same as the CHO antibody, but unfortunately it was not possible to demonstrated 
receptor usage reliably. Deglycosylation of the NSO antibody reduced but, unlike ADCC, 
did not ablate, the response as was also demonstrated for the CHO antibody. 
The carbohydrate analysis of the NSO antibody isolates revealed interesting data which 
could possibly explain the differences in biological properties. The first NSO antibody 
isolated, that from serum containing medium, was found to contain less than 1% 
agalactosyl, 6.38% monogalactosyl and 2.87% digalactosyl oligosaccharide. In ADCC 
assays this was the least active antibody. When the antibody was isolated from protein- 
free medium, both the activity and the carbohydrate profile altered. The NSO. PF 
antibody was demonstrated to perform more efficiently than NSO. S in ADCC assays, but 
remained less active than both CHO and YO Campath-1H. There was no improvement 
over the NSO. S antibody in the monocyte cytostasis experiments. At the carbohydrate 
level, the NSO. PF antibody was found to possess 8.38%, 22.64%, 6.59% (agalactostyl, 
monogalactosyl and digalactosyl oligosaccharides respectively). Cholesterol-free medium 
resulted in NSO antibody which was of similar activity to NSO. PF antibody in ADCC 
and monocyte assays whilst the carbohydrate composition varied slightly with 8.17% 
agalactosyl, 12.21% monogalactosyl and 3.64% digalactosyl oligosaccharides. The most 
active NSO antibody was that cultured under protein-free fermentor conditions. This 
antibody, NSO. F, contained 16.69% agalactosylated oligosaccharide, 28.45% 
monogalactosyl and 10.56% di-galactosyl. Whilst it was compatible with NSO. PF and 
CF in ADCC, it was superior in monocyte assays. When compared to CHO and YO 
antibodies, the NSO. F Campath was less active than both CHO and YO in ADCC but 
superior in monocyte experiments. Dr. Robert Lifely had previously demonstrated CHO 
and YO antibodies to possess agalactosyl, monogalactosyl and digalactosyl 
157 
rh=ter Four: Results Cloning and expression of Campath-IH antibody in NSO cells. Comparison with CHO-derived 
antibody 
oligosaccharide ratios of 21.39%, 40.29%, 15.42% (CHO) and 6.43%, 16.54%, 7.56% 
(YO) respectively (Lifely et al 1995). I suggest that as NSO antibody glycosylation 
becomes more similar, in ratio, to CHO its action in ADCC improves (see Table 5.7). YO 
antibody is very different from both CHO and NSO in terms of glycosylation in that it 
contains bisecting GLcNAc moieties. 
It has been suggested that for ADCC activity, IgG Fc RIII on the effector cells is 
important, whilst all three IgG Fc receptors on the monocyte effector cells are indicated 
to interact to mediate cytostasis. Perhaps these results indicate differences in affinity. If 
the carbohydrate on the antibody is not of the correct structure, the overall antibody 
conformation might alter and affect the interaction with one receptor more critically than 
that of three. This may explain why NSO antibody is less active than CHO and YO 
Campath in ADCC, but more comparable in monocyte induced inhibition. 
The comparison of NSO IgGl with NSO IgG4 Campath-1H also highlights the fine 
balance that carbohydrate imposes on antibodies. Both antibodies share antigen 
specificity and sequence homology and yet IgGI interacted with CD56 positive natural 
killer cells to mediate ADCC and IgG4 did not. Both IgGI and IgG4 antibodies were, 
however, able to mediate monocyte cytostasis. Even after deglycosylation, both 
antibodies were able to mediate cytostasis of a reduced nature suggesting that Fc CH2 
carbohydrate may only effect recognition of Fc Rlll. Thus, the inability of an antibody to 
mediate lysis in a short-term in vitro ADCC assay may not necessarily guarantee that the 
antibody will not deplete target cells in vivo. Indeed it has subsequently been shown that 
an IgG4 version of Campath-1H does deplete peripheral blood lymphocytes in patients 
(Isaacs et al 1996). There are several structural differences between the two subclasses, 
one being that IgG4 has a slightly shorter upper hinge region than IgGl and as such IgG4 
does not activate complement whilst IgGi does. Other differences between the two are 
post-translational modifications such as carbohydrate addition. 
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CHAPTER FIVE: RESULTS- CLONING AND EXPRESSION OF CAMPATH 
ANTIGEN (CDw52) IN MAMMALIAN CELLS: INTERACTION BETWEEN CDw52 
AND CAMPATH-1H 
5.1 Introduction 
The target for Campath-1H is CDw52, an antigen expressed on mature lymphocytes, 
monocytes and sperm (Hale et al 1983). The cDNA sequence of CDw52 encodes a 24 
amino acid leader sequence with a further 37 amino acids forming the protein coding 
sequences of CDw52 (Xia et al 1991). Post-translational modification and cleavage 
generates the mature CDw52 antigen, which is composed of a 12 amino acid backbone 
anchored to the cell surface by a GPI-anchor. Several GPI-anchored molecules have been 
implicated in cell activation and signalling and this is the case for CDw52 (Rowan et al 
1995). The protein backbone of the antigen is known to be modified by N-linked 
glycosylation on the asparagine residue at position three, with the added carbohydrate 
contributing to the total molecular weight of 20-28 kD. Campath-1H recognises an epitope 
formed by the last three amino acids of the mature protein plus components of the GPI- 
anchor (Xia et al 1993b). However, despite these data being available, the cellular function 
of the CDw52 antigen is still unknown. In order to facilitate studies on the function of 
CDw52 and to assist in the generation of assays to quantitate the effects of Campath-IH 
antibody, a source of defined transfected cells was considered desirable. 
5.2 Aims 
Cell lines expressing CDw52, such as the B cell lymphoma Wien 133 (Nacheva et al 1987) 
and the T cell line HUT 78, are suspension cell lines which express high levels of CDw52 
antigen, together with a variety of other surface antigens consistent with their lineage. This 
chapter describes the isolation of cDNA encoding CDw52 antigen from Wien 133 cells, the 
confirmation of the CDw52 gene DNA sequence and the cloning of the CDw52 gene into 
an expression vector at a site suitable for regulated, high level expression in mammalian 
cells. The cell lines selected as host for CDw52 expression were the adherent line CHO 
dhfr- B 11 and the well characterised suspension T cell line, Jurkat J6. Unexpectedly two 
forms of Campath cDNA were identified during PCR analysis, these differing by two 
amino acids in the latter half of the cDNA sequence (this observation had also been made by 
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the Waldman group but was documented as a possible PCR artefact (Xia et al 1991). The 
encrypted signals within this region are those which control the site of GPI-anchorage 
(Moran and Caras 1991a and b). Additional experiments described here attempt to 
investigate the properties of the second form of CDw52 by the transfection of the alternative 
cDNA into cells and comparing the biological properties of the two forms of CDw52. 
Chimeric CD4/CDw52 plasmids were also utilised to -determine the possible role of the 
alternative GPI signal sequences. 
Results 
5.3 The isolation of cDNA encoding the CDw52 Antigen from Wien 133 
cells 
To isolate the cDNA for CDw52 from Wien 133 cells, two PCR primers based on the 
reported DNA sequence were synthesised (Fig. 5.1). The forward primer (#3683) 
corresponded to the 5' sequences of the published coding strand and incorporated a Hind 
III site upstream from the ATG, the reverse primer (#3684) was complementary to the 3' 
sequences of the non-coding strand and incorporated an Eco RI site just downstream from 
the stop sequence. Utilisation of different restriction sites in the strategy allowed for the 
directional cloning of the resulting 206 bp. DNA fragment. 
Figure 5.1 The PCR primers used for isolating the CDw52 antigen. The bases in bold type represent 
restriction sites. 
The 31-mer 5' primer (#3683) 5' GATCCAAGCTTTCCTACCAAAATGAAGCGCT 3' 
The 30-mer 3' primer ( #3684) 5' GATCGAATTCTCAACTGAAGCAGAAGAGGT 3' 
Total RNA was prepared from Wien 133 cells and mRNA was enriched using magnetic 
bead separation. A Gibco BRL 'SuperScript' kit was used to produce both the initial first 
strand cDNA from the resulting mRNA and then to synthesise a second strand DNA copy. 
A PCR performed on 100ng of the cDNA, utilising the primers described above, generated 
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cleavage with Hind III / Eco RI (Fig. 5.2). The purified DNA 
fragment was cloned into 
Hind III/ Eco RI digested pLJC 18 for sequencing. 
Figure 5.2 A-arose gel from which CDw52 cDNA was isolated. The lanes are as follows; Lane I I23bp 
markers, lanes 2 and 4 the PCR product from 10p] Wien 133 cDNA using primers's #3683 and #3684, 
lanes 3 and 5 the PCR control using 10p] Wien 133 cDNA in the absence of primers, lane 6 the kit control 
PCR product of I pi Lambda DNA using relevant primers, lane 7 the kit control using Ill Lambda DNA in 





Sequencing of individual transforinants from the cloning, dcscrihcd above revealed that both 
the upstream and the coding region exactly matched the published DNA sequence of' 
CDw52 except that at a position just four amino acids downstream from the point of GPI- 
anchor attachment (at amino acids numbered 16 and 17), forty-six percent of' the 
independent DNA molecules sequenced had a DNA sequence change that resulted in a 
change in the encoded amino acids from asparagine and isoleucine to serine and methionine 
respectively. Subsequent studies used DNA which conformed to the published authentic 
sequence for CDw52 (Xia et al 1991). 
5.4 Cloning and expression of the CDw52 eDNA in mammalian cells 
Campath cDNA was excised from pUC 18 and cloned into an exhrCSsloll vector pRDN-I 
(Fig. 5.3). pRDN- I encodes the strong (3-actin promotor and polyadenylation signals either 
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side of a polylinker encoding both Hind III and Eco RI sites. Thus, it was possible to 
insert the CDw52 open reading frame in the correct orientation. pRDN- I also encodes a di- 
hydrofolate reductase (dhfr) gene cassette which permits the selection and amplification of 
antigen expressing colonies. After confirming the structure by restriction analysis a plasmid 
encoding CDw52 was named pRDN cAG#35 (later referred to as pRDN AG only). 
Figure 5.3 A diagrammatic representation of the expression vector pRDN- 1.3 The named restriction sites arc 
those routinely used for orientation of inserts. Hind III and Ece RI were utilised for the directional cloning 
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pRDNcAG#35 DNA was used to transfect several cell lines, initially alone into the ('11O 
dhfr line BII and subsequently into the T cell line Jurkat J6 by cotransiection with a 
plasmid encoding neomycin resistance, p321 Neo. 
5.4.1 Transfection into the CHO dhfr- 1111 cell line 
CHO dhfr- cells transfected with pRDN cAG#35 gave detectable surface expression of 
CDw52 antigen with a wide range of levels, as assessed by FACS analysis (Fig. 5.4). The 
addition of increasing amounts of MX into the culture medium led to the selection of 
amplified expression in pooled positive cells. After dilution cloning, individual clone, with 
high level CDw52 expression (Fig. 5.5) were selected for further work. The 10-`M MX 
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clone 10/D4, which had arisen from the 10 cells/well dilution cloning plate, was the most 
frequently used cell line in the following experiment. 
Figure 5.4 A typical FACscan of CHO dhfr cells transfected with the plasmid pRDN AG. The upper 
histogram is representative of untransfected cells. The bottom histogram demonstrates the specific 
expression of cells transfected with the cDNA of CDw52.100 µI of IO` cells per ml were stained with 
either 10. tl of aI in 10 dilution of FITC-Campath-IH or PBS. PBS is phosphate buffered saline pH 7.2. 
CIH is FITC-Campath. 
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Figure 5.5 A FACscan of four 3x 10-K M MX clones (I /B I I, I /E5, I O/D4 and I O/H 10) of CHO dhfr- cells 
transfected with the plasmid pRDN AC, parental CHO cells and Wien 133 cells for comparison. 100 µI of 
10` cells per nil were stained with either I() tl of aI in 10 dilution of FITC-Campath- IH or PBS. PBS is 
phosphate buffered saline pH 72, CIH is FITC-Canipath. 
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5.4.2 Transfection into the Jurkat J6 cell line 
Jurkat J6 T cells which had been transfected with pRDN cAG#35 were cultured in medium 
supplemented with 500 pc/ml of geneticin G418 (Gibco). The resulting cell line was 
analysed for expression by FACS analysis and the pooled cell lines were later dilution 
cloned. All of the individual colonies arising from the 3 cells/well plate were characterised 
for expression and one each of high (3/B 11), low (3/Fl) and two of intermediate 
expression (3/G5 or 3/B5) were maintained for further experimentation alongside the 
parental untransfected line (Fig. 5.6). 
Figure 5.6 A FACscan of five clones (3/FI, 3/G5,3/BI I. 3/G I and 3/B5) of Jurkat J6 cells transfected with 
pRDN AG plus parental Jurkat cells for comparison. 100 pi of Iü cells per ml were stained with either 10 
µl of aI in 10 dilution cif FITC-Campath- IH or PBS. PBS is phosphate buffered saline pH 7.2, CIH is 
FITC-Campath. 
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5.4.3 The confirmation of GPI-anchorage by PIPLC treatment of the 
transfected CHO cell line I0/U4 
To confirm that the expressed antigen was GPI-anchored, enzyme assays using PIPLC 
(Boehringer Mannheim) were performed. PIPLC specifically cleaves the GPI-anchor 
directly above the site of lipid attachment to the cell. FACS data (Fig. 5.7) involving 
extrapolation from the mean fluorescence indices on the X-axis, indicated that 
approximately 80% of the antigen was cleaved from 3x 105 cells by treatment with 10 units 
of PIPLC (308 units/200 µl) whilst the remaining 20% remained un-touched. This was 
also the case for Wien 133 cells (data not shown). It has been proposed that this is probably 
due to the presence of fatty acid attached to the inositol ring of some of the GPI-anchors 
which sterically blocks the site of cleavage (Treumann et al 1995). 
Figure 5.7 A FACscan analysis of CHO cells transfected with the plasmid pRDN AG. Two of three 150 pl 
aliquots of cells at 2x 10" per ml were pre-treated with 10 units PIPLC for 90 minutes at 37"C. All three 
were washed in PBS prior to staining with either 10 pl of aI in 10 dilution of FITC-Campath- IH or PBS 




5.4.4 The cloning of the alternative sequence of CDw52 
During this work two CDw52 negative variants of the Wien 133 cell line became available. 
The MR4 line had lost CDw52 surface expression after exposure to monocytes and was 
able to evade killing via the ADCC mechanism (see Chapter three, section 3.7) and the CV4 
line was similarly raised by Wendy Rowan (Dept. of Cell Biology) in response to 
crosslinking with Campath-1H antibody (Rowan et al 1998). The generation of these lines 
was of interest as it suggested that patients receiving therapeutic injections of Campath-1H 
could possibly develop antigen negative cells. To investigate further, the cDNA from MR4 
and CV4 cells was used as a source of CDw52 template for PCR experiments in which, as 
with the parental Wien 133 cells, the CDw52 cDNA was isolated, cloned into pUC vectors 
and plasmid DNA from the resulting colonies sequenced (Table 5.1). 
Table 5.1 The results of sequencing cloned CDw52 PCR inserts from either MR4, CV4 or Wien 133 cDNA 
Cell 
type CDw52 sequence Alternative sequence 
Ex t. l Ex t. 2 Ex t. 3 total % Ex t. l Ex t. 2 Ex t. 3 total % 
Wien 
133 
1 of 2 4 of 8 2 of 3 53.8 1 of 2 4 of 8 1 of 3 46.2 
MR4 1 of 5 4of8 N/A 38.5 4of5 4of8 N/A 61.5 
CV4 2of6 2of8 N/A 28.6 4of6 6of8 N/A 71.4 
Table 5.1 shows that in the both the MR4 and CV4 lines there is a diversion away from the 
53.8% distribution of the DNA sequences detected in the parental Wien 133 cells towards a 
higher ratio of the alternative sequence, although statistically this is not significant. 
Experiments investigating the comparison of both forms of CDw52 will be now be 
discussed. 
5.4.5 Cloning and expression of the alternative CDw52 sequence (C1H) in 
CHO dhfr- cells 
When CDw52-negative CV4 cells were injected into nude mice, the expression of CDw52 
reappeared (Rowan et al 1998). To investigate whether this phenomenon was related to 
switches in gene expression between the two forms of CDw52, cDNA encoding the 
alternative sequence of CDw52 was isolated from the original PCR-derived clones and 
recloned into the pRDN-1 expression vector. The plasmid was named pRDN AC 1 H. 
Transfections into fresh CHO dhfr- cells with both the authentic and alternative cDNAs 
were performed simultaneously and the cells passaged through the selection procedure up 
to a concentration of 3x10-8 M MX. The pools of cells were then analysed by FACS 
ä 
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utilising FITC-labelled Campath-1H as the detecting reagent. Fig. 5.8 shows that the 
untransfected parental cells exhibit no background staining and cells transfected with pRDN 
AG developed high levels of surface expression. However, the cells transfected with 
pRDN AC1H appear to have very low staining. This observation was confirmed by 
repeating the experiment several times. 
Figure 5.8 A CDw52 FACscan of untransfected parental CHO cells or CHO cells transfected with either 1 
. tg pRDN AG or pRDN OC1H and cultured in 3x10-8 M MX. 100 91 of 105 cells per ml were stained with 
either 10 µl of a1 in 10 dilution of FITC-Campath-1H or PBS. PBS is phosphate buffered saline pH 7.2, 
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There were a number of possible explanations for this observation including: - 1) the 
alternative cDNA encoded a form of CDw52 that was not anchored to the surface by a GPI- 
anchor; 2) due to the sequence change in the cDNA, the anchor was attached to a residue 
different from that in the authentic antigen, (both 1 and 2 would lead to the loss of detection 
by FITC-Campath-1H because of the loss of the antigenic epitope); 3) the antigen was not 
being transported to the cell surface; 4) the alternative form was either poorly or not 
translated from the RNA. Experiments were designed to investigate some of these 
possibilities. 
5.4.6 Morphological differences observed in the transfected cells 
The transfected CHO cells were found to grow at different rates from each other and the 
parental untransfected line. When cell cultures of the same cell numbers were set up and 
compared with time, the CHO cells harbouring pRDN AG grew at a much faster rate 
between sub-cultures compared to their untransfected counterpart. The reverse was seen for 
the cells transfected with pRDN OC1H. When the cells were examined microscopically 
morphological differences were seen (Fig. 5.9). Panel A shows the untransfected CHO 
dhfr- cells which have a uniform packing arrangement. Panel B shows cells transfected 
with pRDN AG, here the cultures take on the appearance of densely packed spindle shaped 
cells forming an overall swirling pattern. Panel C is of the pRDN OC1H transfected CHO 
cells which demonstrate a box shaped phenotype with a disorganised distribution. 
5.4.7 The growth of untransfected CHO cells or CHO cells transfected with 
pRDN AG or pRDN AC1H in nude mice 
To assess whether the cells expressing one or other of the two forms of CDw52 cDNA 
possessed a selective biological advantage, aliquots of either 2x 107 cells/ml parental CHO 
dhfr- cells or 2x107 cells/ml CHO cells transfected with pRDN AG or pRDN AC1H were 
harvested from culture. A sample was analysed for CDw52 expression by FACS staining 
with FITC-Campath-1H to confirm phenotype, and the remaining cells were mixed one to 
one with 6 mg/ml matrigel and 0.1 ml volumes injected intradermally into nude mice, 10 
per group. This experiment was performed by Peter Topley and Rob Shaw (Dept of Cell 
Biology). After several weeks some of the mice developed tumours and these were excised 
and the cells teased into single cell suspensions for CDw52 FACS analysis. 
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Figure 5.9 The morphological differences of CHO cells transfected with the two different plasmids. 
The 
observed differences between either the regular packing of untransfected CHO cells (A), the swirling pattern 
of cells transfected with the plasmid pRDN AG (B) or the disorganised arrangement of cells transfected with 
the plasmid pRDN AC IH (C). 
13 
C 
fahle 5.2 The numhers cif tumours arising from nude mice injected intra dermally with untransh cted ('H( 
cells or CHO cells transfcctcd with either pRl)N AG or pRl)N AC IH 





CHO 0 out of 10 0 out of 10 1) out of 20 
CHO/ RUN A(; 4 out of 10 3 out of 10 7 out of 2t) 
CU O/ RUNAC IH 0 out of )t) 0 out of 10 0 out of 2t) 
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Only mice receiving CHO cells transfected with pRDN AG developed tumours (Table 5.2). 
FACS analysis of cells from excised tumours demonstrated high CDw52 expression. These 
results suggest that there is indeed a biological function associated with the expression of 
CDw52 which could perhaps either act as an adhesion molecule which allows the 
transfected cells to bind to some unknown ligand in vivo, or that the antigen acts as a 
protective molecule similar to another GPI-anchored antigen, DAF (Funabashi et al 1994). 
5.4.8 3H Ethanolamine labelling of the CDw52 GPI-anchor in parental and 
transfected CHO cells 
In an attempt to demonstrate whether the two expressed forms of CDw52 had similar GPI- 
anchors, cell cultures of either the untransfected CHO dhfr- cells or the two transfected 
lines were exposed to 3H Ethanolamine for eighteen hours as described in Materials and 
Methods. Pellets containing equivalent numbers of labelled cells (2x105) were lysed and 
samples of each lysate subjected to SDS-PAGE. Despite overloading of the sample 
containing cells transfected with pRDN AC1H, the only evidence of ethanolamine labelling 
of a protein of 20-28 kD appeared in the lane containing cells transfected with pRDN AG 
(Fig. 5.10). The smeared effect is due to the large carbohydrate moiety attached to the small 
protein backbone. The untransfected CHO cells appeared to also have another, unknown, 
form of a GPI-anchored molecule of about 70 kD which acted as an internal control for 
loading comparisons. 
5.4.9 CDw52 RNA protection assays using parental and transfected CHO 
cells 
RNA protection studies were devised to analyse the levels of CDw52 RNA expression in 
the different cell lines. Equivalent numbers of cells from parental or transfected cells were 
pelletted and lysed and dilutions of the resulting lysates mixed with single stranded 
CDw52-encoding run-on probes of either forward or reverse orientation. After mixing and 
overnight incubation to allow annealing to occur, the annealed products were exposed to 
RNA-ases in order to digest unbound probe and mRNA. The anticipated remaining 
protected products were then separated on 6% sequencing gels which were later dried onto 
paper and autoradiographed overnight. Products of approximately the correct size of 206bp 
were detected in both types of transfected CHO cells at 107/ml and fainter bands of the 
same size are apparent in the 106/ml lanes (Fig. 5.1 1). The data indicate that CHO cells are 
able to transcribe both forms of CDw52 cDNA and that the lack of expression associated 
with pRDN OC 1H might be due to problems related to the translation or transport of the 
product. 
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Figure 5.10 A typical 15c/ SDS-polyacrylamide gel demonstrating Ethanolaminc labelled lysates from 
parental CHO cells or CHO cells transfected with either the plasmid pRDN AG or pRDN 
_C 
I H. Cells were 
incubated for IR hours with 
3H Ethanolamine prior to lysis and electrophoresis. The lanes are I, 14C 
protein molecular weight markers. 3, The lysate of 2x 05 parental CHO cells. 5, The lysate of 2x 1()5 CHO 
cells transfected with the plasmid pRDN AG. 7, the lysate of 2x I CHO cells transfected with the plasmid 
pRDN AC I H. Lanes 2,4,6 K and 9 blank. The antigen CDw52 demonstrates a molecular weight of between 
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Figure 5.1 1A CDw52 RNAase protection gel. CHO cells transfected with pRDN AG or pRDN AC IH 
were used as template for RNA protection studies, either I ()7 cells/ml or 106 cells/ml were incubated with 
Campath antigen probes transcribed in forward or reverse orientation in the Bluescript vector KS+ (IU5 cpm 
per reaction). Lane I, 
32 P end labelled 0174 marker cut with Hinf. Lane 3,5 pl reverse probe; lanes 5-10, 
cell lysates plus reverse probe digested with RNAase of which lane 5 is I07/m1 CHO cells, lane 6 I06/ml 
CHO cells, lane 7 107/ml CHO cells with pRDN AG, lane K 1()6/mI CHO cells with pRDN AG, lane 9 
107/ml CHO cells with pRDN AC I H, lane 10 106/ml CHO cells with pRDN AC I H. Lanes 2,4 11-13 
blank. Lane 14 5 ftl forward probe, lanes 15-20, cell lysates plus forward probe digested with RNAase of 
which lane 15 is I()7/ml CHO cells, lane 16 106/ml CHO cells, lane 17 I()7/ml CHO cells with pRDN 
AG, lane IS 106/ml CHO cells with pRDN AG, lane 19 1()7/1,11 CHO cells with pRDN ACI H, lane 20 
, ()6/11,1 CHO cells with pRDN AC I H. Lanes 21 and 22 blank. 








5.5 The CD4/CDw52 chimeric strategy 
To overcome the technical problem of using a single CDw52 detection reagent (Canlpath 
antibody) to recognise the variant region of CDw52, a new strategy was required. A series 
of procedures were devised to fuse a small extraccllular 5' portion of CD4, from plasmid 
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pT4B, in frame to the 3' ends of the two CDw52 cDNA molecules. The full upstream 
extracellular region of CD4 could then be recreated by straight forward cloning of the 
chimeric molecule as a Sau I/ Bam HI DNA fragment. The different chimeric forms and 
parental CD4 could then be cloned into pRDN- l for expression in mammalian cells. The 
molecule CD4 was chosen primarily for three reasons 1) it was readily available; 2) there 
were several detection antibodies of different specificities available commercially; 3) it was 
a large surface antigen not expressed on CHO cells. Within both of the cDNAs for CD4 and 
CDw52 there were sequences for proline residues at suitable positions for in-frame fusion. 
The proline in the CD4 extracellular region was at base 1263 just upstream to the membrane 
spanning domain and in CDw52 the proline residue was at amino acid position 11, just one 
amino acid upstream to the GPI-anchor attachment site. 
Figure 5.12 A diagrammatic representation of the polypeptides and the regions ofinterest. The top one a) is 
CD4, the middle one h) is CDw52 and the bottom one c) is the CI)4/CDw52 chimera. The portions 
mentioned are the CD4 and CDw52 extracellular regions (EC), the CD4 t ansmembrane region (TM), the 
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Four 30-31 mer DNA primers were designed as shown in Fi g. 5.13. The first Iorwai'(t 
primer (AT 35) exactly matched part of the 5' end of CD4 cDNA amino acids 1009-1038 
and incorporated both Hind /H and HpH I sites for cloning purposes. The second 
primer, a reverse primer (AT 36), wits complementary to the CDw52 3' coding strand 
residues 15-11 and was also complementary to the 3' end of' the extracellular coding strand 
of the CD4, bases 1263-1245. Primer number three (AT 37), another forward primer, was 
the coding equivalent of primer number two and matched the 3' extracellular portion of 
CD4 (bases 1245 - 1263) and the overlap into CDw52 (amino acids II- I5). A fourth 
primer (AT 39), was similar to the reverse primer #3684 used to originally isolate the 
CDw52 cDNAs. This reverse primer was complementary to the coding region containing 
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the stop signal in the 3' end of CDw52 (common to both forms of CDw52) amino acid 
numbers 38-34, plus Bam HI and Eco RI cloning sites. 
Figure 5.13 The PCR primers used to form the in frame fusion of extracellular CD4 to the CDw52 GPI- 
anchors. The underlined bases are those of CD4 origin. Those in bold type represent restriction sites. 
AT 35 a 30-mer CD4 primer 5' GTGAAGCTTGTGGTGATGAGAGCCACTCAG 3' 
AT 36 a 30-mer CDw52 and CD4 primer 5' GCTGGATGCTGAGGGCTGCACCGGGGTGGA 3' 
AT 37 a 30-mer CD4 and CDw52 primer 5' TCCACCCCGGTGCAGCCCTCAGCATCCAGC 3' 
AT 39 a 31-mer CDw52 primer 5' GATCGGATCCGAATTCTCAACTGAAGCAGAA 3' 
To form the fusion between the CD4 extracellular region and either of the two CDw52 tails 
using PCR, two approaches were feasible. One approach was to perform three PCR 
reactions concurrently to obtain either the desired 286bp CD4 region with CD4 plasmid 
pT4B DNA as template and utilising primers AT 35 and 36, or to obtain the two relevant 
110bp CDw52 tail portions utilising CDw52 plasmids pRDN AG or pRDN OC1H DNA as 
template and primers AT37 and 39. The final step for this approach would be to combine 
the products from the CD4 PCR experiment with either of the CDw52 PCR products and 
perform the last PCR in the presence of primers AT35 and 39 only. The second quicker, 
but more difficult, approach was to use a combination of both CD4 and CDw52 DNAs as 
template at the same time, in the presence of equal amounts of primers AT35 and 39, but 
also to incorporate 1 in 25 dilutions of primers AT36 and 37 in the reaction. This latter 
method should allow for limited amplification of the intermediate products whilst favouring 
the amplification of the final 390bp product. The second PCR approach was used as a 
modification of that described in Material and Methods. PCRs were performed in which 
100 ng amounts of total plasmid DNA were exposed to amplification reagents in the 
presence of all four of the described primers. 
As can be seen in Fig. 5.14, PCR DNA fragments of the correct size were obtained, 
purified and cleaved with the relevant restriction enzymes prior to cloning into pUC vectors 
as Hind III / Bam HI inserts (data not shown). Several of the resulting colonies were 
used to prepare mini preparations of plasmid DNA and these were sequenced in both 
orientations to confirm the sequence. Nearly all of the DNA samples tested were correct 
(data not shown). DNA preparations from selected colonies were scaled up to maxi 
preparation scale and the DNA retrieved on caesium gradients. Cleavage of the resulting 
DNA with both Sau I and Bam HI generated DNA fragments of 200 bp. (data not shown). 
The fragments were cloned into pT4B which had been cleaved with the same enzymes to 
remove the portion of CD4 corresponding to the end of the extracellular region, the 
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transmembrane region and the cytoplasmic region. This resulted in the reconstruction of the 
full extracellular CD4 region now hearing CDw52 GPI-anchor signals. 
Figure 5.14 CD4/CDw52 PCR gel in which duplicate products of the correct size can he seen. Lane I 
I23bp markers, lanes 2 and 4 286hp PCR products ltom pT4B with printers AT 35 and 36, lanes 3 and 5 
mock reaction of' pT4B lane minus primers. lanes f{ and 10 I IU bp product from pRDN AG with printers 
AT 37 and 39, lanes 9 and II mock reaction of' pRDN AG minus primers, lane', 14 and 10 39I)hp product 
of both p"1'4B and pRDN AG with primers AT 35,36.37 and 39, lanes 15 and 17 mock reactions of p f4B 
and pRDN AG minus primers. Lanes 6,12 and 18 water controls minus DNA but with printers lanes 7.13 





TO coil 11), 11C ([It' N', I OII OI IIit' M (I( I) I; ( I)vý. ý' , 1111m i. 1 I )\ \ -II, -III1,1 ,, 111 ,I 
was cleaved from the modified T 4B using Leo Ri and the resulting 1362 hp I )NA 
fragment was ligated into the similarly cleaved pRI)N- I to generate pRl)N ('I)4/A(; ut 
pRDN CD4/AC I H. From the original T4f3, the 2901 hp DNA fragment encoding the ('1)4 
molecule containing the extracellular and intracellular sequences, was also ligated into 
pRI)N-I as an Leu RI fragment and the orientation checked by restriction enzyme analysis 
(results not shown). A plasnud with the correct sequence was namrel pRl)N ('1)1 
Plasmids pRDN AG and pRl)N AC III were already available as controls. 
5.5.1 The transfection of 1)NA encoding ('I)4/('I)w52 chimeras, ('I)4 or CDw52 into CHO cells 
pRDN CD4/AG, pRDN ('1)4/ACI11. pR[)N ('O4 and pRDN AG were independently used 
to transf'cctcd CHO dht'r- cells and the transfected cells were gradually pass a aged through the 
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selection procedure. The selection of high expression levels was obtained by gradually 
increasing the MX concentration to 3x10-8 M. Throughout the amplification steps, pools of 
the transfected cells were analysed for both CD4 and CDw52 expression utilising FACS 
analysis. Once the cells were growing stably in the 3x10'8 M MX selection medium they 
were dilution cloned. The results of the FACS analysis of typical clones are shown in 
Fig. 5.15. As expected cells transfected with the CD4/CDw52 chimeras lost CDw52 
staining whilst the expression levels of the controls were normal. However, cells 
harbouring pRDN CD4/OC1H not only developed CD4 expression but to a level higher 
than that seen in the cells transfected with pRDN CD4/AG. This would indicate that the 
previous loss of CDw52 expression in CHO cells transfected with pRDN AC1H was a 
transport rather than translation problem. To confirm the expression levels, the same cells 
were utilised in CD4 immunoprecipitation experiments. 
Figure 5.15 CD4 and CDw52 FACS analysis of typical transfected CHO clones. CHO cells transfected with 
either pRDN CD4 or pRDN AG were compared with CHO cells transfected with pRDN CD4/AG or pRDN 
CD4/iC1H for expression of CD4 or CDw52.100 µl of 106 cells per ml were stained with 10 p. 1 of a1 in 
10 dilution of either FITC-Campath-1H (C1H) or FITC-anti CD4 (a-CD4). Phosphate buffered saline pH 







Aliquots of 2x107 cells of all of the four transfected cell lines were lysed and the lysates 
immunoprecipitated with 50 p1 of a F(ab)2 fragment of anti-CD4 antibody bound to 
177 
ts& ss94aoea1vtI-MSU-M. ºd, t 
Chapter Five: Results- Campath antigen (CDw52). The cloning and expression in mammalian cells: The interaction 
between CDw52 and Campath-1H 
sepharose beads. The products were separated on 8% non-reducing SDS-polyacrylamide 
gels and transferred, by Western blotting, onto nitrocellulose paper for detection of the 
protein. Cells harbouring pRDN CD4/AG (1), pRDN CD4 (2) and pRDN CD4/tC 1H (3) 
all show CD4 precipitates whilst the cells with pRDN AG (4) are negative for CD4 
(Fig. 5.16). The precipitates of (1) and (3) are of a smaller size than the full length CD4 (2) 
because of the presence of the CDw52 GPI-anchor. Cells harbouring pRDN CD4/AC1H 
have higher levels of CD4 precipitates. 
Figure 5.16 A typical CD4 western blot of transfected CHO cells. Lysates from 2x107 CHO cells 
transfected with lane 1 pRDN CD4/AG, lane 2 pRDN CD4/OC1H, lane 3 pRDN CD4 or lane 4 pRDN 
AG, were immunoprecipitated using anti-CD4 sepharose and the resulting proteins separated by SDS- 
PAGE. After transfer to nitrocellulose by western blotting, the filters were probed with anti-CD4 







5.5.2 The treatment of the CD4/CDw52 transfected CHO cells with PIPLC 
To confirm that the CD4/CDw52 chimeras have GPI-anchors, the four cell lines were 
exposed to PIPLC treatment. The treated cells were later FACS analysed with either FITC 
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labelled anti-CD4 or Campath-1H as relevant (CDw52 data not shown). PIPLC treatment 
of cells transfected with either pRDN CD4/AG or pRDN CD4/AC 1H led to a decrease in 
the surface expression of CD4 (Fig. 5.17). Cells harbouring pRDN CD4 were not affected. 
CHO cells transfected with the plasmid pRDN AG never expressed detectable CD4. 
Figure 5.17 FACS analysis of PIPLC treated transfected CHO cells. Transfected CHO cells bearing either 
pRDN CD4/AG (top), pRDN CD4/OC1H (upper middle), pRDN CD4 (lower middle) or pRDN AG 
(bottom) were treated with and without PIPLC prior to staining with FITC-anti CD4 (a-CD4). Phosphate 
buffered saline (PBS) was used as control. 
t5t"94CH09%IFtI- P. Fu-n. id t 
CHO + pRDN CD44AG 
. O4 PIPLC 
. Co. 
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No 99940=1 IVLl-N4U-IN17I 
CHO pRDNAG (CD4 NEGATIVE CONTROL) 
com. 
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5.5.3 The tranfection of Jurkat J6 cells with pRDN AG and pRDN ACM H 
As an independent test of whether pRDN AC1H could be expressed in mammalian cells, 10 
µg was co-transfected with 1 µg of the p321neo plasmid, into Jurkat J6 cells. 
Concurrently, pRDN AG was used as control. After selection in G418 containing medium, 
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both cell lines were FACS analysed for CDw52 expression in comparison with the parental 
line utilising FITC-labelled Campath-1H. Both plasmids were able to direct CDw52 
expression but with different profiles (Fig. 5.18). The pRDN AG transfected cells 
demonstrated high expression levels of CDw52 as expected however, in contrast to the 
large difference in expression seen between the two variants in CHO cells, the Jurkat cells 
transfected with pRDN OCIH also showed good expression of CDw52. There was still 
however a quantitative difference in levels of expression observed. 
Figure 5.18 CDw52 FACS analysis of transfected Jurkat J6 cells. Aliquots of 100 µl (1x106 cells per ml) 
of parental cells or cells transfected with pRDN AG or pRDN AC1H were stained with 10 µl of aI in 10 






5.6 Utilisation of transfected cells 
5.6.1 In ADCC assays 
Clones of CHO CDw52 transfectants never proved to be reliable targets in ADCC assays 
due to their inability to be readily lysed in response to antibody (data not shown). 
However, some data was obtained using Jurkat 3B/11 transfectants as target cells 
(Fig. 5.19). These were lysed efficiently in the presence of Campath (I µg/ml) at all effector 
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to target cell ratios greater than 10: 1. Unlike Wien 133 cells, moderate lysis was still 
observed when antibody was omitted. Conversely, untransfected Jurkat cells demonstrated 
some lysis in the presence of antibody which increased to that of the transfected cells when 
antibody was omitted. The significance of the data, if any, is unclear, but it does suggest 
that the presence of CDw52 might be protective against lysis from non-ADCC mechanisms. 
The situation needs to be clarified by studying several clones and it should be stated that the 
site of integration of the plasmid into each cell genome is not known and therefore the 
transfected cell phenotype may be altered. 
Figure 5.19 The use of CDw52 transfected Jurkat cells as ADCC target cells. 10 transfected or parental 
Jurkat cells were used as target cells in a Campath- IH (I µ, t/inI) ADCC assay at different ofIector to target 
cell ratios. Symbols represent transfected Jurkat cells with 0 or without " Campath- I H, represents parental 
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5.6.2 Transfected Jurkat cells in crosslinking experiments 
The untransfected and the pRDN AG transfected Jurkat clones were used in experiments 
where signalling events were monitored by crosslinking the expressed antigen (see 
Chapters three and four). The cells assayed had been co-transfected with the expression 
plasmid plus a neomycin resistance encoding plasmid and subsequently selected by culture 
in medium containing G418, an analogue of neomycin. Recent evidence now indicates that 
drugs similar to neomycin interfere with signalling events probably by blocking the Protein- 
Kinase C step (Lin et al 1991). As a consequence, the transfected cells were cultured minus 
G418 for a week prior to repeating the experiments The Jurkat cell line is it 'T cell line 
that does not express surface Ig and therefore the observed effects are due entirely to the 
transfected CDw52 antigen. 
181 
Cher Five: Results Gampat antigen (CDw52) The cloning and exp sinn in mamm , lian ce11s The 
interat lion 
between CDw52 and am path-IR 
5.7 Discussion 
The antigen CDw52 has been known since the early 1980s and has been sequenced and 
characterised (Xia et al 1991 and 1993b, Hale et al 1990). Extensive studies on the 
carbohydrate composition have been undertaken and the data published (Treumann et al 
1995). The antigen has also been used as a means of activating T cells (Rowan et al 1995) 
and has been utilised as a therapeutic target. However despite all of this information there 
has been little progress on determining the function or even possible function of CDw52. 
The antigen is one of a significant number of molecules which are attached to the cell 
surface via a GPI-anchor. Other molecules which share this property have been identified. 
In protozoan parasites they include VSG (variant surface glycoprotein) on typanosomes 
(Cross 1990) and gp63 on Leishmania. In rats Thy-1 has been shown to be GPI-anchored 
(Fasel et al 1989) and several antigens including CD46 or MCP (Simpson and Holmes 
1994), CD55 or DAF (Funabashi et al 1994) and CD59 (Morgan et al 1993) have been 
identified in mammals. In parasites, the GPI-anchored molecules may pack more closely on 
the external surface as a consequence of their anchorage and thus act as a protective shield 
from host immune response. The molecules found in mammals are also thought to have a 
protective function in that they are found on sperm in the male genital tract and are present 
on cells which are prone to lysis during immune attack (Simpson and Holmes 1994). 
Ailments such as PNH (Ueda et al 1992, Takeda et al 1993), in which GPI-anchors on 
plasma membrane proteins are defective or absent, leads to the loss of red cells through 
lysis. 
The interaction of CDw52 and Campath- I H, either in the presence of complement or by the 
activation of effector cells, leads to cell lysis (Hale et al 1983 and 1985). When cDNA 
equivalent to the published sequence of CDw52 was expressed in either the CHO and 
Jurkat cell systems it exhibited similar properties to the natural antigen expressed on 
lymphocytes (Hale et al 1996). The CDw52 transfected cells proved to be amenable to 
experimental analysis and could be used as an alternative to isolated mononuclear cells or 
suspension T and B cell lines. The authentic CDw52 was recognised by Campath-1H and 
was shown to contain a GPI-anchor by utilising the specific enzyme PIPLC (Hale et al 
1996). As with CDw52 expressed on mononuclear and Wien 133 B cells, PIPLC treatment 
resulted in the substantial reduction but not complete loss of antigen expression. This may 
be a consequence of excess palmitylation of the GPI-anchor inositol ring leading to 
blockage of the cleavage site on a percentage of the molecules (Treumann et al 1995). 
The discovery of the second variant of CDw52 sequence was not in itself a novel finding, 
but the variant had previously been described as a possible PCR artefact (Xia et al 1991) 
and similar variant of CDw52 sequence was also described by Perry (et al 1992). Amongst 
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cDNA prepared from Wien 133 cells both forms of PCR product were found to be present 
in approximately equal proportions. When antigen negative variants of Wien 133 cells were 
obtained by selective pressure, the ratio altered towards higher levels of the alternative 
sequence. The variation from the authentic sequence was found to reside outside of the 
mature protein in residues 16 and 17. The resulting change in amino acids was from 
asparagine and isoleucine to serine and methionine respectively. These residues are in a 
context which is critical for determining the correct positioning of the GPI-anchor and 
potentially creates an alternative GPI-anchor site (Moran and Caras 1991 a and b). In our 
investigation the alternative CDw52, CIH, was not expressed at high levels in CHO cells 
transfected with a plasmid encoding that sequence (Hale et al 1996). The expression of the 
two forms in CHO cells was demonstrated by FACS analysis and correlated with 
reproducible morphological differences in culture. Ethanolamine labelling of transfected 
cells was consistent with the low expression levels of the alternative form however, 
RNAase protection assays indicated that mRNA was being transcribed in these 
transformants. The introduction of both cell lines into nude mice revealed striking 
differences, in that only those mice receiving cells bearing the authentic cDNA, developed 
tumours. 
The reason for the lack of expression in cells, detected by FACS, was postulated to be 
either a lack of recognition of the antigen by the antibody due to an altered epitope or loss of 
the epitope. The epitope for recognition by the antibody Campath-1H has been 
demonstrated to reside within residues 9-12 of the mature protein in addition to an 
undefined component of the GPI-anchor (Hale et al 1990). The anchor is added post- 
translationally via the serine residue at position 12. It was suggested that the alternative 
CDw52 might have its GPI-anchor attached to a different residue or that the antigen may no 
longer possess a GPI-anchor. Since the Campath-IH epitope may be modified in the 
alternative form of CDw52 it was unreliable to use Campath antibody as detecting regent. 
To overcome the technical problem, both the authentic and alternative sequences of the 
CDw52 GPI-anchor were cloned downstream of the extracellular sequence of CD4 cDNA 
in expression vectors and these were transfected into CHO cells and expressed under 
selection with high concentrations of MX. Surprisingly, not only were both forms 
expressed and recognised by anti-CD4 antibody, but both were also demonstrated to be 
GPI-anchored by PIPLC treatment (Hale et al 1996). Ethanolamine labelling of the 
resulting cells confirmed this, as did immunoprecipitation of the lysed labelled cells with 
anti-CD4 antibody. Both CD4/CDw52 chimeras were detected as precipitated protein of the 
same mobility on SDS-polyacrylamide gels. When compared to the control CD4 cDNA, 
which was transfected and expressed with its original transmembrane and cytoplasmic 
regions, the mobility of both of the GPI forms was less then the intact CD4, reflecting the 
addition of GPI-anchors. Subsequently, Jurkat cells transfectants were produced in which 
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both forms of the antigen were expressed. However, the originally described CDw52 
variant was always expressed at a higher level suggesting that this form of CDw52 gene 
was more efficiently processed and transported to the surface. 
The development of the CDw52 expressing Jurkat cell lines proved to be of considerable 
importance in antigen binding studies for several reasons. Firstly, in the definition of the 
mode of action of CHO Campath in ins vitro assays (Chapter three) and for comparison of 
antibodies isolated from different host cells or of different isotype (Chapter four). 
Secondly, for assessing the functional changes in NSO antibody associated with the 
development of media (Chapter four). Furthermore, a number of potential uses for the 
CDw52 expressing CHO cell line, 10/D4, have now also emerged. Dr. R. Lifely 
(Wellcome, personal communication) successfully evaluated the cell line as a source of pure 
antigen. Prior to the development of the transfected cells, the antigen was isolated from 
human spleens which had been surgically removed for medical reasons and thus not in 
abundant supply. The purified recombinant CDw52 antigen could be used as a reagent for 
studying antibody responses in Campath treated patients, in assays to compare the affinity 
of Campath antibodies and for further studies on the structure of the antigen itself. The 
10/D4 line was used to assist in the evaluation of radio-labelled Campath-1H for the 
treatment of solid tumours (Hutchins et al 1995). 
The derivation of the CDw52 negative, CV4 and MR4, Wien 133 cells in the laboratory 
pre-empted the natural development of CDw52 negative cells in patients receiving Campath- 
1H. The use of these cells in in vitro assays helped to predict the possible consequences in 
patients (Chapter three, section 3.7). In the early stages of Campath therapy, antigen 
bearing lymphocytes are severely depleted but the numbers of cells slowly recover with 
time. By monitoring both cell type and CDw52 expression with FACS staining, this 
recovery can be followed. The T cells appear to be most severely affected and it is these 
cells that can exhibit loss of antigen. Publications now arising from several groups 
monitoring CHO Campath clinical trials, reveal that a number of the patients develop 
partially or fully CDw52 negative T cells (Hertenstein et al 1995, Brett et al 1996a). When 
studied at Wellcome Research Laboratories, totally antigen-negative T cells from patients 
were found to be also CD55 and CD59 negative (Rowan et al 1998). She demonstrated that 
the lack of antigen was not only a surface phenomenon but could also be visualised at the 
RNA level. Vanessa Taylor, another Ph. D student at Wellcome, utilised samples from 
partially GPI-defective patients to separate the CDw52 negative cells from positive cells by 
cell sorting. She found that the defect in the negative cells could be monitored by culturing 
the cells in radioactive precursors for GPI-anchor synthesis (Field and Menon 1992, Taylor 
et al 1997) but did not involve the glycotransferase gene PIG A. This work also determined 
that patients exhibited both cDNA sequences previously isolated from Wien 133 cells and 
184 
Chapter Five- Results- Campath antigen (CDwS2). The cloning and expression in mammalian cells: The interaction 
between CDw52 and Campath-IH 
that both were detectable by Campath-1H antibody (Taylor et al 1997). This data could 
predict undesirable consequences for the use of some depleting antibodies in therapy. The 
reason for depleting CDw52 expressing cells in vitro is to remove graft versus host (GVH) 
reactive cells in bone marrow transplants or in vivo to either reduce the numbers of self 
reactive cells in autoimmune diseases or to ablate lymphocytic tumour cells. If in any of 
these situations, antigen negative variants arose, it could be a most undesirable 
consequence. Rawstron (et al 1999) have recently produced data demonstrating that some 
patients exhibit low numbers of CDw52 negative cells prior to immunotherapy and so it 
may be that after depletion with Campath-IH it is these cells that survive. 
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CHAPTER SIX: THE GENERAL DISCUSSION 
This thesis was designed to clarify earlier observations that mononuclear effector cells 
isolated from volunteers responded differently in ADCC assays when targeted by either 
hamster CHO or rat YO Campath-IH (J. Tite, personal communication). Rademacher (et al 
1988) and Leatherbarrow (et al 1985) had previously shown that the removal of antibody 
N-linked carbohydrate led to the loss of activity in certain cell based assays. As an 
extrapolation of this data plus our own observations, it had been hypothesised, that 
antibody isolated from different species of host cells might possess different N-linked 
sugars on the Fc CH2 domain. The project was planned to enable both the manufacture of 
Campath-1H antibody from mouse NSO cells, the media development for those cells and 
the comparison with CHO and YO Campath-IH in in vitro assays representing mechanisms 
thought to be utilised in vivo during immunotherapy. In addition oligosaccharides, released 
from the antibody isolates, were compared for carbohydrate composition. 
The assays tabulated in Chapter Three were defined utilising Campath-1H sourced from 
CHO cells. Repeated ADCC and monocyte-mediated assays using effector cells purified 
from volunteers confirmed that responses did vary between donors but, the reasons why 
were never sought. Evidence from Moretta (et al 1993) regarding recognition of MHC class 
1 type by NK cells and data produced from the classification of IgG Fc receptor 
polymorphism's (Koene et al 1997, Salmon et al 1992 and Sanders et al 1995) in relation to 
IgG binding may be relevant. To properly define the mechanisms involved in the assays it 
would be advantageous to characterise donors for both MHC 1 plus IgG Fc Rll and Rill 
type prior to the experiment. It may even be possible to develop an immortalised NK 
effector cell line for use in ADCC assays. The removal of CD56 cells was always 
demonstrated to ablate the ADCC response and the Fc receptor blocking experiments 
implied that Fc Rlll was the receptor mediating the effect. The observation that 'y IFN could 
induce increased inhibition by monocytes was very exciting and could have implications for 
therapeutic use of antibodies such as Campath-IH in that lower concentrations of antibody 
might be required. This may reduce the side effects associated with Campath-1H 
administration. Unfortunately these were the last assays attempted and future work could 
centre around the investigation of cytokine involvement. 
Assays studying the engagement of antigen on naturally expressing CDw52 cells or 
transfected cells were both reproducible and simpler to control. In these studies the presence 
of antibody carbohydrate was irrelevant and suggested that the mode of action was merely 
influenced by antigen recognition and not antibody conformation. The inclusion of 
unrelated antibodies in the assays substantiated the antigen specificity. There was obviously 
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a requirement for crosslinking as 80% aggregated CHO antibody alone could match 
crosslinked monomeric antibody whilst YO (22% aggregate) antibody could not. Perhaps 
the level of aggregation is important. 
In Chapter Four the expression of Campath-1H antibody from mouse NSO cells is 
described and followed by the utilisation of the isolated antibody in the assays defined 
previously. The NSO Campath-IH antibodies tested were those isolated from cells during 
the process of media development, from serum-containing to protein-free media, as well as 
from cells cultured under fermentor conditions in the latter medium. The N-linked 
oligosaccharide content of the antibodies generated at each stage of development was 
isolated and investigated. Attempts to correlate these latter findings with the biological assay 
results were made and tabulated. For several antibody isolates (NSO. S, and . 
PF), the cells 
were cultured as monolayers on laboratory scale and the most obvious failing of this system 
was that the C02 content and pH of the media were not constantly monitored and could 
theoretically have led to differences in glycosylation (Patel et al 1992). The CHO and NSO 
fermentor batches of antibody were from cells which were maintained in suspension culture 
under defined conditions. The results presented compare favourably with the data of Lund 
(Lund et al 1993) who demonstrated that antibodies isolated from monolayers of cells, such 
as NSO. S and PF, contained more galactose than cells cultured in suspension (NSO. F) 
and contradict Patel (Patel et al 1992) who showed that cells cultured in serum (NSO. S) 
contained lower levels of galactose than those cultured in serum-free medium (NSO. PF). 
The correlation of NSO carbohydrate content with assay result was more difficult to 
determine as the oligosaccharide was of three types altering in ratio and attempts to 
sequentially remove monosaccharides from CHO antibody had not been very successful. 
This work should certainly be repeated and the range of sugars to be removed extended. In 
terms of assays, NSO. S was the least active in ADCC but equivalent to other isolates in 
assays with no effectors. NSO. F antibody isolated from cells cultured under fermentor 
conditions proved to be similar to NSO. PF and CF in ADCC but superior in monocyte 
assays. It could be suggested that, as levels of di-galactosylation decreased and 
agalactosylation increased, activity in ADCC improved. To fully define the relationship 
between assay response and carbohydrate composition it would be necessary to develop 
NSO cell lines deficient in characterised glycotransferases so' that antibodies lacking in 
specific glycosylations could be generated. There are CHO cells of this nature (Lec series) 
but they are not dhfr deficient and so cannot be utilised for the CHO expression vectors 
described. It is theoretically possible to select for defined oligosaccharide structures with 
lectin columns but whether this is feasible for antibodies I am unsure. It is documented as 
being a difficult procedure due to the way in which the carbohydrate is buried within the 
CH2 domain (Wright and Morrison 1997). It may be easier to culture antibody producing 
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cells in the presence of various inhibitors which act at different steps in the glycosylation 
pathway prior to selection on lectin columns. 
To overcome the problem of the incorrect glycosylation of therapeutic products it may be 
necessary for manufacturers to either utilise host cells deficient in the addition of all 
glycosylations and complete the process in vitro or develop transgenic host cell lines 
containing human glycostransferases. Recent experiments performed by Umana (Umana et 
al 1999) describe the use of CHO cells expressing chimeric anti-neuroblastoma IgGI of low 
ADCC activity. These were transfected with the transferase gene 3(1,4)-N- 
acetylglucosaminyltransferase lll. In the N-linked glycosylation pathway this gene, which is 
absent in murine and CHO cells, adds bisecting G1cNAc and by controlling the level of 
gene expression with drug selection the level of bisecting GlcNAc addition could be 
modified. It was found that as antibody bisecting GlcNAc content increased, ADCC activity 
improved substantially. This supports the hypothesis of this thesis and re-enforces the 
finding that YO derived Campath-IH antibody, which contains bisecting GlcNAc (Lifely et 
al 1995), was superior to both CHO and NSO derived antibody in ADCC assays. Naturally 
occurring bisected oligosaccharides form 18% of human IgG (Furakawa and Kobata 1991). 
Some of the most interesting data obtained was that from NSO. IgG4 antibody because 
whilst acting as expected in ADCC assays i. e. not inducing target cell lysis, it was found to 
be as active as NSO. IgGI in both crosslinking and monocyte assays. Even deglycosylation 
of NSO. IgG1 and NSO. IgG4 failed to ablate their activity in these assays. This is similar to 
data published reporting that aglycosylated IgG3 can mediate the phagocytic respiratory 
burst (Pound et al 1993a). It would have completed this aspect of the project if experiments 
designed to identify the receptors involved in the monocyte assays had been more 
informative or if deglycosylated antibody had been assessed for receptor usage. Data not 
presented implied that receptors RI and Rll were contributing to the inhibitive effect but the 
assays were unreliable especially as far as demonstrating the involvement of Fc Rlll. These 
assays should be properly controlled and repeated. It would be interesting to determine 
whether IgG4 interacts with Fc Rlll or not. 
The final results chapter, Chapter Five, encompasses the data from the isolation and cloning 
of two similar CDw52 open reading frame cDNA sequences which had been isolated from 
Wien 133 cells. The cDNA open reading frames differed at two nucleic acids which led to 
two altered amino acids. Interestingly, the amino acids were not within the region which 
formed the mature Campath antigen but, were in the portion of cDNA governing GPI- 
anchorage (Moran and Caras 1991b). When the cDNA, which is accepted to be that of 
CDw52 (Xia et al 1991), was cloned into vectors and expressed in both CHO cells and 
Jurkat T cells it led to detectable surface expression. The alternative cDNA did not lead to 
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expression in CHO cells but was later found to be expressed competently in Jurkat cells. 
The divergence in Campath-1H detectable expression in CHO cells was thought to be 
caused by the loss of CDw52 epitope as a result of aberrant GPI-anchorage. This was 
investigated via the construction of CD4/CDw52 chimeric cDNA which utilised the 
extracellular domain of the antigen CD4 linked to either of the CDw52 GPI-anchor 
determining cDNA sequences. On expression in CHO cells, both chimeras led to detectable 
CD4 surface expression which differed from the conventional CD4 in molecular weight and 
PIPLC sensitivity. Both chimeras were of lower molecular weight, indicating the loss of 
some of their transmembrane and cytoplasmic domains plus they were both PIPLC 
sensitive which demonstrated the presence of GPI-anchors. It was only at this point that 
both CDw52 cDNAs were introduced into Jurkat cells and surface CDw52 expression 
demonstrated for each. It indicates that CHO cells may lack certain glycotransferases. The 
studies on the Wien cell cDNA coincided with the findings of CDw52 negative patients 
arising from Campath-IH therapy (Brett et al 1996a, Hertenstein et al 1995) and was 
initially thought to reflect the in vivo data. This was not to be but, patients were 
demonstrated to possess one or other or both forms of CDw52 cDNA (Taylor et al 1997) 
and the defect shown to involve GPI-anchor synthesis (Hertenstein et al 1995, Taylor et al 
1997). Derivation of the Campath negative cell lines MR4 and CV4 (Rowan et al 1998) 
proved to be advantageous as their use in ADCC assays revealed the possibility of those 
cells evading immune intervention in vivo. Since that time it has been demonstrated that 
some patients have a low percentage of CDw52 negative cells prior to treatment which may 
be selected for by Campath therapy (Rawstron et a] 1999). To finalise this aspect of the 
thesis it would be necessary to determine the exact defect, if any, in the CDw52 negative 
cells by checking genes which are involved in the early stages of GPI-anchor biosynthesis. 
The data presented here does appear to support the original hypothesis that method of 
culture and culture medium are able to influence antibody functional ability. Extension of 
the project would strengthen the case. 
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Abstract 
A protein-free growth medium (W38 medium) had previously been developed for the NSO mouse myeloma cell 
line which is cholesterol-auxotrophic. This paper describes the development of a protein-free growth medium for 
NSO cells expressing humanised monoclonal antibody using GS (glutamine synthetase) as a selectable marker. 
Several GS-engineered NSO cell lines expressing humanised monoclonal antibody grew in a modification of W38 
medium which maintained GS-selection, supplemented with cholesterol, phosphatidylcholine and ß-cyclodextrin. 
Further studies showed that additional glutamic acid, asparagine, ribonucleosides and choline chloride improved 
cell growth. Amino acid analysis identified a number of amino acids that were being depleted from the culture 
medium. NSO cell lines 9D4 and 2H5 expressing CAMPATH-1 H' were adapted to enable them to grow serum-free 
in the absence of cholesterol and ß-cyclodextrin. Cholesterol-independent 9D4 (9D4. CF) cells grown in shake 
flask culture using an enriched protein-free medium (WNSD medium), supplemented with human recombinant 
insulin (Nucellin), reached a maximum cell density to 1.86 x 106 cells ml-I producing 76.6 mg 1-1 of antibody. 
CAMPATH-1H antibody produced using serum-free medium was found to be functionally active in vitro in the 
Antibody Dependant Cellular Cytotoxicity (ADCC) assay. 
Abbreviations: C- cholesterol; CD - cyclodextrin; dhfr - dihydrofolate reductase; F68 - Pluronic F68; GS - 
glutamine synthetase; MSX - methionine sulphoximine; P- phosphatidylcholine; PC-FBS - phosphatidylcholine, 
cholesterol and foetal bovine serum; RPMI - RPMI 1640 medium, ADCC - Antibody-dependant cellular cytotox- 
icity 
Introduction 
NSO (Galfre and Milstein, 1982) is a cholesterol- 
auxotrophic (Keen and Steward, 1995) mouse myelo- 
ma cell line that does not contain endogenous glu- 
tamine synthetase (GS) (Brown et al., 1992) and is 
therefore unable to synthesise glutamine from other 
amino acids. For this reason NSO cells have an essential 
requirement for exogenous glutamine and are particu- 
CAMPATH is the registered trade mark of Wellcome Group 
Companies. 
laxly well suited for use in recombinant gene technolo- 
gy which utilises glutamine synthetase as a selectable 
marker (Bebbington et al., 1992). The GS expression 
system exploits the lack of cellular GS in the host 
cell line using a plasmid containing both the GS gene 
and the product gene. The plasmid contains the DNA 
encoding for the antibody heavy and light chains driv- 
en by the strong hCMV promoter regions and DNA 
encoding for glutamine synthetase controlled by the 
weak SV40 promoter. Transfected cells can be isolat- 
ed by culturing in a selection medium which lacks glu- 
tamine. The GS and product gene can be co-amplified 
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by exposure with methionine-sulphoximine (MSX), a 
GS-inhibitor. 
Monoclonal antibodies from different mammalian 
species can be humanised by grafting the complemen- 
tary determining regions (CDRs) from the antibody 
of one species on to a suitable human antibody donor 
framework (Winter and Milstein, 1991). Humanised 
antibodies are expected to be of greater therapeu- 
tic use in man than chimeric or murine antibodies 
which are known to generate an anti-species or an anti- 
frame work immune response, such as the human anti- 
mouse antibody response (HAMA response) (Wallace 
et al., 1994; Isaacs, 1990). An additional advantage of 
humanisation is that the isotype of the human Fc frame- 
work can be selected to support the desired effector 
functions. 
Cloned GS-engineered NSO cell lines expressing 
CAMPATH-1H or humanised anti-CD2 monoclonal 
antibody were used in this study. CAMPATH-1H is a 
humanised IgGI monoclonal antibody (Riechmann et 
at., 1988) which binds to the CD52 antigen, which is 
an abundant glycoprotein present on the vast majority 
of human lymphocytes (Hale et al., 1990), monocytes 
and most lymphoid malignancies (Hale et al., 1988b). 
CAMPATH-1 antibodies have been used successful- 
ly in the therapy of transplant rejection (Hale et al., 
1988a), rheumatoid arthritis (Isaacs et at., 1992) and 
non-Hodgkins lymphoma (Hale et al., 1988b). Previ- 
ously, CAMPATH-IH had been engineered into the 
CHO DUK B 11 cell line (Urlaub and Chasin, 1980) 
using a dihydrofolate reductase (dhfr) selection system 
(Page and Sydenham, 199 1). CAMPATH-1H is known 
to initiate cell death through antibody-dependant cel- 
lular cytotoxicity (ADCC) (Hale et al., 1985; Dyer et 
al., 1989). 
Fully defined protein-free media offers a num- 
ber of potential advantages for manufacture of anti- 
bodies, vaccines and other therapeutic products from 
mammalian cells relating to cost, reproducibility, reg- 
ulatory considerations and purification of product. 
Protein-free culture media are now available that will 
support the growth of some hybridoma and myelo- 
ma cell lines. Cells that require exogenous choles- 
terol, such as NSO, will not grow in these media. 
We have described the growth of NSO cells in W38 
protein-free medium containing cholesterol rich lipid 
with, -cyclodextrin and their subsequent adaptation to 
cholesterol-independence (Keen and Steward, 1995). 
In this study a protein-free medium was developed for 
GS-engineered NSO cells which supported cell growth 
and the production of functionally active antibody. 
Materials and methods 
Media and reagents 
The following materials were used: Glutamine, non- 
essential amino acids, and trypan blue were obtained 
from ICN-Flow (High Wycombe, UK); RPMI 1640 
product 31870-025 (RPMI), Dulbecco's medium 
product 21969-035 (DMEM), DMEM without ferric 
nitrate product 73-860-54 and Iscove's modified Dul- 
becco's medium (Iscove's) product 21980-032 from 
Life Technologies (Paisley, UK); dialysed and non- 
dialysed New Zealand foetal bovine serum (FBS) from 
Bioclear (UK); ferric citrate product 28381 from BDH 
(Poole, UK); tissue culture plastic from Costar (Badho- 
evedorp, Holland) and Erlenmeyer flasks from Corn- 
ing (New York, USA). The cyclodextrins used were a 
generous gift from Wacker Chemicals (Munich, Ger- 
many). All other Chemicals and supplements were 
obtained from Sigma (Poole, UK). 
Ferric citrate was dissolved at 10 mg ml-t in boil- 
ing water, allowed to cool, then 0.2 µm filtered using 
a Millex GV filter (Millipore, France). Cyclodextrins 
were prepared as a 10 mg ml-t solution in water then 
0.2 um filtered. WNSA, WNSB and WNSD media 
(Table 2) were prepared by the Medium Production 
Unit, Wellcome (method of preparation available on 
request). .I 
Preparation of vesicles containing 
phosphatidylcholine and cholesterol 
Phosphatidylcholine (P) and cholesterol (C) were dis- 
solved at 10 mg ml-1 in absolute ethanol. A choles- 
terol rich lipid solution (CR-lipids) was prepared by 
mixing P and C in a ratio of 2: 1 with 0.25 mg ml-I 
c -tocopherol to give a final total concentration of 
10.25 mg ml-1. For experimental purposes this solu- 
tion was treated as being sterile. Both cholesterol and 
phosphatidylcholine have a very low solubility in aque- 
ous solution; cholesterol forms a precipitate while 
phosphatidylcholine becomes uniformly suspended in 
solution. When phosphatidylcholine and cholesterol 
are mixed together in ethanol, then rapidly added to 
aqueous solution small unilamellar vesicles are formed 
(Stryer, 1988). Vesicles were thus prepared in the cul- 
ture medium by the addition of CR-lipids to give a final 
concentration of 10.25 mg 1-t. 
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GS-engineered cell lines and routine culture 
conditions 
The serum-containing GS-selection medium used 
('select' medium) was a modification of Celltech 'GS- 
selection medium' (Bebbington and Yarrington, 1989) 
which contained DMEM without ferric nitrate with 
60 mg 1-I glutamic acid (G) and asparagine (A), 7 mg 
1-1 adenosine, guanosine, cytidine and uridine, 2 mg 
1-1 thymidine, ICN-Flow non-essential amino acids at 
single strength and 5% dialysed FBS. Only cells which 
express GS are able grow in this medum. 
In order to express antibody in NSO cells, the anti- 
body heavy and light chain cDNA's were cloned into 
glutamine synthetase selection based vectors obtained 
from Celltech Ltd, Slough, UK. This construct was 
transfected into the NSO cell line by electroporating 
twice using a Bio Rad Gene Pulser set at 1500 volts 
and 3 µF. The transfected cells were cultured in using 
GS 'select' medium. Screening by ELISA assay iden- 
tified the colonies that produced the highest level of 
antibody. High secreting single colonies were expand-, 
ed, amplified by exposure to various concentration (5- 
50 /2m) of MSX, then dilution cloned. , NSO 9D4.5A11(9D4) and 9D4.4F8 (4F8) express- 
ing CAMPATH 1H were derived from the same pri- 
mary well and amplified with 5µM MSX. NSO 2115 
(2H5) expressing CAMPATH 1H was amplified with 
10µM MSX. Specific antibody production rates (SPR) 
for 9D4,4F8 and 2H5 were 11,17 and 4 ag 106 
cells-1 day-t. The SPR was determined over 24 
hours, in a sub-confluent static culture using serum- 
containing `select' medium. The 8C9.50B5 (8C9) cell 
line which expressed humanised anti-CD2 antibody 
was not amplified with MSX. These cells were routine- 
ly grown in static culture using 75 cm' flasks contain- 
ing 30 ml of serum-containing `select' medium with 
MSX which was incubated at 37 °C with 7.5% C02- 
The cells grew slowly, lightly attached to the plastic 
reaching a maximal concentration of around 6x 105 
cells m1'1. Every few days the cells were diluted to 
approximately 105 cells ml-1 in fresh growth medi- 
um . The adherent cells were easily removed from 
the plastic by firmly tapping the side of the flask. Non- 
engineered NSO cells were grown in static culture using 
DMEM, 5% FBS and 2 mM 1-glutamine (NSO growth 
medium). 
Growth curves were performed using duplicate 
shake flask cultures. 250 ml Erlenmeyer flasks con- 
taining 35 ml of culture were incubated at 37 °C in an 
Innova shaking incubator (New Brunswick Scientific, 
USA) and shaken at 100 revolutions per minute (rpm). 
The cultures were re-gassed daily for half a minute 
with 5% CO2 and a sample removed for cell count- 
ing and antibody assay. Daily gassing ensured that cell 
growth was not inhibited by 02 depletion or CO2 build 
up. 
Washing procedure and cell counting method 
Cells grown in serum-containing medium were washed 
by pelleting at 1200 xg for 5 minutes at +4 °C, resus- 
pended in protein-free medium without addition, pel- 
leted again, resuspended in fresh medium at 2x 106 
cells ml-1, then diluted to the required concentration 
in the media under test. All media were pre-warmed to 
room temperature before use. 
Culture samples were diluted with an equal volume 
of 0.1 % w/v isotonic trypan blue (trypan blue), mixed 
by pipetting, then counted using trypan blue exclusion. 
In serum-containing static cultures the cells were first 
dislodged by tapping the side of the flask. 
Amino acid analysis 
Amino acid composition of the culture medium was 
analysed before and after cell growth in order to deter- 
mine usage by the cells. Centrifuged medium samples 
were first hydrolysed by addition of HCl to a final 
concentration of 0.1 M and proteins removed by pre- 
cipitation with 80% ethanol. The supernatant was dried 
(speedvac concentrator), reconstituted with a 250 ppm 
tripotassium EDTA solution and passed through a filter 
with a 10,000 molecular weight cut off. The amino acid 
composition was then determined using an Applied 
Biosystems model 420A dedicated derivitiser/amino 
acid analyser. 
Detection of antibody levels by ELISA and functional 
activity by ADCC 
Culture supernatant was clarified by microfuge cen- 
trifugation at 13 000 rpm and stored at +4 'C for up to 
2 weeks prior to assay. The amount of humanised anti- 
body was determined using a sandwich ELISA assay. 
The wells of a 96 well maxisorp ELISA plate (Nunc, 
Roskilde, Denmark) were coated with 2 µg ml-I sheep 
anti-human IgG heavy and light chain (Seralab, UK, 
cat. no. SDL2015) in phosphate buffered saline (PBS). 
The excess protein binding sites were blocked with 
diluent (1% Bovine serum albumin fraction V in PBS). 
The binding of triplicate antibody samples to the coated 
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wells was detected using peroxidase conjugated sheep 
anti-human IgG and then measured by the colour gen- 
erated from the tetra-methyl benzidine substrate (Sig- 
ma, Poole, UK). The reaction was stopped with 2M 
H2S04 and the colour measured at an absorbance of 
450 nm. The amount of antibody in the test samples 
was quantified from a curve generated using a purified 
CAMPATH-1H antibody standard. Between each step 
of the ELISA the plates were washed 6 times with wash 
buffer (PBS with 0.05% Tween 20 detergent). 
For the Antibody dependant cellular cytotoxici- 
ty assay (ADCC) peripheral blood mononuclear cells 
(PBMC) were separated from defibrinated fresh human 
blood by centrifugation over a lymphoprep (Nycomed) 
gradient. Wien 133, a human B cell lymphoma cell 
line (Nacheva et al., 1987) expressing the CD52 anti- 
gen on its cell surface membrane was grown in log 
phase, labelled with 51 Cr, washed, resuspended at 2x 
105 ml-t, then aliquoted into 96 well `U' bottomed 
tissue culture plates at 50 Al well-1. Wien 133 were 
cultured using Iscove's medium, 10% FBS and 2 mM 
1-glutamine (Wien growth medium). CAMPATH-1H 
antibody dilutions (50 Al) in Wien growth medium, 
were added to triplicate wells in the plate. Nine con- 
trol wells without antibody were also included in each 
assay. The plates were incubated at 37 °C for 1.5 hours 
in a humid CO2 incubator prior to the addition of 
100 Al of PBMC effector cells at a concentration of 
2.5 x 106 m1 1, in Wien growth medium, to each 
antibody-containing well. This resulted in a ratio of 
25 effector cells for each target cell. The effector cells 
were also added to one triplicate set of control wells 
(non-antibody mediated lysis control), Wien growth 
medium alone was added to yet another set of con- 
trol triplicates (spontaneous lysis control) and 100 Al 
of 1% w/v Triton X100 detergent in H2O was added 
to the final set of control wells (total release control). 
The plates were spun for 5 minutes at 1500 rpm before 
being replaced at 37 °C for 5 hours. At the end of 
the incubation period 100 Al of medium was removed 
from each well and counted in ay counter (Wallac 
Wizard, model 1470, Turku, Finland). The level of 




Growth characteristics in serum-containing `select' 
medium 
Each of the GS-engineered NSO cell lines grew differ- 
ently in serum-containing 'select' medium. Duplicate 
static cultures of line 9D4 seeded at 105 cell ml-I 
reached an average density of 5.75 x 105 cells ml-t, 
while line 8C9 reached an average density of 12.9 x 
105 cells ml- 1. NSO 9D4 cells were pre-adapted to sus- 
pension growth in `select' medium. Duplicate shake 
flask cultures of these cells, seeded at 105 cells ml-t, 
reached an average density of 6.75 x 105 cells ml-1 
after 4 days with an average antibody level 12.01 mg 
1't after 6 days. 
The protein free growth of GS engineered NSO 
cells 
GS-engineered cells require glutamine-free culture 
medium in order to maintain selection pressure. Glu- 
tamine synthetase produces glutamine directly from 
glutamic acid and indirectly from other amino acids 
such as asparagine. The catabolism of glutamine is 
essential for the de novo synthesis of ribonucleosides. 
GS-selection media should therefore contain glutamic 
acid, asparagine and ribonucleosides but be free of glu- 
tamine. W38 protein-free medium (Keen, 1995) sup- 
plemented with CR-lipids and ß-cyclodextrin supports 
high density growth of non-engineered NSO cells. A 
modification of W38 medium, designated WNSA, was 
produced (Table 1), which was free of glutamine and 
contained additional glutamic acid, asparagine, adeno- 
sine, guanosine, cytidine, uridine and thymidine. 
9D4 and 2H5 cells were adapted to protein-free 
growth in 25 cm2 flasks. Cells grown in serum- 
containing `select' medium were washed using WNSA 
medium, resuspended at 105 cells ml-1 in 5 ml WNSA 
medium supplemented with CR-lipids and cyclodex- 
trin (WNSA + lipids), then incubated at 37 °C with 
7.5% CO2. Every few days the cells were subcultured 
by dilution with fresh medium taking great care to 
ensure that the cells did not overgrow. Both 9D4 and 
2H5 readily adapted to protein-free growth (Tables 2A 
and 2B), with the non-viability remaining between 
10% to 30% throughout. The high non-viability may 
have been due to cell death occurring immediately after 
antibody mediated release) - (mean cpm. 
cpm. total release) - (mean cpm. spontaneous release 
x 100 
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Table 1. Composition of WNSA and WNSD select medium. The final osmolality of these media was between 330 and 
350 mOSM. The differences in WNSD medium are highlighted 
Final concentration of medium components mg 1- t 
WNSA WNSD WNSA WNSD 
Amino acids OTHER COMPONENTS 
L-Alanine 0 0 
L-Arginine 142 192 EDTA° 6 6 
L-Asparginine 85 505 Oxalacetic acid 2 2 
L-Aspartic acid 10 20 Progesterone 0.006 0.006 
L-Cystine 61.7 61.7 Sodium nitroprusside 5 5 
L-Glutamic acid 70 490 Taurine 30 30 
Glycine 20 30 Tween-80 0.2 0.2 
L-Histidine 28.5 58.5 Glucose 6250 3000 
L-Hydroxy-proline 10 10 Hypoxanthine 0.272 0.272 
L-Isoleucine 77.4 177.4 Adenosine 7 14 
L-Leucine 77.4 177.4 Guanosine 7 14 
L-Lysine 93 193 Cytidine 7 14 
L-Methionine 22.5 82.5 Undine 7 14 
L-Phenylalanine 40.5 60.5 Phenol red 10 10 
L-Proline 10 10 Putrescine 2.2 2.2 
L-Serine 36 36 Pyruvic acid 165 165 
L-Threonine 57.8 57.8 Thymidine 2.41 4.81 
L-Tryptophan 10.5 30.5 MOPS buffer 3000 3000 
L-Tyrosine 57.2 57.2 Sodium bicarbonate 2850 2850 
L-Valine 56.8 116.8 
TRACE ELEMENTS 
VITAMINS Aluminium chloride 0.001 0.001 
b-Pantothenic acid 2.1 2.1 Barium chloride 0.002 0.002 
Choline chloride 4.2 104.2 Calcium chloride 167 167 
Flavin adenine- Chromium potassium- 
dinucleotide 0.02 0.02 sulphate 0.001 0.001 
Folic acid 2.5 2.5 Copper sulphate 0.0025 0.0025 
Glutathione 0.5 0.5 Ferric citrate 1 1 
i-Inositol 21 21 Ferrous sulphate 0.8 0.8 
Nicotinamide 2.5 2.5 Lithium chloride 10 10 
P Aminobenzoic acid 0.5 0.5 Magnesium sulphate 150 150 
Pyridoxin 2.5 2.5 Molybdic acid 0.0001 0.0001 
Riboflavin 0.3 0.5 Nickel chloride 0.0002 0.0002 
Thiamin 2.5 2.5 Potassium bromide 0.0001 0.0001 
a-tocopherol 0.00025 0.00025 Potassium chloride 400 400 
Cyanocobalamin 0.68 0.68 Potassium iodide 0.00001 0.00001 
Biotin 0.1 0.1 Rubidium chloride 0.00001 0.00001 
Silver chloride 0.000005 0.000005 
OTHER COMPONENTS Sodium chloride 6200 6200 
Adenine 0.4 0.4 Sodium fluoride 0.004 0.004 
Citric acid 25 25 Sodium phosphate 471 471 
Phosphatidylcholine I I Sodium selenite 0.03 0.03 
Ethanolamine 3 3 Stannous chloride 0.0001 0.0001 
Zinc sulphate 0.8 0.8 
EDTA = Ethylenediaminetetraacetic acid-disodium salt. 
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Table 2. Adaptation to serum-free growth 
Pass number day viable non-viable subcultured % residual FBS 
Cell count x 10- cells 
Table 2A, line 9D4 
17 5.3 4.6 1 to 8 0 
2 13 2.0 0.65 l to 4 0 
3 18 2.45 0.6 1 to 3 0 
4 20 2.4 0.25 1 to 3 0 
5 25 3.0 0.65 1 to 5 0 
6 30 3.0 0.8 cryopreserved 
Table 2B, line 2H5 
1 7 7.15 0.5 l to 8 0 
2 13 2.3 0.7 l to 4 0 
3 18 6 0.95 1 to 3 0 
4 20 3.8 0.65 1 to 3 0 
5 25 4.4 0.95 1 t05 0 
6 30 3.5 0.9 cryopreserved 
Table 2C, line 4F8 
15 5.0 2.95 1to5 0.2 
2 10 9.1 2.7 1 to 5 0.04 
3 14 4.2 1.1 1 to 5 0.008 
4 19 3.7 1.3 l to 5 0.016 
5 24 10.9 3.2 1 to 5 0 (cells washed) 
6 28 5.4 0.7 cryopreserved 
Tables 2A and 2B. The NSO 9D4 and 2H5.10 cell line secreting CAMPATH-1H antibody 
were washed to remove serum then adapted to growth in WNSA protein-free medium 
containing Nucellin, ß-cyclodextrin and cholesterol-containing lipids. 
Table 2C. The NSO 4F8 cell line secreting CAMPATH-1H antibody was adapted to 
growth in WNSB protein-free medium containing recombinant insulin, ß-cyclodextrin 
and cholesterol-containing lipids. The residual FBS was diluted on sequential passage 
then finally remove by washing the cells after 24 days in culture. 
subculture and to the relatively slow growth rate. 
An attempt was made to improve adaptation by 
using a weaning process. Cells in serum-containing 
medium were diluted in WNSA + lipids without wash- 
ing and the residual serum sequentially diluted out as 
the cells were passaged. This method of adaptation 
(Table 2C) was also successful but seemed to offer 
no benefit over direct transfer to protein-free growth. 
Out of 11 different GS-engineered cell lines that were 
transferred to grow in WNSA + lipids, 10 adapted 
to protein-free growth. The other line grew only in 
WNSA + lipids containing glutamine suggesting that 
it was unable to synthesise glutamine when cultured 
in this medium. 9D4 , 2H5 and 8C9 were sequential- 
ly passaged in WNSA + lipids. The addition of 5 mg 
1-1 of human recombinant insulin (Nucellin) slightly 
increased the cell growth rate and improved viability 
(data not shown). For this reason Nucellin was then 
routinely added to the medium. 
Enrichment of WNSA protein free medium with 
additional glutamic acid, asparagine and 
ribonucleosides (select additives) improves growth 
and antibody secretion 
WNSA medium was enriched to try and improve cell 
growth. Figure 1 shows the growth of serum-free 
adapted 9D4,2H5 and 8C9 in 5 ml static cultures with 
WNSA medium containing additional select additives. 
In the cultures with 'extra ribonucleosides' or `extra 
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8C9 with medium I 
8C9 with medium 2 
8C0 with medium 3 
8C9 wu h medium 4 
904 with medium 1 
904 with medium 2 
9D4 with medium 3 
9D4 with medium 4 
2H5 with medium 1 
2H$ with medium 2 
2H5 with medium 3 
2145 with medium 4 
viable cell count x 10-5 cells ml-1 
Fig. 1. Effect of adding extra amino acids and ribonucleosides on the growth of three GS-engineered NSO cell lines in medium 1. WNSA 
protein-free medium with lipid, ß-cyclodextrin and recombinant insulin (WNSA + lipids), medium 2. WNSA + lipids with extra ribonucleosides, 
medium 3. WNSA + lipids with extra G+A and medium 4. WNSA + lipids with extra G+A and ribonucleosides. Mean counts of duplicate 
shake flask cultures. G+A= glutamic acid and asparagine. 
G+A' the level of ribonucleosides was doubled, glu- 
tamic acid was at 190 mg 1-' and asparagine at 205 mg 
1-1. Duplicate 5 ml cultures seeded at 0.5 x 105 cells 
ml-1 in 25 cm2 flasks were incubated with 7.5% C02- 
For all three cell lines, best growth occurred in the pres- 
ence of additional G+A and additional ribonucleoside 
('fully supplemented' medium). The cell concentration 
in the 'fully supplemented' 9D4,2H5 and 8C9 cultures 
were respectively 4.95,7.2 and 5.7 x 10-3 cells ml-1, 
with antibody concentrations of 29.1,13.8 and 8 mg 
1-t. 
Amino acid and glucose utilisation of GS-engineered 
NSO in WNSA medium 
In order to examine nutrient depletion, media samples 
pooled from duplicate cultures of 9D4,2H5 or 8C9, in 
`fully supplemented' WNSA medium were harvested 
after 6 days growth and the amino acid, glucose and 
lactate composition analysed (Table 3). The nutrient 
levels detected after 6 days growth were compared 
with the levels detected in unused culture medium. 
Several amino acids notably glutamic acid, asparagine, 
histidine, valine, methionine, cystine, isoleucine and 
leucine were heavily depleted with both glutamic acid 
and leucine being practically exhausted. In contrast 
glucose levels in the medium did not appear to be 
growth limiting. 
Adaptation of NSO 9D4 to cholesterol 
independence 
One aim of this study was to achieve cell growth 
in a medium free from animal derived components. 
Cholesterol is the only animal derived component in 
WNSD medium. However, NSO cells have an essen- 
tial requirement for cholesterol, which is extracted 
from Sheep wool. The use of ß-cyclodextrin and lipid 
vesicles to supply the cholesterol requirement of NSO 
cells caused several problems. Addition of cholesterol- 
containing vesicles to the medium resulted in lipid pre- 
cipitation and increased cell death (data riot shown). 
The shelf life of media containing vesicles was limit- 
ed as after a few days +4 °C storage a lipid precipitate 
slowly formed. A precipitate could also be seen in slow 
growing cultures, after several days incubation, result- 
ing in reduced cell viability. The precipitation problem 
could be reduced by the use of cholesterol: methyl-ß- 
cyclodextrin complex (Sigma product C3175). 
It was decided to adapt the 2H5 and 9D4 cell lines 
to cholesterol-independence using a method similar 
to that used for non-engineered NSO cells (Keen and 
Steward 1995). Briefly, 0.1 ml of CR-lipids at a total 
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Table 3. Amino acid (aa) utilisation by the GS-engineered NSO cell lines 
Actual amino 
acid of content 
of unused medium 
Amino acid levels detected by the analyser in 
unused 8G9 2H5.10 9D4 
medium supn't supn't supn't 
L-aspartic acid 10 26.3 11.3 10.3 13.3 
L-glutamic acid 190 170.7 0 0 0 
L-asparagine 205 205.8 35.6 4.6 136 
L, serine 36 44.6 24.7 41 33.9 
L-glutatnine 0 6.9 4.4 8.8 9.9 
L-glycine 20 21 15.4 15 16.1 
L-histidine 28.5 21.3 8.1 12 9.3 
L-taurine 30 23.4 21.9 23.4 22.5 
L-arginine 142 121.4 78.7 90.9 49.2 
L-threonine 57.8 61.3 35.7 44.6 35.1 
L-alanine 0 3.1 37.8 81.7 44.1 
L-proline 10 9.2 5.8 21 4 
L-tyrosine 57.2 44.3 24.9 29 28.5 
L-valine 56.8 54.7 9.7 14 12.9 
L-methionine 22.5 24.2 5.6 6 6.7 
L-cystine, L-cysteine 61.7 39.0 15.0 14.4 14.4 
L-isoleucine 77.4 76 9.2 10.5 5.2 
L-leucine 77.4 74.3 1.6 4.3 0 
L-phenylalanine 40.5 49.1 24.3 21.9 17.7 
ornithine 0 0 6.8 9.7 40.1 
L-tryptophan 10.5 3.6 4.6 4.1 2.6 
L-Lysine 93 79.9 32.1 40.5 35.8 
glucose 6250 6164 ND ND 4490 
lactate 0 0 ND ND 1350 
The first column shows the actual level of each amino acid in unused culture medium. The other 
four columns show the levels detected in unused medium and in culture medium harvested from 
cultures of NSO 8G9,2H5.10 and 9D4 cells grown in static culture for 6 days using 'supplemented' 
WNSA medium. The highlighted amino acid values are much lower than in the unused culture 
medium, indicating that they were being depleted from the medium. 
lipid concentration of 10.25 mg ml-1 in ethanol was 
added to 10 ml of dialysed FBS (CR-FBS). Cells grow- 
ing in WNSA + lipid medium were subcultured into 
WNSA medium containing 1% CR-FBS, but lacking 
CR-lipids or ß-cyclodextrin. The 9D4 cells were sub- 
sequently subcultured four times with 0.3% CR. FBS, 
then cultured serum-free and cholesterol-free, whereas 
the 2H5 cells were sequentially subcultured once with 
1% CR. FBS, twice with 0.5%, twice in 0.15%, then 
grown cholesterol-free. The adapted cell lines were 
renamed 9D4. CF and 2H5. CF respectively. 
Enriched WNSA medium with additional amino acid, 
ribonucleosides and choline gave increased biomass 
and antibody secretion 
The effect of further medium enrichment on cell 
growth was investigated using potentially beneficial 
additives identified in the nutrient depletion studies. A 
modification of WNSA protein-free medium (WNSB) 
was prepared in which the glucose level was reduced 
to 3g 1-1, asparagine increased to 265 mg 1-1 and 
glutamic acid increased to 250 mg-t. A 100x con- 
centrate amino acid supplement (GS-aa) was prepared 
in water containing 10 mg ml-' isoleucine, leucine 
and lysine, 6 mg ml-t valine and methionine, 5 mg 
ml't arginine, 3 mg ml-t histidine, 2 mg ml-t pheny- 
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Fig. 2. NSO 9D4. CF cell growth and antibody production in medium 1. WNSB medium with Nucellin, medium 2. WNSB medium with 
Nucellin, GS-aa, extra ribonucleosides and extra G+A or medium 3. WNSB medium with Nucellin, GS-aa, extra ribonucleosides, extra G+ 
A and choline chloride. Mean of duplicate shake flask cultures. G+A= glutamic acid and asparagine. 
aspartic acid. In previous unpublished studies it was 
found that choline improved YO mouse myeloma and 
Chinese hamster ovary cell growth. A 100x concen- 
trate solution containing 100 mg ml-I choline chloride 
was prepared in water. These solutions were sterilised 
by filtration. 
Figure 2 compares the growth of 9D4. CF cells 
in WNSB medium with Nucellin supplemented with 
additional nutrients using duplicate shake flasks seed- 
ed with 105 cells ml-1. Medium 2 and 3 contained 
double ribonucleosides, 490 mg 1-I glutamic acid and 
505 mg 1-1 asparagine. The choline chloride in medi- 
um 3 had a dramatic effect on growth increasing the 
maximal cell density to 18.55 x 10 S cells ml-1 with 
76.6 mg 1-1 antibody. The composition of medium 3 
(without Nucellin) was renamed WNSD (Table 1). In 
WNSD medium with added Nucellin the cell densi- 
ty and accumulated antibody was far higher than in 
serum-containing select medium. Amino acid analysis 
of supernatant from the 7 days culture with WNSD with 
Nucellin (Figure 3) showed that there was a high rate 
of depletion of asparagine, glutamic acid, isoleucine 
and leucine. From this data it seemed probable that 
a lack of glutamic acid, isoleucine and leucine was 
inhibiting cell growth. Unfortunately, increasing the 
amino acid levels resulted in toxicity and inhibited 
cell growth. Removal of Nucellin had no detectable 
effect on cell growth or antibody production (data not 
shown). Electronmicrographs of cells in late log phase 
showed a condensation of chromatin that is character- 
istic of death by apoptosis. Further development of this 
medium for use in fed batch culture in stirred bioreac- 
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Fig. 3. Final concentration of amino acids and amino acid utilisation by NSO 9D4. CF cells cultured in shake flask using WNSD medium with 
recombinant insulin. 
Antibody produced in serum free medium is 
functionally active 
CAMPATH-1H antibody produced in static or shake 
flask cultures in serum-containing or serum-free medi- 
um was examined for functional activity by ADCC. 
All preparations were found to have functional activ- 
ity at 0.02 pg ml-1. Further studies relating to the 
glycosylation and biological activity of CAMPATH- 
IH expressed in different cell lines and grown under 
different culture conditions will be published shortly 
(Lifely et al., 1995). 
Discussion 
There are considerable advantages in the use of media 
that do not contain serum and that are essentially 
protein-free. In this study we have shown that GS- 
engineered NSO cells expressing humanised mono- 
clonal antibody can be grown in a novel protein-free 
medium, WNSA medium, supplemented with choles- 
terol rich lipid and ß-cyclodextrin. WNSA is a complex 
medium of defined composition, containing a number 
of additional trace elements and vitamins. Poor growth 
of GS-engineered NSO cell lines expressing human- 
ised monoclonal antibody in serum-containing `select' 
medium and WNSA suggested that these media were 
sub-optimal. 
The nutritional requirements of NSO cells are com- 
plicated by NSO having an essential requirement for 
exogenous cholesterol. In this respect NSO are similar 
to the NS-1 cell line that is deficient in 3-ketosteroid 
reductase activity and unable to convert lathosterol to 
cholesterol (Sato et al., 1987). As NSO are derived 
from NS-1 it is likely that they also lack 3-ketosteroid 
reductase activity. In serum, cholesterol and other 
lipids are found attached to carrier proteins such as 
LDL, HDL and albumin. The use of phosphatidyl- 
choline: cholesterol vesicles with a carbohydrate carrier 
ß-cyclodextrin enabled these cells to grow moderately 
well in protein-free medium. In order to overcome the 
complications caused by the cholesterol requirement, 
GS-engineered NSO cells were adapted to cholesterol- 
independence. Several cloned GS-engineered NSO and 
NSO hybridoma lines secreting monoclonal antibody 
have also been adapted to cholesterol-independent 
growth (data not shown), with a 100% success rate. 
This implies that the majority, if not all, of individual 
cells within the NSO cells population contain the genet- 
ic information required to produce active 3-ketosteroid 
reductase, but perhaps in a repressed form. 
Nutrient depletion studies using cholesterol- 
requiring engineered NSO cell lines in WNSA medium 
identified a number of amino acids that were being 
almost completely consumed. Interestingly the amino 
acid utilisation by the cholesterol-independent cell 
lines was found to be practically identical to that of the 
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lines prior to adaptation (data not shown), suggesting 
that amino acid metabolism was similar. An enriched 
medium (WNSD) was developed containing addition- 
al amino acids, choline chloride and ribonucleosides. 
Cholesterol-independent 9D4. CF cells grown in shake 
flask culture with WNSD reached a density of 1.86 x 
106 cells ml-1 accumulating 76.6 mg litre-1 function- 
ally active (by ADCC) CAMPATH-1H antibody. In 
addition 9D4. CF reached a density of over 2.5 x 106 
cell ml-1 in a one litre stirred bioreactor using WNSD 
supplemented with 0.1% w/v Pluronic F68 (data not 
shown). In WNSA medium it was found that human 
recombinant insulin (Nucellin) slightly improved cell 
growth, but that in WNSD Nucellin was not required. 
Amino acid analysis of spent WNSD culture super- 
natant showed that certain amino acids were still being 
fully depleted. A modification of WNSD medium 
which contained additional nutrients and a lower con- 
centration of sodium salts (to adjust the osmolality) was 
toxic and inhibited cell growth. Future studies should 
concentrate on different feeding regimes to increase 
biomass, accumulated antibody and cell viability and 
on the prevention of cell death. 
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Engineered Anti-CD38 Monoclonal Antibodies for 
Immunotherapy of Multiple Myeloma 
Jonathan H. Ellis, '* Karen A. Barber, * Alison Tutt, * Christine Hale, * Alan P. Lewis, ' 
Martin J. Glennie, * George T. Stevenson, * and J. Scott Crowe* 
*Molecular Immunology Group and "Structural Biology Group, Wellcome Foundation Ltd, Beckenham, Kent, United 
Kingdom; and *Tenovus Research Laboratory, Southampton General Hospital, Southampton, United Kingdom 
Multiple myeloma is a malignancy of plasma cells for which there is no effective treatment. To develop an 
immunotherapeutic agent, we have raised a high affinity mAb (AT13/5) against CD38, one of the few well- 
characterized surface Ags present on myeloma cells. Since murine monoclonals have many disadvantages as 
human therapeutics, we prepared two engineered forms of the Ab: a CDR-grafted humanized IgG1 and a 
chimeric FabFc2 (mouse Fab cross-linked to two human yi Fc). To retain affinity in the humanized Ab, a 
number of changes were required to the human framework regions of the heavy chain. In particular, through 
systematic mutagenesis and computer modeling, we identified a critical interaction between the side chains 
of residues 29 and 78, which may be important for the humanization of other Abs. The properties of the 
humanized IgG1 and FabFc2 constructs were compared in a series of in vitro tests. Both constructs efficiently 
directed Ab-dependent cellular cytotoxicity against CD38-positive cell lines, but C was activated only poorly. 
Neither construct caused down-modulation of CD38, nor did they affect the NADase activity of CD38. 
Despite their differing structures, both Abs showed similar activity in most assays, although the humanized 
IgG1 was more potent at inducing monocyte cytotoxicity. These data represent the first direct comparison of 
CDR-grafted and chimeric FabFc2 forms of the same Ab, and offer no support for the perceived advantages 
of the FabFc2. These Abs show promise for therapy of multiple myeloma and other diseases involving CD38- 
positive cells. The Journal of Immunology, 1995,155: 925-937. 
Multiple myeloma is a fatal neoplasm character- 
ized by an accumulation of a clone of plasma 
cells, frequently accompanied by the secretion 
of Ig chains. Bone marrow invasion by the tumor is asso- 
ciated with anemia, hypogammaglobinemia, and granulo- 
cytopenia with concomitant bacterial infections. An ab- 
normal cytokine environment, principally raised IL-6 
levels, often results in increased osteoclasis leading to 
bone pain, fractures, and hypercalcemia. 
A variety of chemotherapeutic protocols have been tried 
over recent years with little impact on the overall prognosis 
for myeloma patients (1). As an alternative approach, several 
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workers have proposed immunotherapeutic strategies target- 
ing the IL-6-signaling system. IL-6 has been suggested to be 
a major growth factor for myeloma cells (2,3) functioning in 
either an autocrine (4,5) or paracrine fashion (6). Two mu- 
rine monoclonals that neutralize IL-6 suppressed the prolif- 
eration of myeloma cells in a patient with a leukemic variant 
of the disease (7), although the tumor relapsed after 60 days. 
Similarly, the IL-6R has been investigated as a target for both 
blocking Abs (8) and IL-6-cytotoxin conjugates (9-12). A 
humanized anti-IL-6R Ab has been prepared for possible hu- 
man therapeutic use (13), but its utility in myeloma patients 
remains to be demonstrated. 
Our preference is for a more direct approach, targeting 
myeloma cells for killing by the host immune system. The 
surface Ag CD38 (14) is strongly expressed by a large 
majority of multiple myeloma cells (15-17) and its suit- 
ability as a target for lytic immunotherapy has been dis- 
cussed (18). The same report also demonstrated the com- 
petence of effector cells from myeloma patients to lyre 
target cells coated with a chimeric anti-CD38. 
Copyright 0 1995 by The American Association of Immunologists 0022-1767/95/$02.00 
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A prerequisite of such a strategy is that the therapeu- 
tic Ab is both maximally efficient in engaging human 
effector mechanisms and also acceptable to the host im- 
mune system. Conventional Ab derivatives, such as chi- 
meric (19-21) and CDR2-grafted (22,23) Abs, offer the 
potential for reduced immunogenicity compared with 
murine monoclonals, and have a spectrum of effector 
functions determined by their isotype. However, 
straightforward CDR-grafting often results in a drop in 
Ag-binding affinity, requiring changes to the framework 
regions to restore activity (23-28). Despite attempts to 
identify key framework residues of general importance 
for successful grafting (28-31), and the exploitation of 
computer models (24-26,32) selection of appropriate 
mutations remains essentially an iterative experimental 
procedure required for each individual Ig. 
Unnatural combinations of Ig domains have also been pro- 
duced in attempts to produce molecules with enhanced ef- 
fector function (33-39). One such molecule with particularly 
attractive potential is the FabFc2-a monovalent Fab arm 
from a murine monoclonal chemically cross-linked to two Fc 
fragments of human IgG1. Such a construct offers the possi- 
bility of a weaker down-modulatory effect on surface Ag (40) 
while presenting a dual Fc array to effector cells-a feature 
that may enhance effector function (33). 
In this report we describe the preparation of a humanized 
IgGi monoclonal with specificity for anti-CD38. Through 
computer modeling and systematic mutagenesis, we identify 
an important heavy chain framework residue interaction re- 
quired for full binding and effector activity. We also present 
the first direct comparison of the properties of a humanized 
IgGl and a FabFc2 with the same Id in a variety of functional 
assays. 
Materials and Methods 
Restriction and modification enzymes were purchased from New En- 
gland Biolabs (Beverly, MA) and Boehringer Mannheim (Mannheim, 
FRG). AmpliTaq polymerase was from Perkin-Elmer Cetus (Norwalk, 
CT). Chemicals were obtained from Sigma Chemical Co. (Poole, UK), as 
were ELISA reagents. U1966 myeloma cells were a kind gift of Dr. 
K. Nilsson (University of Uppsala, Sweden). Monoclonal 1134 (41) was a 
kind gift from Dr. F. Malavasi (University of Turin, Italy). Anti-CD38 
monoclonal B-A6 was from Serotec (Oxford, UK) and HB7 was from 
Becton Dickinson (Mountain View, CA). OKT10 hybridoma cells were 
obtained from the American Type Culture Collection (Bethesda, MA). 
FACS detection reagents were from Becton Dickinson and Sigma Chem- 
ical Co. 
Immunization and production of the mouse 
monoclonal 
The hybridoma AT13/5 was produced by standard hybridoma technol- 
ogy. Briefly, a BALB/c mouse was immunized s. c. at four sites with 5X 
2 Abbreviations used in this paper: CDR, complementarity-determining region; 
ADCC, Ab-dependent cellular cytotoxicity; CDRH1, complementarity-deter- 
mining region I of the heavy chain; FabFc2, monovalent Fab arm from a mu- 
rine monoclonal chemically cross-linked to two Fc fragments of human IgGI; 
CHO, Chinese hamster ovary. 
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106 Namalwa cells emulsified in CFA (Difco, Detroit, MI). Three weeks 
later, the animal was boosted with an i. p. injection of 5X 106 Namalwa 
cells in IFA. A second i. p. boost was given at 4 mo, consisting of the 
same dose of cells in PBS. Three days after the final boost, a single cell 
suspension was prepared from the spleen and fused at a ratio of 1.6: 1 
with the mouse myeloma line NSI (P3-NS-1/1-Ag 4.1). Hybridoma cells 
were screened after 10 days by flow cytometry against Namalwa cells, 
and clonal lines obtained by limiting dilution cloning. 
Chemically engineered Abs 
The chimeric Ab derivative FabFc2 was prepared by thioether-linking 
hinge cysteines of mouse monoclonal Fab'y with hinge cysteines of nor- 
mal human Fcy (33). Mouse IgGi Ab AT13/5 was digested by pepsin to 
provide F(ab'y)2, which upon reduction with DTT yielded Fab'(SH)5. 
Human IgG in the form of cold ethanol precipitate (Bio-Products Lab- 
oratory, Elstree, Herts, UK) was further purified by anion-exchange chro- 
matography on DEAE-SepharoseFF (Pharmacia Biotechnology, St. Al- 
bans, Herts, UK) discarding the most acidic third of the protein. The 
resulting basic IgG was digested briefly by papain (50 µg/ml, pH 6.6,30 
min at 37°C) to yield Fcy1: radial immunodiffusion revealed Fcy2 at 
<1% of total protein and failed to detect Fcy3 or Fcy4. The Fcyl was 
then subjected to reduction, temporary blocking of one hinge SH by 
SS-bonding to plasma albumin while the contralateral SH was alkylated, 
and further SS-interchange to yield Fc(SH)1(42). Reaction with a 20-fold 
molar surplus of the bismaleimide linker o-phenylenedimaleimide (Al- 
drich Chemical Company, Poole, Dorset, UK) led to Fc-maleimide. 
Fab(SH)5 and Fc-maleimide, at a molar ratio of 1: 2.7 and a total 
protein concentration of 2 to 3 mg/ml, were allowed to react at pH 5.0 
and 25°C for 18 h. The proteins were concentrated by a cycle of absorp- 
tion/desorption on the cation exchanger S-SepharoseFF (Pharmacia), and 
the major product FabFc2 was purified by recycling chromatography on 
Superdez 200 (Pharmacia). 
cDNA cloning 
cDNA was prepared from 5X 106 AT13/5 cells using the Micro Fast 
Track (Invitrogen; San Diego, CA) and Superscript Preamplification 
(Life Technologies, Inc., Paisley, Scotland) systems. The heavy chain V 
region was cloned by a PCR strategy using primers hybridizing to the 
signal peptide and proximal CH1 portions of the heavy chain message 
(43). The light chain V region was amplified using the primers MKVRev 
(43) and VK1-BACK (44). Reaction products were cloned into pUC18 
for sequencing by the dideoxy terminator method using Sequenase v2 
(USB; Cleveland, 01-I). 
Humanization 
Humanized V regions were constructed by a recombinant PCR technique 
(45). The general strategy has been described previously (46). In this 
approach, a Spel site is introduced into the J domain of the humanized 
heavy chain, allowing the V region to be fused to an appropriately-en- 
gineered human C region cDNA cassette. The primers used for human- 
ization of the heavy chain were: 
AH: 5' GATCAAGCTTTACAGTTACTCAGCACACAG 3' 
BH: 5' GTGGACACCATAACTGGTGAAGGTGAAGCC 3' 
CH: 5' AGTTATGGTGTCCACTGGGTGAGACAGCCA 3' 








HH: 5' TAGAGTCCrGAGGGAATTCGGACAGCCGGGAAGGTG 3' 
The humanized heavy chain V region is produced as a 650-bp frag- 
ment, which is cleaved with HindIII and SpeI to allow fusion with the C 
region. The template used for recombinant PCR of the heavy chain V 
region was Campath-1H heavy chain cDNA (47). The primers used for 
the humanization of the light chain were: 
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AL: 5' GATCAAGC1TCTCTACAGTTACTGAGCACA 3' 




DL: 5' AGTTTCCAAACTGGTTGCACCAGAGATCAGCAGCTTT 
GG 3' 
EL: 5' GGTGCAACCAGTTTGGAAACTGGTGTGCCAAGCAGA 3' 
Fr,: 5' GTACGGATTACTCCAATACTGTTGGCAGTAGTAGGTG 
GC 3' 
Gß: 5' CAGTATTGGAGTAATCCGTACACGTTCGGCCAAGGGA 
CC 3' 
HL: 5' GATCAAGCTTCTAACACTCTCCCCTGTTGA 3' 
The humanized light chain is produced as a 750-bp fragment encoding 
the entire human K light chain. Primer nomenclature is according to Sims 
et al. (46). The template for the light chain humanization was Cam- 
path-1H light chain cDNA (47). 
A chimeric heavy chain was produced by amplifying the murine V. 
with the primers BLO (GTACAAGCTTCAGGACCTCACCATGGCT 
GTGTTTAGCGCTG) and BL1 (GATCGACTAGTGTTCCTTGAC 
CCCAGGA), which insert restriction sites in the 5' untranslated se- 
quence and the J sequence, allowing fusion with the human C region 
cassette. 
Variant humanized heavy chains containing additional murine frame- 
work residues were generated by recombinant PCR using the humanized 
chains as templates. These reactions used primers AH and HH together 
with a pair of primers encoding the desired mutation: residues 67-71, 
primers IH and JH; residues 28-29, primers KH and LH; residue 76, prim- 
ers MlH or M2H (for wild-type and mutant 67-71 templates, respec- 
tively) and NH; residue 78,01H or 02H (for wild-type and mutant 67-71 
templates, respectively) and PH. 
IH: 5' GTTGTCCTTGGTGATGTTCAGTCTGGACATGAAAGCTG 
C 3' 
JH: 5' CFGAACATCACCAAGGACAACAGCAAGAACCAGTTC 
AGC 3' 
K,,: 5' ACTGGTTAACGAAAAGCCAGACACGGTGCAGGTCAG 3' 
L,,: 5' GGCTITI'CGTTAACCAGTTATGGTGTCCACTGGGTG 3' 
MIH: 5' AAATTGCCGTTTCGAAGTGTCTACCAGCATTGTCAC 3' 
M2H: 5' AAATTGCCGTTTCGAATTGTCCTTGGTGATGTTCAG 3' 
NH: 5' TTCGAAACGGCAATTTAGCTTGAGACTCAGCAGC 3' 
01H: 5' TCTTAAGCTCACCTGGTTCTTGCTGGTGTCTAC 3' 
O2H: 5' TCTTAAGCTCACCTGGTTCTTGCTGTTGTCCTT 3' 
PH: 5' AACCAGGTGAGCTTAAGACTCAGCAGCGTGACA 3' 
Typically, recombinant PCR was performed using the following cycle 
definition: step 0: 94°C for 120 s; step 1: 94°C for 60 s; step 2: 50°C for 
60 s; step 3: 72°C for 60 s, go to step 1, repeating this loop for 25 cycles; 
and step 4: 72°C for 10 min. 
Expression of humanized antibodies 
For expression, cDNA encoding VH regions of humanized heavy chains 
were cloned into a derivative of pUC18 containing the distal portion of 
the human J domain and the y1 C region, to regenerate a complete heavy 
chain. Coding regions of the heavy and light chains were then transferred 
into pEE6. hCMV and pEE12 (Celitech, Slough, UK) (48,49), respec- 
tively. The resulting plasmids were transfected into CHO DUK-B11 cells 
using Transfectam (Promega; Madison, WI) and culture supernatant was 
assayed for human Ig by ELISA after 3 days. 
Large amounts of recombinant Ab were prepared by stable expression 
in NSO or CHO cells. NSO expression was performed as described (46). 
For stable CHO expression, the heavy and light chain genes were cloned 
into vectors pBAN2 and pRDN1, respectively (50). These plasmids were 
introduced into CHO Bil cells as described above. Selection, metho- 
trexate amplification, and cloning procedures have been described (51). 
Stably transfected clones were grown in medium depleted of bovine Ig, 
and the recombinant Ab purified by protein A affinity chromatography. 
Ab modeling 
Ab Fv regions were modeled using the AbM package (Oxford Molecular 
Ltd., Oxford, UK), which implements a combined algorithm of homology 
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and conformational generation techniques (52). Steepest descents energy 
minimization and constant temperature simulations (5000 sat 30 K) of sol- 
vated models were performed using SYBYL (Tripos, St. Louis, MO). 
Flow cytometry 
Cells for flow cytometry were washed in PBS + 5% FCS and resus- 
pended to approximately 106/ml in the same buffer. Following the addi- 
tion of Ab, cells were incubated at 4°C for 30 to 60 min and washed 
several times in PBS + 5% FCS. Bound Ab was visualized by incubating 
the cells with FITC-conjugates of anti-mouse IgG or anti-human IgG 
(Becton Dickinson and Sigma) for 30 min at 4°C. After washing, reac- 
tions were analyzed by flow cytometry using a FACScan (Becton Dick- 
inson). FITC-labeled anti-CD38 (clone HB7; Becton Dickinson) was 
used as a positive control for CD38 expression. For inhibition studies, the 
first Ab was incubated with the cells for 45 min, and then the second Ab 
added without washing. After a further 45 min, the cells were washed and 
then visualized as above. 
Ag modulation 
A total of 1.6 XW U1966 cells were incubated in medium with dilutions 
of Ab at 37°C for 6 h. The cells were then washed and bound Ab was 
visualized with FTTC-anti human antisera as above. The median fluores- 
cence signal was calculated and compared with that obtained from duplicate 
control wells incubated with the same anti-CD38 for 45 min at 4°C. 
Ab-dependent cellular cytotoxicity assays 
The function of Abs in mediation of antibody-dependent cellular cyto- 
toxicity was examined in a europium release assay (53-55). A total of 10° 
Wien 133 cells/well of a 96-well microtiter plate were labeled with 
europium-DTPA and then exposed to freshly prepared human PBL in the 
presence of Ab at an E: T ratio of 50: 1. Lysis was estimated by deter- 
mining release of europium after 4h using a Delfia system (Wallac). 
Controls without Ab and/or effector cells were used to estimate sponta- 
neous release. Maximum releasable europium was determined by Triton 
X-100 lysis of target cells. As a positive control, a humanized anti-CD52 
mAb (Campath-1H; Wellcome Foundation Ltd. ) was used. 
Monocyte cytotoxicity 
The ability of Abs to stimulate monocyte cytotoxicity was tested in a 
growth inhibition assay. Human peripheral blood monocytes were al- 
lowed to adhere to tissue-culture plastic for approximately 14 days, and 
assayed for CD14 expression by FACS. The cells were then harvested 
and dispensed at 10' cells/mi. A total of 10° monocytes were cultured 
with 4X 103 Wien 133 target cells in the presence of Ab for 5 days. 
Target cell proliferation rate was then assessed by incorporation of 
[3H]TdR. Growth suppression due to monocyte cytotoxicity was deter- 
mined by reference to duplicate cultures without monocytes. 
Complement-mediated lysis 
A total of 5X 1Os target cells/well were labeled with europium and 
incubated for 4h in medium containing 10% human serum in the pres- 
ence of Ab. Determination of europium release was as for ADCC assays. 
Maximum releasable europium was determined by Triton X-100 lysis of 
target cells. Incubations without serum or without Ab were used to assess 
background release. 
Cl q binding 
Clq binding was assessed by flow cytometry as described above. Briefly, 
5X 105 cells were stained with Ab at 4°C for 45 min. After washing, the 
cells were resuspended in medium containing 10% fresh human serum at 
4°C for 30 min, washed briefly again, and then labeled with FITC-anti- 
Clq (Seratec) and visualized by FACScan. Ab binding was assessed in 
parallel experiments using FITC-anti-Ig reagents. As with the ADCC, 
Campath-1H was used as a positive control reagent. 
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NADase activity assays 
These were performed essentially as described by Kontani et al. (56). A 
total of 2.5 X 105 cells were preblocked with 20 µg/ml Ab in medium for 
30 min at 37°C, and then incubated with 100 µM 1, N6-etheno-NAD 
(Sigma) in 100 Al PBS containing 10 µg/ml Ab for 15 min at 37°C. 
Twenty-five-microliter samples were taken and mixed with 50 Al 5% 
SDS and 1 ml sodium phosphate (pH 7.4). NADase activity was deter- 
mined by fluorometry using an excitation wavelength of 300 nm, with 
emission intensity measured at 410 nm. 
Results 
Ab specificity 
The specificity of the AT13/5 Ab was examined in a series 
of FACS experiments. The Ab stained Wien-133, U1966, 
and anti-CD3-stimulated human PBL, all of which express 
CD38 (data not shown). The Ab also stained CHO cells 
expressing human CD38 on their surface, but not wild- 
type CHO cells (Fig. 1). 
The relationship between the AT13/5 epitope and those of 
other anti-CD38 monoclonals was also addressed by looking 
for inhibition of FACS staining. IB4, but not OKT10, could 
inhibit the binding of FITC-conjugated AT13/5 to CD38- 
positive cells (data not shown). Similar studies with a hu- 
manized derivative of AT13/5 showed inhibition of binding 
of two further anti-CD38 monoclonals, B-A6 and HB7 (data 
not shown). 
Finally, AT13/5 immunoprecipitated a band of approxi- 
mately 40 kDa, the m. w. of CD38. OKT10 precipitated a 
band of identical size from the same extract (Fig. 2). Taken 
together, these results demonstrate the specificity of the Ab. 
cDNA cloning 
Heavy and light chain V regions were cloned from the 
AT13/5 hybridoma by PCR. Several independent clones of 
each chain were sequenced on both strands and found to 
be identical. The sequences are given in Figure 3. The 
murine heavy chain uses aV gene from the Q52 family 
(Kabat group IB) and the J4 minigene. The light chain uses 
the J2 minigene and aV gene from the recently described 
Igk-V34 family (58). 
Inadequacy of simple complementarity-determining 
region grafting 
Human frameworks were chosen to receive the murine 
CDRs according to a best-fit homology strategy (46). The 
chains selected were REI (59) for the light chain, and 
NEW (60) with framework identities of 60% and 67%, 
respectively. The initial design of humanized Ab incorpo- 
rated murine framework residues at positions 27,30, and 
94 of the heavy chain and position 49 of the light chain. 
The first two of these are residues shown to be important 
in another humanization using the same human chains 
(23). Residue 94 in the heavy chain is grafted as a standard 
part of the humanization strategy in our laboratory, and 
has been shown to be involved in the retention of binding 
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activity (61). Light chain residue 49 is the final residue of 
FR2 and is substantially different in the AT13/5 and REI 
chains (Ser and Tyr, respectively). Humanized Ab genes 
were produced by recombinant PCR using Campath-1H 
heavy (NEW frameworks with murine residues at 27 and 
30) and light (REI frameworks) chain cDNA clones (47) 
as templates. 
On transient expression of the humanized chains in 
CHO cells, human Ig was secreted into the tissue culture 
medium, demonstrating association of the engineered 
heavy and light chains. However, the tissue-culture super- 
natant showed no significant reactivity for CD38-positive 
Wien 133 cells when analyzed by flow cytometry. Co- 
expression of the humanized light chain with a chimeric 
heavy chain (murine AT13/5 V. fused to human Cy1 at 
the engineered Spel site) produced functional anti-CD38 
Ab (here called hybrid Ab), indicating that the light chain 
had retained Ag-binding characteristics, but that the hu- 
manization of the heavy chain was inadequate. 
Framework changes 
To restore high-affinity binding in the humanized Ab, a 
systematic series of changes was made to the humanized 
heavy chain. Computer models of the mouse and human- 
ized V regions were constructed using the AbM package 
(Oxford Molecular) and used in conjunction with se- 
quence analysis to select four regions for further study: the 
stretch of residues from 66 to 73, residues 28 and 29, res- 
idue 76, and residue 78. 
Variants of humanized heavy chain were prepared by 
PCR mutagenesis using the original humanized construct 
as template. Each heavy chain gene was co-expressed with 
humanized light chain in CHO cells, and the supernatants 
were assayed for binding to Wien 133 cells by FACS (Ta- 
ble I and Fig. 4). Of the 12 variants tested, four showed 
activity, although only one was comparable with the hy- 
brid Ab (Fig. 5). This construct, h3S, was selected for 
further analysis. 
Chemical chimera 
Apart from humanization, other strategies have been pro- 
posed to enhance the utility of murine monoclonals as hu- 
man therapeutics. In particular, chemical cross-linking of 
two human IgG1 Fc fragments to one murine Fab arm, to 
produce a monovalent FabFc2 molecule, has been sug- 
gested to yield markedly enhanced effector function and 
reduced down-modulation of cell surface Ags (40). 
To allow direct comparison of such a construct with a 
humanized IgG1 with the same specificity, a FabFc2 was 
prepared from AT13/5 (data not shown), and compared 
with the h3S Ab in a variety of functional assays. 
Modulation 
One mechanism by which cells may escape Ab-directed 
lysis is by internalization or shedding of bound Ab-Ag 
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complexes from the cell surface (down-modulation). The 
AT13/5 FabFc2 and h3S Abs were compared for their 
ability to induce down-modulation of CD38 from the sur- 
face of U1966 myeloma cells. After 6-h incubation in the 
929 
presence of Ab, there was no evidence for loss of Ag-Ab 
complexes from the cell surface (Fig. 6). A similar exper- 
iment, in which the cells were incubated with Ab for 24 h, 
yielded a similar result. 
FIGURE 1. Specific staining by AT13/5 of CHO cells transfected with human CD38 as visualized by FACS. Untransfected 
CHO B11 (A) and CHO B11 transfected with CD38 (B) were stained with 5 µg/ml AT1 3/5 and HB7 (anti-human CD38, Becton 
Dickinson; concentration as recommended by manufacturer) and visualized with FITC-conjugated goat anti-mouse IgG serum. 
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FIGURE 2. Immunoprecipitation of CD38. Namalwa cells 
were surface iodinated, soluhilized, and immunoprecipitated 
as previously described (36), using hybridoma culture super- 
natant from a control (nonbinding mouse IgGI), AT13/5, or 
OKT10. Samples were analyzed on 12.5%, SDS-gels under 
reducing conditions followed by autoradiography. Molecular 
weight markers are indicated in kilodaltons. 
Effector function 
To assess the biologic activity of the different engineered 
forms of the anti-01)35 Ab, direct comparisons were made 
in cytotoxicity assays using Wien 133 cells as targets. This 
cell line is of human lymphoid origin (62) and expresses both 
CD35 and CD52 at high levels, allowing comparison of the 
anti-CD38s with a highly-lytic humanized anti-('D52 numo- 
clonal, Carnpath- IH (23). Also, as one ref the main prospec- 
tive targets for these engineered Als are the tumor cells of 
multiple mycloma, cytotoxicity studies were also performed 
on the human mycloma-derived line U 1966. 
All forms of anti-('D3K were effective in killing Wien 133 
cells by ADC(' (Fig. 7), although ('ampath- III was consis- 
tently three- to fivefold more potent at inducing killing. Half- 
maximal lysis was obtained with Ah concentrations in the 
low nanogram/milliliter range. Similarly, U1966 target cells 
were also killed by AI)('( in the presence of engineered 
anti-01)35 Abs (data not shown). 
In it preliminary experiment to determine whether the 
Ahs were capable of directing C-mediated lysis, Wien 133 
cells were exposed to hybrid and FabFc, Abs in the pres- 
encc of human C. No lysis was observed, although FACS 
staining revealed that the target cells were labeled by the 
Ahs. In a parallel experiment, Wien 133 cells were ett'ec- 
lively killed by Campath-IH (data not shown), demon- 
strating that the cells are susceptible to lysis by human C. 
Incubation of U1966 cells with humanized IgG I and 
FahFc, Als and human serum also failed to produce lysis. 
This was associated with an absence of Clq binding as 
determined by FACS staining (Fig. 8). To determine 
whether the failure to engage C was due to an intrinsic 
property of the Abs or to sonic unfavorable disposition of 
the Ag on the target cells, the C lysis assay was repeated 
using transfcctcd ('HO cells expressing high levels of sur- 
face CD38 (J. H. Ellis and K. A. Barber, unpublished 
data). Using these cells as targets, both ('-mediated cytol- 
ysis and CIy binding were obtained using both anti-CD38 
constructs (Fig. 8). 
Finally, because a major in vivo mechanism for the 
clearance of Ah-coated target cells may he phagocytosis 
by cells of the monocyte lineage, the opsonizing effect of 
slic Abs was examined. Both Abs induced monocvte tox- 
ite toward Wien 133 target cells, although the human- 
iicd Ah was significantly more effective (Fig. 9). 
Inhibition of NAWse ýi tivity of CD_I8 
Human CD38 has been shown to catalyze the production 
of cADPR from NAD (63,64). cADPR has calcium-mo- 
bilizing activity and in one study (65) was shown to po- 
tentiatc the proliferation of stimulated mouse lympho- 
cytcs. If this activity operates in vivo, it represents it 
possible auto-stimulatory pathway for CD38-positive 
cells. To determine whether the engineered anti-('D38 Abs 
might suppress such a signal, their effect on the CD38_ 
catalyzed breakdown of it NAD analogue was measured 
by fluoromctry. Neither the humanized Ab nor the FahFc, 
construct affected the CD38 NADasc activity of trans- 
fected C'HO cells (Fig. It)). 
Discussion 
Fluni, lniz. ition 
Although the process of' transferring a specificity from one 
Ab molecule to another was originally conceived as being 
it graft primarily of the complemcntarity-determining re- 
gions (22,66), it has become increasingly clear that it 
number of residues outside these domains exert a critical 
influence on the affinity of Ag binding. Certain positions in 
the heavy chain frameworks seem to he important in the 
retention of Ag-binding activity in a variety ()f difi'erent 
Ahs (23,25,26,28,30,61 ). In particular, many investi- 
gators have reported the grafting of donor residues at po- 
sitions 67,69,71, and 73. These residues form it [3-sheet 
in contact with the interior aspect of' the CDRH2 loop: prc- 
sumably mismatches at these positions distort the CDR 
shape. Also, donor residues at positions 91 and 94 appear to 
he required for correct CDRI13 confirmation in many VDI. 
In addition to these general observations, there may be 
other framework residues that are important in particular 
classes of Vi, structure or even individual Abs. The 
AT13/5 VII illustrates this point, in that despite incorpo- 
ration of the framework modifications described above, 
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M: GGTCGACTGGCTGTGTTAGCGCTGCTCTTCTGCCTGGTGACATTCCCAAGCTGTGTCCTG M: GACATTCAGCTGACCCAGTCTCCATCCTCCTTTTCTGTTTCTCTAGGAGACAGAGTCACC 
1 _________+_________+_________+_________+_________+_________+ 1 ________+_______ 
M: GRLAVLALLFCLVTFPSCVLM: DIQLTQSPSSFSVSLGDRVT 
H: H: DIQMTQSPSSLSASVGDRVT 
M: TCCCAGGTGCAOCTGAAGCAGTCAGGACCTGGCCTAGTGCACCCCTCACAGAGCCTGTCC M: ATTACTTGCAAGGCAAGTGAGGACATATATAATCGGTTAACCTGGTATCAGCAGAAACCA 
61 __-______+_________+_________+___________________+_________+ 61 _________-_________+_________+_________+_________-_________- 
M: SQVQLKQSGPGLVHPSQSLSM: ITC [L-A__ 
-N-R--L-WYQQKP 
H: QVQLQESGPGLVRPSQTLSH: ITCKASEDIYNRLTWYQQKP 
M: ATAACCTGCACAOTCTCTGGTTTCTCATTAACTAGTTATGGTGTCCACTGGGTTCGCCAG M: GGAAATGCTCCTAOGCTCTTAATATCTGGTGCAACCAGTTTGGAAACTGGGGTTCCTTCA 
+_________+___________________r_________+_________+ 121 _________+_________+_________+_________+_________t_________- 121 ------'-' 
M: ITCTVSGFS.. _ 
LTSYGVWVRQM: GNAPRLLI$ G- A-. 
_T _SLETGVPS IIIIIIiII! IIIIIIIIITI1111111 
H: LTCTVSGFTFTSYGVHWVRQH: OKAPKLLISGATSLETGVPS 
M: TCTCCAGGAAAGGOTCTGGAGTGGCTGGGAGTGATGTGGAGAGGTGGAAGCACAGACTAC M: AGATTCAGTGGCAGTGGATCTGGAAAGGATTACACTCTCAGCATTACCAGTCTTCAGACT 
181 _________+___________________+_________-_________-_________+ 181 _________r_________+_________+_________+_________+_________- 
M: SPGKGLEWLGV M- Wg QG-5 T_ M: RFSGSGSGKDYTLSITSLQT 
H: ppGRGLEWIGVMWRGGSTDYH: RFSGSGSGTDFTFTISSLQP 
M; AATGCAGCTTTCATGTCCAGACTGAACATCACCAAGGACAACTCCAAGCGCCAGGTTTTC M: GAAGATGTTGCTACCTATTACTGTCAACAGTATTGGAGTAATCCGTACACGTTCGGAGGG 
241 _________+_________+_________+_________+_________+_________+ 241 ___________________+_________+_________t_________y_________- 
M: N_A- AF M_ _S R L-_N I- I--L__. 0 NSKRQYFM: EDVATYYCY. TFGG 
H: NAAFMSRVTMLVDTSKNQFSH: EDIATYYCQQYWSNPYTFGQ 
M: TTTAAAATGAACAGTCTACAAGCTGATGACACTGCCATATACTACTGTGCCAAATCGATG M: GGGACCAAGCTGGAAATAAGACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCA 
301 +_________+___________________+_________ a _________. 301 _________-_________+_________+_________+_________+_________4 
M: FKMNSLQADDTAIYYCAKSM. _ 
M: GTKLEIRRADAAPTVSIFPP 
IIIIIIIIIIII 
H: LRLSSVTAADTAVYYCAKSMH: GTKVEIKRTVAAPSVFIFPP 
M: ATTACGACOGGCTTTOTTATGGACTCCTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA M: TCCA 
361 _________+___________________I_________+_________+_________+ 361 ---- 
M: I T_T 9 F__V _N... 
Q... S WGQGTSVTVSSM: S 





FIGURE 3. cDNA and deduced amino acid sequences of the framework regions of the heavy (A) and light (ß) chains 
Oi the AT] 1/5 Ah. CDR residues as defined by Kahat et al. (571 are underlined. Murine framework residues incorporated 
into one or more of the humanized chain variants are doubly underlined. The amino acid sequence of the initial design 
of humanized Ab is shown underneath the Al l3/5 se<luem c, identity between the ( hairs is indicalecl by vertical lines. 
There is 67'/ identity between the fr, miework residues of the heavy < hain and 00 '% identity between those of the light 
chain. TIle murine sequences reporter) here have been submitted lo Gen bunk under the accession numbers U27I 10 and 
U27111. 
[able I. The (# (-1 of by vy ( h., i) i-111-vv nk "Wilutio n, nn the 
hindin/' of huntanizcd anti-CI)i8 Al) to CO 7i8-positive t rills in 
FAGS assays" 











ilk +-+ (+) 
++-+ +i vi 3s 
` In the body of the table, - denotes that the human residue is used at a 
framework pusitirm, r that the corresponding residue from the murine V was 
used. With regard to binding, - indicates no deaeUablc binding, and (+), ,, 
and + +, progms, +ively stronger binding, as estimatrd by measuring the flu')- 
rem I-nt signal pn>dut ed by a determined quantity 01 antibody. 
the initial humanized construct failed to hind Ag. To min- 
imize the number of additional nonhuman residues re- 
quired to regain binding, we have used a combination of 
sequence analysis, molecular modeling, and systematic mu- 
tagencsis to identify pivotal residues responsible for func- 
tional diti'crcnces between the mouse and humanized V1, s. 
When the mouse and h2 humanized Fv domains were 
modeled using AhM alone, the ('DRs of the two Abs exhih- 
ited identical conformations; however, experimental data 
demonstrated that the h2 humanized construct was without 
binding activity. Since incorporation of' murinc residues at 
positions 2 and 29 resulted in partial recovery of affinity, the 
modeling appeared to he incomplete. ('I)RN I, adjacent to 
these residues, was modeled as a class I canonical loop by 
AbM due to conservation of defined key residues (29). Res- 
idues 27-37 and 78 of the heavy chain were subjected to 
minimization and dynamics simulation, resulting in the eon- 





FIGURE 4. The C1)38-binding activity of humanized Ab 
variants was determined in a series of FACS assays using 
Wien 133 cells. The traces for h3P and h3Q overlie the neg- 
ative control data, as did the traces for the other nonbinding 
variants hl, h2, h 11, h3L, h3M, and h3N in other experi- 
ments. The control and nonbinding Ah distributions are hi- 
modal: the smaller peak arises from nonspecific binding of 
the FITC-conjugated anti-human staining Ab to a subpopu- 
lation of cells. The concentrations of Ab used in this exper- 
iment were: h3P, 340 ng, /ml; h3Q, 400 ng/ml; h3S, 125 ng/ 
nil; and hybrid, 125 nt; /ml. A total of 10,000 cells were 
analyzed for each distribution. 
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FIGURE 5. The relative binding , activity of the active human- 
iied heavy chain vari, inis wa,, determined in af ACS assay using 
Wien IH calls. I he mean flux ws( (n(e signal obtained from a 
dilution of Al) is plotted normaIi/((I to that obtained from a 
saturating amount of hybrid Ah. A tootal of 10,000 cells were 
analyied ("r ea h distribution. The binding curve for the h3S 
construct indicates ha Il-maximal binding at 6X 10 "' M, giv- 
ing an apparent K, of 1.6 x 10" M '. This is in good agreement 
with a K, of 3X 10" M' ohtained for Alt 3/5 by binding of 
iodinated Al) to Namalwa cells (unpublished observations). 
Comparison of' models fair niurinc and humanized vari- 
able rcgiuns reveals an interaction between two frame- 
work residues that indirectly affects ('DRH I. In the mouse 
kNlJNI_Iki \NII (1)>t;. AI» 
m CD 
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FIGURE 6. U1966 cells were incubated at 37"C in medium 
containing the specified concentrations of anti-CD38 Ab for 6h 
before visualization of Ab binding. Median fluorescence inten- 
sity was normalized to that obtained frone cell stained for 45 
min at 4°C. Points represent the mean and standard error of two 
experiments, differing slightly in cell number. A third experi- 













FIGURE 7. Lysis of europium-loaded Wien 133 cells by 
fresh human PBMC directed by humanized, FabFc, and hy- 
brid anti-CD38 Abs. Campath-1 H is a highly-lytic human- 
ized anti-CD52 used here as a positive control for ADCC 
activity. Points are the mean and SE of triplicate determina- 
tions. For clarity, SE are shown for two of the four Ahs: those 
for the remaining two are conilmrable. 
Vti, the side chains of Leu-29 and Val-78 pack together in 
a small hydrophobic pocket close to CDRIII. In the hu- 
man Vii selected as the graft recipient, the analogous po- 
sitions are occupied by two Phc residues. It appears that 
the larger aromatic side chains are too bulky to pack in the 
same fashion, and so alter the disposition of neighboring 
surface residues, resulting in a dill'crent conformation of 
', uU 12! ) 
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FIGURE 8. Engagement of C by anti-CD 18 Abs as assessed 
by cell lysis and Cly binding. Cell lysis was determined by 
europium release points represent the mean and SE of trip- 
licate determinations. C1 y binding was visualized in a FACS 
assay: the traces indicate the staining produced by 50 tig/ml 
of humanized IgGI and FabFe, Abs. Negative control traces 
are also included on the FACS plots. In additional control 
experiments (not shown), an irrelevant humanized Ig(; 1 nei- 
ther hound Cl i nor lysed the target cells, and no CI (I bind- 
ing was observed when the Abs were incubated with wild- 
type CHO cells. 
(`DRI II (Fig. II). Substitution of Phc-29 by the smaller 
murine residue partially relieves this effect, allowing Ag 
binding, albeit at reduced affinity. Full affinity was rc- 
stored only by the replacement of' oth residues. 
('DRH I class I canonical loops have lie, Phe, or Len 
defined as it key residue at position 29, but do not specify 
residue 78. Analysis of' the AhM Ah datascl revealed that 
all class I canonical loops in that database have nonaro- 
matic hydrophobic residues (Ala, Leu, or Val) at position 
78. The only Ah structure to have Pile residues at both 
positions 29 and 78 is 7FA13 (NEW), which due to other 
key canonical residues has a CDRIII with a class 2 ca- 
nonical definition. Our data suggests that the combination 
of two Pile residues at positions 29 and 78 in it class I 
canonical environment may shift the CDRH I conforma- 
tion away from the class I canonical form. 
The question arises as to whether these results have ap- 
plicability to the humanization of other marine Abs or 
simply reflect an idiosyncrasy of the AT13/5 Vii structure. 
In support of'the former view, we note that the AT 13/5 Vii 
is a good match to the consensus for Kabat group It3 mu- 










0.0000 0.01 0.1 1 10 100 1000 
Antibody concentration 
(ng/ml) 
FIGURE 9. Proliferation of CD38-positive Wien i 'H cells 
is suppressed by macrophages in the presence of anti-CD-18 
Abs. Pioliferation was determined by incorporation of a 
11HITdK pulse, and is expressed normalized to that obtained 
in the absence of Ah. Duplicate cultures lacking macro- 
phages showed no dose-dependent inhibition of growth. 
Points are the mean and standard error of triplicate determi- 
nations. One hundred percent target cell proliferation corre- 
sponds to the incorporation of 112,000 cpm. Maximum in- 
hibition was achieved with 10(1 ng/ml h IS, yielding a count 
of 58,594 clam 0 7.41% of maximum proliferation). 
Vul-78 are almost invariant. These data suggest that the 
requirement for small side chains at these positions may he 
a feature of a group of structures. Accordingly, we suggest 
that if ('l)Rs from such V, ,s are to 
he grafted onto human 
frameworks containing bulky residues at these positions, 
then transfer of murine residues or similar small residues 
at 21) and 78 may be required to maintain the desired 
(i)RIII conformation. 
With regard to the role of the ATI3/5 light chain in Ag 
binding, our data do not allow any firm conclusions to be 
drawn. The similarity in the apparent affinities of the hy- 
hrid and parental murinc Abs suggests that the humanized 
light chain possesses similar Ag-binding activity to the 
murinc light chain: however, we cannot exclude the pos- 
sibility that the properties of the light chain are simply of 
minor importance in determining the binding of the 
ATI3/5 epitope. 
Function, dl studies 
We have compared the performance ref' a humanized IgG I 
and ýi FahFc, construct in in vitro functional assays. Both 
feature the same high-affinity ('I)3, S-bindiIll" site, but offer 
potential differences in other aspects of their interaction 
with target cells and ethcctor systems. Given the markedly 
different structures of' he humanized IgG I and FabFc, 
constructs, it might be expected that substantial functional 
differences may he observed, however, in the present ex- 
periments, both Abs showed broadly comparable activity, 
-. - Humanised IgG1 
FabFc2 n3S Fabfcl h'IS 
U1966 cells CD38-CHO cells 













FIGURE 10.1 he NADase activity of CHO cells transfected 
with human CD38 is unaffected by incubation with 10 µg/ml 
of humanized or FabFc, Ab. Points are the mean of triplicate 
determinations, error bars indicate SE. Fluorescence signal 
was corrected for background activity using duplicate sam- 
ples where CD38-positive CHO 131 1 cells were replaced 
with untransfected 1311 cells, and normalized to the value 
obtained with CD38-CHO cells in the absence of Ab (back- 
ground activity, 374 fluorescence units; control CD38-CHO, 
464 U= 100%)). The sensitivity of the assay to CD M func- 
tion is indicated by the value obtained using U1966 cells, 
which have a lower surface expression of CD38 than the 
CHO transfectants. 
being strongly cytotoxic for CD38-positive cells in the 
presence of etl'ector cells. 
Although the Abs are of the yI isotypc, which is com- 
petent for C fixation, no C lysis of two human cell lines 
was obtained, even at high concentrations of Ah. This may 
reflect the operation of proteins with a protective function 
against autologous C, such as CD55 and CD59 (67). 1low- 
ever, the failure of the anti-CD38 Abs to cause lysis was 
accompanied by an absence of C ly binding, a step not 
known to he inhibited by such proteins (68,69). Also, 
Campath- IH lyscd C'D38-positive CD52-positive Wien 
133 cells under the same conditions. 
Alternatively, the AT13/5 epitope may offer an intrin- 
sically poor target for Ah-directed C attack. To explore 
this possibility, high-expressing CD3K-transfected ('110 
cells were tested in the C assay. Both Clq-hinding and 
lysis were obtained, showing that the epitope per se is 
compatible with C activation. Although the transfectants 
do express ('D38 at higher levels than the human cell 
lines, it seems unlikely that the results can be explained 
purely by Ag density, as Wien 133 and U1966 cells are 
strongly CD38 positive. Perhaps more likely is a favorable 
disposition of Ag on the transfectants, a variable known to 
affect (' binding (711,71 ). Other workers have also reported 
humanized IgG I Abs lacking (' I cl-binding activity (46), 
and in at least one case, two such Abs against CD4 show 




FIGURE 11. A detail from the computer models of the 
mouse (AU and humanized h2 (8) anti-CD38 V regions con- 
structed using AhM (Oxford Molecular) and SYBYL (Tripos) 
and visualized using RasMol (R. Sayle; Glaxo, Middlesex, 
UK). Replacement of human frameworks containing A, 
Phe-29 and Phe-78 (hall-and-sti(k; white arrows) with B, res- 
idues Leu-29 and Val-78 (ball-and-stick; white arrows) re- 
I ieves the distortion of CDRH1 (black arrowhead). 
Although the dual Fc of the FabFc, construct has been 
reported to substantially improve C activation in compar- 
ison with a homologous FahFc derivative (42), a similar 
enhancement was not seen relative to the humanized IgG I 
construct in this study. The FahFc, showed no superiority 
under sehoptimal conditions for C activation (with the hu- 
man cell lines as targets), or under permissive conditions. 
These findings are in accordance with those of Greenwood 
et al. (39), who found that incorporation of a tandem du- 
plication of Fc in a derivative of a humanized anti-CD52 
Ah had little effect on C activation. 
In cell-mediated cytotoxicity assays, both the FabFc, 
and humanized IgG I showed strong lytic potential, with 
lysis detected down to nanogram per milliliter concentra- 
tions of Ab. Both Abs recruited fresh human PI3MC to kill 
CD38 CHO CD38 CHO CD38 CHO U1966 
h3S + FabFc, 
C1)38-positive target cells with equivalent potency. How- 
ever, in a second assay using purified monocytes as effec- 
tor cells, the humanized IgG I construct was clearly supe- 
rior to the FabFc,. 
These results may reflect differential binding of the two 
Abs to the various FcR. The PE3MC-effector assay requires 
the presence of (D56-positive cells, presumably NK cells 
expressing FcyRll I, whereas the monocyte cytotoxicity assay 
is partially inhibited by Abs to each of FcyRI, FcyRll and 
FcyRIll (C'. Hale, unpublished observations). These ohscrva- 
tiuns suggest that the humanized IgG 1 may be more effective 
than the FabFc, construct in engaging FcyRl and/or FcyRII. 
Further experiments with blocking Abs to FcR may yield 
insight into these issues. Comparison with a FahFc construct 
may also he useful in this respect. 
With regard to target cell interactions, the data presented in 
this report suggest that binding to the A'1713/5 epitopc is not 
strongly down-modulating, in agreement with previous re- 
ports for other anti-C [)38 Abs (18). Under these conditions, 
one of the perceived advantages of' the FabFc, construct is 
not realized. However, it has been argued that Ag modulation 
is more pronounced in vivo (74), and it may he that under 
these more complex conditions, the univalency of the FahFc, 
construct will become important. 
Itnn unother, ipy with anti-"C038 
A central consideration in the design of any lytic immu- 
notherapy is that of specificity. ('D38 is by no means as 
tumor-specific Ag, in that it is widely expressed on cells of 
the hematopoietic system (75). During ontogeny, ('l)3 
first appears on ('D34-positive committed stem cells and 
lineage-committed progenitors of lymphoid, crythroid, 
and myeloid cells (76). ('1)38 expression persists only in 
the lymphoid lineage, through the early stages of 1' and B 
cell development. Mature resting lymphocytes generally 
express ('D38 at low or undetectable levels. ('D38 up- 
regulation is a marker for lymphocyte activation and par- 
ticularly lr 13 cell differentiation along the platimacvtoicl 
pathway. Plasma cells are universally strongly positive for 
CD 38 (l6,77). 
Most importantly, however, for the use of anti-('D38 as an 
immunothcrapeutic, the most primitive pluripotent stem cells 
of the hcniopuictic system are ('D38-negative (77,78). Anti- 
('D38 immunotherapy would therefore be expected to have 
only transient effects on normal cells of the blood, 
'There is a solitary report of ('D38 expression on mature 
nonlymphoid cells: a C'D38-immunorcactive protein has 
been purified from E (79). The Ah described in this report 
does not label E in flow cytomctry experiments (J. It. Ellis 
and K. A. Barber, unpublished observations). 
Lytic anti-C13138 Als have also therapeutic potential be- 
yond the treatment of multiple mycloma. Plasma cells secret- 
ing self-reactive Ah underlie the pathology of conditions such 
aý systemic lupus erythcnuüosus and niycstltenia gravis: 
these too should he lysed by the Ahs described in this report. 
Indeed, the lack of restriction of CD31i expression to plasma 
cells widens the therapeutic relevance of anti-CD38 Abs. 
Other lymphoid tumors, most notably a subgroup of non- 
Hodgkins lymphomas, also exhibit it ('D38-positive pheno- 
type (80,81), and presumably would be susceptible to anti- 
CD38-mediated cytotoxic attack. Also, as ('D38 expression 
is up-regulated after activation of lymphocytes, this may offer 
a route to ablation of the self-reactive T lymphocytes found in 
rheumatoid arthritis and other non-Ab-mediated autoimmune 
diseases. 
Finally, we note that despite the effectiveness of the 
humanized and FabFc, constructs in these simple in vitro 
tests, there is no assurance that their performance will he 
similar in the more complex in vivo environment of the 
mycloma patient. Although the data presented here pro- 
vide no support for favoring it FahFc, construct over it 
conventional humanized IgG I. a direct comparison in vivo 
is required to provide a definitive assessment of immuno- 
therapeutic potential. This issue is being addressed in on- 
going clinical studies. 
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Recognition of CD52 allelic gene products by CAMPATH-1H antibodies 
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SUMMARY 
Cloning of the CD52 from a B-lymphocyte tumour cDNA library revealed two closely related 
sequences differing only at two amino acids C-terminal to the proposed point of glycosyl- 
phosphatidylinositol (GPI)-linkage. When transfected into CHO cells only one of these sequences 
gave high-level expression of the antigen recognized by the prototypic anti-CD52 antibody 
CAMPATH-1 whereas in JURKAT cells good expression levels were obtained with both 
sequences. Fusion of the sequence from the second sequence to DNA encoding the extracellular 
domain of CD4 indicated that this sequence was capable of directing GPI linkage. The possible 




The CD52 gene product is the antigen recognized by the 
CAMPATH-1 series of monoclonal antibodies. ' This series of 
antibodies was identified by their ability to give very efficient 
lysis of human lymphocytes in the presence of human comple- 
ment. Because of this property the CAMPATH-1 series has 
been developed for the serotherapy of lymphoid malignancies 
and autoimmune disease. CAMPATH-1 was the first antibody 
to be fully humanized and this humanized version (CAM- 
PATH-IH) has been shown to have beneficial effects in non- 
Hodgkin's lymphoma2 and rheumatoid arthritis. 3 The antigen 
recognized by the CAMPATH-1 series is CD52 and the 
structure of this molecule is now known in some detail. The 
mature peptide is a mere 12 amino acids in length and it is 
attached to the cell membrane via a glycosyl-phosphatidyl- 
inositol (GPI) linkage. 4, The polypeptide is N linked glyco- 
sylated6 explaining the apparent mobility on sodium 
dodecylsulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) analysis of 20 000-28 000 MW. The cDNA for the 
CD52 gene has been cloned and sequenced and shown to 
encode a 37-amino acid prepeptide which is subsequently 
processed to yield the mature CD52 peptide. It is postulated 
that the efficiency of anti-CD52 antibodies in lympholysis is 
partly due to the small size of the molecule and its lateral 
mobility in the membrane due to its GPI-anchorage. Both 
features which would allow antibody redirected complement or 
other effector mechanisms to be more effective. 
In this study we report the successful expression of the 
CD52 in heterologous cells and confirm the presence of a 
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second related sequence in human lymphocytes. Transfection' 
of the second cDNA sequence gave much lower levels of 
expression of the CD52 antigen than the original sequence in 
CHO cells whereas in JURKAT cells the levels of expression 
were much more comparable suggesting differences in the 
efficiency of processing the gene product of the CD52 alleles in 
different cell types. 
MATERIALS AND METHODS 
Cell culture 
Wien 133 cells were cultured in filter-sterilized Iscove's modified 
Dulbecco's medium (IMDM) supplemented with 10% (v/v) 
heat-inactivated fetal calf serum (FCS), 2mM t-glutamine and 
5001U/ml penicillin/500µg/ml streptomycin. CHO dihydro-. 
folate reductase (dhfr)- cells were detached by pretreatment 
with 0.02% versene containing 1.25% trypsin, washed in 
medium and cultured in filter sterilized Dulbecco's modified 
Eagles medium (DMEM) supplemented with 10% (v/v) heat- 
inactivated FCS, 2 MM L-glutamine, non-essential amino acids, 
hypoxanthine, thymidine and 5001U/ml penicillin/500µg/ml 
streptomycin. Transfected CHO dhfr- cells were cultured in 
DMEM supplemented with 10% (v/v) heat-inactivated dialysed 
FCS, 2 MM L-glutamine, non-essential amino acids and 500 IU/ 
ml penicillin/500µg/ml streptomycin. As the gene of interest 
became expressed, methotrexate, an inhibitor of dhfr, was 
added to the medium at an initial level of 3x 10-8 M. This 
procedure selected for random amplification of the resident 
plasmid DNA associated with higher level gene expression-,,,, 
Once growth of the transfectants was stable at 3x 10-8 Ni the 
methotrexate concentration was increased to 1x 10'1M. -'A 
repeat of several rounds of amplification led to : maximAl 
expression levels for the selected gene. The highest concentra- 
tion of metbotrexate employed was in the order of 1x 10 '6M. 
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FA CScan analysis and flow cytometry 
Cell lines were washed and resuspended in fluorescence activated 
bell sorter (FACS) buffer (5% (v/v) FCS, 0.1% sodium azide 
(NaN3) in phosphate-buffered saline (PBS)) at Ix 105 cells/ml. 
The cells were dispensed into 96-well U-bottomed microtitre 
plates at l00pl per well and l0, ul fluorescein isothiocyanate 
(FITC)-labelled antibody was then added. The cells were 
incubated at 4° for 30 min, to stain, before the plate was 
centrifuged at 1000g in a Sorvall RT6000B bench centrifuge for 
5 min. The excess liquid was removed and the cell pellets were 
resuspended in l00µ1 wash buffer (0.1% sodium azide in PBS) 
and the process was repeated twice more. Once the cells had 
been fluorescently labelled they were finally resuspended in 
100µl FACS fix buffer (1% paraformaldehyde in PBS) and 
analysed on a FACScan (Becton Dickinson, Oxford, UK). 
PIPLC treatment 
Transfected CHO cells were diluted to 106/ml in medium and 
100µl either treated with 5 units of the enzyme phosphatidyl- 
inositol-specific phospholipase C (PIPLC, Boehringer Mann- 
heim, Lewis, East Sussex, UK) or medium alone for 1 hr at 37 °. 
The cells were then washed and stained with either FITC- 
labelled anti-CD4 or FITC-labelled CAMPATH-IH. 
cDNA cloning and expression 
To isolate the cDNA for the CD52 antigen from Wien 133, two 
25-base pair (bp) polymerase chain reaction (PCR) primers 
were made which corresponded to either the 5' sequences of the 
coding strand and which incorporated a Hin dill site or to the 3' 
sequences of the gene plus an included EcoRI site comple- 
mentary to the coding strand, both based on the published 
sequence. 4 The Wien 133 cells were used to prepare total RNA 
by the guanadinium isothiocyanate method and the mRNA 
was isolated by magnetic separation on a Dynal column. 
`Superscript', (Gibco BRL, Paisley, UK), was used to produce 
a first strand cDNA and then a second strand copy was 
synthesized. A PCR performed on the resulting cDNA utilizing 
the primers mentioned previously produced an expected band 
of 206 bp. The band was purified on an agarose gel after cutting 
with the enzymes HindIII/EcoRI and the insert was cloned into 
either PUC 18 or PUC 19 cut with HindIII/EcoRI. After 
checking the sequence utilizing a Sequenase 2 kit (USB), the 
correct bands were excised from the holding vectors and cloned 
into an expression vector pRDN-1. 
The vector, pRDN-1, contains the strong B-actin promoter 
and polyadenylation signals either side of a polylinker containing 
both Hin dill and EcoRl sites therefore, it was possible to insert 
the CD52 antigen directly into the correct orientation. The 
vector also contains a dhfr gene cassette which permits possible 
selection and amplification of the correct antigen expressing 
colonies with methotrexate. After mapping positive colonies by 
restriction analysis the final selected plasmids pRDN AG and 
pRDN ACIH were grown up in large shake flasks and the 
plasmid DNA purified by caesium gradients. The CD52 
containing DNA, was transfected into the CHO dhfr--. line 
B! I using Promega Transfectam. Successful transfection with 
the CD52 constructs was monitored by methotrexate resistance 
and surface expression of the antigen, as assessed by FACS 
analysis, with a wide spread of expression levels seen only for 
the authentic CAMPATH-1 construct. Following amplifica- 
tion of both constructs in 3x 10'8M methotrexate, single 
highly expressing or resistant clones of the transfected cell lines 
were isolated by dilution cloning. 
CD4/CAAIPATH antigen chimeric constructs 
Full length extracellular CD4 was jointed to the GPI-displaced 
signal peptide of either the construct pRDN AG or pRDN 
AC1H via PCR utilizing overlap primers designed to corre- 
spond to either the proline residue at residue + 373 in CD4 or 
the proline residue + 11 in CAMPATH antigen CDw52 whilst 
retaining the original frame. The resulting constructs named 
pRDN CD4AG and pRDN CD4AC1H were confirmed as 
correct via sequencing with the Sequenase 2 kit supplied by 
USB. Both constructs, as well as full length CD4 or 
CAMPATH antigen in pRDN-1, were transfected into CHO 
dhfr- cells as before and amplified to 3x 10-8 M methotrexate 
prior to dilution cloning. 
RNAase protection assay 
CHO cells containing either pRDN AG, pRDN AC1H or the 
parental cells were used as a source of template for RNAase 
protection assays. A certain number of cells, i. e. 107/ml or 106/ 
ml, were lysed with the lysis buffer from a USB RNA protection 
kit and the lysates were mixed with either single-stranded 
forward or reverse 32P-labelled probes made by RNA runoffs 
from the whole CAMPATH antigen cloned into a Bluescript 
vector. The reactions were left overnight at 37° before the 
products were treated with RNAase to remove excess probe 
and the products separated on a 6% sequencing gel. The dried 
get was autoradiographed. 
In vivo experiments 
Parental or transfected CHO cells to be studied were harvested 
from flasks, washed and resuspended in PBS at 2x 107/ml 
before being mixed with an equal volume of 6 mg/ml matrigel 
for injection subcutaneously (0.1 ml) into nude mice. After 1 
month, approximately, tumours were excised from the animals, 
teased into single cell suspensions and either analysed by FACS 
for CD52 expression. 
Inimunoprecipitations and Western blotting 
CHO cells were lysed in 3% nonidet P-40 (NP-40) lysis buffer 
(containing 20 mm MOPS, 15 mm EGTA, 3% NP-40,2 mm 
phenylmethylsulphonyl fluoride, 1 mm Na2VO4 (10 µg/ml apro- 
tonin, 2 mm EDTA) for 15 min on ice. After which time the 
lysate was centrifuged at 10000g for 5min at 4°. The clarified 
supernatant was precleared with Sepharose-4B for 30 min at 4°, 
and the precleared lysäte incubated with Q4120 (anti-CD4, 
Sigma, St Louis, MO)-coupled Sepharose for 1 hr at 4° with 
end-over-end rotation. The beads were then washed twice in 
lysis buffer and resuspended in non-reducing SDS-PAGE 
sample buffer and boiled for 3 min. The samples were run on 
8% SDS-PAGE gels, blotted onto nitrocellulose and the blots 
blocked with 3% non-fat milk in PBS. The blots were then 
probed with biotin-Q4120 followed by streptavidin-horse- 
radish peroxidase and developed by enhanced chemilumines- 
cence (ECL, Amersham, Amersham, UK). 
t "Fc x 
RESULTS 
Cloning and expression of the CD52 gene 
Complementary DNA was prepared from the B-cell lymphoma 
Wien 133 and used as a template for the PCR amplification 
Q 1996 Blackwell Science Ltd, Immunology, 8,8', 183-J90 
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CD52 gene product recognition by CAMPATH-'JH 
of a 206-bp fragment containing the cDNA for CD52. A cDNA 
clone corresponding to the reported sequence for CD524 was 
cloned into the mammalian expression vector pRDN-1 and the 
resulting construct transfected into both dhfr/CHO cells and 
JURKAT T cells. In the case of CHO cells there was no 
requirement for co-transfection with plasmid containing a 
selective marker as pRDN-1 contains the dhfr gene. JURKAT 
were co-transfected with the CD52 gene in pRDN-1 and the 
p321 plasmid which confers neomycin resistance. Both cell lines 
70 
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Figure 1. Heterologoüs expression of CD52. The cDNA for CD52 was 
transfected into either CHO cells or JURKAT cells. After appropriate 
selection, cells were stained with FITC-labelled CAMPATH-1H and 
analysed by flow cytometry. Treatment with PIPLC td remove GPI- 
anchored proteins was performed as described in the Materials and 
Methods. (JURKAT, control JURKAT cells; JURKAT + CDw52, 
JURKAT cells transfected with cDNA encoding CD52). s, ' 
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expressed the CD52 gene product as recognized by the anti- 
CD52 antibody CAMPATH-1H (Fig. 1), indicating that there 
are apparently no stringent species or cell lineage requirements 
for the expression of this human leucocyte antigen. Untrans- 
fected CHO cells did not stain with CAMPATH-1H (data not 
shown and Fig. 2). Parental JURKAT cells have low to 
negligible levels of CD52, Fig. I shows three subclones of 
JURKAT cells expressing different levels of CD52 after 
transfection, indicating that there is some clonal variation in 
the expression of CD52, analysis of pooled transfectants was 
subsequently used to assess efficiency of expression of CD52. 
The expression of CD52 on CHO cells was reduced by 
treatment with PIPLC indicating that, as in lymphocytes, the 
CD52 antigen is linked to the membrane via a GPI-anchor 
(Fig. 1). 
Sequence analysis of the CD52 gene 
During the cloning and sequencing of the PCR products from 
the Wien 133 cDNA it became apparent that two sequences 
were represented in the cDNA. These were found in approxi- 
mately equal proportions amongst independent clones (Table 
1). The two sequences were AAC ATA and AGC ATG at 
positions 151-156 which would result in changes from Asn-Ile 
to Ser-Met at positions 16 and 17 of the mature peptide, a site 
CDw52 sequence 
5' PCR PRIMER 
ß4 
CCT ACC AAA ATG AAG CGC TTC CTC TTC CTC CTA CTC 
MET LYS ARG PHE LEU PHE LEU LEU LEU 
ACC ATC AGC CTC CTG GTT ATG GTA CAG ATA CAA 
THR LE 6ER LEU LEU VAL MET VAL GLN LE GLN 
12345e7 
ACT GGA CTC TCA GGA CAA AAC GAC ACC AGC CAA 
THR GLY LEU SER GLY GLN ASN ASP TiR SER OLN 
e9 10 11 12 
ACC AGC AGC CCC TCA GCA TCC AGC AAC ATA AGC 
1HR SER SER PRO SER ALA 6ER SER ASN ILE 6ER 
GGA GGC ATT TTC CTT TTC TTC GTG GCC AAT GCA ATA 
GLY GLY LE PHE LEU PHE PHE VAL ALA ASN ALA LE 
ATC CAC CTC TTC TGC TTC AGT TGA GAA TCA CTG GCC 
LE HIS LEU PHE CYS PHE SER STOP 
3' PCR PRIMER 
GTC GGT TTA CAC GTC GTG ACT GGA AAC, a 
Figure 2. The DNA sequence of the CD52 gene is'shown with the 
primers use for the PCR reactions to amplify the gene.:, tw,,, 
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Table 1. Sequence analysis of 
PCR inserts 
CDw52 ACIH 
Exp. 1 1/2* 1/2 
Exp. 2 4/8 4,18 
Exp. 3 2/3 1/3 
Total 7/13 6/13 
" Data are expressed as the 
number with that particular 
sequence divided by the total 
number sequenced for each 
experiment. 
C. Hale et al. 
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Control 
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on the C-terminal side of the proposed GPI-anchorage site 
(Fig. 2). This difference was also noted by Xia et a!. 4 in 
independently isolated cDNA clones but since only one clone 
was isolated the authors were unable to conclude whether this 
sequence represented a second allele or a cloning artefact. Since 
the observed changes were in the region of the site for the 
addition of the GPI-anchor (Fig. 3) we decided to clone and 
express this second variant. Figure 4 shows the result of stable 
transfection of the two forms into CHO cells. The original 
version (CD52) led to high-level expression of CD52 as 
measured by CAMPATH-1H staining. The second form 
AC1H showed only a very low level of expression of the 
CD52 antigen. Ribonuclease protection assay analysis indi- 
cated that both transfectants were making the appropriate 
mRNA (Fig. 5). The difference in expression levels was 
maintained throughout the amplification with methotrexate 
(data not shown). The epitope recognized by the CAMPATH- 
1H antibody is composed of contributions from both the 
peptide sequence and the GPI-anchor. 5 Thus it is possible that 
if the observed change in peptide sequence leads to a change in 
the position of the attachment of GPI-anchor then the antigen 
expressed from the alternative sequence will not be recognized 
by the CAMPATH-IH antibody. In order to test whether the 
alternative sequence could function as a membrane-anchoring 
CAMH'ATH antigen (CDw52) 
N-Carbohydrate 
r_TV-AQl -aRP-THR-SEB-OLN-THR-SER-SER-PRO SER-EtN 
P04 
EtN-P04-Mannnose core 
Inositol + Palmitate 
P04 
Lipid tail 
Figure 3. The amino acid sequence of the CD52 gene product with the 
proposed site of the GPI-anchor is shown. 
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Figure 4. Expression of the two related CD52 genes; cDNA for CD52 
(pRDN AG) or the alternative sequence pRDN ACIH were transfected 
into CHO cells and appropriate selection and amplification applied. 
Untransfected CHO cells (CHO DHFR-) pRDN AG-transfected 
CHO cells (CHO + pRDN AG), or pRDN ACTH-transfected CHO 
cells were stained with FITC-labelled CAMPATH-1 H and analysed by 
flow cytometry. 
sequence it was therefore necessary to attach another deter- 
minant, to the potential anchor sequences. 
Construction of CD4 extracellular domain-CD52 chimerae 
In order to determine whether the CD52 sequence could 
function as a membrane-anchoring sequence, chimeric genes 
were constructed consisting of the coding regions for extra- 
cellular domains of CD4 and the anchoring sequence from 
CD52 or ECIH. These constructs were transfected into CHO 
cells and monitored for CD4 expression. Both chimeric 
molecules were expressed as detected by staining with anti- 
CD4 antibody (Fig. 6). The replacement of the extracellular 
domain of CD52 with that of CD4 prevented the detection with 
anti-CD52 antibodies. In fact, transfectants expressing the 
CD4/OCIH chimera showed higher levels of CD4 staining than 
either the CD4/Ag chimera or the transmembrane - CD4 
construct. Furthermore, immunoprecipitätion; analysis' indi- 
cated that the transfected constructs yielded recombinant 
proteins of the correct size, those constructs encoding' GPI- 
anchored molecules being smaller than the full-length CD4 
molecule (Fig. 7). Thus both , structures can f 
direct ` the 
extracellular domain of CD4 to the cell, membrane. " The 
Q 1996 Blackwell Science Ltd, Immunology, 88, - 183-190 
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Figure S. Measurement of mRNA levels by RNAase protection; CHO 
cells transfected with pRDN AG or CHO cells transfected with pRDN 
ACTH were used 'as template for RNA protection studies. Either 
107cells/ml or 106cells/ml were incubated with CAMPATH antigen 
probes transcribed in forward or reverse orientation in the Bluescript 
vector KS" (105c. p. m. per reaction). Lane 1,32P end-labelled 0174 
marker cut with Hinf; lane 3,5µl reverse probe; lanes 5-10, cell lysates 
plus reverse probe digested with RNAase of which lane 5 107/ml CHO 
cells, lane 6106/ml CHO cells, lane 7107/ml CHO cells plus pRDN AG, 
lane 8 106/ml CHO cells with pRDN AG, lane 9107/mI CHO cells with 
pRDN ACIH, lane 10106/ml CHO cells with pRDN AC1H; lanes 2,4, 
11-13 blank; lane 14,5µl forward probe; lanes 15-20, cell lysates plus 
forward probe digested with RNAase of which lane 15 107/ml CHO 
cells, lane 16 106/ml CHO cells, lane 17 10'/ml CHO cells plus pRDN 
AG, lane 18 106/ml CHO cells with pRDN AG, lane 19 107/ml CHO 
cells with pRDN ACIH, lane 20 106/ml CHO cells with pRDN ACIH; 
lanes 21-27 blank. Lanes 7-10 show the expected band at 206bp. 
transfectants were treated with PIPLC to determine whether 
the CD4 was linked via a GPI-anchor, in both cases expression 
levels were diminished by this treatment. By contrast CHO cells 
transfected with a construct encoding a full-length CD4 eDNA 
containing a transmembrane and cytoplasmic domain expressed 
` CD4 which was unaffected by PIPLC treatment (Fig. 6). 
: Expression of CD52 alleles in JURKAT cells and normal human 
peripheral blood mononuclear cells 
In order to determine whether the inefficient expression of the 
alternative CD52 allele in CHO cells was related to cell type, the 
cDNA for both alleles were transfected into JURKAT T cells 
and the transfected pools were subjected to flow cytometric 
analysis. Figure 8 shows that both alleles are efficiently expressed 
in this lymphocytic cell line. However, even in this cell line the 
expression of the alternative allele is somewhat lower than the 
originally described allele, possibly reinforcing the notion that 
this gene product is less efficiently processed, the originally 
described allele showing an approximately sevenfold higher 
peak fluorescence than the alternative allele. The expression of 
the two alleles in normal peripheral blood mononuclear cells 
(PBMC) was investigated by sequencing the PCR products 
amplified from cDNA prepared from 11 normal individuals. In 
two of 11 individuals only the originally described allele could 
be found, in six the alternative allele was the only product 
present and in the other three both products could be isolated. 
Q 1996 Blackwell Science Ltd, Immunology, 88,183-190 
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Figure 6. PIPLC treatment of transfectants; pRDN CD4/Ag, pRDN 
CD4/ACTH and CD4 CHO cell transfectants were incubated with 
either medium alone or PIPLC and then stained with FITC-labelled 
anti-CD4 and analysed by flow cytometry. 
Flow cytometric analysis of the PBMC indicated that all the 
individuals expressed CD52 at approximately the same level 
(data not shown). 
Morphological and functional characteristics of transfectants 
The function of the CD52 gene product is currently unknown. 
Other GPI-anchored structures such as CD597 and CD558 have 
been shown to act to protect cells from complement attack. 
During the course of experiments in which we expressed the two 
CDw52 sequences we noticed a major difference in morphology 
between the two transfected cell lines. Whereas untransfected 
CHO cells and CHO cells transfected with the OCIH gene 
product were rounded in appearance, cells transfected with the 
originally described CD52 gene adopted an elongated, spindly 
morphology (Fig. 9). We wished to determine whether this", 
difference may have any corollary in terms ' of . 
functional 
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Figure 7. Immunoprecipitation analysis of trtnsfcctants: L)satcs from 
C'HO pRDN CD4AG. CIIC) pRDN CI)4 ACTH, CIIO-('D4 or ('110 
cells were inimunohrceihitated using anti-C'D4 Sepharose and the 
immunoprecihitated proteins sere separated by SDS PAGE. trans- 
fcrred to nitrocellulose by Western blotting and probed ssith anti-('1)4 
antibodies. Lane A, pRDN CD4, AG; lane B, pRDN CD4, AC l 11; Eine 
C, Cl 10-('1)4: lane D, ('11O. 
genes had an effect on growth in tiro, IX I06 cells of each cell 
type were transplanted subcutaneously into nude mice and 
monitored for tumour growth. Table 2 shows the data from t% o 
separate experiments in which the identical results ýýcre 
obtained. Only mice receiving C'HO cells expressing the CI)5' 
29.13995JUR001'FL 1-H\FL 1. height 
50 Control JURKAT 
CO w52 
0 
Y^ ý.. r. ... ......, 
100 10t 102 103 10" 
50 29.13995JUR004, FL1-MFL1-height 





10° 101 102 103 10° 
50 29 13995JUR007\FLi-H\FL1-height Contra 
JURKAT + pRDNOCIH 
C0w52 
0 
10° 10' 102 103 104 
Figure 8. Expression of CD52 alleles in Jurkat T cells; Jurkat T cells 
were transfected w ith either pR DN AG or pR DN AC I}i as described in 
the Materials and Methods. The transfected T cells were stained after 
passage in select medium with FITC-labelled CAM PATI I-I H antibody 
as indicated. 
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Figure 9. Morphological differences between transfected cell line 
photomicrographs of subcunfucnt Cl 10 cells. (a) Parental CI 10 cell 
(b) pRDN AG-transfected CHO cells, and (c) pRDN ACII 
transfected cells. 
(CHOjpRDN AG) gene presented with tumours, mice recei' 
in,, untransfected CHO cells or CHO cells transfected with ti, 
ACIH gene (CI-to pRDN ACTH) showed no sign of tumor 
growth. These data may indicate that the C'll52 gene produu 
may play a role in either cell cell adhesion or protection of tli 
Table 2. Growth of C110 transfectants in vivo 
CHO CtlO/pRDN AG ('110, pRDN ACI 
FX11.1 (I I0' 4; 10 0110 
B. p. 2 0/1(l 3,10 0,10 
Exp. 3 (l! 10 9,10 NDt 
"Total (1 30 16,130++ 0/20 
* Data are expressed as the number of mice exhibiting tumo 
growth divided by the total number of mice inoculated. 
t ND, not determined. 
$P< 0-001 according to X2 analysis. 
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Figure 7. Immunoprecipitation analysis of transfectants; Lysates from 
CHO pRDN CD4/AG, CHO pRDN CD4/ACTH, CHO-CD4 or CHO 
cells were immunoprecipitated using anti-CD4 Sepharose and the 
immunoprecipitated proteins were separated by SDS-PAGE, trans- 
ferred to nitrocellulose by Western blotting and probed with anti-CD4 
antibodies. Lane A, pRDN CD4/AG; lane B, pRDN CD4/AC1 H; lane 
C, CHO-CD4; lane D, CHO. 
genes had an effect on growth in vivo, 1x 106 cells of each cell 
type were transplanted subcutaneously into nude mice and 
monitored for tumour growth. Table 2 shows the data from two 
separate experiments in which the identical results were 
obtained. Only mice receiving CHO cells expressing the CD52 
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Figure 8. Expression of CD52 alleles in Jurkat T cells; Jurkat T cells 
were transfected with either pRDN AG or pRDN AC1 H as described in 
the Materials and Methods. The transfected T cells were stained after 
passage in select medium with FITC-labelled CAMPATH-I H antibody 
as indicated. `' r` 
Figure 9. Morphological differences between transfected cell li 
photomicrographs of subconfluent CHO cells. (a) Parental CHO c 
(b) pRDN AG-transfected CHO cells, and (c) pRDN AC 
transfected cells. 
(CHO/pRDN AG) gene presented with tumours, mice rec, 
ing untransfected CHO cells or CHO cells transfected with 
ACTH gene (CHO/pRDN ACIH) showed no sign of tum 
growth. These data may indicate that the CD52 gene prod 
may play a role in either cell-cell adhesion or protection of 
Table 2. Growth of C1HO transfectants in vivo 
CHO CHO/pRDN AG CHO/pRDN AC1H 
Exp. 1 0/10" 4/10 0/10 
Exp. 2 0/10 3/10 0/10 
Exp. 3 0/10- . 9/10 NDt 
Total 0/30 . 16/30$ :.. , 0/20 ,' 
" Data are expressed as the number of mice exhibiting 'tumou 
growth divided by the total number of mice inoculated. '` 
t ND, not determined. "hý': ý'> . P<0.001 according to X2 analysis. i; 1. 
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cell from extracellular influences, both roles would be con- 





The CD52 antigen was first discovered by screening for 
antibodies which were effective in fixing human complement. ' 
Rat antibodies of the CAMPATH-1 series were the prototype 
anti-CD52 antibodies and these have been developed for 
therapeutic use as lymphocyte-depleting agents in the treat- 
ment of lymphoid malignancy and autoimmune disease. .3 The 
interest in the potential therapeutic exploitation of the 
CAMPATH-1 series has been paralleled by research into the 
nature of the antigen. Xia el al. showed that the CD52 antigen 
is a 12-amino acid-glycosylated polypeptide which is linked to 
the plasma membrane via GPI-linkages The determinant 
recognized by CAMPATH-1 is formed from a contribution 
from both the peptide backbone and the GPI-anchoring. The 
requirements for she attachment of a GPI-anchor are to have a 
small amino acid such as serine-to which the anchor is 
attached-separated by 10-12 amino acids from a strongly 
hydrophobic domain 9"0 
During the cDNA cloning of CD52 Xia el al. 4 noted that 
two closely related sequences were found, differing at two 
amino acids C-terminal to the GPI-anchoring site. Whereas the 
CD52 cDNA codes for Asn-Ile in these two positions, the 
alternative ACIH encodes Ser-Met. When transfected into 
CHO cells the `wild-type' version of the gene encoding Asn-Ile 
at positions 16 and 17 led to high-level expression of the antigen 
recognized by the CAMPATH-1H antibody, Subsequently 
there has been an independent report in which the two 
sequences have been noted. " We first expressed CD52 in 
CHO and JURKAT cells and were able to detect the antigen 
with CAMPATH-1H antibody. The antigen was sensitive to 
treatment with PIPLC indicating a GPI-linkage to the cell 
membrane. The expression in both hamster and human cells of 
differing tissue origin suggests that there is no tissue or species 
specificity controlling the expression of the originally described 
CD52 allele. This is similar to other GPI-anchored proteins 
such as CD55 and CD59 which have also been expressed in 
heterologous cell lines such as CHO or Hela cells. 12.13 CHO 
cells transfected with the alternative Ser-Met version of the 
gene expressed much lower levels of CD52 despite an identical 
sequence in the coding region for the predicted CD52 peptide 
backbone. Two possible explanations for this observation are 
first, that the GPI-linkage differs for this sequence and forms an 
antigen not recognized by CAMPATH-1H despite being 
expressed, or second, that the alternative sequence is ineffi- 
ciently processed in these transfectants. The analysis of the 
processing of the CD52 GPI-anchor is hampered by the fact 
that there are a limited number of anti-CD52 antibodies and 
the majority recognize the same epitope which is at least 
partially made up of elements of the GPI-anchor. Therefore, to 
study further the properties of the CD52 sequence we 
constructed CD4/CD52 chimeric genes and expressed these in 
CHO cells. Flow cytometry of the transfectants indicated that 
both the CD52 and the ACIH sequences allowed the membrane 
expression of CD4 and furthermore in both cases the expression 
was sensitive to treatment with PIPLC, CHO cells expressing 
full-length transmembrane-anchored CD4 were also treated 
with PIPLC and in this case CD4 expression was found to be' 
® 1996 Blackwell Science Ltd, Immunology, 88,183-190 
189 
PIPLC-insensitive. Thus, the ACIH sequence can be processed 
to generate a GPI-anchor with the CD4 extracellular domains, 
in fact expression levels are somewhat higher than with the 
original CD52 sequence. It is therefore possible that the 
inability to obtain CAMPATH-IH reactivity with ACTH is 
due to an inefficiency of the entire ACIH sequence to be 
processed and transported to the cell surface. This is not 
however due to an intrinsic inability of the ACIH sequence to 
form a GPI-linkage. Other possibilities are that the ACIH gene 
product is processed but that the product is not recognized by 
antibodies of the CAMPATH-I series possibly due to the 
attachment of the GPI-anchor at an alternative site or possibly 
due to more rapid turnover or degradation. 
The existence of two forms of the CD52 gene has now been 
reported by several independent laboratories. 4"11 If the CD52 
gene has different alleles it is interesting to speculate what 
effect this would have on expression of CD52. In the normal 
population there have been no reports of CD52" patients 
suggesting that if people homozygous for the alternative form 
exist they express the antigen efficiently. Indeed our analysis of 
PBMC from normal donors indicates that a significant propor- 
tion have only the second allele and yet express high levels of 
CD52 on their lymphocytes. This is consistent with our data 
obtained with CD4-CD52 chimeric molecules but not with the 
low-level expression of CD52 in CHO cells transfected with the 
alternative sequence. A possible explanation is that the alter- 
native gene product is less efficiently processed in CHO cells' 
leading to low expression levels. In lymphocytes the gene may 
be processed more efficiently leading to higher levels of 
expression, consistent with this possibility is the fact that the 
expression of CD52 on normal lymphocytes is very high. The 
experiment shown in Fig. 8 supports this hypothesis. Both 
alleles are efficiently expressed in JURKAT T cells, however 
even in the T-cell line there is better expression in the 
transfected cell pool with the original allele, with almost a 
sevenfold difference in the peak fluorescence. This compares to 
an approximate tenfold difference in the CHO cell transfectants. 
The function of the CD52 gene product is not known at 
present. The data presented here suggest that expression of 
CD52 in CHO cells gives them a selective growth advantage in 
vivo. Interestingly, the pRDN ACIII transfectants were similar 
to CHO cells both morphologically and in terms of in vivo 
tumorigenicity. This suggests that the relatively inefficient 
expression of CD52 by these cells does not lead to the changes 
in morphology and the same selective advantage. Such an 
observation would be consistent with either a role for CD52 in 
cell protection from the host environment or with a role in cell- 
cell adhesion both of which would favour enhanced survival. 
The transfected cell lines described here may prove to be 
extremely useful reagents for the elucidation of the function of 
CD52. 
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Glycosylation and biological activity of CAMPATH-1H expressed in 
different cell lines and grown under different culture conditions 
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CAMPATH-1H (where CAMPATH is a trade mark of Well- 
come group companies), a humanized IgG antibody used 
in the therapy of lymphoma, leukaemia and rheumatoid 
arthritis, has been expressed in Chinese hamster ovary, YO 
myeloma and NSO myeloma cell lines. These engineered cell 
lines were grown under different culture conditions, and the 
antibody isolated and purified. N-Linked oligosaccharides, 
on the CH2 heavy chain region of the antibody, were isolated 
and analysed by hydrazinolysis, high-performance anion- 
exchange chromatography 'with pulsed amperometric detec- 
tion, laser-desorption mass spectrometry and sequential 
exoglycosidase treatment. Both the glycosylation pattern 
and the biological activity of CAMPATH-1H, as measured 
by antibody-dependent cell-mediated cytotoxicity, were 
markedly affected by the cell line used to express the anti- 
body. It is concluded that glycosylation of the antibody may 
be important in the clinical outcome of therapy. 
Key words: ADCC/antibody/CAMPATH/glycosylation/61igosac- 
charide 
Introduction 
Glycosylation of therapeutic antibodies can have a critical 
effect on biological activity and pharmacokinetics (Nose and 
Wigzell, 1983; Parekh et al., 1985; Wright et al., 1991). The 
removal of the N-linked oligosaccharide from the CH2 heavy 
chain region of the antibody abrogates target cell killing by 
complement-mediated lysis (CML) and antibody-dependent 
cell-mediated cytotoxicity (ADCC) (Nose and Wigzell, 1983; 
Tao and Morrison, 1989). Circulatory lifetime, immunogenic- 
ity and antigenicity of the antibody may also be affected by 
glycosylation of the molecule (Rademacher et al., 1988). There 
are several factors that can influence glycosylation. The 
species, tissue and cell type have all been shown to be import- 
ant in the way that glycosylation occurs (Rademacher et al., 
1988). In addition, the extracellular environment, through 
altered culture conditions such as serum concentration, may 
have a direct effect on glycosylation'(Goochee and Monica, 
1990; Maiorella et al., 1993). 
CAMPATH-1H (where CAMPATH is a trade mark of 
Wellcome group companies), a humanized I8G1 antibody 
(Riechmann et al., 1988), is directed against the CD52 
antigen (Hale et al., 1990; Treumann et al., 1995) present on 
the cell surface of the majority of normal and malignant 
lymphocytes. This antibody has been expressed in several 
mammalian cell lines, including YO rat myeloma, NSO mouse 
myeloma and Chinese hamster ovary (CHO), grown using 
different culture conditions, and extensively tested in clinical 
trials of lymphoproliferative disorders (Hale et al., 1988) and 
rheumatoid arthritis (Isaacs et al., 1992), with some major 
successes. 
This study was initiated in order to determine whether 
differences in glycosylation in CAMPATH-1H were apparent 
between the different cell lines expressing the antibody, and 
whether there were corresponding differences in in vitro bio-. 
logical activity, the natural consequence being that glycosyla- 
tion of the antibody may be important in the clinical outcome 
of therapy. 
Results 
Purification and chemical characterization of CAMPATH-1H 
CAMPATH-1H was purified from culture supernatants by 
protein A-Sepharose chromatography. SDS-PAGE (data not 
shown) showed a single band at 150 kDa (non-reducing gel), 
and bands at 50 and 25 kDa (reducing gel) for heavy and light 
chains, respectively. No evidence for free heavy or light chain 
was observed. Size-exclusion HPLC indicated that the material 
was present as the monomer with <I% aggregate. 
Preparation and analysis of oligosaccharide standards 
A series of oligosaccharide standards was obtained commer- 
cially, and further standards were derived from these by treat- 
ment with exoglycosidases, using ß-galactosidase, a-fucosidase 
and/or ß-N-acetylhexosaminidase. Table I shows the relative 
retention times of these oligosaccharide standards, analysed by 
high-performance anion-exchange chromatography (HPAEC), 
together with the corresponding [M + Na'J molecular ions 
observed by laser-desorption mass spectrometry (LD-MS). All 
structures were as expected and fully confirmed by LD-MS. It 
is clear that removal of galactose (Gal) and/or N-acetylglucos- 
amine (G1cNAc) from the outer arm of the oligosaccharide 
reduces, whereas removal of the core fucose (Fuc) residue 
increases, the relative retention time on HPAEC. 
N-Linked oligosaccharides from CAMPATH-IH 
Oligosaccharides were released from CHO, 
, 
YO or-, NSO 
CAMPATH-1H antibody by hydrazinolysis. The proportion of 
sialylated oligosaccharides was estimated following release 
of N-acetylneuraminic acid (NeuNAc) and quantitation by . HPAEC. The low levels of NeuNAc observed suggested the, 
presence of <5% sialylated oligosaccharides in all antibodies. ' 
0 Oxford University Press 813 
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Table I. Relative retention times of N-linked oligosaccharide standards by 
HPAEC-PAD 
Oligosaccharide HPAEC-PAD ° [Ni + Na'] 
structure' (retention time) molecular ion 
by LD-MS 
002300 0.39 934 
002301 0.33 1080 
013300 0.51/0.58° 1298 
003301 0.38/0.42c 1283 
013301 0.45/0.52° 1444 
004300 0.69 1340 
014300 0.78 1502 
024300 0.91 1664 
- 004301 0.59 1486 
014301 a 0.68 1649 
024301 0.78 1811 
004310 0.84. 1544 
014310 0.94 '1706 
024310 1.06 1868 
004311 0.74 1690 
014311 0.83 1852 
024311 0.94 2014 
'Nomenclature for otigosaccharide structure in Materials and methods. 
°Retention times relative to an internal standard of NeuNAc. 
°Structures were derived from exoglycosidase treatment of CHO 
oligosaccharide Peak II (014301). as described in Table II and Scheme 1. 
Two peaks suggest isomers are being separated. 
Oligosaccharides were separated by HPAEC (Figure 1) and 
showed significant differences in their profiles. 
Oligosaccharides from CHO-derived CAMPATH-1H, 
whether grown in the absence (Figure 1A) or presence (Figure 
IB) of serum, gave the simplest profile. Comparison of the 
relative retention times of the three main peaks (I-III; Table II) 
with those of standards suggested the presence of a major 
fucosylated series (Figure 2; Family 1) whose members dif- 
fered in terminal galactosylation. LD-MS of the unfractionated 
oligosaccharides. (Figure 3A) confirmed the presence of this 
series, as well as a. minor non-fucosylated series (Figure 2, 
Family 2). Each of the main peaks (I-III) was separated by 
chromatography on HPAEC and further analysed by LD-MS. 
LD-MS of PeakI (Figure 3B) indicated a [M + Na+] molecular 
ion at 1487, suggesting the non-galactosylated structure, 
004301; Peak lI (Figure3C) had a [M + Na'] molecular ion at 
1645, indicating the monogalactosylated structure, 014301; 
lastly, Peak III (Figure 3D) was a mixture of two major [M + 
Na'] molecular ions at 1501 and 1809, indicative of the mono- 
galactosylated, non-fucosylated structure, 014300, and the 
digalactosylated structure, 024301, respectively. Each of 
the fractionated oligosaccharides (Peaks I-III), as well as the 
unfractionated oligosaccharides, was treated with exoglyco- 
sidases and analysed by HPAEC and LD-MS. The strategy of 
exoglycosidase digestion is shown in Scheme 1 and the results, 
summarized in Table II, are fully consistent. 
Oligosaccharides from Y0-derived CAMPATH-IH gave a 
far more complicated profile (Figure IC), although the major 
peaks (I-III) that dominated the CHO oligosaccharide profile 
:; were present. In addition, however, the presence of a fucosyl- 
ated and non-fucosylated series containing a bisecting GlcNAc 
(Figure 2. Family 3 and Family 4, respectively) was indicated, 
based on the relative retention times of standard oligosac- 
charides. LD-MS of the unfractionated oligosaccharides was 
fully consistent with this interpretation (Table 1II). Confirma- 
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Fig. 1. HPAEC-PAD of oligosaccharides released by hydr3zinolysis -- 
trcatment of CAMPA7H-1H. (A) CHO (serum-free culture conditions): 
(B) CHO (serum-containing culture conditions). (C) YO: (D) NSO. 






determination of N-linked oligosaccharides from 
CHO-derived CAMPATH-IH 
Oligosaccharide Exoglycosidase HPAECC MW Structures 
treatments (peak no. ) (LD-MS)d 
Unfraction- None 0-59(1) 1484 la (0(4301) 
ated 0.67 (II) 1646 lb (014301) 
1338' 2a(004300) 
0.78(111) 1809' Ic ((Y24301) 
1501' 2b(014300) 
G 0.58 1486 la (004301) 
0.68' 1340 2a(004300) 
F 0.68 1339 2a (004300) 
0.77 1501 2b(014300) 
0.89 1664 2c (024300) 
G+F 0.68 1339 2a(004300) 
Peak I None 0.59 1487 la (004301) 
H 0.32 1079 002301 
H+F 0.38 934 002300 
Peak II None 0.68 1645 lb (014301) 
G 0.57 1483 la (004301) 
H 0.45/0.52v 1444 013301 
H+G 038/0.42' 1283 003301 
H+F 0.5110.581 1298 013300 
Peak III None 0.78 1809 is (024301) 
1501 2b(014300) 
G 0.58 1485 la(004301) 
0.67 1340 Za(004300) 
F 0.90 1664 2c(024300) 
0.78 1501 2b(014300) 
'Minor peak. 
'Released from CAMPATH-IH by hydrazinolysis and fractionated on 
HPAEC (see Figure 1A and B). 
°Oligosaccharides were incubated with exoglycosidases prior to analysis. 
G= ß-galactosidase; F= a-fucosidase; H= ß-N-acetylhexosaminidase; 
+ indicates treatment with a mixture of exoglycosidases. 
CRetention time relative to NeuNAc (see Table 1). 
4. Molecular weight of the [M + Na'] ion (see Table I). 
tDeduced structure (see Table I and Figure 2 for nomenclature). 
'Two peaks observed by HPAEC, consistent with isomeric structures. 
treatment of the unfractionated oligosaccharides with 
a-fucosidase (Figure 4A) or 0-galactosidase (Figure 4B), or a 
combination of both a-fucosidase and ß-galactosidase (Figure 
4C), followed by chromatography on HPAEC and LD-MS. 
Treatment with a-fucosidase revealed the presence of both 
non-fucosylated series (Figure 2; Family 2 and Family 4). 
whereas treatment with ß-galactosidase showed the presence of 
the non-galactosylated oligosaccharide from each of Families 
1-4. Treatment with both exoglycosidases simplified the 
HPAEC trace further (Figure 4C) to the non-galactosylated 
oligosaccharide from each of Family 2 and 4. LD-MS of each 
of the exoglycosidase-treated oligosaccharide mixtures con- 
firmed the proposed assignments. The strategy of exoglyco- 
sidase digests is shown in Scheme 2. and the results are 
summarized in Table III. 
The profile of oligosaccharides from NSO antibody (Figure a G2 1D) was similar to that from CHO material. The major peaks 
(I-1II) were again present, and their structures were deduced by 
LD-MS, suggesting that the major fucosylated series, Family 1, 
is a major contributor and the non-fucosylated series, Family 2 
(Figure 2), is a minor contributor to the HPAEC profile. These 
structures were confirmed by exoglycosidase treatment, as 
described for YO oligosaccharides, followed by HPAEC and 
LD-MS. However, two minor peaks (Figure ID; Peak A and B) 
Glycosytation and biological activity of CAMPATII-111 
I FlmiLl % 
(±Gal)-GIcNAc-Man Fuc la Cal -0 (00430I) 
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3a Gal -0 (004311) 
3b Gals 1 (014311) 





4a Gal -0 (004310) 
4b Cal -I (014310) 
4c Cal -2 (024310 
Fig. 2. Typical complex N-linked oligosaccharide structures found on the 
CH= domain of the Fc region of IgG antibody. Terminal NeuNAc is omitted 
for simplicity. Shorthand nomenclature is in parentheses. 
with short retention times were observed, that were not found 
in the CHO or YO oligosaccharide HPAEC profiles. Although 
these structures were not analysed in detail, they appear to be 
the result of underglycosylation. as outlined below. 
Peak 11 from CHO -oligosaccharides was determined to be 014301. Exoglycosidase treatment of this fraction (see 
Scheme 1) with 13-N-acetylhexosaminidase (to give 013301). 
followed by ß-galactosidase (to give 003301) or a-fucosidase 
(to give 013300), produced a series of underglycosylated 
oligosaccharides whose structures were fully consistent with 
LD-MS data. They could all be separated into two isomers 
by HPAEC, with overlapping relative retention times in the 
range 0.38-0.58 (Table I). The two minor peaks from NSO 
31 





















Fig. 3. LD-MS profile of oligosaccharides released by hydrazinolysis of CHO CAMPATH-IH and fractionated by HPAEC-PAD (see Figure IA). 
(A) Unfractionated oligosaccharides; (B) Peak I; (C) Peak II; (D) Peak III. Assigned structures are based on retention times by HPAEC-PAD, LD-MS and 
exoglycosidase treatment of the oligosaccharide fractions. (Figures C and D are shown on following page. ) 
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Scheme 1. Strategy for the structural determination of N-linked 
oligosaccharides from CHO-derived CAMPATH-IH 
Oligosaccharide' Sequence of exoglycosidase digests° 
Peak 1 004301 -H-* 002301 -F-4 002300 
1437c 1079 934 
Peak 11 014301 -14-º 013301 -F-4 013300 







Peak III 024301 + 014300 -G- 004301 + 004300 
1809 1501 1485 1340 
1 
F 
024300 + 014300 
1664 1501 
'Peaks isolated by fractionation on HPAEC (see Figure IA and Table II). 
°Exoglycosidase treatments: G= ß-galactosidase; F= a-fucosidase; 
H= ß-N-acetylhexosaminidase. 
`Molecular weight of the [M + Na'] ion by LD-MS. 
oligosaccharides had retention times (Figure 1D; Peak A= 
0.44, Peak B=0.52) consistent with any or all of these 
underglycosylated oligosaccharides. However, LD-MS of the 
unfractionated oligosaccharides indicated [M + Na~] mole- 
cular ions at 1283 and 1445, suggesting the presence of 003301 
and 013301, respectively. Interestingly, oligosaccharides 
from an NSO-derived anti-CD4 antibody had a very similar 
profile, with the same evidence of underglycosylation (data not 
shown). 
Biological activity of CAMPATH-IH 
The concentration of CAMPATH-1H was measured by adsorp- 
tion at OD 280 nm and by human IgG enzyme-linked immuno- 
sorbent assay (ELISA). The- ability to bind to CD52 antigen by 
ELISA and by fluorescent activated cell scan (FACS) staining 
of antigen-bearing cells was similar for all antibody prepara- 
tions. Surface plasmon resonance (SPR) analysis indicated no 
differences in the affinities (range 1.06-1.57 x 108/M) of the 
three CAMPATH-IH antibodies (Y0, NSO and CHO) for the 
antigen over a range of dilutions. It can be concluded that dif- 
ferences in glycosylation of the various antibody preparations 
are not reflected in differences in the ability to bind to the 
CD52 antigen or in the affinity for such an interaction. 
The ADCC'activity of CAMPATH-1H antibodies from dif- 
ferent cell cultures (CHO, YO and NSO) was measured using ef- 
fector cells from a range of donors. The results shown (Figure 5) 
are typical of several assays, using isolated donors on each 
occasion, and indicate that. at the lower doses utilized in the 
assay. YO antibody was consistently more active. These results 
are exemplified by the concentration required to achieve 50% 
specific lysis (i. e. 0.0001 µg/ml for the YO antibody, and 0.001 
and 0.001-0.01 . tg/ml for the NSO and CHO antibodies, 
respectively). As expected, removal of N-linked oligosaccha- 
rides from CAMPATH-1H abrogated activity (data not shown). 
In contrast, no differences between the antibodies in the 
TableIII. Structural determination of N-linked oligosaccharides from 








Unfraction- None 0.59 (1) 1486 " la (004301) 
ated 0.69 (11) " 1647 ---- .- -' Ib (QI4301) "K- - 1340 -`2a (00300Y `': `' 
0.74 (IV) 1688 
_"3a 
(00431I) 
0.78 (III) 1808 "" ;1 (0243(1) :.. 1501 '" -2b (014300); :"- 
0.83 (V) 1850 ' 3b (014311)" 
1543 4a(004310) 
0.94 (VI) 1704 4b(014310) 
G 0.59 1484 la (004301) 
0.69 1340 2a (004300) ". _ 0.73 1686 3a(004311) 
0.84 1545 4a (004310) 
F 0.69 1340 2a (004300) = ;;; 
0.78 1502 - " " 2b'(014300) 
0.84 1542 4a (004310) 
0.91 1664 2c (024300) 
0.93 1704- 4b(014310) 
G+F 0.69 1339 2a(004300) 
0.83 1544 . 4a (004310) 
'Released from CAMPATH-IH by hydrazinolysis and fractionated on 
HPAEC (see Figure IC). 
°Oligosaccharides were incubated with exoglycosidases prior to analysis. 
G= ß-galactosidase; F= a-fucosidase; H= a-N-acetylhexosaminidase: 
+ indicates treatment with a mixture of exoglycosidases. 
'Retention time relative to NeuNAc (see Table I)_ 
°Molecular weight of the [M + Nal ion (see Table I). 
'Deduced structure (see Table I and Figure 2 for nomenclature). 
monocyte killing assay were found, although good activity was 
observed in all cases (data not shown). 
Discussion 
It is known that both the culture conditions and the cell line can 
affect the glycosylation pattern of an antibody. It is equally 
clear that glycosylation plays a role in the biological activity of 
the- antibody. This study was initiated to determine whether 
expression of the clinically important, humanized monoclonal 
IgGI antibody, CAMPATH-1H, from different cell lines had an 
effect on glycosylation and, if so, whether in vitro biological 
activity was also altered. 
The results from this study demonstrate that major differ- 
ences in antibody glycosylation occur between cell lines, and 
minor differences occur for a given cell line grown under dif- 
ferent culture conditions. Glycosylation patterns differ mark- 
edly between the antibodies expressed in CHO (Figure IA), YO 
(Figure 1C) and NSO (Figure ID) cells. YO CAMPATH-1H is 
remarkable in being the only antibody with a bisecting GIcNAc 
on the core oligosaccharide (see Figure 2; Family 3 and 4), and 
there is evidence to suggest that the NSO antibody has a signi- 
ficant degree of underglycosylation (Figure 1D; Peaks AIB). 
In contrast. the different culture conditions used in this study 
result in less significant effects on CHO antibody glycosylation 
(Figure lA and B), although quantitative differences are ob- 
served. suggesting that a higher proportion of oligosaccharide 
chains have terminal galactose residues when grown in serum- 
containing medium (FigurelB; Peak III > Peak 1) rather than 
protein-free medium (Figure IA; Peak I> Peak III). ;", 
CAMPATH-1H binds to an antigen (CD52), abundantly 
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Glycosylation and biological activity of 
Scheme 2.. Strategyior the structural determination of N-linked 
oligosaccharides from YO-derived CAMPATHJH 
Sequence of exoglycosidase digests' 
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Fig. 4. HPAEC-PAD of oligosaccharides released by hydrazinolysis Fig. 5. ADCC activity of CHO (A). YO (0) and NSO (M) CAMPATH- IH 
treatment of YO CAMPATH-1H. followed by exoglycosidase treatment with antibodies. measured by specific release of 31Ct from Wien 133, a human 
(A) a-fucosidase. (B) ß-galactosidase. (C) a-fucosidase and ß-galactosidase. B-cell lymphoma cell line. SEs of triplicate samples are included. 
An internal standard of NeuNAc was included. Shorthand nomenclature is 
used to assign peak structures. 
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lymphocytes, and is remarkably effective in both -CML-and 
ADCC in vitro. The antibody has been"in major clinical trials 
for several years, and has proved to be very effective in lym- 
phocyte depletion. The mechanism of lymphocyte depletion 
does not appear to be via CML, since CAMPATH-1M, a rat 
IgM, has excellent CML activity in vitro but is ineffective in 
vivo. In contrast, there is a good correlation between ADCC 
activity in vitro and lymphocyte depletion in patients. 
In this study, the biological activity of CAMPATH-111 was 
measured by both ADCC and monocyte killing. The ADCC 
assay measures the capacity of CD16, CD56* killer cells 
(effector cells) to lyse antibody-coated target cells. The specific 
lyric mechanism is via the CD16 receptor on the effector cell, 
which binds to the Fc CH2 region of IgG when bound to the 
target cell, and can be affected by the glycosylation pattern of 
the antibody. The monocyte killing assay is performed over a 
5 day time period and. utilizes cells of the CD 14+ lineage=The 
mechanism of action is also mediated via antibody interactions, 
but is monitored by the growth inhibition of the target cells 
rather than by killing. The IgG Fc receptors found displayed on 
the monocytes vary with time in culture, and a combination of 
CD16, CD32 and CD64 is thought to be involved. 
Although all antibodies had similar activity in the monocyte 
killing assay, YO CAMPATH-1H had enhanced activity over 
both NSO and CHO antibodies in the ADCC assay. Moreover, 
the deglycosylated antibody had no ADCC activity, demon- 
strating the requirement for an N-linked oligosaccharide on the 
CH2 region of the heavy chain. This result suggests a relation- 
ship between the glycosylation pattern and biological activity, 
and that oligosaccharide structures containing a bisecting 
GIcNAc may play an important role. The implication for clin- 
ical efficacy is obvious: should the mechanism of lymphocyte 
depletion in vivo be via ADCC rather than monocyte killing 
activity, then YO CAMPATH-1H would have a significant 
benefit over CHO or NSO antibody. It is interesting that, in this 
study, antibody glycosylation has a markedly different effect on 
the ADCC and monocyte killing activities, even though the 
mechanisms of action are both mediated via Fc receptor bind- 
ing to antibody. It would not be safe to extrapolate these results 
to other antibodies. 
One means of gaining a better understanding of the role of 
antibody glycosylation in biological systems would be to re- 
move monosaccharide residues from the oligosaccharide chain 
on an intact antibody molecule in a stepwise fashion. Prelim- 
inary experiments in our laboratory demonstrated the feasibility 
of this approach with CAMPATH-1H (M. R. Lifely, unpublished 
observations), in which successive treatments with the exoglyco- 
sidases. N-acetylneuraminidase, (3-galactosidase and N-acetyl- 
f3-hexosaminidase, removed the appropriate residues, albeit 
with increased difficulty, without affecting binding activity. 
Materials and methods 
Source of CAMPATH-I H 
The CHO 3D II cell line expressing CAMPATH- IH using dihydrofolate reduc- 
tase as a selectable marker (Page and Sydenham. 1991) was grown in either a 
hollow fibre fermenter (Acusyst-! r) culture using Iscove's medium lacking 
HEPES supplemented with nonessential amino acids. 1 µbl methotrexate and 
317'a fetal bovine serum (FIS), or using Wellcome culture medium S (WCM5) 
serum-free medium with I µM methotrexate in a stirred 8000 I bioreactor. 
WCM5 contains human recombinant insulin, but is otherwise protein free. 
Y0 antibody was prepared using transfectant 7FS7 (Riechmann et A. 1988). 
The cells were grown in roller bottles using Iscove's medium supplemented 
with 2k'o FBS and hypoxanthinelaminopterin/thymidine. 
For re-expression in NSQcetls, the heavy and light chain CAMPATH"1H 
cDNA: was. recloned Into ., glutatnine-synthetase. selection-based. -vectors - (Bebbina on et at, 1992) obtained from Celltech. -Slough, Ur, transferred by 
electroporation. then amplified with 5 tM methionine sulphoximine. NSO9D4,, 
a clonal cell line, selected in serum-containing medium. -wastransferred 
to protein-free growth in WNSD medium, which is of defined composition 
being free"of -protein and other, large-molecular-weight components: ". ARer 
several weeks of protein-free. groowth, in. shake f asks,. culture supetuaLwt awns 
harvested. - '. ý ., 
Antibody purification 
The culture supernatant containing CAMPATH-IH from NSO 9D4 cells wns- ' 
clarified by centrifugation and passed through a 0.2 µm filter. The antibody 
bound to a protein A-Sepharose column was eluted with 0.1 M citrate baffer 
(pH 3): bound to a S-Sepharose ion-exchange column, then eluted with 20 mM 
citrate-phosphate buffer containing 200 mM NaCI. A stock solution at 534-- 
mg/I was prepared and stored at 4°C. Clinical Trial Material grade_serum-free 
CHO 3D11-derived CAMPATH-1H was obtained as. a 10 mg/ml solution in 
phosphate-buffered saline (PBS) in a sealed glass ampoule. and stored at 4°C -"" Clarified supernatants from CHO 3DI I or YO 1F57 were purified using äsim- 
ilar protocol to that above. The S-Sepharose eluate was concentrated, desalted, ' 
and separated from dinier and higher aggregates using a Superdex 200 size- 
exclusion column and stored in PBS. 
Release of oligosaccharides by hydrazinolysis 
CAMPATH-IH (5 mg) was dialysed against water to remove salts and 
freeze-dried in a glass ampoule. Hydrazine (0.1 ml) was added and the sealed 
ampoule heated at 95°C for 5 h. The released oligosaccharides were separated 
from hydrazine and peptides by adsorption to a cellulose (Whatman. CF-Il) 
column (Bio-Rad; 1 ml) in butanol: ethanol: acetic acid (4: 1: 0.5 v/v/v; 1.5 ml). 
After washing the cellulose in butanol: ethanol: water (4: 1: 1 v/v/v: 3xI ml). 
oligosaccharides were N-reacetylated in situ with acetic anhydride: methanol 
(2: 5 v/v; 1.4 ml) for 30 min at room temperature. The column was washed with 
butanol: ethanol: water (4: 1: 1 v/v/v; 4xI ml ), then with methanol (I ml). 
Oligosaccharides were then eluted from the column with 01 M sodium acetate 
(2 xI ml), further treated with acetic anhydride (0.1 ml) for 30 min then with 
0.1 M copper acetate (0.1 ml) for 30 min to convert the acetythydrazone deriva- 
tives to the unreduced oligosaccharides. Cations (Ne and Cu*) were removed on 
an ion-exchange stack column of Chelex 100 (H' form: upper. 0.4 ml) and AG- 
50 (H' form: lower, 1 ml), and oligosaccharides were recovered as the aqueous 
eluant. before lyophilization. 
Desialylation of oligosaccharides 
Oligosaccharides were treated with 40 mbt trifluomacetic acid at 80'C for 1h 
under helium to remove sialic acid. Trifluoroacetic acid was removed under a 
stream of nitrogen at 40°C, and sialic acid content was measured by HPAEC 
using the conditions for separation of oligosaccharides described above. 
Emglycosidase treatment 
The following exoglycosidases were obtained from Oxford Glycosystems G. 
ß-galactosidase from bovine testes (x-5013): F. a-fucosidase from bovine 
epididymis (X-5006); H. ß-N-acetylhexosaminidase from jack bean meal 
(X-5003). Oligosaccharides (5-10 µg) were incubated with enzyme, following 
the manufacturer's instructions, at 37°C for 48 h in a total volume of 50 µl. 
Samples were purified by passage through a column of Dowex AG 50 (H" form; 
0.3 ml) layered upon Dowex AG3 (OH- form: 0.3 ml). The column was eluted 
with 3 ml water and the eluate lyophilized. 
Nninenclature of N-linked oligosaccharides 
N-Linked oligosaccharides present on IgG are made from a core of three man- 
nose (Man) and two GIcNAc residues (see. for example. Figure 2). Additional 
GicNAc. Gal and NeuNAc residues may be present on the two outer arms, and 
Fuc may be present on the penultimate G1cNAc core residue. Finally, a bisect- 
ing GIcNAc may be present, attached to the core Man. The nomenclature 
to describe the oligosaccharide structures uses a six-numbered digit which 
(from left to right) describes the number of NeuNAc (0-21. Gal (0-2). core + 
outer arm GIcNAc (: -4), bisecting GIcNAc (0 or 1) and Fuc (0 or 1) residues. 
Analysis of ofigosaccharides by HPAEGPAD ;'. 
Oligosaccharides released by hydrazinolysis were analysed by HPAEC using 
a Dionex Bio LC system and a Carbopak PA-1 column. eluted with a linear 
Glycosyiation and biological activity of CAMPATH"IH 
gradient from 24 to 36 mM sodium acetate in 125 mM NaOH over 20 min at a 
now rate of I mi/min. and detected by pulsed amperometric detection (PAD) 
using a gold electrode. An internal standard of NcuNAc was included in 
order to determine relative retention times of oligosaccharide peaks. Stand- 
ard oligosaccharides. M3N2F (00'_301), NGA2F (004301). NA2F (024301). 
NGA2FB (004311). NA2FB (024311) and RP-2501 (a mixture of 024300. 
014301.034301,004311.014311,024311) were purchased from Oxford 
Glycosystems. Further standards were derived from a-fucosidase treanaent 
of 002301.004301,024301.004311 and 024311, which gave 002300.004300, 
024300,004310 and 024310, respectively. In addition. a-fucosidase treat- 
ment of RP-2501 gave a mixture of 024300,014300,024300,004310,014310 
and 024310. 
Preparative isolation of CHO oligosaccharide Peaks 1-111 
The oligosaccharide mixture (30 µl) was injected and oligosaccharides 
separated by HPAEC. Each peak was collected separately. desalted on AG-50 
(H' form) and rotary evaporated to dryness to remove acetic acid. The residue 
was dissolved in water and a small proportion was reinjected to confirm lack of 
contamination with other peaks. Each fraction was lyophilized and stored at 
-20°C. 
Structural determination of oligosaccharides by LD-MS 
Samples of desialylated oligosaccharides (1-20 pmol) in water (1 µl) were 
mixed with the matrix component 2.3-dihydroxy benzoic acid (I µ1 of a 
10 mg/ml solution in 50% w/v ethanol) and an aliquot (1 µl) allowed to dry on 
a sample slide. Samples were ionized following irradiation with a pulse of laser 
light, and were analysed with a LASERMAT time-of-flight mass spectrometer 
(Finnigan MAT). 
IgG EUSA 
Culture supernatants were clarified by centrifugation at 13 000 r. p. m. in a 
microfuge. The wells of a 96 well maxisorp ELISA plate (Nunc, Roskilde. 
Denmark) were coated with sheep anti-human IgG (Seralab. UK. catalogue no. 
SDL2015) in PBS (2 µg/ml: 100 µl) and incubated overnight at 4°C. The 
excess protein binding sites were blocked by incubation with I% bovine serum 
albumin (BSA) fraction V in PBS (200 µl/well) at room temperature for 
1 It. The wash buffer used between each step was 0.05% Tween 20-PBS. 
CAh1PATH-1H standard samples (2-fold dilutions from 250 ng/ml) or culture 
supernatants in triplicate in 0.2% BSA. 0.05% Tween 20-PBS (PBT) were 
added (100 ILI/well) and the plate incubated at room temperature for 1.5 h. The 
plate was washed five times and peroxidase-conjugated sheep anti-human IgG 
(Sigma) was added (diluted 1: 2000 in PBT: 100 µl/well). The plates were incu- 
bated at room temperature for 40 min. then washed five times. Tetra-methyl 
benzidine as substrate (Sigma. Poole, UK) was added (100 µl/well) and incu- 
bated at room temperature until a discernible blue colour was apparent. The 
reaction was stopped with 2M H2SO4 (100 µUwell) and the colour measured 
at an adsorbance of 450 nm. 
C4MPATH antigen binding EUSA 
This was performed as described previously (Xia et aL. 1993). 
y counter (Wallac Wizarl, Model 1470, Turku. Finland). The level of specific 
release was calculated as follows: 
(mean c. p. m. antibody-mediated release) - 
% specific release = 
(mean c. p. m. spontaneous release) 
x 100 
(mean c. p. m. total release) - 
(mean c. p. m. spontaneous release) 
Monocyre killing assay 
Human peripheral blood monocytes were isolated from PBb1C by adherence to 
plastic. This was performed by diluting PBMC in RPMI 1640 medium contain- 
ing 10%70 autologous serum (RPMI-S) and incubating for 2h at 37C in a 
75 cm= tissue culture flask. Non-adherent cells were removed by washing twice 
with RPMI 1640 medium. Monocytes were subsequently cultured for-14 days 
in RPMI-S and then assayed for CD14 expression by FACS. The cells were 
harvested and dispensed into 96 well plates at 103/ml and 100 µUwell together 
with 4x 103 CD52-expressing wen 133 target cells. A range of CAMPATH- 
1H antibody dilutions, in triplicate; was then added and the plates incubated for- 
5 days. Target cell proliferation rate was assessed by incorporation -of 
[3H]thymidine. Growth inhibition due to monocyte cytotoxicity was expressed 
as percentage inhibition in comparison with duplicate cultures in the absence 
of monocytes. 
Fluorescent activated cell scan 
To compare antigen binding of the different antibodies, Wien 133 cells were 
washed and resuspended in PBS containing 5% FBS, 0.1% sodium azide at 
103/ml, and 100 Nl aliquoted into the wells of a 96 well plate. A range of anti- 
body dilutions were subsequently added to the wells and the plate placed at 4°C 
for 30 min. After washing in the same buffer, the cells were resuspended in 100 
p1 of fluorescein isothiocyanate-labelled and-human IgG diluted I in 100 and 
again placed at 4°C for 20 min. After extensive washing, the cells were resus- 
pended in PBS containing 1% v/v paraformaldehyde and analysed on a Becton 
Dickinson FACscan. 
Surface plasmon resonance binding 
Real-time biospecific interaction analysis using a BlAcoreTM (Pharmacia Bio- 
sensor AB. Sweden) with SPR was used to determine rate and affinity con- 
stants for the various preparations of CAMPATH-IH. This was accomplished 
by activating the surface of a dextran-coated gold chip with the amine coupling 
kit (Pharmacia) and coupling the purified CAMPATH antigen. CD52 ()Ga 
et aL. 1993) in 10 mM HEPES. 1M NaCl, pH 7.4 (0.4 nmol CDS2 in 80 µl). 
CAMPATH-1H. diluted to 3-100 µg/ml in 10 mM HEPES. 150 mM NaCI 
(pH 7.4). 0.05% BlAcore Surfactant P20 (HBS), was exposed to the coupled 
antigen for 6 min at a flow rate of 5 }tllmin. This was followed by a dissociation 
phase in which HBS alone was injected. Finally. the antigen surface was 
regenerated by exposure to 10 mM NaOH for I min and monitoring binding of 
the antibody to the antigen. 
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Antibody-dependent cell-mediated cyrotoxicity assay 
Peripheral blood mononuclear cells (PBMC) were separated from defibrinated 
fresh human blood by centrifugation over a lymphoprep (Nycomed) gradient. 
Wien 133. a human B cell lymphoma cell line (Nacheva er al.. 1987) express- 
ing the CD52 antigen on its cell surface membrane, was grown in log phase, 
labelled with s'Cr. washed, resuspended at 2x 103/ml. then aliquoted into 
96 well 'U'-bottomed tissue culture plates at 50 µl/well. Wien 133 cells were 
cultured using Iscoves's medium. 10% FBS and 2 mM t. -glutamine (Wien 
growth medium). CAMPATH-1H antibody dilutions (50 µl). in Wien growth 
medium. were added to triplicate wells in the plate. Nine control welts without 
antibody were also included in each assay. The plates were incubated at 37°C 
for 1.5 h in a humid CO incubator prior to the addition of 100 µl of PBMC 
effector cells at a concentration of 2.5 x 106/ml. in Wien growth medium. to 
each antibody-containing well. This resulted in a ratio of 25 effector cells for 
each target cell. The effector cells were also added to one triplicate set of 
control wells (non-antibody-mediated lysis control). Wien growth medium 
alone was added to yet another set of control triplicates (spontaneous lysis 
control) and 100 µl of 1% w/v Triton X100 were added to the final set of 
control wells (total release control). The plates were centrifuged for 5 min at 
1500 r. p. m. before being replaced at 37°C for 5 h. At the end of the incubation 
period. 100 µl of medium were removed from each well and counted in a 
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Abbreviations 
ADCC. antibody-dependent cellular cytotozicity: BSA. bovine serum albumin: 
CHO. Chinese hamster ovary: CML, complement-mediated lysis; ELISA. 
enzyme-linked immunosorbent assay; FACS. fluorescent activated cell scan; 
FBS. fetal bovine serum; Fuc. fucose: Gal. galactose. GaINAc. N-acetylglucos- 
amine. HPAEC-PAD, high-performance anion-exchange chromatography with 
pulsed amperometric detection; LD-MS. laser desorption-mass spectrometry: 
Man. mannose: NeuAc. N-acetylneuraminic acid: PBMC. peripheral blood 
mononuclear cells: PBS, phosphate-buffered saline: PBT, 0.05% Tween 
20-PBS: SPR. surface plasmon resonance. 
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